{
  "responseHeader":{
    "status":0,
    "QTime":9,
    "params":{
      "q":"(Background: melanoma^4 OR Doc_title: melanoma^4) AND (Background: \"KIT amplification\"^4 OR KIT amplification OR Doc_title:\"KIT amplification\"^4 OR KIT amplification OR Doc_title:\"KIT amplification\"^4 OR KIT amplification OR Doc_title:\"KIT amplification\"^4 OR KIT amplification)"}},
  "response":{"numFound":229,"start":0,"docs":[
      {
        "Meeting_name":" Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.",
        "Background":"['Background', '  Three phase II trials have shown an overall response rate (ORR) around 20% with imatinib in melanoma carrying KIT mutations. The aim of this study was to study the interest of nilotinib a Kit inhibitor with  pharmacological advantages compared to imatinib.  Methods', '  this multicenter uncontrolled open Herns single-stage Phase II study enrolled patients with advanced melanoma and KIT amplifications and/or mutations and no BRAF and NRAS mutation, nor previous Kit targeted therapy or active brain metastasis.Patients received Nilotinib 400 mg bid. ORR was the primary endpoint. Secondary endpoints included disease control, metabolic response rate and biomarkers associated to response . Based on type I and II error rates fixed at 0.05 and 0.10, respectively, a sample size of 25 patients was required to test the level of response, p 7.5% against > 30%, with at least 5 successes tindicating that the treatment was effective. Analysis was based on intent to treat.  Results', '  25 patients were enrolled from 2010-07-27 to 2012-08-27', ' 13 females (52%); median age  70 years(range, 43-87); 23 (92%)  tumors with KIT mutations, 5 (20%) KIT amplifications, and 3 (12%) both. One patient  (4%)  had primary unresectable melanoma, 3(12%) unresectable stage III melanoma, 21 (84%) stage IV melanoma .13 (52%) patients were chemotherapy naive, 12 (48%) had previously received dacarbazine or fotemustine, 1 immunotherapy . Median follow-up was 3 months ([IQR', ' 2-7], range 0.3-12).One patient reached CR and 4 partial responses, concluding to treatment effectiveness with an ORR  of 20% (95%CI', ' 6.8-40.7) all in patients with KIT mutation . Six patients died and 1-year overall survival was 68.3% (95%CI', ' 46.5-1.00).The 25 patients experienced a total of 236 adverse events , 2/3 imputed to the drug mostly of grade 1 (n=146 in 21 patients) and grade 2 (47 in 13 pts), and less frequently of grade 3 (39 in 18 pts) or grade 4 (3 in 3 pts', ' 2 dyspnea, 1 renal failure) and 1 death. Five patients had drug withdrawal because of toxicity.  Conclusions', '  According to our hypothesis, nilotinib is an effective drug in KIT mutated melanoma in the absence of BRAF and NRAS mutations and should be added to our armamentarium. Clinical trial information', ' NCT01168050.']",
        "Doc_id":"ASCO_130225-144",
        "Doc_title":" Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.",
        "_version_":1606189026987999233},
      {
        "Meeting_name":" A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas",
        "Background":"['Background', ' Effective therapy for advanced melanoma remains elusive. Preclinical studies report a critical role of c-KIT amplification and mutations in mucosal, acral, and solar melanomas. Preliminary data from clinical trials of KIT-directed therapy suggest their potential efficacy in these subtypes of melanomas. Targeting KIT, PDGFR, and SRC family kinases (SFK), dasatinib has inhibitory effects not seen with imatinib and nilotinib in melanoma cell lines with the most common KIT mutation, 11L576P. E2607 tests the efficacy of dasatinib in treatment-naive or previously treated patients with advanced or metastatic melanoma with these subtypes. Methods', ' We plan to enroll up to 110 patients with acral (palms, soles, or subungual sites), mucosal, or cutaneous melanomas with chronic sun damage (solar elastosis in the skin adjacent to the melanoma). Solar elastosis must be confirmed centrally. Patients receive dasatinib 70 mg PO twice daily on an open-label, single-arm basis. Cycle length is 21 days, without breaks between cycles. The primary endpoint is objective tumor response rate for dasatinib using RECIST criteria. Secondary objectives include response duration, progression-free survival, and safety. Correlative studies include assessing KIT expression, amplification and mutation, PDGFR expression, and SFK activation in tumor samples and correlating these findings with response. The study is designed in two stages, with accrual open to molecularly proven KIT+ and KIT- patients in the first stage. If responses are seen only in KIT+ patients at interim analysis (n=56 patients), strictly KIT+ patients will be enrolled (n=22 in each melanoma subtype). If response rate appears unrelated to KIT status, with response rate of at least 20%, the study will remain open to all patients (n=110).']",
        "Doc_id":"ASCO_43420-74",
        "Doc_title":" A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas",
        "_version_":1606189025210662912},
      {
        "Meeting_name":" Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification",
        "Background":"['Background', '  A recent  French national phase II clinical trial (NCT01168050) evaluating nilotinib in KIT mutated advanced melanoma showed an overall response rate of 20% (Lebbe et al, ASCO 2014). We conducted a pharmacodynamic study to evaluate potential biomarkers  associated with clinical response and disease control.  Methods', '  25  patients had tumor specimen available at baseline and tested for c-KIT mutation, amplification and c-KIT expression. Twelve had available follow-up biopsies, 5 with a progressive disease (PD), 8 with a stable disease (SD), 1 with a partial response (PR). Follow-up biopsies were tested for c-KIT secondary mutations, gene copy number variation and expression related to angiogenesis, apoptosis and proliferation. IHC staining was performed on sections at baseline and after treatment for c-KIT, p-ERK, p-AKT and p-MEK.  Results', '  C-KIT expression was confirmed in all patients treated with nilotinib at baseline. The presence of a c-KIT exon 11 or 13 mutations was associated with clinical response. No secondary c-KIT mutations were detected at progression. c-KIT gene copy number revealed an amplification in 5 out of 25 patients prior to treatment without association with response rate. However, 1 SD patient had a decrease in c-KIT amplification after treatment. VEGFR-2 gene copy number whose co-amplification with c-KIT is frequent in other solid cancers was not associated with clinical outcome. pMek and pErk decreased in some SD and PR patients, with no variation of pAKT. Interestingly, using transcriptomic analyses FGF2 overexpression prior to treatment was observed in all PR and SD patients studied.  Conclusions', '  Clinical response is associated with c-KIT exon 11 or 13 mutations, and not with the sole amplification of c-KIT. In this study, we found no mutation associated with primary resistance. Albeit no evident biomarker signature was identified in this pharmacodynamics analysis, further studies are needed to evaluate the predictive value of FGF2 expression for nilotinib response. Clinical trial information', ' NCT01168050']",
        "Doc_id":"ASCO_148846-156",
        "Doc_title":" Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification",
        "_version_":1606189039007825920},
      {
        "Meeting_name":" Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.",
        "Background":"['Background', ' Metastatic acral melanoma is a rapid progressing and refractory disease which accounts for 50% in China. VEGF, MAPK and NF-KB, which are targets of bevacizumab, sorafenib and temozolomide (TMZ) respectively, are vertical joint which inhibits melanoma cells from membrane, cytoplasm to nuclei. We conducted a phase II trial of the triple combination to test synergistic effects on metastatic acral melanoma. Methods', ' Patients (Pts) with stage IV (M1c) unresectable acral melanoma, who have failed at least one systemic regimen, are eligible. The pts were treated with TMZ 200 mg/m2/d (days 1- 5), bevacizumab 5 mg/Kg (days 1, 14) and sorafenib 400 mg/bid (days 1-28), repeatedly every 28 days. KIT, VEGFR and PDGFR protein of tumor tissue were detected and genetic aberrations including KIT and BRAF were analyzed by Immunohistrochemistry (IHC) assay and DNA sequencing respectively. The endpoints were progression-free survival (PFS), overall survival (OS), response and toxicity. Correlation was decided between gene mutations, IHC results and clinical response. Results', ' 50 patients were planned to recruit. 35 pts were currently enrolled and evaluated. One patient has achieved complete response (CR) lasting 16+months. Eight pts have achieved partial response (PR) (duration range', \" 4.4~7.2+ months). 15 pts received SD (> 3 m) with duration from 3.2 to 12+months. The response rate was 25.7% (9/35). PFS has not reached (at least 3.8 months). It's too early to assess overall survival. 30 pts had IHC and aberration results. The positive rates of KIT protein were 35% (PR+SD) pts and 42% in PD pts, of VEGFR were 26% s and 57%; of PDGFR were 84% and 57% respectively (p > 0.05). Five patients were found harboring BRAF V600E mutations (1CR, 4PD) and one of them had KIT amplification simultaneously (response\", ' PD). The common toxicity was moderate including hand-foot syndrome (G3/4', '11.4%), myelosuppression (G3/4', '11.4%), diarrhea (G3/4', '2.8%), fatigue and hoarse. Conclusions', ' The triple combination regimen preliminary achieved durable clinical response. The regimen is safe and well tolerated. It seemed no correlation between positive IHC results, gene mutations and responses.']",
        "Doc_id":"ASCO_51724-74",
        "Doc_title":" Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.",
        "_version_":1606189022785306624},
      {
        "Meeting_name":" Frequency and outcomes of melanoma subtypes in a diverse population",
        "Background":"['Background', ' Melanoma is a biologically heterogeneous disease that varies by ethnicity and histology. While superficial spreading (SSM) histology is the most common subtype in non-Hispanic whites (NHW), acral lentiginous (ALM) and other subtypes occur more frequently in Hispanics, Asians and African Americans. There are no known risk factors for ALM, and further investigation is warranted. Methods', ' We retrospectively reviewed a database of melanoma patients diagnosed between 2001-2016 at LAC-USC. Overall survival (OS) was estimated using Kaplan-Meier methodology, and comparisons performed using log-rank testing. Fishers exact test was used to evaluate associations between relevant clinicopathological variables. A p-value < 0.05 was considered statistically significant. Results', ' Among 272 melanoma patients, there were 140 Hispanics (51.5%), 105 NHW (38.6%), 14 Asians, and 4 African Americans. The most frequent histology among Hispanics was ALM (30.7%), while SSM was the most frequent among NHW (33.3%). BRAF V600 mutations were found in 34.5% (10/29) and 58.8% (10/17) of Hispanics and NHW, respectively. A total of 52 patients with ALM were identified, including 43 Hispanics (82.7%). There was a significant association between no prior history of non-melanoma skin cancer (NMSC) and ALM (p < .0001). Median Breslow thickness for ALM was 4.2 mm, and 32.7% were ulcerated. The rate of BRAF V600 mutations among 13 ALM patients tested was 0%. NRAS mutations were found in 3 ALM patients; KIT amplification/mutations were found in 2 ALM patients. Conclusions', ' We identified a population enriched for Hispanic patients with ALM. We found an association between no prior NMSC and ALM, suggesting that UV exposure is not a causative risk factor. BRAF mutations are less common amongst Hispanics, and nearly absent in ALM. Survival differences were not statistically significant, but cannot be ruled out due to low number of patients in this early study. ALMNon-ALMP-valueBRAFn = 13n = 39+0 (0.0%)22 (56.4%)P = 0.001-13 (100%)17 (47.2%)NRASn = 8n = 7+3 (37.5%)0 (0.0%)P = 0.491-5 (62.5%)7 (100%)KITn = 7n = 7+2 (28.6%)0 (0.0%)P = 0.99-5 (71.4%)7 (100%)']",
        "Doc_id":"ASCO_184818-199",
        "Doc_title":" Frequency and outcomes of melanoma subtypes in a diverse population",
        "_version_":1606189007746629633},
      {
        "Meeting_name":" Sunitinib therapy for metastatic melanomas with KIT aberrations.",
        "Background":"['Background', ' Recent studies have shown that KIT gene aberrations can be found in melanomas originating from mucosal or acral sites, or skin with chronic sun-damage (CSD), and may respond to treatment with KIT inhibitors such as imatinib. We wanted to determine the predictors of response to therapy with the KIT inhibitor sunitinib. Methods', ' We screened tumors for KIT aberrations using sequencing of exons 9, 11, 13, 17, and 18, FISH analysis, and immunohistochemistry for CD117. Patients with KIT mutations, amplification > 1.5, or CD117 staining 2+ in over 50% of cells were eligible for therapy with sunitinib 50mg/day 4 weeks on 2 off, and responses were evaluated using RECIST criteria. Results', ' See Table. Six patients had KIT mutations; five in exon 11 and one in exon 13. All were wild type for BRAF, NRAS, and GNAQ. Two also had KIT copy number increase determined by FISH. Three could be started on treatment. One patient with mucosal melanoma and KIT mutation exon 11 W557G had a partial response lasting for 7 months, one progressed, and one was non- evaluable. Of the 11 patients who had KIT copy number increase without mutations three were treated', ' one had a transient partial response lasting three months and two had progressive disease. Two patients without mutations or amplification that were CD 117 positive were treated and one had a partial response. Conclusions', ' At this early point in the trial, KIT mutations may indicate sensitivity to sunitinib. PrimaryNo. of patientsKIT mutationKIT amplificationCD117+ Acral16249 Mucosal28377 CSD28127 Totals7261323']",
        "Doc_id":"ASCO_40701-74",
        "Doc_title":" Sunitinib therapy for metastatic melanomas with KIT aberrations.",
        "_version_":1606189024365510656},
      {
        "Meeting_name":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "Background":"['Targeted deep massive parallel sequencing (MPS) has been implemented in routine molecular diagnostics for high-throughput genetic profiling of formalin-fixed paraffin-embedded cancer samples. This approach is now widely used to interrogate simple somatic mutations but experience with the analysis of copy number variations (CNV) is still limited. Here, we retrospectively analyzed CNVs in 822 cancer cases (n = 135 melanoma, n = 468 non-small cell lung cancers (NSCLC), n = 219 colorectal cancers (CRC)) that were sent to our institution for routine molecular profiling using a semiconductor based sequencing platform. Amplifications and deletions inferred by MPS coverage data were independently validated by a qPCR assay. We observed a decreasing frequency of CNV in clinically actionable genes from melanoma to NSCLC to colorectal cancer.Of 56 melanomas with genetic aberrations in BRAF, 31 showed co-occurring CNV in other genes, mainly affecting CDKN2A. Some tumors (5 cases each) revealed clustered deletions affecting either ABL1, NOTCH1, and RET or STK11, GNA11, and JAK3. 8.1% of the cases had amplifications in clinically actionable genes. In the group of NRAS mutant tumors (n = 39), 26 showed co-occurring CNVs in other genes, such as CDKN2A and FGFR3, and 9 NRAS mutant cases were additionally mutated in BRAF. 19.1% had amplifications in clinically actionable genes. In contrast to BRAF mutant tumors, we did not see any specific CNV clusters. In the group of BRAF/NRASwt tumors (n = 11), we observed 5 cases with co-amplification of KDR, KIT, PDGFRA and another 6 cases with KIT mutations. While co-amplified cases had many gene deletions, KIT mutated tumors harbored only very few genetic aberrations in other genes.Across both NSCLC data sets, we identified 14 cases with amplified EGFR (10 of them harboring co-occurring EGFR mutations) and detected 8 NSCLC with KRAS amplifications (of which 7 had co-occurring mutations of KRAS). KRAS mutated tumors displayed frequent amplifications in MYC (n = 10) and MDM2 (n = 5). Of the 22 BRAF mutant tumors, two harbored mutated KRAS. In contrast to melanoma, we observed no clustering of CNVs in BRAFmut NSCLCs. Within the group of KRAS/EGFR/BRAFwt tumors, we identified 15 cases harboring genetic aberrations in MET (n = 8 mutations, n = 7 amplifications).Compared to melanoma and NSCLC, the number of CNV in CRC was rather low. IGF2 amplifications were most prevalent (n = 13) followed by MYC (n = 9). Two cases showed amplified wild-type alleles of KRAS. Two KRAS mutant tumors showed concomitant amplification of NRAS and three cases harbored amplified EGFR.In conclusion we demonstrate that i) detection of CNVs by targeted MPS data obtained from FFPE material is feasible and ii) could be validated independently, iii) this approach enables detection of known CNV patterns, and iv) uncovers new CNV patterns in clinically actionable targets across cancers.']",
        "Doc_id":"AACR_2016-3167",
        "Doc_title":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "_version_":1606188994698149888},
      {
        "Meeting_name":" A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT.",
        "Background":"['Background', ' Three prior phase II studies of Imatinib mesylate (IM) in 62 pts with advanced melanoma reported only 1 response in a pt with acral melanoma. A proportion of melanomas arising from acral, mucosal, and chronic sun damaged (CSD) sites are characterized by KIT mutations (mut) or amplifications (amp) and we hypothesized that this subset of tumors would be sensitive to IM. We thus designed this phase II study of IM restricted to pts with melanoma harboring such alterations in KIT. Methods', ' Pts with unresectable melanoma arising from acral, mucosal, and CSD sites whose tumor harbored a 4q12 amp by FISH or mut in KIT and who had measureable disease by RECIST were eligible. Pts received IM 400 mg BID continually. Response was assessed every cycle (6 wks). A Simon 2-stage design was employed where initially 16 pts would be treated; if  2 responses were observed, a total of 25 pts would be enrolled. If 5 responses were seen in 25 pts, the study was to be considered positive. Results', ' Of 81 pt tumors screened, 17 (21%) had a KIT mut or amp', ' 5/22 (23%) acral, 12/45 (27%) mucosal, 0/13 (0%) CSD, 0/1 (0%) unknown primary. 12 (15%) had a mut only; 4 (5%) had an amplification only; 1 (2%) had both. Thus far, 7 have been treated, with 5 currently evaluable for response. Median age', ' 64 yrs (range, 61-86); 2 male/5 female; median KPS', ' 90 (range, 80- 90); median # of prior therapies', ' 1 (range, 0-4). 3 pts (43%) achieved a PR (18 wks - exon 13 mut; 21 wks, ongoing - exon 11 mut; 18 wks, ongoing - exon 11 mut & amp); 2 pts (28%) achieved SD (12 wks - exon 11 mut; 11 wks - amp). 3 pts required a dose reduction to 400 mg QD for rash, GI toxicity and fatigue. 1 pt required a second dose reduction to 300 mg QD for visual changes. Conclusions', ' In this pt population, 21% of tumors are characterized by mut or amp of KIT. The 3 responses observed have allowed expansion to the second stage of enrollment which is currently on-going. While IM has limited activity in a non-selected melanoma pt population, a substantial proportion of melanomas harboring KIT mut or amp appear to respond. It may be possible to identify appropriate pts prospectively for treatment with IM. (Supported by R01FD003445-01, ASCO YIA, N01CM62206, and the Live4Life Foundation.)']",
        "Doc_id":"ASCO_31247-65",
        "Doc_title":" A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT.",
        "_version_":1606189024448348160},
      {
        "Meeting_name":" A phase II study of imatinib for advanced melanoma patients with KIT aberrations.",
        "Background":"['Background', ' KIT is an important oncogene in acral and mucosal melanomas, which account for 70% of melanomas in Asian patients (Pts). We conducted a phase II study (NCT00881049) to test the KIT inhibitor imatinib in metastatic melanoma pts with KIT aberrations. Methods', ' Pts with metastatic or unresectable melanoma whose tumor had KIT aberrations (KIT mutation [mut] and/or KIT gene DNA amplification [amp]) and who had measurable disease were enrolled. Pts received imatinib 400 mg/d continually until disease progression or intolerable toxicity. The dosage of Imatinib was escalated to 600 mg or 800 mg per day if progression was observed. Response was assessed monthly using RECIST criteria. The endpoints were progression-free survival (PFS), overall response rate (ORR) and toxicity. Results', ' Of 390 cases screened, 67 (17.4%) had a KIT mut or amp', ' 26/137 (18.9%) acral, 21/110 (19.1%) mucosal, 9/26 (34.6%) CSD, 6/75 (8%) NCSD, 5/42 (11.9%) unknown primary. 41 (10.5%) had a mut only; 23 (5.9%) had an amp only; 3 (0.8%) had both. Thus far, 28 patients have been treated with 26 pts currently evaluable', ' 5 stage M1a/3 M1b/20 M1c; median prior therapies', ' 2. Six patients (21%) achieved PR (5 mut, 1 amp, 4~10+m); nine patients (35%) received SD ( 3 m, 3.5~9+m). Pts who failed on 400mg also failed on escalation to 600mg and could not tolerate 800mg due to toxicities. Samples of new or progressive lesions were obtained from 5 PR pts after they failed on imatinib 400mg, and were analyzed in KIT, BRAF and PDGFRA. In one pt (emerging metastasis in liver) new mutations were found in BRAF (V600E) and PDGFRA (W559stop) which were wild-type before treatment, and loss of the KIT mutation present at baseline. Common toxicities at 400 mg were rash, vomiting, edema and myelosuppresion. Conclusions', ' Imatinib (400mg/d) provides a beneficial therapeutic effect for a significant proportion of Chinese metastatic melanoma pts with KIT aberrations. Acquired genetic mutations after treatment may account for emergence of resistance in some pts. Supported by the National Natural Science Foundation of China (30973483), 985-2-085-113 and Novartis Oncology in China.']",
        "Doc_id":"ASCO_49055-74",
        "Doc_title":" A phase II study of imatinib for advanced melanoma patients with KIT aberrations.",
        "_version_":1606189016749703168},
      {
        "Meeting_name":" Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma",
        "Background":"['Melanoma causes the greatest morbidity and mortality of all skin cancers and often harbors amplifications or activating mutations in KIT, a type III transmembrane receptor tyrosine kinase (RTK) involved in cancer cell growth, migration, invasion and metastasis. At present, no treatment that provide either sufficient response rates or a significant prolongation of overall survival are available for melanoma. In the last decade, several inhibitors of RTK (RTKi) have been developed for the treatment of cancer, however, a number of short-comings was observed. Therefore, novel TK inhibitors with improved selectivity were developed for the treatment of diseases associated with KIT activation. Masitinib (AB1010), a RTKi capable of blocking selectively KIT, is one such new drug. Using B16 melanoma subcutaneous graft on C57Bl6 mice, we demonstrate that Masitinib is able to limit tumor growth in vivo and increase mice survival. This anti-tumoral effect was not observed for other RTKi targeting KIT. Suprisingly, Masitinib has no effect on melanoma proliferation in vitro, suggesting instead that modulation on tumor environment takes place. Indeed, mast cells that accumulate in the tumors secrete several biologically active factors involved in the modulation of tumor growth. In vivo, Masitinib treatment completely abrogates mast cell maturation and migration resulting in decreased tumor invasion and down-regulation of several angiogenic factors. Using a mouse line deficient for mast cells (Wsh/Wsh), we confirmed that Masitinib effect is in part dependent of its inhibition on mast cell migration and maturation. Indeed, additional effect occurs on macrophage polarization leaning from tolerogenic toward anti-tumoral phenotype. Furthermore, in vivo macrophage depletion favored tumor promotion and reverses Masitinib effect on tumor growth. The results provided by this study suggest that Masitinib may be a useful therapy on melanoma by its dual role on tumor environment. It can block mast cell maturation and infiltration in the tumor site, avoiding the angiogenic effects of mast cells. It can revert tumor tolerent macrophage status leading to an increased inflammatory activity within the tumor microenvironment.These effects are not observed only on melanoma, but also on other types of cancer, suggesting the cellular mechanisms triggered by Masitinib occur in various tumoral process. For instance, a phase III clinical trial with Masitinib as GIST treatment is currently ongoing.']",
        "Doc_id":"AACR_2016-4868",
        "Doc_title":" Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma",
        "_version_":1606189010994069504},
      {
        "Meeting_name":" Genomic classification of cutaneous melanoma",
        "Background":"['We describe here the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 resected primary and/or metastatic melanomas from 331 patients. We establish a framework for genomic classification based on the pattern of the most prevalent significantly mutated genes into one of four subtypes', ' mutant BRAF, RAS, NF1, and Triple-WT (wild-type). Integrative analysis reveals enrichment of mutations in KIT, focal amplifications and complex structural rearrangements as a feature of the Triple-WT subtype. We find no significant outcome correlation with genomic classification, but samples assigned to a transcriptomic subclass enriched for immune gene expression are significantly associated with improved patient survival. That favorable prognosis of the immune transcriptomic subclass is associated with high LCK protein expression, a T-cell marker, and presence of lymphocyte infiltrate on pathology review. This clinicopathological and multi-dimensional analysis suggests prognosis of melanoma patients with nodal metastases is influenced by immunobiology of the tumor stroma, offering insights to further personalize therapeutic decision-making.']",
        "Doc_id":"AACR_2015-2972",
        "Doc_title":" Genomic classification of cutaneous melanoma",
        "_version_":1606189022381604864},
      {
        "Meeting_name":" Genomic diversity in established melanoma cell lines and human melanoma tumors.",
        "Background":"['Background', ' Melanoma progression is often associated with a mutation in the BRAF oncogene that promotes constitutive activation of the MAPK signaling cascade. Analysis of malignant transformation of melanocytes and melanoma progression frequently utilizes immortalized melanoma cell lines that propagated in the laboratory. We studied the diversity of genetic mutations in the MAPK pathway in established melanoma cell lines and compared it to that of human melanoma tissue samples. Methods', ' We screened 30 well-established human melanoma cell lines, the majority of which were derived from melanoma metastases at dermal or nodal locations, for 85 mutations found within the AKT1, BRAF, KIT, KRAS, HRAS, NRAS, PIK3CA and PTEN genes by RT-PCR. We then interrogated 263 melanoma genomes available in the TCGA (The Cancer Genome Atlas) skin cutaneous melanoma dataset for the presence and frequency of these mutations. Mutational frequencies were determined by sorting the data in MS Excel. Results', ' BRAF was mutated in 39% of TCGA melanoma genomes and 53% of cell line genomes. NRAS genes were mutated in 26% of TCGA samples and 13% of cell lines. Cell lines were 34 times more likely to bear a KIT mutation than TCGA samples. Mutations in each of the 8 tested genes except PTEN were found in TCGA genome samples, while cell lines contained mutations in BRAF, KIT, NRAS, PTEN, and lacked any of the tested mutations in AKT1, KRAS, HRAS, PIK3CA. Cell lines exhibited a higher frequency of unique mutational combinations. Both BRAF and KIT were mutated in 13% of cell lines, and each of NRAS and KIT; NRAS and PTEN; and NRAS, BRAF and PTEN in 3.3% of cell lines; all these combinations were absent in TCGA melanoma genomes. Mutations in PIK3CA combined with either BRAF or NRAS were found in 1% of TCGA samples but absent from cell lines. Conclusions', ' These data indicate that mutational status and frequency of individual mutations and mutation combinations found in melanoma cell lines can diverge from that observed in clinical tissue specimens. Additional changes observed in cell lines may provide insight into evolutionary mutations in progressive melanoma. Understanding of genetic profiles of cell lines may provide additional information in their sensitivity to pathway inhibitors.']",
        "Doc_id":"ASCO_171467-176",
        "Doc_title":" Genomic diversity in established melanoma cell lines and human melanoma tumors.",
        "_version_":1606189003853266944},
      {
        "Meeting_name":" KIT melanomas are developmentally racially biased",
        "Background":"['KIT is a critical pathway for melanocytic homeostasis and it is often down-regulated in cutaneous melanoma. However, KIT activation plays a critical role in a subpopulation of melanomas especially those in acral locations and melanomas on chronically sun damaged skin. We analyzed exome and RNAseq data from The Cancer Genome Atlas (TCGA) Network (321 cutaneous melanomas in the data set) to identify patterns unique to KIT activation. The melanomas were divided based on known mutually exclusive mutations (BRAF, NRAS and KIT) vs those without (WT). We compared RNA data between each group. KIT group had significantly higher expression of KIT than BRAF, NRAS and WT (p<0.01, FDR<0.01) and isoform 2 expression was higher than 1. KIT melanomas were found to overexpress Wnt pathway, pigmentation and genes involved epithelial-mesenchymal transition. From the exome data, germline SNPs with incidence in ethnic groups (Caucasian, Asian and African) and more likely to be present in a specific melanoma groups were selected. Comparing the 3 ethnicity groups across the 4 tumor groups Asian SNPs were significantly enhanced in KIT tumors, African in WT and Caucasian in BRAF and NRAS melanomas. We evaluated the tumors for the primary type of genetic damage. The three signatures that appeared most divergent were CC>TT for UV, (G/A)C(G)>(G/A)T(G) for deamination, and G>T for oxidative damage. UV and deamination appeared inversely proportional, while oxidative damage appeared to be independent of those other two features. KIT and WT had a greater% of non UV high deamination tumoral environments. A fraction of these tumors also had very high oxidative signatures. We then compared 2 KIT subgroups UV vs non UV (absence of CC>TT mutations) for germline ethnicity differences. Asian SNPs were highly increased in non UV subgroup whereas Caucasian SNPs were in UV subgroup. Further, we divided KIT non UV subgroup into deamination and oxidative damage subgroups and compared ethnicity differences. Deamination was significantly higher in Asians whereas oxidative damage was higher in Caucasians. A similar analysis was done to the WT group, where African SNPs were significantly increased in the non UV subgroup and were primarily associated with oxidative damage. This data implies that KIT mutant melanomas develop in a unique genetic and mutational environments and makes this an ideal system to in which study racial disparities at the molecular level.']",
        "Doc_id":"AACR_2016-4510",
        "Doc_title":" KIT melanomas are developmentally racially biased",
        "_version_":1606189040239902720},
      {
        "Meeting_name":" C-Kit isoforms predict melanoma drug sensitivity.",
        "Background":"['The receptor tyrosine kinase c-Kit is an essential regulator of melanocyte and melanoma development. Alternative splicing of c-Kit produces one long variant, c-Kit(+), with a tetrapeptide GNNK located in the extracellular juxtamembrane domain, and one short variant, c-Kit(-), which lacks this sequence.In this study we characterize for the first time the function of the GNNK tetrapeptide sequence in melanoma. Our results show that step by step elimination of the GNNK tetrapeptide gradually increases receptor tyrosine phosphorylation, ubiquitination and downstream MAP kinase ERK activation. Successively increasing insert length, progressively leads to reduced melanoma cell survival during dacarbazine or rapamycin drug treatment. Our results indicate that the ratio between c-Kit isoforms might be useful as a prognostic marker for melanoma drug response.']",
        "Doc_id":"AACR_2013-5245",
        "Doc_title":" C-Kit isoforms predict melanoma drug sensitivity.",
        "_version_":1606189004167839744},
      {
        "Meeting_name":" Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P).",
        "Background":"['Background', ' Point mutations in the KIT receptor tyrosine kinase gene have recently been identified in melanomas from mucosal, acral lentiginous (AL), and chronically sun-damaged (CSD) sites. An improved understanding of the molecular characteristics of melanoma-prevalent KIT mutations may lead to more effective therapeutic approaches. Methods', ' Human melanoma cell lines were screened by mass-spectroscopy based genotyping for KIT mutations, and a cell line with an endogenous L576P KIT mutation was identified. The cell line was treated in vitro with a panel of small molecule KIT inhibitors and the effects on cell viability were quantified. Molecular modeling of the interaction of the inhibitors with the KIT L576P mutant protein was determined to estimate binding affinity. PET/CT studies were performed on patients with mucosal melanoma harboring the L576P mutation pre- and post-dasatinib treatment. Results', ' We have identified the first human melanoma cell line with an endogenous L576P mutation, the most common KIT mutation in melanoma. In vitro testing demonstrated that this cell line is resistant to imatinib, nilotinib and sorafenib (0 - 1 uM), KIT inhibitors shown to be effective in non-melanoma cells with other KIT mutations. However, the mutant cell line was inhibited by dasatinib at concentrations as low as 10 nM, and was significantly more sensitive than melanoma cell lines with wild-type KIT (p = 0.02). No difference in sensitivity to Src inhibitors was observed, supporting that this sensitivity was due to KIT inhibition. Molecular modeling demonstrated that the L576P mutation induces structural changes in KIT that reduce the affinity for imatinib but not for dasatinib. Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction and elimination of tumor FDG- avidity by PET imaging after dasatinib treatment. Conclusions', ' This data supports that dasatinib has a selective inhibitory effect against the most common KIT mutation in melanoma and has implications for the development of AL, CSD, and mucosal melanoma treatment.']",
        "Doc_id":"ASCO_31944-65",
        "Doc_title":" Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P).",
        "_version_":1606188997020745728},
      {
        "Meeting_name":" Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma.",
        "Background":"['Background', ' To investigate the possible relationship between sunitinib response and KIT mutation as well as KIT expression. Methods', ' We find that a 75-year male patient with KIT-mutated metastatic mucosal (primary', ' nasal, metastasis', ' left adrenal gland, lungs and right eye) melanoma has a very good response to sunitinib 37.5mg/d consecutively. We apply IHC sp assay to detect S100, HMB-45, CD117, VEGFR, PDGFR and EGFR in the melanoma sample of this patient. DNA is also extracted from paraffin-embedded melanoma sample of this patient and PCR is carried out to amplify several exons of C-KIT (exon11,13,17,18),B-RAF(exon11, 15) and N- RAS(exon1, 2). PCR products are sent to be directly sequenced. Clinical response, PFS and OS of the patient are evaluated. Results', ' Strong expression of S100, HMB45, CD117, VEFGR and PDGFR is detected by IHC in the tissue sample of the patient. Furthermore, direct sequencing after PCR reveals that V559A substitution is detected in exon 11 of KIT, with mutation of T into C at 1776, leading to substitution of Valine by Alanine at 559. No mutation was detected in exon 9, 13, 17, 18 of KIT, B-RAF15, 11 or N-RAS1, 2. The patient received sunitinib 37.5mg/d from July 2008 consecutively and evaluated PR (Recist', ' tumors shrink 70%) lasting for 5 months with Grade II myelosuppression and stomatitis. Now the patient is still alive and received sunitinib. Conclusions', ' Our case report suggests that response of melanoma patients to sunitinib might be correlated to KIT mutation and expression, and large-scale clinical trial in patients with KIT mutation and over-expression might be useful to shed light on treatment of melanoma patients with individual targeted therapy.']",
        "Doc_id":"ASCO_32579-65",
        "Doc_title":" Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma.",
        "_version_":1606189028727586816},
      {
        "Meeting_name":" Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events.",
        "Background":"['Background', '    To date, little is known about how primary melanomas clonally evolve to distant metastases, including brain, and how driver mutations are selected during melanoma progression. To identify new driver and clonal evolution genetic events beyond the known mutations in BRAF/NRAS, we performed WEPS of same-pt PEB.   Methods', '    DNA from tumor (T) and adjacent normal (AN) was extracted from macrodissected tissue slides. DNA libraries were captured using Agilent SureSelect Human All Exon v4 and sequenced at 2x48 bp. Variant calling was performed on T vs. matched AN using VARSCAN (default settings). Single nucleotide variations (SNV) were filtered using prior knowledge (COSMIC). We report only genes having probably or possibly damaging non-synonymous SNV (PolyPhen2 score >  0.45) by ANNOVAR analysis and nonsense mutations. Focused analysis for gene copy number alterations previously described in melanoma was performed using our previously published NGScopy package (Bioconductor). We considered analysis for gene copy number alterations if median coverage depth >  20X. We computed T/AN copy number ratio at the gene against the chromosome level.   Results', '     To date, 4 pts with all four tissues (PEB-AN) have been analyzed. Mean coverage depth was 68X and read quality was 37. 85% of reads were uniquely mapped. The 10 most frequently mutated genes across all 12 T samples were APC, ARID1A, CDKN2A, EGFR, FBXW7, KIT, KMT2C, NF1, PTEN, and TET2 (FDR <  0.0001). NF1 mutations were present in all T from 4 pts. All T from 3 out of 4 pts had mutations in BRAF (2 with confirmed V600E), PTEN, IDH2, TET2, CCDC6, PCSK7, and members of the ARID and KMT2 gene family. Both metastatic T from 2 pts had mutations in TRIM27, NCOA1, BCL6, and BCL10 that were not present in primary. All T from 2 pts and all T from one pt had >  30% amplification of the KIT and KDR genes, respectively.   Conclusions', '     Aggressive melanoma bears known mutations in signaling pathways that coexist with mutations in genes associated with chromatin modification, histone/nucleotide methylation, and metabolism. Identifying such mutations in primaries may predict future prognosis.']",
        "Doc_id":"ASCO_143715-156",
        "Doc_title":" Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events.",
        "_version_":1606189009564860416},
      {
        "Meeting_name":" A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas",
        "Background":"['Background', ' Pre-clinical studies report a critical role of c-KIT mutations in some mucosal, acral, solar, and vulvovaginal melanomas. Clinical trials of KIT-directed therapy with imatinib and sunitinib demonstrated activity in these subtypes. Unlike other TKIs, dasatinib has activity in melanoma cell lines with the most common KIT mutation at exon 11L576P. E2607 assessed the efficacy of dasatinib in treatment-nave or previously-treated patients (pts) with unresectable melanoma of these subtypes. Methods', ' Pts were assigned to receive dasatinib 70 mg PO twice daily with adjustment for toxicity. The primary objective for this two-stage phase II trial was response rate (RR', ' RECIST). Stage I was open to KIT mutated (KIT+) and wild-type (KIT-) tumors with mucosal, acral, and solar melanomas (n = 57). Depending upon the interim analysis, stage II would be for pts with KIT+ (n = 30) tumors; to enrich for KIT+, vulvovaginal was added and solar melanomas removed. Secondary objectives included progression-free survival (PFS), overall survival (OS), and safety. Results', ' From May 2009 to Dec 2010, 57 pts were accrued to stage I. These data were presented at ASCO 2012. Three pts had KIT+ tumors, with 13.2+ months (mo) as the longest OS. Stage II opened in Nov 2011, accrued 24 pts with KIT+ tumors, and closed in Dec 2015 due to slow accrual. Six pts had mucosal (25%), 9 acral (37.5%), and 9 vulvovaginal melanomas (37.5%). As of Jan 2016, 16/24 have progressed (median PFS', ' 4.0 mo, 95% CI', ' 1.3-25.0) and 14/24 died (median OS', ' 12.3 mo, 4.5-29.7). Among 10 surviving pts, median follow-up is 15.2 mo (0.5-36.1 mo). Of 17 pts from stage II with mature response data, 4 had partial response (PR', ' 23.5%), 6 stable disease (35%), 5 progression (29.5%), and 2 were unevaluable (12%). Grade III (11/23', ' 48%) treatment-related toxicities were fatigue, (5 pts), anemia (3 pts) and dyspnea (2 pts). One pt had grade IV dyspnea. Conclusions', ' E2607 is closed to accrual, and finalized results, including type of KIT mutation and durations of disease control from stages I and II will be presented. Among pts with these KIT+ melanoma subtypes, dasatinib is an active agent. Clinical trial information', ' NCT00700882']",
        "Doc_id":"ASCO_168490-176",
        "Doc_title":" A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas",
        "_version_":1606188993818394624},
      {
        "Meeting_name":" Genomic characterization of acral lentiginous melanoma",
        "Background":"['Background', ' Acral lentiginous melanoma (ALM) is a histologic subtype of melanoma with distinct clinical and biological features compared to common cutaneous melanoma. KIT alterations have been implicated as oncogenic drivers, yet phase II trials of KIT inhibitors in advanced ALM demonstrate limited clinical efficacy. Identification of effective targeted treatment strategies remains a challenge given the limited existing data on the molecular underpinnings of ALM. Methods', ' We examined a cohort of ALM patients enrolled in NYUs melanoma biorepository to identify genetic alterations underlying ALM. Whole exome sequencing (WES) was performed in a discovery cohort on genomic DNA extracted from fresh-frozen ALM tumors and matched whole blood. RNA sequencing (RNAseq) data were then incorporated with WES to increase confidence in identifying recurrent nonsynonymous somatic mutations. Genes with recurrent mutations were examined in an independent validation cohort using target capture probes. Results', ' In the discovery cohort (n = 8), we identified recurrent somatic mutations in known cancer-related genes, in addition to KIT and NF1, involving', ' metabolism (GPAT2), epigenetic regulation (EZH2), and growth factor receptors (FGFR2). We also identified 10 genes with recurrent somatic mutations not previously catalogued in COSMIC and validated by RNAseq, some of which involve', ' cytokinesis (CNTROB), metabolism (SLC13A3), NF-kappaB signaling and cell death (CARD14), tumorigenesis (KIAA1109) and neuronal regulation (TENM3). Targeted sequencing of these genes in the validation cohort (n = 26) confirmed the incidence of somatic mutations in CNTROB (15%), SLC13A3 (8%), CARD14 (11%), KIAA1109 (23%) and TENM3 (23%). Conclusions', ' We identified genes involved in metabolism that have recurrent mutations in ALM tumor samples. These findings may support a role for targeting metabolic pathways in ALM. The highest confidence mutations have been prioritized for in vitro functional assays to test their candidacy as impactful drivers with potential for future targeted therapeutic approaches.']",
        "Doc_id":"ASCO_164474-176",
        "Doc_title":" Genomic characterization of acral lentiginous melanoma",
        "_version_":1606188993240629248},
      {
        "Meeting_name":" Whole genome and RNA sequencing reveal the distinct genomic landscape of acral melanoma.",
        "Background":"['Background', ' Acral melanoma is a common subtype of melanoma in Asians with extremely poor prognosis, and therapy strategy has not been clearly established for acral melanoma. The aim of this study is to perform genomic and RNA profiling of acral melanoma to obtain the comprehensive genomic view of this subtype of melanoma. Methods', ' Genomic DNA was extracted with Qiagen DNeasy Blood or Tissue Kit . DNA libraries were prepared using a CancerPROTM-P88 BOX library Prep kit and sequencing was performed using the Illumina HiSeq X10. RNA was isolated with Qiagen RNeasy mini-spin column. cDNA was synthesized from total RNA using the SuperScript III first-strand synthesis system . RNA libraries were prepared using the NEBNext Ultra II Directional RNA Library Prep Kit and sequencing was performed using the Illumina HiSeq X10. Results', ' To obtain a comprehensive genomic and functional genomic view of acral melanoma, we sequenced the genomes of 14 acral melanoma and transcriptomes of 11 of these melanoma samples. We found a new mutation in the V28 codon of BRAF in three patients. Furthermore, we identified recurrent non-synonymous single nucleotide variants in previously described oncogene NRAS, as well as in genes encoding keratin associated proteins (KRTAP4-7, KRTAP4-5) and mucin (MUC2, MUC21). Notably, a recurrent noncoding hotspot mutation was discovered in 4 of 11 cases. By analyzing the RNA sequencing data, we found significant divergence on transcriptome between patients with or without ulcer. In total, we identified 201 genes were significantly up-regulated and 386 genes significantly down-regulated in acral melanoma patients with ulcer. Differentially expressed genes were enriched in pathways associated with cancers, melanogenesis, cell death signaling, skin diseases, etc. Conclusions', ' Our study reveals potentially different driver mutations and distinct transcriptome in acral melanoma patients compared with cutaneous melanoma patients and sheds lights to the further personalized medicine for acral melanoma patients.']",
        "Doc_id":"ASCO_189273-199",
        "Doc_title":" Whole genome and RNA sequencing reveal the distinct genomic landscape of acral melanoma.",
        "_version_":1606189012706394112},
      {
        "Meeting_name":" BRAF mutation and PD-L1 expression in melanoma",
        "Background":"['Background', ' BRAF mutation and PD-L1 expression appear independent in melanoma. We have established that PD-L1 clones 22C3 and 28.8 show almost identical results. In this study we correlated between BRAF mutation and PD-L1 expression as detected by 22C3/28.8 and SP142 in melanoma clinical samples. Methods', ' Melanoma samples were tested for PD-L1 expression and BRAF mutation. IHC testing for PD-L1 22C3 or 28.8 were tested using FDA-approved kits as recommended. Testing with SP142 (Spring Biosciences; LDT) was performed using standard techniques. BRAF testing in combination with SP142 PD-L1 testing was performed using next generation sequencing covering exons 11 and 15. Samples tested with 22C3 and 28.8 clones were tested using FDA-cleared BRAF kits (Cobas, Therascreen) testing V600 only. Results', ' 68 samples were tested for PD-L1 expression with clone 22C3, 67 with 28.8, and 56 with SP142. There was no overall statistical difference between the three clones in PD-L1 expression (P = 0.41). For combined 22C3 and 28.8, 61 of 135 cases (45%) had PD-L1 expression and 31 (23%) had BRAF mutation detected using FDA kits (V600). There was no statistical correlation between PD-L1 expression and BRAF mutation in this group (P = 0.9) at any cut-off. In cases tested with SP142 clone, BRAF mutation was detected in 31 cases (55%) by NGS, higher than using the FDA kit (P < 0.0001). In V600 mutations by NGS, 14 cases (25%) were positive, similar FDA kits. In SP142 cases, PD-L1 was positive in 45% of cases. There was no correlation between BRAF mutation and PD-L1 using SP142 expression as a continuous variable (P = 0.59) or cut-off points of 5% or 50%. When cut-off of 20% was used, significant inverse correlation with BRAF mutation (P = 0.004) was identified and was maintained if V600 codon only was evaluated. Conclusions', ' There is no correlation between BRAF mutation and PD-L1 expression as detected using clones 22C3 and 28.8. With SP142, a negative correlation between PD-L1 expression and BRAF mutation is identified with a 20% cut-off. The rate of BRAF mutations practically doubles when NGS is used and exons 11 and 15 are included in the testing, in contrast to FDA approved testing.']",
        "Doc_id":"ASCO_190785-199",
        "Doc_title":" BRAF mutation and PD-L1 expression in melanoma",
        "_version_":1606188970297786368},
      {
        "Meeting_name":" Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.",
        "Background":"['Background', ' Therapeutics for metastatic acral melanoma have not been successfully established. This study aims to investigate gene aberrations of CDK4 pathway in acral melanoma and evaluate the potential application of CDK4 inhibitors in targeted therapy of acral melanoma. Methods', ' A total of 428 cases of primary acral melanoma samples were included. The copy number variations of CDK4 pathway-related genes, including CDK4, CCND1 and p16INK4a, were examined by QuantiGenePlex DNA Assay. The aberrations of these genes were further correlated with the clinicopathological features of patients. And the sensitivity of established cell lines and patient-derived xenograft (PDX) models containing typical CDK4 aberrations to CDK4 inhibitors was also analyzed. Results', ' Among the 428 samples, 173 cases (62.0%), 117 cases (27.3%) and 265 cases (62.0%) showed CDK4 amplification,CCND1 amplification and p16INK4a loss respectively. Moreover, 36.4% of acral melanomas contained more than two simultaneous aberrations of these three genes, and 9.1% of the samples contained three aberrations. The frequency of acral melanomas that contain at least one aberrations in CDK4, CCND1 and p16INK4a was about 84.1%. The median survival time for acral melanoma patients with simultaneous CDK4 amplification and p16INK4a losswas significantly shorter than that for patients without CDK4 amplification and p16INK4a loss(P = 0.003). In acral cells with concurrent CDK4 amplification and p16INK4a loss, concurrent CCND1 amplification and p16INK4a loss, AT7519 and PD033299l dramatically inhibited the cell proliferation. AT7519 and PD033299l also abrogated tumor growth in a PDX model with concurrent CDK4 amplification and p16INK4a loss. Conclusions', ' It is the first study indicates that CDK4 pathway aberration is predominant in acral melanoma (more than 80%). The acral melanoma cells and PDX model containing CDK4 pathway aberration are sensitive to CDK4 inhibitors, thus providing key evidence for the significance of CDK4 inhibitors for acral melanoma and facilitating the establishment of strategy for targeted therapy to acral melanoma.']",
        "Doc_id":"ASCO_167622-176",
        "Doc_title":" Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.",
        "_version_":1606189011179667457},
      {
        "Meeting_name":" Cross-platform comparison of techniques to detect BRAF mutations in circulating tumor DNA of melanoma patients.",
        "Background":"['Background', ' Circulating tumor DNA is an alternative source of tumor DNA that could be used for noninvasive identification of BRAF mutations at various time-points during the course of the disease. The main objective of our work was to compare the performance of several assays to detect mutant BRAF in plasma. Methods', ' A total of 54 patients with stage IIIc-IV melanoma (38 BRAF V600 mutated and 16 BRAF wild type) were tested prior to any treatment. Blood samples were collected in EDTA-containing tubes. Cell-free DNA was extracted from plasma using the QIAmp Circulating Nucleic Acid (Qiagen). We evaluated 3 technologies ', ' 2 assays based on allele-specific PCR, the Therascreen BRAF RGQ kit (Qiagen) and the ctBRAF Mutation Detection Kit (Entrogen), and a digital PCR platform, the QuantStudio 3D system (Life Technologies). Results', ' Using the Therascreen assay, we were able to detect a BRAF mutation in plasma of 28/38 patients, yielding a positive percent agreement (PPA) of 73.7% when compared with tumor as the reference sample. Similar results were obtained using the Entrogen assay, with a PPA of 68.4% (26/38). The 2 most common activating mutations, V600E and V600K, had a similar PPA with both Qiagen and Entrogen tests. For all patients with wild type BRAF tumors, the research was negative on plasma DNA with both techniques (negative percent agreement, NPA = 100%). The QS3D digital PCR system concluded on the presence of a BRAF mutation in only 20/34 samples (PPA = 58.8%) mostly because of an insufficient number of circulating DNA copies to reach a relevant statistic value. Conclusions', ' The Qiagen and the Entrogen assays are based on allele-specific amplification, a technique easy to use without a specific training, unlike dPCR which requires specific equipment and training to acquire technical and interpretation skills. The unexpectedly low PPA of dPCR was attributed to the limited amount of DNA extracted from some samples. These findings suggest that the Qiagen and Entrogen plasma tests are more adapted as a screening tool for non-invasive assessment of BRAF mutation in metastatic melanoma but could be complemented with dPCR as an absolute quantification tool for follow-up. Supported in part by a grant from Roche Pharma.']",
        "Doc_id":"ASCO_164844-176",
        "Doc_title":" Cross-platform comparison of techniques to detect BRAF mutations in circulating tumor DNA of melanoma patients.",
        "_version_":1606188978050957312},
      {
        "Meeting_name":" KIT/D816V induces SRC-mediated tyrosine phosphorylation of MITF and altered transcription program in melanoma",
        "Background":"['The oncogenic D816V mutation of the KIT receptor is well characterized in systemic mastocytosis and acute myeloid leukemia. Although KITD816V has been found in melanoma, its function and involvement in this malignancy is not understood. Here we show that KITD816V induces tyrosine phosphorylation of the microphthalmia-associated transcription factor (MITF) through a triple protein complex formation between KIT, MITF and SRC family kinases. In turn, phosphorylated MITF activates target genes that are involved in melanoma proliferation, cell cycle progression, suppression of senescence, survival and invasion. By blocking the triple protein complex formation, thus preventing MITF phosphorylation, the cells become hypersensitive to SRC inhibitors. We have therefore delineated the mechanism behind the oncogenic effects of KITD816V in melanoma and provide a rationale for testing SRC family kinase inhibitors to treat KITD816V-transformed melanomas.']",
        "Doc_id":"AACR_2016-1127",
        "Doc_title":" KIT/D816V induces SRC-mediated tyrosine phosphorylation of MITF and altered transcription program in melanoma",
        "_version_":1606189011890601984},
      {
        "Meeting_name":" Skp2, a prognostic marker and potential therapeutic target in metastatic melanoma.",
        "Background":"['Background', ' Skp2, a known oncogene, is overexpressed in several types of tumors and is associated with worse recurrence rate and overall survival in primary melanoma patients. Moreover, the anti-proliferative effects of Skp2 siRNA on various tumor cell lines have prompted the preclinical testing of Skp2 small molecule inhibitors. In this study, we assessed the clinical relevance and molecular mechanism(s) underlying Skp2 overexpression in metastatic melanoma patients. Methods', ' Skp2 protein levels were measured in 122 metastatic melanoma specimens using immunohistochemistry (IHC), and the association between Skp2 overexpression and post-recurrence survival was examined. Moreover, 22 cell lines (2 normal primary melanocytes, 2 primary immortal melanocytes, 4 primary melanoma cell lines, and 18 metastatic melanoma cell lines) were evaluated for Skp2 genomic amplification using Single Nucleotide Polymorphism (SNP) arrays (Affymetrix 6.0) and Skp2 gene expression using mRNA arrays (Affymetrix U133A 2.0) and quantitative RT-PCR. We also screened 18 cell lines for Skp2 mutation by sequencing. Results', ' Skp2 overexpression, defined as >25% tumor cells, was associated with shorter 3-yr post-recurrence survival (37%) compared to Skp2 expression 25% (55%) (HR=1.89, 95%, CI= 1.04, 3.42, p=0.04). Skp2 overexpression was significantly associated with the site of melanoma metastasis', ' visceral (n= 12; 89%), lymph node (n=49; 36%), brain (n=15; 14%), and soft-tissue (n=36; 6%) (p<0.001). SNP array revealed genomic amplification at the Skp2 locus in 6 (33%) metastatic cell lines and one primary melanoma cell line. Skp2 genomic amplification was associated with increased transcript expression. No Skp2 mutations were identified. Conclusions', ' Skp2 protein overexpression is associated with worse prognosis in metastasis in melanoma. Our results also support that gene amplification, rather than a Skp2 gene mutation, may be the major mechanism responsible for Skp2 aberrant expression in metastatic melanoma.']",
        "Doc_id":"ASCO_31365-65",
        "Doc_title":" Skp2, a prognostic marker and potential therapeutic target in metastatic melanoma.",
        "_version_":1606188993920106496},
      {
        "Meeting_name":" A phase II trial of dasatinib in advanced melanoma.",
        "Background":"['Background', ' Direct or indirect inhibition of Src kinases (non-receptor tyrosine kinase signaling intermediates) reduces melanoma cell proliferation in vitro. Dasatinib is a well tolerated, small molecule inhibitor of src kinase family members c-Src, c-Yes, Lck, and also inhibits c-KIT, PDGFR and EPHA2. We initiated a CTEP-sponsored phase 2 trial of dasatinib in melanoma to assess response rate, PFS and toxicity. The secondary objective is to evaluate the association between clinical response and expression of dasatinib targets in tumors obtained pre-treatment. Methods', ' Adults with stage III/IV unresectable melanoma with a PS of 0- 1, who have not received prior chemotherapy are eligible. Dasatinib was administered at 100mg PO BID continuously to the first 18 patients. Subsequently, the starting dose was decreased to 70mg BID. Cycles are 4 weeks, tumor assessments occur q2 cycles. Results', ' Thirty patients have been accrued, five are too early to evaluate. Five, four and three patients had acral-lentiginous, ocular or mucosal primaries, respectively. Median age was 62, M', 'F 18', '12, six received prior non-cytotoxic therapy. Three patients had confirmed partial responses lasting 16, 6, and 5 months, and one had a non-confirmed partial response, progressing after 4 cycles. One patient had a minor response and remains on study after 24 cycles. A patient with an exon 13 mutation in c-KIT responded to therapy, while another with a c-KIT exon 11 deletion mutation did not. Common toxicities are grade II fatigue, grade II-III dyspnea and pleural effusions. Chronic toxicities required reduction of the starting dose, and have been observed in all patients on dasatinib for over two months, all of whom required two dose reductions. Conclusions', ' Daily dasatinib has modest activity in melanoma. Accrual is almost complete. Toxicities are frequent, alternate schedules providing breaks in dosing might be better tolerated and should be evaluated. Combination studies may be warranted based on preclinical evaluation in molecularly defined subsets of patients.']",
        "Doc_id":"ASCO_31811-65",
        "Doc_title":" A phase II trial of dasatinib in advanced melanoma.",
        "_version_":1606189031845003264},
      {
        "Meeting_name":" Vemurafenib-induced RhoB expression leads to melanoma cell resistance.",
        "Background":"['Most of melanoma harbour mutations leading to the constitutive activation of the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway (i.e', ' activating mutations of BRAF, NRAS, c-KIT). Addiction of melanoma to the MAPK pathways led to the development of inhibitors targeting either mutant BRAF, such as Vemurafenib (PLX4032), or MEK. Melanoma treatment recently met a breakthrough with the clinical evaluation of Vemurafenib that demonstrated an unprecedented 80% response rate among patients with BRAF V600E melanomas treated with Vemurafenib, but rapidly limited by drug resistance, which still requires to be elucidated.The MAPK pathway regulates the expression of many genes which can mediate therapeutic response but also resistance, such as RhoGTPases. We analysed the mRNA expression of the RhoGTPases in two BRAF mutated melanoma cell lines, WM266-4 and A375, in response to inhibition of the MAPK pathway by PLX4032. We observed that the mRNA of RhoB was increased by PLX4032 treatment. This result was confirmed in many other BRAF mutated melanoma cell lines by inhibition of the MAPK pathway with BRAF inhibitors (PLX4032 or SB-590885) as well as MEK inhibitors (AZD6244 or AS703026). MEK inhibitors (AZD6244 or AS703026) upregulate RhoB in BRAF wild-type melanoma cells harbouring N-Ras, K-Ras or c-KIT mutation suggesting that inhibiting MAPK pathway is critical for RhoB expression modulation. It is noteworthy that this modulation is cell type dependent, while it was not found in BRAF mutated non-melanoma cells as colon carcinoma cells (Colo205 and RKO).To investigate the role of RhoB induction in cellular responses to BRAF and MEK inhibitors, the RhoB induction was suppressed using RNA interference. The cells treated with siRNA targeting RhoB, WM266-4 and A375 cells, were more sensitive to PLX4032 and AZD6244. Moreover the blockade of RhoB induction led to a significant increase of PLX4032-induced apoptosis as shown by the increase of the subG1 population and PARP cleavage.Our findings show that RhoB upregulation is involved in PLX4032 response and both inhibitions of MAPK pathway and RhoB expression trigger cell death and should prompt a search for agents. Indeed co-targeting MAPK and RhoB pathways, could lead to a synthetic lethality and prevent resistance to either BRAF or MEK inhibitors. Ongoing work focuses on confirming this role in tumour-xenografted mouse models.']",
        "Doc_id":"AACR_2013-3401",
        "Doc_title":" Vemurafenib-induced RhoB expression leads to melanoma cell resistance.",
        "_version_":1606189008087416832},
      {
        "Meeting_name":" Identifying targets for melanoma therapy",
        "Background":"['Recurrent driver mutations in BRAF (V600), NRAS (G12/13, Q61), KIT (W557, V559, L576, K642, D816), GNAQ (Q209) and GNA11 (Q209) have previously been identified in malignant melanomas, but over one-third of cases have no known potentially actionable targets. To identify novel drivers, we performed whole-genome sequencing of a tumor-normal pair from a patient with an aggressive, chemotherapy-nave metastatic melanoma which was pan-negative for the mutations listed above. Our data analysis pipeline revealed the landscape of somatic single nucleotide polymorphisms (SNPs), insertions and deletions, copy number variations, and structural variants. A subset of the nonsynonymous SNPs was validated by direct sequencing, resulting in the identification of a somatic BRAF L597R mutation. Surrogate kinase assays suggest that this mutant is sensitive to both BRAF and MEK inhibitors. Subsequent mutational analyses showed that BRAF L597 mutations were in 2 of 34 (6%) pan-negative tumors. Collectively, these data demonstrate the frequency and potential therapeutic implications of BRAF L597 mutations in melanoma.']",
        "Doc_id":"AACR_2012-5102",
        "Doc_title":" Identifying targets for melanoma therapy",
        "_version_":1606188978300518400},
      {
        "Meeting_name":" Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma.",
        "Background":"['Background', ' The prognosis of metastatic uveal melanoma is poor; the median overall survival is reportedly less than 6 months. A significant proportion of metastatic uveal melanomas express C-kit receptors (CD117). They also produce stem cell factor. Autocrine stimulation through C-kit receptors might play a critical role in disease progression. Sunitinib is a multitargeted receptor tyrosine kinase inhibitor of C-Kit, vascular endothelial growth factor and platelets-derived growth factor receptors; therefore, sunitinib might be effective in treatment of metastatic uveal melanoma. Methods', ' Patients with stage IV uveal melanoma whose metastases have at least 10% C-kit expression were treated. The initial dose of sunitinib was 37.5 mg daily over a 28-day cycle. The treatment was continued until disease progression or grade 3 or greater toxicity after dose reduction to 25 mg. The primary objectives were assessment of safety and potential efficacy of sunitinib. Clinical response was evaluated every 8 weeks using RECIST criteria; toxicity was assessed every 4 weeks. Results', ' Twenty patients aged 29-78 years including 17 patients who received at least one previous treatment were enrolled. One patient had partial response (PR), 12 stable diseases (SD), 5 progressive diseases (PD), and 2 non- evaluable due to withdrawal before response assessment. The clinical benefit rate (CR+PR+SD) for intent-to-treat patients was 65.5%. Median overall and progression-free survivals were 8.2 months (range 0.9-33.8 months) and 4.0 months (0.6-29.2 months), respectively. Eight patients survived more than 12 months. Three patients have no PD for more than 12 months. The most common side effect was grade 1-2 fatigue, occurring in 90% of the patients. Eleven patients required a dose reduction to 25mg due to grade 3 adverse events', ' diarrhea (n = 2), fatigue (n = 3), pneumonia (n = 1), neutropenia (n = 1), cardiac dysfunction (n = 1), thrombocytopenia (n = 1), hand-foot syndrome (n = 1), and headache (n = 1). Patients who needed a dose reduction were able to maintain their best response with the lower dose. Conclusions', ' Sunitinib at 37.5 mg daily is a feasible treatment with an acceptable safety profile and potential efficacy in metastatic uveal melanoma.']",
        "Doc_id":"ASCO_51773-74",
        "Doc_title":" Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma.",
        "_version_":1606189006704345088},
      {
        "Meeting_name":" Gnaq/11 mutant uveal melanoma is susceptible to Brd4 inhibition by JQ1",
        "Background":"['Uveal melanoma (UM) represents the most common intraocular malignancy in the United States, and there are no effective treatments for this aggressive disease. Uveal melanoma is characterized by oncogenic mutations in Gnaq and Gna11, which activate the mitogen-activated protein kinase pathway (MAPK). Furthermore, both primary and metastatic UM are characterized by genetic abnormalities, including the amplification of the chromosomal arm 8q and monosomy of chromosome 3, which are significantly associated with poor prognosis. The oncogene MYC, which is located on 8q24.1, is amplified in nearly 70% of uveal melanoma, and is also regulated by the MAPK pathway. Chromatin regulators have become attractive targets for cancer therapy. In particular, the BET-bromodomain inhibitor JQ1 has shown selective inhibition of c-Myc expression, followed by the suppression of c-Myc-dependent target genes. We examined the effects of JQ1 in a panel of 8 UM cell lines, including cell lines with Gnaq/Gna11 mutations (92.1, Omm1.3, Mel270, Mel202, Omm1), a cell line with MYC amplification (Mel290), and cells without either mutation or amplification (C918, Mel285). The Gnaq/Gna11 mutant cells were the most sensitive to growth inhibition at nanomolar concentrations of JQ1 (IC50=200nM), followed by the cell line with amplified MYC (IC50=1M), while the cells without mutation or amplification exhibited little inhibition. We also examined the biochemical effects of JQ1 treatment, which caused a dose- and time-dependent suppression of c-Myc as well as survivin, XIAP, ERK1 and E2F1, while p21and the pro-apoptotic protein Bim were induced in all the cell lines. Interestingly, JQ1 also suppressed the anti-apoptotic protein Bcl-xL and induced PARP cleavage only in the Gnaq/Gna11 mutant cells. Flow cytometric analysis indicated a cell cycle arrest in G1 in all the cell lines and an apoptotic population in sub-G1in the mutant cells. Furthermore, treatment with JQ1 resulted in significant antitumor activity in mouse xenograft models of uveal melanoma with Gnaq mutation. All together, these observations support the evidence that JQ1 represent a promising therapeutic approach for uveal melanoma with Gnaq/Gna11 mutations.']",
        "Doc_id":"AACR_2014-1410",
        "Doc_title":" Gnaq/11 mutant uveal melanoma is susceptible to Brd4 inhibition by JQ1",
        "_version_":1606189029387141120},
      {
        "Meeting_name":" Triple negative (c-KIT, BRAF, NRAS) acral lentiginous melanoma in Hawaii",
        "Background":"['Background', ' Acral lentiginous melanoma (ALM) is the least common subtype among patients with melanoma. There is a higher preponderance in the minority population. A different pathogenesis has been proposed for ALM. Previous studies have profiled the importance of c-KIT, BRAF and NRAS mutations in melanoma treatment and prognosis. However, characterization of these somatic mutations in a specific non-Caucasian ALM population has not been reported. The Pacific Basin provides a unique opportunity to study diseases in diverse ethnic groups, including Pacific Islanders and Filipinos. We sought to determine the frequency of a triple negative genotype in our multi-ethnic cohort. Methods', ' IRB approval was obtained for this molecular analysis. From 1999 to 2011, 12 non-Caucasian patients (8-Filipino, 3-Pacific Islander and 1-Vietnamese) histologically confirmed to have ALM were evaluated at a tertiary institution. Data including age, gender, tumor location, Breslow thickness, Clark level, ulceration, regression, and mitoses per mm squared were compiled. Direct sequencing (c-KIT [Exons 8,9,11,13,17,18], NRAS [Exons 2,3]) and real-time PCR (BRAF [Exon 15]) was performed on formalin-fixed/ paraffin-embedded archived biospecimens (primary lesions). Results', ' Our findings demonstrated that 7/12 (58%) patients exhibited the triple negative genotype. Mutually exclusive somatic mutations (4 c-KIT and 1 BRAF) were identified in the remaining 5/12 (42%) patients. Those in the triple negative group trended toward a deeper Breslow thickness, when compared to those with a mutation (depth 4.73 mm vs. 3.07 mm). Demographics of the entire non-Caucasian cohort included a mean age of 72.0 years old (range 52-87) and male gender 6/12 (50%). Tumor location principally involved the foot 10/12 (83%); mean Breslow thickness was 4.04 mm (range 2.20-7.75), Clark IV or higher 11/12 (92%), ulceration 8/12 (67%), regression 12/12 (100%), and mean mitoses per mm squared was 5.71 (range 0-30). Conclusions', ' Non-Caucasian patients with ALM were found to have a high prevalence of the triple negative genotype. Those within that group appeared to have thicker tumors. Nearly half of our cohort had thick primary lesions with a high propensity for ulceration. This is the first study to our knowledge that has profiled somatic mutations (c-KIT, BRAF, NRAS) in a multi-ethnic population of ALM patients and examined the histologic correlates of a triple negative genotype. This novel concept highlights the relevance of alternate pathways and molecular targets, such as PI3KCA in prognosis and therapy.']",
        "Doc_id":"AACR_2012-3591",
        "Doc_title":" Triple negative (c-KIT, BRAF, NRAS) acral lentiginous melanoma in Hawaii",
        "_version_":1606188997979144192},
      {
        "Meeting_name":" Brazilian melanoma genome project",
        "Background":"['Melanoma is the most aggressive form of skin cancer with increasing prevalence in Brazil. The comprehensive molecular profiling of these tumors and the recent genomic classification has improved the knowledge of melanoma biology and foster the identification of potential clinical biomarkers. The aim of this project, as part of the International Cancer Genome Consortium (ICGC) is to perform a genomic profile by whole genome sequencing (WGS) of Brazilian melanomas patients. We reported the WGS using Illumina paired-end sequencing strategy (>30 X-fold coverage) of 66 cases (45% primary and 55% metastatic) and respective matched normal. Overall we observed an average of 46K mutations/genome. The most frequent type of substitutions identified were', ' C>T (22.5%), T>C (6.4%), T>G (4.4%), T>A (2.9%), C>A (2.8%) and C>G (1.7%). A significative difference between frequency of C>T substitutions was observed among histological subtypes, i.e., acral lentiginous (11.3%), nodular (31.2%) and superficial spreading (25.9%). Among the classic genes involved in melanoma biology, we found that 31.8% of patients had BRAF mutations, being the V600E the most frequent (82.6%). A total of 6.1% of patients had NRAS, 3.0% showed KRAS, one case (1.5%) showed HRAS, and 12.1% showed NF1 mutations. TERT promoter mutation (C250T) was found in 28.8% of patients. TP53 mutations found 4.5% and RB1 in 1.5% of cases. Oncogenic KIT and PDGFRA mutations were observed in 6.1%and 1.5%, respectively. BRAF, NRAS, HRAS, KRAS and NF1 mutation were mutually exclusive. BRAF and TERT mutations were significantly more frequent in superficial than acral lentiginous melanomas. We showed that Brazilian melanoma patients exhibit a high number of single mutations and a similar mutation profile to the one reported in other populations. Acral/lentiginous melanoma subtype, which is a common subtype in our setting, showed a distinct mutation frequency. Further analysis will extend to other relevant genes and will also include the study of additional genomes to reach the goal of genomic landscape of 100 Brazilian melanomas cases.']",
        "Doc_id":"AACR_2017-3386",
        "Doc_title":" Brazilian melanoma genome project",
        "_version_":1606188991779962880},
      {
        "Meeting_name":" Characterization of rare germline variants in somatically mutated melanoma genes in melanoma-prone families.",
        "Background":"['CDKN2A and CDK4 are the two major susceptibility genes for melanoma identified so far. However, these two genes only account for melanoma susceptibility in a small proportion of melanoma-prone families, suggesting the existence of other susceptibility genes. In addition, melanoma is among the tumors with the highest mutation rate and a large number of mutated genes have been identified that affect multiple key biological pathways. The goal of this study is to examine whether rare germline sequence variants and/or copy number variations (CNVs) in these genes may influence melanoma risk in melanoma-prone families without known CDKN2A/CDK4 mutations. Methods', \" We conducted exome sequencing in blood-derived DNA in 75 melanoma cases from 23 American melanoma families with 3 affected members. We evaluated rare non-synonymous variants, defined as allele frequency less than 0.1% reported in public databases (dbSNP, 1000 Genomes, or NHLBI's Exome Variant Server), in 37 genes (including BRAF, NRAS, KIT,PTEN, CDKN2A, GRIN2A, etc.) that are frequently mutated in melanoma. We also screened CNVs in these genes using data from the Nimblegen 3x720k exon-focused CGH tiling arrays, in which blood-derived DNA from 79 melanoma cases and 25 spouses were analyzed in the same mutation-negative families. We used the Nexus Copy Number built-in FASST2 algorithm to identify significant CNVs (significant threshold=0.000001; minimal number of probes per segment=5; log2 ratio>0.3 for gains and -0.3 for losses). Results\", ' We identified 10 rare variants in 10 genes that showed partial/complete co-segregation with disease and were absent in our internal controls (N400). Four of these variants occurred in all cases within their respective families and 3 of them were novel. We did not identify any disease-related CNVs in these genes except for a deletion in exon 1 of CDKN2A/ p14ARF in 6 out of 7 melanoma cases in one big family. Our findings suggest that rare variants in somatically mutated genes may confer susceptibility to melanoma risk in a subset of families. However, these variants need to be validated, checked for functional relevance, and evaluated in a large number of cases and controls to determine their role in disease susceptibility.']",
        "Doc_id":"AACR_2013-2553",
        "Doc_title":" Characterization of rare germline variants in somatically mutated melanoma genes in melanoma-prone families.",
        "_version_":1606188973479165952},
      {
        "Meeting_name":" Genomic profiling of melanomas of unknown primary.",
        "Background":"['Background', ' Approximately 2-10% of metastatic melanoma patients present without an identifiable primary melanocytic lesion. These melanomas of unknown primary (MUP) are clinically classified into stage III or stage IV based upon extent of spread of metastatic disease. Previous studies, evaluating MUP using a limited sequencing of BRAF, NRAS, and KIT, have shown a similar frequency of mutations as cutaneous samples. Methods', ' We identified and performed retrospective chart review on 43 patients treated at the University of Colorado who presented with a melanoma of unknown primary. We excluded patient who presented with a preceding pigmented lesion treated with excision or cryotherapy without a histological diagnosis. After informed consent, DNA was extracted from the tumor samples of these 43 patients. Whole exome sequencing (WES) was performed with exome capture on an Illumina HiSeq sequencer. Results', ' Our cohort showed a male predominance at 58.1%. The median age at diagnosis was 50.6 years. In our cohort, 93% were Caucasian, while 4.7% were Hispanic and 2.3% were of unknown ethnic origin. 9.3% of patient had a family history of melanoma. Sun exposure was documented in 39.5% of patients and its presence was associated with an increased survival (Median OS of 3.7 vs 1.3 years, p = 0.026). Patients with stage III melanoma had an increased survival (Median OS of 6.8 vs 1.3 years, p = 0.013). Genomic analysis showed mutational pattern similar to cutaneous melanoma with 50% harboring a BRAF mutation, 12% with an NRAS mutation, and 19% carrying an NF1 variant. We found mutational signatures for each tumor and classified each against a larger cohort of cutaneous, mucosal and acral melanomas. Conclusions', ' We present the genomic data of a large cohort of MUP. The mutational profile of MUP is consistent with other cutaneous melanomas.']",
        "Doc_id":"ASCO_190947-199",
        "Doc_title":" Genomic profiling of melanomas of unknown primary.",
        "_version_":1606189039194472448},
      {
        "Meeting_name":" Systematic analysis of circulating tumor DNA in melanoma patients to uncover mechanisms of resistance and disease clonality",
        "Background":"['Recent advances in targeted and immunotherapies have unlocked potent treatment options for malignant melanoma patients. However, targeted therapies are associated with limited response durations and only a fraction of patients benefit from immunotherapies. The analysis of circulating tumour DNA (ctDNA) provides a powerful tool for the continuous assessment of treatment responses in melanoma patients.We have established a robust pipeline for the serial, prospective analysis of ctDNA in melanoma patients. By combining next generation sequencing (NGS)- and droplet digital PCR (ddPCR)-based approaches we make ideal use of currently available technologies. To date, plasma samples from over 120 individuals have been collected, with follow-up times surpassing one year in many cases.For routine monitoring of patients commencing BRAF-mutant targeted therapies, pre-treatment DNA, derived from tumour biopsy or plasma, is tested to confirm the exact BRAF mutation and rule out pre-existing resistance-associated mutations using a custom NGS sequencing panel. Timely follow-up throughout treatment is achieved by measuring mutant BRAF fractions in ctDNA using ddPCR. When increasing BRAF variant allele frequencies are detected, additional ddPCR-based profiling for NRAS mutations and NGS-based re-sequencing for other resistance-associated mutations is initiated. We demonstrate superiority of ctDNA monitoring over LDH measurements and present a strategy to detect emerging resistant disease ahead of clinical scans in a cost-effective, timesaving and low technology way.In addition to the basic characterization of BRAF-mutant cases undergoing targeted therapy, we have used the analysis of ctDNA to uncover clonally distinct tumour sub-populations resulting in complex responses to treatment. For instance, we monitored a case of metastatic vaginal mucosal melanoma undergoing sequential targeted, immuno- and chemotherapy. Despite the presence of a KIT mutation in the primary tumour, response to KIT inhibitor imatinib was mixed. In the absence of tumour biopsies, we used whole exome-wide NGS of ctDNA to study the underlying mechanisms. This strategy revealed a KIT-mutant tumour sub-clone that responded to imatinib and a second sub-clone including an SF3B1 mutation that did not respond. The sub-clones also responded differentially to immunotherapies, but both responded to chemotherapy.The analysis of ctDNA is a powerful approach to monitor responses to systemic therapies in melanoma. By providing early warning of resistance and crucial information of clonal composition/evolution of the disease, ctDNA analysis has the potential to revolutionize the implementation of precision medicine.']",
        "Doc_id":"AACR_2016-469",
        "Doc_title":" Systematic analysis of circulating tumor DNA in melanoma patients to uncover mechanisms of resistance and disease clonality",
        "_version_":1606189027049865216},
      {
        "Meeting_name":" Genotyping melanoma in Colombia.",
        "Background":"['Background', '  Melanoma has high clonal heterogeneity which follows a geographical pattern. The advent of therapy involving BRAF-specific inhibitors has enabled many efforts at exploring these neoplasias genotype around the world, documenting V600E and V600K alterations in about 50% of affected patients born in the USA, Western Europe and Australia. Few studies have evaluated the presence of alterations in the BRAF and KIT in the Hispanic population, finding a frequency between 39 and 77%, and 0%, respectively.  Methods', '  216 patients were explored for BRAF (V600E/V600K), NRAS (exons 1 and 2) and cKIT (exons 9, 11, 13 and 17) mutations using sequencing and RT-PCR (COBAS) techniques, following confirmation of histology and micro-dissection. Several outcomes were recorded in 98 cases.   Results', '    median age was 55.4 years old on average (SD13.8), 62% were older than 50 when diagnosed and 112 cases (52%) were female. When ascertaining the origin of the tumors 30% of the melanomas were found in skin which had been chronically exposed to sunlight, 43.1% could not be typed, 13.9% were acral-lentiginous melanomas, 7.9% were primary mucosal melanomas and 0.5% were uveal tumours. Tumour representation in paraffin-embedded tissue was good (80%), the site from which the sample was taken was usually the skin (43%), lymph nodes (24%), soft tissues (7%) and the lungs (6.5%). Tumour stage was greater than III in 75% and unknown in the rest. BRAF mutation frequency was 32.5% (67/206), 8.4% (11/131) for cKIT and 6.9% (9/131) for NRAS. KI67 was greater than 20% in 57% (101/175); this finding was greater in patients suffering lesions in chronically-exposed skin (p=0.054) and in those carrying a BRAF mutation (p=0.038). Median follow-up was 14.5-mo (95%CI 4.0-42.0) and overall survival was 18-mo (95%CI 16.8-19.1). Survival was modified by Clark (p=0.036) but not by different genotypes.   Conclusions', '  The mutational profile of Colombian melanoma patients reported in this study differ with that described previously in other Western countries, especially for BRAF; however, such findings did agree with greater prevalence of mucosal and acral-lentiginous lesions.']",
        "Doc_id":"ASCO_135310-144",
        "Doc_title":" Genotyping melanoma in Colombia.",
        "_version_":1606189012875214848},
      {
        "Meeting_name":" Genomic signatures of melanoma maintenance",
        "Background":"['Melanoma is the malignant tumor of melanocytes and considered as one of the most aggressive human cancers. While the worldwide incidence rate of melanoma has increased during the last decade, current therapies for melanoma do not provide long-term effect. The highly heterogeneous expression signature of melanoma underlies the inefficient therapy and accentuates the inevitability of profound molecular understanding of melanoma, its maintenance and progression. In this study, we aimed to reveal the complex patterns of distinct molecular mechanisms underlying the progression and maintenance of melanoma using high-throughput sequencing technologies. Series of melanoma tumor tissues representing discrete stages of the malignant progression were deeply sequenced. Integrative analysis revealed hard-wired genomic aberrations and associated transcriptomic consequences. These genomic aberrations included clusters of oncogenes brought together by structural variations, which cooperated in their amplifications and subsequent up-regulated expressions. We believe that these hard-wired genetic changes are biologically significant; they sustain the survival of the tumor and offer the advantage of the distant metastasis. We reconstituted the architecture of melanoma progression and maintenance and we identified gene cassettes with a putative role in sustaining tumor growth. The correlation of these gene cassettes with the cancer phenotype and the feasibility of these putative oncogenes as candidates for targeted therapy were addressed using cell-based assays on a high content screening platform. Analysis of the matched cell lines derived from the same patient offered a valuable resource for in vitro manipulation, testing of drugs and functional validation. A detailed molecular characterization of the functionally validated genes and their contribution in the cancer signaling pathways will provide a better understanding of the molecular basis of tumor evolution.']",
        "Doc_id":"AACR_2014-3414",
        "Doc_title":" Genomic signatures of melanoma maintenance",
        "_version_":1606189032329445376},
      {
        "Meeting_name":" Novel targeted combinational therapies for melanoma",
        "Background":"['The BRAFV600E mutation is frequently observed in over 60% of melanomas. Development of the small molecule inhibitor PLX4032, which specifically targets the mutated BRAF protein, offers a novel therapeutic approach by effectively blocking the activation of key signaling molecules of the mitogen-activated protein kinase (MAPK) pathway, such as Mek and Erk, effectively leading to arrest in cell proliferation. Provided that MAPK signaling targets the micropthalmia transcription factor (MITF), which is linked to the expression of various melanoma associated antigens (MAAs), we hypothesized that the inhibition of BRAFV600E can modulate the expression of MAAs. Since MAAs are essential in the development of a melanoma vaccine, due to their increased immunogenicity, altering their expression can be a useful immunotherapeutic approach to targeting melanoma. Using patient derived melanoma cell lines, which express various MAAs; our laboratory has developed a vaccinia virus based immunotherapeutic vaccine. These melanoma cell lines have been characterized by their status of BRAFV600E mutation and found to be either homozygous or heterozygous for the mutation. Inhibition of two key MAPK pathway molecules, namely Mek and Erk, denotes that the melanoma cell lines are responsive to PLX4032. Phenotypically, the cells invasive and migratory properties were also modulated upon treatment with PLX4032. Moreover, we observed that the expression of various MAAs was enhanced upon treatment with PLX4032. An amplification of gp100, MART-1 and tyrosinase expression on the RNA level as well as on the protein level was observed. Lastly, expression of MMAs was conserved in vivo following the analysis of melanoma cell xenografts in BALB/c nude mice. Based on our observations in that PLX4032 modulates MMA expression, further studies are warranted to determine the clinical effectiveness of combinational immunologic therapy using BRAFV600E inhibitors with our vaccinia virus melanoma cell line derived preparation.']",
        "Doc_id":"AACR_2015-3540",
        "Doc_title":" Novel targeted combinational therapies for melanoma",
        "_version_":1606189025382629376},
      {
        "Meeting_name":" BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity.",
        "Background":"['Background', '  Determination of the BRAF mutation status is a requirement for treatment selection of metastatic melanoma patients. However, the inter and intra-tumor genetic heterogeneity for BRAF status has been described supporting the need for testing multiple sites for the same patient. Circulating DNA is considered a promising non-invasive tool for cancer monitoring. The objective of our work was to determine the potential of plasma DNA to detect BRAF mutations, particularly in patients presenting discordant BRAF status from different tumor sites.  Methods', '  Plasma DNA was extracted using the iPrep PureLink Virus Kit on an iPrep purification system (Invitrogen). BRAF mutations were detected using the Therascreen BRAF RGQ kit (Qiagen).  Results', '  Ninety-nine patients were included, and plasma was collected at baseline. Nine stage III melanoma patients presenting a mutant BRAF (6 V600E, 2 V600K and 1 V600D) were tested and for 4 of them we detected the corresponding mutation (including the V600D and both V600K) in circulating DNA (sensitivity 44.4 %). Similarly, 20 stage IV patients were tested (17 V600E, 2 V600K and 1 V600R). The corresponding mutation (including the V600R and both V600K) was detected in 15 of these patients (sensitivity 75.0%). Interestingly, 4 stage IV patients included in our series presented discordant BRAF mutation status on different sites (1 patient with a WT primary tumor (PT) and a V600E lymph node (LN) metastasis; 1 patient with a V600E PT and WT LN metastasis; 2 patients with a V600E PT, V600E LN and WT liver metastasis). We were able to detect the expected BRAF mutation in circulating DNA for all these patients.  Conclusions', '  The sensitivity of our procedure, based on approved kits, suggests a high interest for use in clinical practice, even for non-V600E mutations. Plasma DNA might be less sensitive to heterogeneity between tumor samples, and therefore might represent an interesting alternative source of DNA to detect BRAF mutations in clinical setting.']",
        "Doc_id":"ASCO_132370-144",
        "Doc_title":" BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity.",
        "_version_":1606189007445688320},
      {
        "Meeting_name":" Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma.",
        "Background":"['Background', '  An estimated 70,000 diagnoses of brain metastases (BM) occur each year in the U.S., with an incidence of 5-7% in breast and melanoma and 20% in lung cancer.  Despite its prominence, the biology of BM remains poorly understood.  Several theories of BM development exist, including the linear progression model, which suggests that the metastatic capabilities of tumor cells develop at primary sites following the accumulation of alterations. The parallel progression model argues that tumor cells disseminate early and accumulate changes independently at the secondary site.  We compare the tumor profiles of BM from common cancers to understand the biology and to identify differential treatment strategies.  Methods', ' Tumor samples were profiled using a multiplatform service (Caris Life Sciences, Phoenix, AZ), including sequencing (Sanger, NGS), protein expression (IHC) and amplification (ISH).  Results', '  5,391 NSCLC (293 BM, 5,098 lung), 3,595 breast cancer (99 BM, 3496 breast) and 761 melanoma (101 BM, 660 skin) unpaired samples were included. No significant differences were found in 48 genes between BM and the primary tumor sites, with the exception of PIK3CA in breast cancer, which was mutated less in BM vs. the breast samples (10% vs. 26%, p=0.02). In contrast,  expression of TOP2A, TOPO1 and TS, and amplification of EGFR, were more prevalent in BM as compared to the primary sites (Table).  Conclusions', '  A similar genetic landscape with limited differences was seen in BM of NSCLC, melanoma and breast cancer compared to primary tumors.  The limited differences are more consistent with a linear progression model of cancer metastasis. Additionally ,this suggests that both primary tumor and BM would respond to similar chemotherapeutics with the consideration of effective blood-brain barrier-penetrant drugs. Small molecule inhibitors of EGFR could be considered due to increased EGFR amplification and the higher TOP2A, TOPO1 expression prompts consideration of topoisomerase inhibitors like etoposide or irinotecan.  Brain met %Primary met%PNSCLCTOPO2A7555<0.01TOPO164550.02TS3522<0.01EGFR FISH3628nsBreastTOPO2A7850<0.01TOPO17863<0.01TS39280.04EGFR FISH3114<0.01MelanomaTOPO2A7646<0.01TOPO16157nsTS5645nsEGFR FISH506<0.01']",
        "Doc_id":"ASCO_151096-156",
        "Doc_title":" Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma.",
        "_version_":1606188991768428545},
      {
        "Meeting_name":" Concordance between mutations identified by bar-coded multiplexed sequencing of BRAF, NRAS, and KIT in formalin fixed (FFPE) tissue from melanoma patients using the Ion Torrent Personal Genome Machine (PGM) and a real-time PCR assay",
        "Background":"['The standard chemotherapy for metastatic melanoma is dacarbazine, however, progression free survival with dacarbazine is a dismal two months. Efforts to improve the treatment of melanoma have focused on specific molecular defects following the discovery that the majority of patients have a mutation in one of three members of the BRAF-MAPK signaling pathway', ' KIT, BRAF, and RAS. Recent clinical trials have shown promise for drugs that target the molecular defects in melanoma, including the recently approved mutant BRAF inhibitor vemurafenib. As new drugs that target specific mutations move through clinical trials, the opportunity to perform precision medicine is becoming a reality. To deliver on the promise shown by the new generation of drugs it will be necessary to detect specific mutations in patients so they can be matched with the right drug. To this end, we have used an Ion Torrent Personal Genome Machine to sequence the six most commonly mutated codons in melanoma (BRAF 600, NRAS 12 and 13, NRAS 61, KIT 576, and KIT 642) from formalin fixed paraffin embedded tissue of late stage melanoma patients. All six codons of interest were sequenced in forty-six patients and mutations identified by comparison to normal controls. The A375 cell line, containing the known mutation V600E in BRAF was used as a positive control. Samples were sequenced in a multiplexed format using bar coding of the amplicons which allowed 14 patients and two controls to be sequenced simultaneously on each chip. Results were confirmed by real time RT-PCR assay specific for the BRAF V600E mutation. We demonstrate the feasibility of using rapid low cost next-generation sequencing to provide robust detection of mutations in fixed patient samples.']",
        "Doc_id":"AACR_2012-1641",
        "Doc_title":" Concordance between mutations identified by bar-coded multiplexed sequencing of BRAF, NRAS, and KIT in formalin fixed (FFPE) tissue from melanoma patients using the Ion Torrent Personal Genome Machine (PGM) and a real-time PCR assay",
        "_version_":1606189036363317248},
      {
        "Meeting_name":" Low incidence of BRAFV600E mutation among melanoma patients in Ireland.",
        "Background":"['Background', ' Aberrant activity of the mitogen-activated protein kinase (MAPK) signalling pathway represents a critical factor in the initiation and development of melanoma. Activation can be the result of largely mutually exclusive somatic mutations of KIT, NRAS, or more frequently, BRAF(V600E). The FDA and EMA approval of a BRAF inhibitor (vemurafenib) that blocks the function of the BRAFV600E protein established a new paradigm for targeted drug development. Currently, BRAF inhibitors are one of the most promising approaches to treat metastatic melanoma.Methods', ' In this study, we applied mass spectrometry-based SNP genotyping (Sequenom) to detect single nucleotide mutations in 33 cancer-related genes including BRAF, NRAS, KIT, CTNNB1, GNAS, and MET. PCR and extension primers for the multiplexed assay were designed with the Sequenom Assay Design software. Samples were processed as recommended by the manufacturer. Matrix chips were assayed on a Sequenom MassArray MALDI-TOF Mass Array system. Visual inspection and Sequenom Typer software were used to perform genotyping based on mass spectra. We compared two independent melanoma cohorts, one from Ireland (SVUH cohort; n=97) and the other from Belgium (Leuven cohort; n=60).Results', ' Intriguingly, patients from Ireland showed significant lower BRAFV600E mutation rates (19.0%) when compared to the mutation frequency seen with the Belgian cohort (43.3%) or with the mutation frequency reported by other studies on non-Irish populations (50-70%). In addition, BRAFV600K mutation is rare in the SVUH cohort (1.0%) compared with the Leuven cohort (6.7%). Mutations in BRAFV600M and V600R were <2% in both groups. Although the number of NRASQ61 mutant cases was slightly higher among the Irish melanoma patients compared with Belgium patients (20.6% and 13.3%, respectively), this does not fully account for the difference in BRAFV600E mutation rate. In contrast, many BRAFV600 WT patients in the SVUH cohort carried significantly increased mutation rates in MET (11.4%) compared to the Leuven cohort (0%) and reported elsewhere (2%). c-MET is a receptor tyrosine kinase that activates multiple signal transduction pathways, including MAPK, PI3K, WNT, and Notch. MET inhibitors that are currently in clinical trials include cabozantinib and foretinib and might be a valuable alternative treatment strategy for patients exhibiting this mutation. Mutation rates of the other examined genes were always <5% and did not significantly differ between the groups.Conclusion', ' Our observation of reduced BRAFV600E mutation rates in Irish patients will directly impact future treatment strategies for these patients. The identification of substantial mutation rates in MET opens up opportunities for targeting a significant subset of melanoma patients with MET inhibitors.']",
        "Doc_id":"AACR_2013-23",
        "Doc_title":" Low incidence of BRAFV600E mutation among melanoma patients in Ireland.",
        "_version_":1606189033631776768},
      {
        "Meeting_name":" Biomarker patterns of metastatic melanoma with implications for therapy.",
        "Background":"['Background', '  Annually, metastatic melanoma (MM) is responsible for approximately 10,000 deaths in the United States and 48,000 deaths worldwide.  Prognosis worsens dramatically once disease metastasizes distantly.  Targeting molecular changes involved in metastasis may be an effective strategy to slow disease progression.  In this study, we investigated changes in theranostic biomarkers that may be important for MM, which may provide insight into new therapeutic strategies.   Methods', '  1,369 cutaneous melanoma cases referred to Caris Life Sciences between 2009 and 2013 were evaluated.  Biomarker profiling included a combination of sequencing (Sanger, NGS), protein expression (IHC), and gene amplification (CISH or FISH).   Results', '  We examined profiling data from 1,369 cutaneous melanomas (355 primary skin and 1014 skin metastases).  Differential expression between primary and MM using IHC included loss of expression of cKIT, ERCC1, PTEN, SPARC, TOPO1, and TUBB3 (p-values range <0.001 to 0.02) in MM, compared to primary skin specimens.  Conversely, MET, MRP1, and TOP2A were overexpressed (p-values', ' 0.006, 0.01 and <0.001) in MM.  MET overexpression was observed in 15% of BRAF-mutated MM in our series. EGFR is amplified by ISH in 35% of the MM set vs. 6% in primary specimens (p<0.001).  NGS revealed increased BRAF, PTEN, and PIK3CA mutation rates in MM (p-values', ' 0.02, 0.02, 0.09), implicating PTEN/PIK3CA in disease progression.  Of interest, PTEN mutations co-occurred with BRAF mutations in 13% of patients.     Conclusions', '  Molecular changes observed in MM, as detected by IHC, ISH, and sequencing may provide actionable targets that are important for disease progression.  Using a multiplatform approach, we identified subgroups of BRAF-mutated patients that exhibit MET overexpression, EGFR amplification, and PTEN mutations.  Since MET and EGFR have been implicated in resistance to BRAFi, our data support using a dual-targeted treatment strategy.  Since prognosis varies based on dissemination site, further investigation to determine site-specific metastases would be of high interest.']",
        "Doc_id":"ASCO_134703-144",
        "Doc_title":" Biomarker patterns of metastatic melanoma with implications for therapy.",
        "_version_":1606188999803666433},
      {
        "Meeting_name":" Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic",
        "Background":"['Background', ' Circulating tumor cells (CTCs) represent a surrogate biomarker for hematogenous metastases. The detection of CTCs has gained increasing interest for prediction of clinical outcome. However, it remains to be determined whether uveal melanoma cells circulating in a peripheral vein predict systemic recurrence and poorer overall prognosis.Uveal melanoma, the most common primary cancer of the eye in adults, is unique in that the uveal tract is devoid of lymphatics. Since systemic recurrence develops exclusively via hematogenous spread, patients with uveal melanomas present a special opportunity to explore the prognostic potential of CTCs. Although the lung is the first organ through which venous drainage from the affected eye passes and indeed the only organ through which all venous blood must pass, 80-95% of systemic metastases are found first in the liver without development of lung metastases. To address these issues, we investigated the numbers of CTCs in paired arterial (femoral) and venous (antecubital) blood specimens obtained from uveal melanoma patients with hepatic metastases.Methods', ' CTCs in blood specimens were measured in 17 uveal melanoma patients with multiple hepatic metastases, including 10 patients with liver-only metastases and 7 patients with hepatic and extra-hepatic metastases. Peripheral arterial and venous blood specimens were collected at the same time prior to liver directed treatment. CTCs were analyzed using CellTracks Circulating melanoma Cell Kit by CellSearch System. The clinical information and sources of blood specimens were blinded when CTCs were analyzed.Result', ' CTCs were detectable from all 17 arterial blood specimens (100%) (median 5, range 1 to 168). In contrast, much smaller numbers of CTCs were detectable in 52.9% (9/17) of venous blood specimens (median 1, range 0 to 8) from the same patients. In terms of degree of tumor burden, patients who have hepatic as well as extra-hepatic metastasis showed higher numbers of arterial CTCs (median 12, range 5 to 168), compared to patients who have liver-only metastasis (median 4, range 1 to 11). More importantly, there is no significant correlation between numbers of arterial CTCs and the degree of tumor volume in the liver in patients who have liver-only metastases.Conclusions', ' Using this technology, the detection of uveal melanoma cells in peripheral blood is feasible. Peripheral capillary beds effectively filter CTCs from venous blood; thus venous blood might not be the best source for measurement of CTCs in patients with metastatic uveal melanoma. The paucity of clinically evident non-hepatic metastases despite the effective filtration by peripheral capillary beds remains unexplained and may be a demonstration of the seed and soil hypothesis. CTCs are a non-invasive source of uveal melanoma cells for evaluating tumor biology. Further investigation is warranted.']",
        "Doc_id":"AACR_2015-384",
        "Doc_title":" Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic",
        "_version_":1606188993561493504},
      {
        "Meeting_name":" A retrospective analysis of nonmetastatic primary mucosal melanoma of the vagina",
        "Background":"['Background', ' Mucosal melanoma of the vagina (MMV) is a very rare entity. Optimal treatment is still controversial. We report clinical presentation, treatment modalities and outcome profiles of 31 patients with MMV. Methods', ' This is the first large retrospective study of 31 patients with a nonmetastatic mucosal melanoma of the vagina treated in curative intent between 1990 and 2007 within 9 institutes. Data analyzed included age, tumor stage, type of treatment, type of recurrence and status at the end of the follow-up. Results', ' Median age was 65 years. Tumor stage distribution according to the TNM classification was', ' T1 (73.1%), T2 (15.4%) and T3/4 (11.5%). Nodal status at diagnosis was available for 20 patients, most of them were N0 (n=15). Twenty-nine patients had surgical resection (nonconservative surgery', ' n = 16 including 2 pelvic exenterations, atypical resection ', ' n = 12 and lymph node expertise n = 13). Eight patients received adjuvant treatment (radiation therapy n = 4; chemotherapy n = 5; brachytherapy n = 3; immunotherapy n = 2). Median follow-up was 37 months. C-Kit status was evaluated by immunohistochemistry for 7 patients ', ' all were positive (> or = 10% labelled cells). The median survival and the 3 years relapse-free survival (RFS) were 10.3 months and 7.7% respectively. Most of first events were loco-regional relapses (n=16). Three-year cumulative incidence was 54% and 38.3% for loco-regional recurrence and distant metastasis. At diagnosis, high tumors stage (T2,3,4) was associated with poor RFS compared to T1 (p = 0.04). Median survival and 3-year overall survival rates were 34.6 months and 46.9% respectively. Conclusions', ' In this retrospective study, we confirmed the pejorative prognosis of MMV. The high rate of local recurrences emphasizes the need of local optimal treatment, which could be combined in selected patients with adjuvant therapy with tyrosine-kinase inhibitors blocking c-Kit.']",
        "Doc_id":"ASCO_49299-74",
        "Doc_title":" A retrospective analysis of nonmetastatic primary mucosal melanoma of the vagina",
        "_version_":1606189033187180544},
      {
        "Meeting_name":" Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency.",
        "Background":"['Background', '  Mutant BRAF DNA can be detected in plasma of melanoma patients bearing a mutation in their tumor. Detection of these genetic alterations in circulating DNA has potential clinical applications. We investigated the relationship between mutant BRAF in plasma DNA and treatment response.  Methods', '  DNA was extracted from plasma using the iPrep PureLink Virus Kit on an iPrep purification system (Invitrogen). BRAF mutations were detected using the Therascreen BRAF RGQ kit (Qiagen).  Results', '  Seventeen patients (1 stage IIIC and 16 stage IV) with a mutated BRAF melanoma (V600E in all cases) were included. Pretreatment plasma samples were available in 10 of them, and the BRAF mutation was detected in 8 samples (80% sensitivity). Twelve patients were treated with a BRAF inhibitor, 4 with a combination of a BRAF inhibitor and a MEK inhibitor, and one patient was treated with chemotherapy (DTIC). After 3 months of melanoma treatment, the BRAF V600 mutation was detected in the plasma of 9 patients (9/17; 53,9%). The presence of mutant BRAF in plasma DNA was compared to the clinical response of patients. The BRAF mutation was present in the plasma of 6 out of the 7 patients who did not respond to treatment. In contrast, mutant BRAF DNA was absent from plasma in 7 out of the 10 patients with partial response to treatment (Fishers exact test ', ' p = 0.04977). Mutant BRAF in circulating DNA was not associated with the number of metastatic sites at the same time (mean 2.625 in patients with mutant BRAF, and 2.22 in patients without mutant BRAF; p = 0.4266, Wilcoxons test).   Conclusions', '  The sensitive detection of mutant BRAF in plasma would be useful for predicting treatment response to targeted therapy.  Supported in part by a grant from Roche.']",
        "Doc_id":"ASCO_132152-144",
        "Doc_title":" Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency.",
        "_version_":1606189013708832768},
      {
        "Meeting_name":" Molecular markers in malignant melanoma",
        "Background":"['Background', '    As knowledge of the molecular make-up of malignant melanoma (MM) evolves, multi-gene panel testing by next generation sequencing (NGS) is an increasingly important tool to uncover actionable mutations and provide prognostic information.  Given the plethora of FDA-approved and investigational drugs which target specific pathways, NGS may enhance potential treatment options.  Methods', '    Archived tumor samples from patients with high-risk and recurrent MM were analyzed for mutations in targeted regions of 50 cancer-related genes using a NGS platform.  The mutational profiles of MM samples were summarized for all patients and correlated with notable clinicopathologic features.  Results', '    MM samples from 60 patients were included.  Median age was 71 years (range 28-90) and 66.7% were male (n = 40).  A total of 101 mutations affecting 25 unique genes were found.  Two or more mutations were found in 43.3% (n = 26) of MM while 13.3% (n = 8) of MM had no genetic alterations identified.  The most common mutations included', ' NRAS (33.3%, n = 20), BRAF (30.0%, n = 18), p53 (23.3%, n = 14), and CDKN2A (11.7%, n = 7).  BRAFV600 accounted for 88.9% (16/18) of all BRAF mutations, of which 87.5% were BRAFV600E(14/16).  Potentially actionable mutations with commercially available drugs (BRAF, KIT, NRAS) were found in 68.3% of patients (n = 41), while another 21 genes could be targetable on a clinical trial.  Twelve patients had either an acral (n = 7) or mucosal (n = 5) MM, of which 58.3% (n = 7) had no identifiable mutation.  Of the 48 remaining patients, only one had no mutations (2.1%).  One patient with metastatic cutaneous melanoma had a GNAS mutation discovered but did not have a history of ocular melanoma.           Conclusions', '  Multi-gene targeted panel testing by NGS reveals a significant number of actionable mutations in patients with MM.  Patients with non-cutaneous MM were less likely to have identifiable mutations.   Gene mutationMM Samples with mutations (n)Percentage of total MM samples (n=60)NRAS2033.3BRAFV6001626.7TP531423.3CDKN2A711.7PTEN58.3CTNNB146.7KRAS46.7KIT35.0EGFR35.0FLT335.0BRAFNon-V60023.3RB123.3ERBB423.3FGFR323.3ATM23.3KDR23.3Others (HRAS, SMAD4, FBXW7, PIK3CA, FGFR2, HNF1A, CSF1R, GNAS, PDGFR, APC)1016.7']",
        "Doc_id":"ASCO_148082-156",
        "Doc_title":" Molecular markers in malignant melanoma",
        "_version_":1606189008649453568},
      {
        "Meeting_name":" Deficient expression of oncogenic Wip1 (PPM1D) negatively regulates melanoma progression and metastasis",
        "Background":"['PPM1D belongs to the magnesium-dependent serine/threonine phosphatase family. It is well demonstrated that PPM1D amplification and overexpression is a frequent event in many human cancer types; however, its role in melanoma development and metastasis is not yet defined. The objectives of this study were to evaluate the role of Wip1 in melanoma progression and to evaluate correlations between Wip1 expression and clinical pathological parameters, such as grade and metastasis. In order to investigate the role of Wip1 in melanoma progression, we crossed Grm1 transgenic (TG3) mice, a well-characterized mouse model for melanoma, with Wip1 null mice (PPM1D-/-) to generate TG3', 'PPM1D-/- mice, and observed the rate of spontaneous melanoma formation. Compared with TG3 mice, TG3', 'PPM1D-/- mice exhibited dramatic reductions in melanoma incidence and metastasis to lymph nodes, lungs, liver and spleen. In addition, in-vitro down-regulation of Wip1 in Mass20 melanoma cells significantly decreased cellular proliferation and migration. Further, human melanoma tissue microarrays (TMAs) were used to determine PPM1D mRNA and protein expression levels in human tumors at different stages of progression. In situ staining of PPM1D mRNA and its corresponding protein Wip1 in human melanoma TMAs revealed higher expression levels in at least 50% of the metastatic tumors analyzed.Overall, our results demonstrate abundant expression of Wip1 in late stage/high grade melanoma and suggest that therapeutic strategies targeting Wip1 in individuals with select tumor subtypes might improve the survival advantage in Wip1-positive melanoma patients. However, further studies are required to elucidate the interactions between Wip1 signaling and established pathways of melanoma progression.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-1998",
        "Doc_title":" Deficient expression of oncogenic Wip1 (PPM1D) negatively regulates melanoma progression and metastasis",
        "_version_":1606189005432422401},
      {
        "Meeting_name":" Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations",
        "Background":"['Desmoplastic melanomas (DMs) comprise 4% of the overall melanoma burden and have a 5-year survival rate of 85%. DMs are dermal tumors characterized by spindled melanocytes situated within abundant desomplastic stroma. These unusual histological features commonly lead to misdiagnosis. Currently, there are no known genetic drivers. A better understanding of the underlying biology of desmoplastic melanoma would provide biomarkers and therapeutic opportunities. Towards this goal, we performed low-coverage genome and high-coverage exome sequencing of 20 DMs in a discovery cohort, followed by targeted sequencing of 293 candidate genes on a validation cohort of 42 cases. Additionally, high-resolution aCGH was performed on samples from both cohorts. A high mutation burden (median 62 mutations/Mb) ranked desmoplastic melanoma among the most highly mutated cancers sequenced to date. Mutation patterns strongly indicate that UV-radiation is the dominant mutagen and implicate a superficially located cell of origin despite their predominantly intradermal presentation. Novel alterations included recurrent promoter mutations and amplification of NF-kappa B inhibitor epsilon, NFKBIE (IkB) in 14.5% of samples. The promoter mutations typically affect both alleles and occur over a highly conserved DNA region. The mutations are predicted to disrupt a canonical Ets Like Factor 1 (ELF1) binding site. In total, these data imply aberrant NF-kappa B signaling as a pathogenic feature of desmoplastic melanoma. Commonly mutated oncogenes in melanomas, in particular BRAF V600E and NRAS Q61K/R, were absent. Instead, other genetic alterations known to activate the MAPK and PI3K signaling cascades were identified in 73% of samples, affecting NF1, CBL, ERBB2, MAP2K1, MAP3K1, BRAF, EGFR, PTPN11, MET, RAC1, SOS2, NRAS, and PIK3CA. Rb and p53 pathway alterations occurred respectively in 71% and 66% of tumors, affecting RB1, FBXW7, CDK4, PPP6C, CCND1, CDKN2A, TP53, and MDM2. Finally, TERT promoter mutations or amplifications occurred in 90% of tumors. The consequences of the mutations on protein expression levels was confirmed by immunostaining for NF1, EGFR, Rb, CDK4, CCND1, p16, p53, and Mdm2. Collectively, many of these oncogenic mutations are potentially druggable. In conclusion, desmoplastic melanomas harbor distinct genetic alterations that explain their unique biology, and this study illuminates genetic biomarkers and nominates targets for therapeutic intervention.']",
        "Doc_id":"AACR_2015-2968",
        "Doc_title":" Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations",
        "_version_":1606188997834440704},
      {
        "Meeting_name":" Frequent allelic imbalance in NRAS mutant melanomas.",
        "Background":"['Background', ' We recently showed that 19% of BRAF mutant melanomas have an increased mutant allele percentage ( > 60%) (BMC Cancer 2015). This allelic imbalance was mainly related to a polysomy of chromosome 7. We investigated the percentage of NRAS mutant allele in BRAFwild type (WT) melanomas. Methods', ' We searched for NRAS Q61 mutation by pyrosequencing method in 216 FFPE samples of cutaneous melanomas WT for BRAFV600. FISH was performed with probes specific for NRAS (RP11-245I3) and 1p34.1 (RP11-269F19) on 105 cases NRAS WT (n = 42), or NRAS mutant with equilibrate (E%, n = 43) and high (H%, n = 20) mutant allele percentage. Loss of Heterozygoty (LOH) was evaluated with 8 microsatellite (MS) markers (3 localized near NRAS, 3 at 1p and 2 at 1q) on 17 samples (E% n = 8 or H% n = 9). Pathological data of 73 NRASmutant melanomas, clinical characteristics and survival data of matching patients were analyzed. Results', 'NRAS mutation was detected in 109 (50.5%) of BRAF WT samples, of which 31 (34%) were H%. Allelic NRAS imbalance was observed in all mutation types', ' Q61R (n = 22), Q61K (n = 6), Q61L (n = 2) and Q61H (n = 1). Chromosome 1 disomy, disomy with rare polysomic cells and polysomy were observed in 24% (24% WT vs 24% mutant NRAS), in 24% (33% WT vs 18% mutant NRAS) and in 12% (3% WT vs 18% mutant NRAS) of samples, respectively. NRAS amplification and monosomy of chromosome 1 were rare aberrations in both groups (3.4% and 4.6%, respectively). Intra-tumor heterogeneity concerning chromosome 1 was defined as monosomic or polysomic cells (or both) accompanying disomic tumor cells. Heterogeneity was observed in 24% WT and 35% mutant NRAS samples (P < 0.01), and was more frequent in H% than E% mutant NRAS (47% vs 29.7%). MS analysis revealed no LOH in 8 E%, while LOH was present in 9 H% NRAS samples. No differences were observed between E% and H% NRAS mutant melanomas for clinic, histology and survival data. Conclusions', ' Allelic imbalance is more frequent in NRAS than in BRAF mutant melanomas (34% versus 19% of H%, P < 0.01). Amplification was rare in NRAS, as shown in BRAF mutant melanomas. NRAS mutant melanomas had high intra-tumor heterogeneity. Allelic imbalance of H% NRAS was closely related to LOH.']",
        "Doc_id":"ASCO_169489-176",
        "Doc_title":" Frequent allelic imbalance in NRAS mutant melanomas.",
        "_version_":1606188989590536192},
      {
        "Meeting_name":" The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma.",
        "Background":"['Background', '    Mucosal melanoma (MM) is a molecular and clinical subset of melanoma distinct from cutaneous melanoma (CM). The activity of systemic therapy (tx) in MM has not been rigorously evaluated.  We performed a retrospective, single center analysis of MM patients (pts) treated with systemic tx.  Methods', '    Using institutional databases, we identified pts with MM who were 1) treated at MSKCC between 1998-2012; 2) developed unresectable or metastatic disease (dz); 3) received 1 non-adjuvant systemic tx; 4) had scans available for blinded central radiology review using RECIST 1.1. Pt demographics and clinical outcomes were extracted.  Results', '    61 pts met inclusion criteria. Median age at diagnosis 64 years (range, 35-84); 71% female; primary site', ' 28 anorectal, 19 vulvovaginal, 13 head/neck, 1 gallbladder. Mutation (mut) status', ' 8/35 KIT mut (7 exon 11; 1 exon 13); 3/33 BRAF mut (all non V600mut); 3/33 NRAS mut. At time of 1st tx, 55 had metastatic dz (10 M1a, 6 M1b, 39 M1c) and 6 had locally advanced dz. Pts received 106 1st or 2nd-line systemic tx', ' 81 cytotoxic (24 single-agent alkylators [eg. TMZ, DTIC]; 47 alkylator-based combinations [eg. Cisplatin/Vinblastine/TMZ]; 10 other combinations); 11 immunotherapy [7 ipilimumab, 2 high-dose IL-2, 2 other]; 9 targeted [8 KIT inhibitors, 1 BRAF inhibitor]; 4 biochemotherapy; 1 other investigational tx. Overall response rate (RR) rate to 1st and 2nd-line tx was 16% and 13%, respectively, with no complete responses. 24-week (wk) dz control rate with 1st and 2nd-line tx was 20%, and 9%, respectively. RR in either 1st or 2nd-line to single-agent and combination alkylator tx was 8% (2/24), and 15% (7/47), respectively (p=0.71). RR to targeted tx and immunotherapy was 33% (3/9), and 9% (1/11), respectively. Median time to treatment failure (earlier of date of progression or change in therapy) was 11 wks (95% confidence interval [CI] 8-14 wks) for both 1st and 2nd line tx. Median overall survival (OS) from initiation of 1st-line tx was 11 mo (95% CI 8-13 mo).  Conclusions', '    The efficacy of systemic tx in MM is modest and appears similar to that seen in CM. Clinical outcomes for this pt population are poor. Further investigation into the biology and treatment of MM is needed.']",
        "Doc_id":"ASCO_132545-144",
        "Doc_title":" The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma.",
        "_version_":1606189003833344000},
      {
        "Meeting_name":" Effects of selective androgen-receptor and estrogen-receptor modulators on telomerase activity in melanoma and prostate cancer cells.",
        "Background":"['Male hormones and the androgen receptor (AR) are well-known key targets for prostate cancer therapy. The potential cause of a gender-based disparity in melanoma has been suspected for many years. A recent analysis suggests that female patients have a 30% survival advantage in cutaneous melanoma. Telomerase has been shown to add protective telomere repeats to chromosome endings and cause cancer cells to become immortal. We have recently discovered that the AR is expressed in melanoma cell lines. In current report, we tested the telomerase activity in lysates of both melanoma and prostate cancer cell lines. Telomeric repeat amplification protocol (TRAP) was carried out to test the activity of telomerase in melanoma A375, androgen-sensitive prostatic cancer LNCap and androgen-insensitive prostatic cancer PC-3 cell lines under treatments of steroid hormones, SARM and SERM compounds. The effects of sex hormones, selective androgen-receptor modulators (SARMs), and estrogen-receptor modulators (SERMs) on telomerase activity in both melanoma and prostate cells were investigated.']",
        "Doc_id":"AACR_2013-1320",
        "Doc_title":" Effects of selective androgen-receptor and estrogen-receptor modulators on telomerase activity in melanoma and prostate cancer cells.",
        "_version_":1606189038055718913},
      {
        "Meeting_name":" Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR.",
        "Background":"['Background', '  Cell-free tumor DNA (cftDNA) is released into the circulation and its recovery from plasma is a non-invasive alternative to tumor biopsy for applications related to molecular profiling. A potential use in therapeutic interventions is the periodic monitoring of cftDNA for the identification of molecular changes associated with resistance to target-specific treatments or when the mutational status in tumor tissue is not available. Methods', '  Samples (6 ml) of peripheral blood were drawn from patients with colorectal (CRC, n= 19) and thyroid (n= 1) cancers and melanoma (n= 8). CRC tumors were KRAS wild-type (n= 3) or carried the BRAF V600E (n= 6), KRAS G12D (n= 9) and G12V (n= 4) mutations. All melanomas and the thyroid cancer carried the BRAF V600E mutation. DNA was extracted from plasma with QIAamp Circulating Nucleic Acid Kit to recover DNA fragments of 1000 bp. PCR amplification was carried out with a QX100 ddPCR System (Bio-Rad) on 20 L-samples containing cftDNA and TaqMan probes for BRAF V600E (1799T>A), KRAS G12D (35G>A) and G12V (35G>T) labeled with FAM/VIC. Samples were then loaded into a droplet reader, which discriminates the difference in fluorescence amplitudes on the basis of target gene amplification. Results', '  The concordance between mutations in tumors (T) and plasma (P) for BRAF V600E was', ' melanomas 8 T vs. 6 P; thyroid cancer 1 T vs. 0 P; CRC 6 T vs 3 P. Concerning KRAS in CRC the results were', ' G12D 9 T vs. 7 P, G12V 4 T vs. 0 P. Overall, the percentage of concordant samples were', ' V600E 60%, G12D 77,8%, G12V 0%. Interestingly, in 2 patients with wild-type KRAS tumor, the G12D and G12V mutations were found in plasma.  Conclusions', '  ddPCR is a third-generation PCR technique for highly sensitive detection of DNA fragments. Detection of mutations in cftDNA by advanced technological platforms has important applications in the monitoring of patients for the occurrence of secondary mutations, amplifications and expansion of cell clones that render their tumors resistant to target-specific anticancer agents, unraveling the resistant phenotype before the clinical progression of the disease. Acknowledgments', ' this study was funded in part by MIUR/PRIN 2011-2012 (Rome, Italy).']",
        "Doc_id":"ASCO_113827-132",
        "Doc_title":" Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR.",
        "_version_":1606188998751944704},
      {
        "Meeting_name":" Role of store-operated Ca2+ entry in proliferation and cell cycle in melanoma",
        "Background":"['Background', ' Melanoma has a poor prognosis due to its rapid progression and a high metastatic ability. Ca2+ homeostasis plays a pivotal role in proliferation in cancer cells, but little is known about the role of Ca2+ in melanoma. Store-operated calcium entry (SOCE) is defined as Ca2+ entry from extracellular space triggered when Ca2+ store in the endoplasmic reticulum (ER) is depleted. SOCE is regulated by coordination between Orai (ORAI calcium release-activated calcium modulator) in the plasma membrane, and STIM1 (stromal interaction molecule 1) in the ER. We examined the role of Ca2+ in melanoma cells especially focusing on SOCE. Method', ' Intracellular Ca2+ level was measured by using Fluo4-AM, a Ca2+-sensing fluorescent dye. Cell proliferation was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were stained with propidium iodide and cell cycle was assessed using flow cytometer. Protein phosphorylation microarray was performed by using a commercially available kit (Cancer Signaling Phospho-Antibody Array). Results', ' SOCE, as demonstrated by enhancement of Ca2+ entry from extracellular space after Ca2+ depletion in the ER, was observed in SK-MEL-2, C8161, SK-MEL-24, UACC257 (human) and B16 (mouse) melanoma cell lines, suggesting that the existence of SOCE is universal among melanoma cells. SOCE was attenuated by Pyr3, a pyrazole compound which is known to inhibit SOCE, as well as by EGTA that chelates extracellular Ca2+. Pyr3 inhibits cellular proliferation in SK-MEL-2 cells (IC50', ' 5.1uM) and C8161 cells (IC50', ' 2.1uM). Cell cycle was analyzed in C8161 cells, and the cell number in the G2 phase was increased by both Pyr3 and EGTA, indicating that SOCE plays a role in the transition of G2/S phase. Protein microarray data showed that Pyr3 reduces phosphorylation of signal transducers and activators of transcription 5 (STAT5) by 93%, suggesting that the JAK/STAT pathway may be involved in SOCE-induced alteration of cell cycle. Conclusion', ' Our results showed that inhibition of SOCE suppresses proliferation in melanoma, thus it could be a new strategy for melanoma therapy.']",
        "Doc_id":"AACR_2012-1864",
        "Doc_title":" Role of store-operated Ca2+ entry in proliferation and cell cycle in melanoma",
        "_version_":1606189020322201600},
      {
        "Meeting_name":" Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma.",
        "Background":"['Background', ' TKI258 (dovitinib lactate), is a multi-tyrosine kinase inhibitor of VEGF receptors-1,2,3, FGF receptors-1, 2, 3, PDGFR-, and c-KIT. A phase I study was conducted to determine the maximum tolerated dose (MTD), the biological activity and the preliminary efficacy of TKI258 in patients with advanced melanoma. A panel of plasma biomarkers of angiogenesis and soluble receptors were evaluated to determine the pharmacodynamic effect of TKI258. Methods', ' Patients were treated orally with 200, 300, 400 or 500 mg/day on a once daily continuous dose schedule. The MTD was defined at 400 mg/day. Plasma samples from 43 patients were collected. Plasma concentration of TKI258 was measured by LC/MS/MS. Plasma VEGF, placental growth factor (PLGF), basic FGF (bFGF), and soluble VEGFR1 and VEGFR2 (sVEGFR1 and 2), and c-Kit were measured by multiplex assays using the Meso-Scale Discovery platform. Plasma FGF23 was evaluated by ELISA as a pharmcodynamic marker of FGFR1 inhibition. Results', ' Following 400 mg or 500 mg continuous daily dosing, the mean plasma exposure (AUC24hr) was approximately 3000 ng/mL*h and 4100 ng/mL*h, respectively. No accumulation in TKI258 plasma exposure was observed at doses of 400mg or below, while accumulation up to 2.5-fold was observed on day 15 following the 500 mg daily dose. At the end of the first treatment cycle, mean plasma VEGF, PLGF and FGF23 levels increased over baseline by 100%, 198% and 68%, respectively, while mean plasma sVEGFR2 levels decreased by 15% in patients treated with 400 and 500 mg/day TKI258. Further analysis of correlations with pharmacokinetic and clinical parameters is ongoing. Conclusions', ' TKI258 therapy is associated with increases of plasma VEGF and PLGF as well as decreases of sVEGFR2 suggesting VEGFR inhibition. Induction of plasma FGF23 suggest that FGFR may be inhibited at doses of 400 mg/day and above. This panel of circulating proteins may have utility as pharmacodynamic biomarkers of TKI258 activity in patients with advanced melanoma.']",
        "Doc_id":"ASCO_34836-65",
        "Doc_title":" Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma.",
        "_version_":1606189039438790656},
      {
        "Meeting_name":" Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial",
        "Background":"['The BRAF kinase, a member of the MAP kinase pathway, has emerged as an attractive molecule to target in melanoma. In an initial attempt to target BRAF in melanoma, a randomized, phase III trial (ECOG 2603) of carboplatin, paclitaxel, and sorafenib versus carboplatin, paclitaxel, and placebo was performed. Patients enrolled on the trial had either unresectable, locally advanced Stage III or Stage IV melanoma. We analyzed patients tumor samples for 74 mutations in 13 genes using a custom iPlex (Sequenom). We have preliminarily analyzed 157 tumor samples from patients enrolled in this clinical trial. Analysis of the initial data set demonstrates that 62 samples (42%, 62/148, 95% CI 34%,50%) carried BRAF mutations - 60 samples with V600 and two samples having a BRAF V601 mutation. Thirty eight samples (26%, 38/148, 95% CI 19%,33%) were positive for NRAS mutations, with 33 with Q61, two G12 and three G13 mutations. With the exception of one tumor sample, the BRAF and NRAS mutations were negatively correlated with each other, consistent with prior observations. We also observed a number of rare mutations in our samples including one in AKT1, one in AKT3, four in CDK4, five in beta-catenin, two in GNAQ and three in KIT. The results of this study demonstrated no difference between the two treatment arms in OS and PFS and no association with treatment outcome and BRAF and NRAS mutations. Consequently, the treatment arms were collapsed, and we examined the relationship of BRAF and NRAS mutations with OS and PFS. Interestingly, our data demonstrated that the BRAF and NRAS mutations did not correlate with OS or PFS. This sample population is unique in that it provides a large data set of melanoma tumor samples, all of whom were entered on a clinical trial, unselected for pre-existing mutations. Using the Sequenom assay platform, we have identified a number of mutations in a subset of genes known to be involved in melanoma in patient tumor samples. In the future, these tumor samples will be informative as we continue to examine and identify additional genetic alterations in melanoma, providing information regarding the natural history and distribution of certain mutations. Future studies will use array comparative genomic hybridization to further investigate additional somatic mutations occurring in melanoma tumors and correlate these with clinical outcome, as well as provide insight into the pathogenesis of melanoma. These results may lead to further opportunities for clinical trials.']",
        "Doc_id":"AACR_2012-5557",
        "Doc_title":" Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial",
        "_version_":1606189018525990913},
      {
        "Meeting_name":" Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.",
        "Background":"['Background', ' In various cancer types, cells with BRCA-like or HR mutations/alterations have been shown to be sensitive to PARP inhibitors in preclinical studies. In ovarian cancer, PARP inhibitors have shown improved response rate and progression-free survival in clinical studies. We investigated the frequency of HR mutations/alterations in melanoma. Methods', ' Comprehensive genomic profiling, (next-generation sequencing [NGS]) that included the entire coding sequence of 315 cancer-related genes was performed on formalin-fixed, paraffin-embedded tumor samples. The patient and tumor characteristics were obtained from electronic health records. Results', ' At our institution (CPMC), 59 patients underwent NGS analysis of melanoma specimens. Eighteen (30.5%) harbored a mutation in at least 1 of the HR genes in their tumor. The patient characteristics are', ' median age 69, male (83%), primary head and neck melanoma (61%), absence of ulceration at the primary site (86%) and mitotic rate >1 mm/m2 (86%). Tumor mutation burden was high in 12 (67%) patients and low in 1 (6%) patient. The most commonly altered gene was ARID2 (11.9%), followed by ARID1A, FANCA, ATM, BRCA1 (3.4% each). Three patients had multiple HR alterations', ' one with mutations in ARID1A, BRCA1 and MRE11A, one with mutations in ARID2 and ATM, and one with mutations in ARID2 and CHEK2. Among the 18 patients with HR mutation(s), concurrent NF1, NRAS, BRAF (V600), and KIT mutations were found in 7 (39%), 6 (33%), 5 (28%) and 1 (6%) patients, respectively. A larger dataset analyzed by Foundation Medicine (FM) (n=1,986) showed a similar pattern', ' The most common mutations/alterations were ARID2, followed by ARID1A, ATM, ATRX, BRCA2, ATR, BRCA1, BRIP1 and FANCA (Table). Conclusions', ' HR mutations / alterations are frequently observed in metastatic melanoma. Melanomas with these alterations may represent a unique subset of patients who could potentially benefit from PARP inhibitors. CPMC (n=59)FM (n=1,986)ARID27 (11.9%)10.2%ARID1A2 (3.4%)5.0%ATM2 (3.4%)4.0%BRCA12 (3.4%)1.3%FANCA2 (3.4%)1.0%BAP11 (1.7%)3.1%ATRX1 (1.7%)2.8%BRIP11 (1.7%)1.1%CHEK2, BARD1, MRE11A and FANCD2', ' 1 (1.7%) each at CPMC']",
        "Doc_id":"ASCO_185966-199",
        "Doc_title":" Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.",
        "_version_":1606188977406083072},
      {
        "Meeting_name":" Circulating cell free DNA to predict recurrence in uveal melanoma.",
        "Background":"['Background', ' Uveal melanoma is the most common primary intraocular malignant tumor in adults. Up to 50% of uveal melanoma patients die of metastasis, usually to the liver. Cell free DNA (cfDNA) provides a commercially available, non-invasive mechanism for monitoring disease activity in malignancy. Recently, studies have investigated cfDNA in uveal melanoma and have demonstrated an association with hepatic metastasis, metastatic volume as well as PFS and OS. It remains unclear if cfDNA can predict recurrent metastatic disease in high-risk uveal melanoma patients. Methods', ' We conductedan exploratory study of cfDNA following treatment for primary intraocular uveal melanoma. Three cohorts were investigated', ' high-risk patients ( > 50% estimated recurrence rate) with no clinical evidence of metastatic disease (cohort 1), patients with newly developed metastatic disease of the liver by surveillance MRI (cohort 2), patients with previously established metastatic disease (cohort 3). cfDNA profiles were provided by Guardant360 complete exon sequencing and analyzed for the presence of GNAQ/GNA11 mutations and MYC amplification which represent driver mutations present in > 80% of uveal melanomas. cfDNA was evaluated within 1 week of surveillance imaging studies. Results', ' Cohort 1 revealed no G-protein/MYC abnormalities by cfDNA (0/32). 34.4% (11/32) of patients in cohort 1 had mutations unrelated to G-protein/MYC. Cohort 2 showed a 10% (1/10) G-protein/MYC detection rate. Cohort 3 showed a G-protein MYC detection rate of 75% (18/24) which approaches the expected mutation rate in uveal melanoma. Interestingly, cfDNA did not detect G-protein/MYC abnormalities in hepatic tumors less than 2.0cm in diameter, regardless of cohort. Conclusions', ' MRI is a more sensitive screening test than cfDNA for detection of hepatic metastasis in uveal melanoma. cfDNA negative for G-protein/MYC alterations correlates with the absence of clinically detectable disease (100% specificity) and a positive result in the adjuvant setting should prompt further evaluation. This study suggests a detection threshold for cfDNA of > 2.0cm hepatic tumor diameter, which may have implications for the utilization of cfDNA across tumor types.']",
        "Doc_id":"ASCO_166814-176",
        "Doc_title":" Circulating cell free DNA to predict recurrence in uveal melanoma.",
        "_version_":1606189023846465536},
      {
        "Meeting_name":" Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080.",
        "Background":"['Background', '  E7080 is an oral TKI targeting VEGFR1-3, FGFR1-4, PDGFR, RET and KIT, which affects tumor cell proliferation and tumor vascularization in laboratory models. Tumor response (RECIST) and prolonged disease stabilization (> 6 months) were observed in melanoma patients treated in phase I.  The present study sought to identify predictive genomic/proteomic signatures.  Methods', '    25 patients with metastatic melanoma received E7080 10mg twice daily continuously. Biopsy of accessible lesions was performed pre-treatment D1 and on D22 post-treatment. The patient responses were', ' 2 PR, 14 SD > 3 months, 1 SD > 2 months and 5 PD (3 patients non evaluable). Tumor biopsies (D1 and D22) were frozen and preserved for sectioning.  Melanoma cells and tumor infiltrating vasculature (IHC CD31+) were separately collected by laser capture micro-dissection for profiling from ~ 5,000 cells on Affymetrix U133+2 microarrays and from ~30,000 cells via a gel electrophoretic-tryptic digest-LC/MS/ MS method.  Results', \"  From 25 patient samples, 22 D1 samples yielded quality melanoma mRNA samples for hybridization and analyses used data from ~24,000 RMA-normalized probes. The genomic data was analyzed using Student's T-test based on clinical benefit (=PR or SD  6 months); regression analysis for the continuous measure of tumor shrinkage and by Cox proportional regression based on PFS.  The analysis identified genes encoding elements of the target RTK signaling pathways. At the intersection of the regression analyses was a set of 46 genes correlating with the observed clinical response.  Conclusions\", '  A small set of genes in melanoma cells may potentially be used to predict clinical response in melanoma patients to E7080. The list will be refined based on on-going proteomic analysis of melanoma cells, gene expression data from the tumor vasculature and genotyping for melanoma-associated mutations from these same tumors.  These will be tested for their predictive value in an ongoing Ph2 trial.']",
        "Doc_id":"ASCO_84053-102",
        "Doc_title":" Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080.",
        "_version_":1606189005273038848},
      {
        "Meeting_name":" The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma.",
        "Background":"['Background', ' E7080 is a TKI targeting VEGFR1-3, FGFR1-4, KIT, RET and PDGFR. Anti-tumor activity has been observed in melanoma patients in phase I. This study examines the mode of action of E7080 in preclinical melanoma models  Methods', '  Mutational status of 18 genes (9 RTKs, 7 oncogenes and 2 tumor suppressor genes) was determined in 14 human melanoma cell lines.  Gene profile and biomarkers of anti-angiogenesis and anti-tumor activity of E7080 were investigated in vitro and in vivo by gene expression analysis in a melanoma cell line panel and in human melanoma tissues.  Results', '  18 types of mutation (mu) were found among 9 RTKs in ten of 14 melanoma cell lines. 2 mu of BRAF, 9 mu of TP53, 3 mu of PTEN, 2 mu of CDKN2a and 1 mu of NRAS were also found among 9, 9, 3, 2 and 1 melanoma of 14 cell lines, respectively. 4 of the 5 melanoma with BRAF wild type (wt) were the most sensitive to E7080 in mouse xenograft models, while 5 of the 6 with BRAFmu/PTENwt were the most resistant,  suggesting 3 sub-groups for sensitivity to E7080 based on BRAF/PTEN status', ' 1; BRAFwt/PTENwt, 2; BRAFmu/PTENmu and 3; BRAFmu/PTENwt. % of pericyte-covered tumor vessels was 25%, 29% and 35% among 3 sub-groups, respectively. Anti-tumor activity of E7080 was correlated to % of pericyte coverage in groups 1 and 2, in which  tumor vessels are sensitive to E7080. DNA microarray analysis demonstrated decreased FGFR1-4 expression in BRAFmu melanoma, while qPCR analysis showed that FGFR2 and FGFR3 expression were significantly higher in BRAFwt than BRAFmu in human melanoma tissues. E7080 inhibited in vitro proliferation of BRAFwt melanoma, which overexpressed FGFR3. Knockdown of FGFR3, FRS-2a, NRAS and AKT-3 genes with siRNA transfection inhibited proliferation of E7080-sensiteve melanoma.  Conclusions', '  BRAF/PTEN mutation status was associated with pericyte coverage of tumor vessels and the expression of FGFR1-4 in a panel of melanoma cell lines. E7080 showed superior anti-tumor activity against BRAFwt melanoma, in which the type of tumor vessels was sensitive to angiogenesis inhibition by E7080 and a subgroup of which were dependent on FGFR3 signaling.']",
        "Doc_id":"ASCO_78644-102",
        "Doc_title":" The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma.",
        "_version_":1606189028850270208},
      {
        "Meeting_name":" LMTK3 as a novel regulator of oncogenic KIT in KIT-mutant cancers.",
        "Background":"['Background', ' Multiple cancers, such as gastrointestinal stromal tumors (GIST) and melanoma, have been shown to be caused by somatic activating mutations in the receptor tyrosine kinase KIT. The major cause of death in patients with advanced KIT-mutant cancers is due to the development of KIT tyrosine kinase inhibitor-resistant (TKI-resistant) metastatic disease. Drug resistance arises almost exclusively from secondary mutations within KIT, highlighting the importance of KIT in the proliferation and survival of these tumors. Methods', ' We performed a human kinase siRNA screen in multiple KIT-mutant cancer cell lines using viability as a read out. We defined candidate targets as those whose knockdown decreased viability in all cell lines. Validation and mechanistic studies were done using a library of KIT-mutant GIST and melanoma cells. Results', ' We identified lemur tyrosine kinase 3 (LMTK3) as candidate target in three KIT-mutant cell lines. LMTK3 silencing reduced the viability of all KIT-mutant GIST and melanoma cells tested to date, including cell lines with KIT TKI-resistance mutations. Importantly, LMTK3 silencing decreased the viability of KIT-mutant cells specifically, but not that of KIT-independent GIST and melanoma cells. Further, we found that decreased cell viability was due to induction of apoptosis, as assessed by measuring caspase 3 and 7 activity within 96 hours of LMTK3 silencing. LMTK3 knockdown also reduced tumor growth in vivo in a GIST xenograft model. Because these cells depend so heavily on KIT and the loss of KIT signaling results in cell death, we hypothesized that LMTK3 silencing may affect this pathway. Indeed, LMTK3 silencing decreased levels of autophosphorylated KIT. We also observed a significant decrease in total KIT protein expression. This phenotype and corresponding viability was rescued with exogenous expression of full length LMTK3. Conclusions', ' LMTK3 is an important regulator of oncogenic KIT expression and activity in KIT-mutant GIST and melanoma and represents a novel, tractable target.']",
        "Doc_id":"ASCO_193306-199",
        "Doc_title":" LMTK3 as a novel regulator of oncogenic KIT in KIT-mutant cancers.",
        "_version_":1606188999879163904},
      {
        "Meeting_name":" Cell-free DNA sequencing-guided therapy in a prospective clinical trial",
        "Background":"['Background', ' Analysis of cell-free circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) is a promising method to identify druggable genomic alterations, especially when tumor specimen is inadequate for genomic sequencing or targeted sequencing. In our previous study, we have demonstrated an extremely high concordance rate between conventional sequencing and ctDNA sequencing. Based on this result, we designed a prospective trial to test the feasibility of the ctDNA genomics and to test the matched therapy rate in metastatic cancer patients focusing on lung cancer, gastric cancer and melanoma. Methods', ' The trial was a prospective, master protocol, trial with ctDNA genomic profiling and several matched trials were aligned to this protocol as independent trials. Guardant360 is the first comprehensive NGS-based liquid biopsy for cancer which is a 70-gene blood test interrogating all four major types of genomic alterations. Results', ' From Aug 2014 to Feb 2016, 210 metastatic cancer patients participated in the trial. Of 210 patients, 200 patients had analyzable ctDNA sequencing data (10 patients excluded due to follow-up loss, withdrawal of consent, etc). 73 patients were lung cancer patients, 78 patients were gastric cancer patients, 36 were melanoma patients and the remaining were rare cancer. The major alterations that were found in ctDNA were EGFR amplification, ERBB2 amplification, MET amplification, PIK3CA H1047R/E545K, TP 53 mutations, KRAS Q12, RET fusion, ALK fusion, EGFR mutation, and KIT mutation. Based on the ctDNA sequencing data, patients were directed to the matched therapy in the context of clinical trials or in clinical practice. The median turnaround time from blood draw to the sequencing report was 14 days. Conclusions', ' In conclusion, we have shown that the feasibility of ctDNA genomics was very high with extremely low failure rate and rapid turnaround time for sequencing report. The matched therapy rate based on ctDNA genomics will be available at the meeting for presentation. Clinical trial information', ' NCT02140463']",
        "Doc_id":"ASCO_169832-176",
        "Doc_title":" Cell-free DNA sequencing-guided therapy in a prospective clinical trial",
        "_version_":1606188991074271233},
      {
        "Meeting_name":" Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.",
        "Background":"['Background', ' MM is a highly targetable malignancy, with both kinase inhibitors and immunotherapies providing meaningful survival benefit. Different subtypes of mm harbor distinct GA that suggest targeted and immunotherapy options. Methods', ' Comprehensive genomic profiling was performed in 2,197 MMs for up to 315 cancer-related genes plus introns from 28 genes commonly rearranged in cancer on hybrid-capture, adaptor ligation-based libraries (mean coverage depth > 600X). TMB was calculated from 1.11 Mb sequenced DNA. We assessed base substitutions, insertions and deletions (short variants; SV), rearrangements, and copy number changes. Results', ' We assessed 6 subtypes', ' routine cutaneous (CT; 90%), desmoplastic (DM', ' 1%), acral lentiginous (AL; 1%), Spitzoid (SP; 1%), mucosal (MC; 2%) and ocular (OC; 5%). Each group harbored characteristic genomic signatures (Table). BRAFwas mutatedin 38% of CT of which 92% were SV GA and 8% were amplifications, fusions or cases with > 1 BRAF GA. High TMB in CT and DM is highly prevalent (42% and 83% with > 20 mut/Mb). BRAFGA were less common in AL (18%), MC (15%), and OC (2%). SP GA were dominated by fusions in BRAF (60%) and other kinases. KIT GA were prominent in MC and AL. TMB for MC and OC mm were very low. Key findings include novel drivers of BRAF inhibitor resistance including BRAFinternal rearrangements and kinase domain duplications. Conclusions', ' In the largest cohort of mm with NGS to date, genomic profiles and TMB differ across mm subtypes. Highly prevalent BRAF GA (including in the SP variant) and high TMB in CT and DM mm permit effective use of targeted and immunotherapies. Although MC and OC have lower BRAF GA frequency and lower TMB, targetable GA can be present. Novel BRAF inhibitor resistance mechanisms were observed. CutaneousDesmoplasticAcral-LentiginousSpitzoidMucosalOcularNumber199112222244105Significant driver GABRAF(38%)BRAF (0%)BRAF(18%)Fusions in', 'BRAF(15%)BRAF (2%)NF1(21%)TP53 (75%)NF1(18%)BRAF(60%)NF1(32%)NF1 (2%)PTEN(12%)NF1 (50%)PTEN(18%)ROS1(3%)KIT(25%)(GA in BAP1, GNAQ, GNA11 or MYC in 100%)KIT (5%)KIT (18%)RET(3%)PTEN (13%)NTRK1(1%)ALK (1%)TMB > 10 mut/Mb61%92%NANA3%3%High TMB > 20 mut/Mb42%83%NANA01%']",
        "Doc_id":"ASCO_187678-199",
        "Doc_title":" Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.",
        "_version_":1606189032519237632},
      {
        "Meeting_name":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "Background":"['Activation of CDK4 by amplification, increased expression of Cyclin D1 (CCND1) or reduced expression of the CDK inhibitor p16 (CDKN2A) can contribute to melanocyte transformation, indicating that CDK4 can act as an oncogene in melanoma. We have analyzed the frequency of gene copy number variations (CNV) in the CDK4 pathway and looked for associations of these alterations with patient survival to assess if CDK4 is a viable target for the treatment of human melanoma. In addition, we screened a panel of melanoma cells with a highly selective CDK4/6 inhibitor PD-0332991 (PD-991) and performed gene expression and mutation analysis on these cells to explore possible genomic predictors of sensitivity.Genomic analysis revealed that 75% of primary melanomas had at least one CNV in the CDK4 pathway, with 55% showing a loss of CDKN2A. 28% of melanomas had two or more CNVs and melanomas with two or more CNVs involving CCND1 had worse overall survival (HR 5.56, P=0.02). From the cell line studies low CDKN2A mRNA expression, mutation or loss predicted sensitivity to PD-991 with 23 out of 27 mutant/loss cell lines being sensitive compared to only 3/7 wild type lines (p<0.03). Expression of CDK4, CCND1 or other cyclins or CDK-inhibitors did not predict sensitivity to PD-991. PD-991 induced an increase in both cell size and SA--galactosidase activity that is indicative of a senescent phenotype, and this was associated with cells having wild type p53. In summary, genomic alterations in the CDK4 pathway are frequent in melanoma and are associated with worse survival, particularly when melanomas harbor two or more CNVs involving CCND1. CDK4 inhibition induces a senescent phenotype in melanoma cells that is associated with loss of CDKN2A and wild type TP53. Taken together these data support evaluation of CDK4 inhibitors in melanoma and suggest that CDKN2A and TP53 maybe genomic predictors of sensitivity.']",
        "Doc_id":"AACR_2013-3416",
        "Doc_title":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "_version_":1606189013606072320},
      {
        "Meeting_name":" Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma",
        "Background":"['Introduction', ' Targeted therapy against BRAF-mutated melanoma with BRAF and MEK inhibitors has shown clinical efficacy. However, resistance to therapy occurred and lead to therapy failure. We evaluated the effect of combining downstream inhibition of RAS/RAF pathways with MEK (AZD6244) and PI3K (XL765) inhibition on BRAF wild-type and mutant melanoma with variable expression of NRAS as possible therapeutic option.Methods', \" Fifteen melanoma cell lines were screened for BRAF mutation status and NRAS expression. BRAF wildtype (Mel628, Mel1098) and BRAF-mutated (Mel1861, Mel1890) cell lines were selected. Drug concentration study with AZD6244 (A, 2.5-40 uM) and XL765 (X, 2.5-40 uM) were performed on Mel628 cells. Subsequently, cells were treated with A (5 uM), X (5 uM), or combination. Cell proliferation assay was performed using Cell Titer Blue assay. Western blotting was performed to for expression of PARP, caspase-9, LC3A/B, Beclin1, pMEK/MEK, pERK/ERK, p-P70S6/P70S6, and p4EBP1/4EBP1. GAPDH was used as internal control. Apoptosis was analyzed using FITC Annexin V Apoptosis Detection Kit (BD Biosciences). Cell migration assay was performed by artificial wounding of melanoma cell monolayer and observing migration of cells into the wound up to 72 hours. Data were presented as means  SD for the three separate experiments. For comparison between groups, the student's t test was used and p< 0.05 was considered to be statically significant.Results\", ' There was dose-dependent inhibition of melanoma cell proliferation with both A and X. Combination A and X had synergistic effect on the anti-melanoma proliferative effect of BRAF mutated cells regardless of expression level of NRAS. Significantly increased apoptosis by Annnexin V assay was detected in BRAF mutated cells (Mel 1860 and Mel1890). Significantly increased expression (p<0.05) of apoptosis markers (PARP and caspases-9) were observed in cells treated with A+X compared with A or X alone. Enhanced phosphorylation of ERK and P70S6 were observed in BRAF mutated cells. No significant difference in autophagy markers (LC3A/B and Beclin1) were observed between A, X, or combination. Variable to minimal additive effect of the combination treatment was observed in BRAF wild-type cells in terms of proliferation, apoptosis, and autophagy. The combination of A and X significantly inhibited melanoma migration compared with either drug alone regardless of BRAF mutation status in the wounding assay model.Conclusion', ' We have observed a synergistic effect on suppressing BRAF-mutated melanoma proliferation with combined inhibition of MEK and PI3K. The effect is not dependent on NRAS expression levels of melanoma.']",
        "Doc_id":"AACR_2016-375",
        "Doc_title":" Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma",
        "_version_":1606189030739804161},
      {
        "Meeting_name":" A phase I/II trial of DTIC and dasatinib in metastatic melanoma.",
        "Background":"['Background', ' Activation of the SRC-Stat pathway is present in melanoma and Stat3 activation is present in a large proportion of melanoma cell lines and human metastatic melanoma tumors. In preclinical models, SRC inhibitors can sensitize cancer cell lines to chemotherapy agents. We tested the hypothesis that dasatinib may increase the effectiveness of DTIC chemotherapy for melanoma. Methods', ' We conducted a prospective phase I/II trial of dasatinib combined with DTIC in patients with unresectable metastatic melanoma. Patients had an ECOG PS 0-1, normal organ function and cutaneous, mucosal or ocular melanoma. DTIC was administered on the first day of each 21-day cycle with dasatinib given on treatment days 2 through 19. In the phase I portion of the trial, dasatinib and DTIC were escalated starting from 50 mg BID of dasatinib with DTIC at 800 mg/m2. Tumor blocks were obtained for IHC/mutation analysis. Results', ' The maximum tolerated dose of dasatinib was 70 BID or 100 mg QD when given with DTIC at 1,000 mg/m2 at this schedule. Dose limiting toxicity and major grade 3/4 toxicity was hematological with thrombocytopenia and neutropenia. Edema, pleural effusions and GI toxicities were infrequent. Of 49 patients treated in this trial, four (8.2%) had partial tumor responses by RECIST criteria, 25 (51.0%) had prolonged stabilization of disease, 15 (30.6%) had disease progression as the best treatment response, and five patients were either unevaluable or data are pending. The rate of clinical benefit (CR+PR+SD) was 59.2%. The median progression-free survival was 13.1 weeks and the median overall survival was 34.4 weeks. We are currently analyzing pSRC and SRC levels as well as B- RAF and c-kit mutation status in paraffin embedded tissue blocks to identify markers of response. Conclusions', ' The maximum tolerated dose of dasatinib is 70 mg BID or 100 mg QD when given on a day 2-19 cycle with DTIC at 1,000 mg/m2. The most common toxicities were hematological, especially thrombocytopenia and neutropenia. This combination appears to be associated with is associated with a high level of clinical benefit and a median PFS that compares favorably to historical controls, and, thus, it warrants further study.']",
        "Doc_id":"ASCO_44308-74",
        "Doc_title":" A phase I/II trial of DTIC and dasatinib in metastatic melanoma.",
        "_version_":1606188989829611520},
      {
        "Meeting_name":" Actionable secondary driver mutations in BRAFWT and NRASWT metastatic cutaneous melanoma using the Caris Molecular Intelligence profiling.",
        "Background":"['Background', ' Malignant melanoma is a genetically diverse disease. Predominantly, hotspot mutations targeting BRAF (V600) or NRAS drive melanoma development and are associated with clinical benefit. Nonetheless, approximately 25-30% of melanomas do not present these hallmark events. This subgroup could benefit from in depth molecular analyses to inform the design of personalized therapeutic protocols. Here, we leveraged the largest collection to date (n = 1929) of mutational and protein profiles of metastatic melanoma patients, the Caris Molecular IntelligenceTM database, to investigate molecular and actionable drivers. This database is purposefully skewed towards BRAF and NRAS wild-type tumors, making it particularly suitable for our analysis. Methods', ' We analyzed immunohistochemistry (IHC) and next generation sequencing (NGS) data available for 906 patient samples for which BRAF and NRAS status was available from Caris. We then defined three main melanoma subtypes characterized by mutations in BRAFV600 (n = 253), NRAS (n = 257, 8 also present BRAFV600), and wild-type for both (2xWT, n = 404). Results', ' Within the 2xWT group, we could identify an enrichment for multiple oncogenic mutations impinging on MAPK signaling and including therapeutically actionable receptor tyrosine kinases. In details we found that 2xWT tumors are enriched for non-V600 BRAF mutations (13% of the 2xWT), KIT (9%), GNAQ (3%), GNA11 (5%), APC (7%), and MET (6%) which also shows elevated protein levels by IHC in 16% of the cases. Interestingly, these alterations are largely mutually exclusive with each other, strengthening the hypothesis of them acting as drivers. Different mutation subtypes show associations with divergent protein and mutation changes. Conclusions', ' Melanomapatients wild-type for BRAFV600 and NRAS hotspot mutations represent today a clinical challenge. This project oversampled for these tumors representing a particularly useful dataset to investigate secondary melanoma drivers. By analyzing these molecular profiles, we identified multiple oncogenic events significantly associated with 2xWT tumors, shedding new light on the genetic bases of this disease.']",
        "Doc_id":"ASCO_167715-176",
        "Doc_title":" Actionable secondary driver mutations in BRAFWT and NRASWT metastatic cutaneous melanoma using the Caris Molecular Intelligence profiling.",
        "_version_":1606189034347954177},
      {
        "Meeting_name":" Molecular underpinning of melanoma histologic subtypes in the metastatic setting.",
        "Background":"['Background', '  The clinical and biologic relevance of the molecular basis of melanoma histopathological subtypes is not yet well studied. We tested the hypothesis that distinct somatic mutation profiles underlie the histologic subtypes of melanoma and that these differences are retained as melanoma progresses to metastatic disease. We reasoned that this might provide a basis for histology-driven targeted therapy, a concept that is more developed in other types of solid tumors but not in melanoma.  Methods', '    We performed whole exome sequencing (WES) on 8 pairs of metastatic tumor and germline DNA from 3 superficial spreading (SSM), 3 nodular (NM) and 2 acral lentiginous (ALM) melanoma patients. For two of the NM patients we also performed WES on DNA from corresponding primary lesions. Tumor DNA was isolated from FFPE samples in quantities that facilitated an average coverage of 100X for 95% of the exon regions; on average, 60M reads per sample were obtained, without applying whole genome amplification. We performed variant calling using paired samples with Somatic Sniper, SAM tools and MuTect. We annotated all the variants and applied functional filters to come up with a candidate list of mutations.  Results', '    Our analysis confirmed known mutations that occur predominantly in each subtype (BRAF V600E more prevalent in SSM than in NM and absent in ALM, ALM being NF1 mutant but not BRAF V600E or NRAS Q61 mutant) and further revealed subtype-restricted somatic mutations in genes not previously reported as associated with melanoma. In particular, matrix-remodeling associated 5 was found to be frequently mutated in the SSM samples tested but not in the ALM or NM samples, and PFN1P2 (profilin 1 pseudogene) in NM samples but not in the ALM or SSM samples. Sanger sequencing is underway to validate the presence of the selected mutations in a larger independent cohort of patient specimens representing the 3 histologic subtypes.  Conclusions', '  Our data support our hypothesis that melanoma histologic subtypes are characterized by distinct mutational signatures. Results of the expanded cohorts will be required to reveal uncommon, but specific mutations for each subtype that have yet to be identified.']",
        "Doc_id":"ASCO_135077-144",
        "Doc_title":" Molecular underpinning of melanoma histologic subtypes in the metastatic setting.",
        "_version_":1606188998648135680},
      {
        "Meeting_name":" Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.",
        "Background":"['Background', ' Vemurafenib has substantially impressive clinical efficacy in cutaneous melanoma (CM). However, compared with their cutaneous counterpart, acral melanoma (AM) and mucosal melanoma (MM) have distinct genetic patterns and worse prognosis. The efficacy and safety profiles of vemurafenib in AM and mm remain unclear. Methods', ' Clinical, pathological, and therapeutic data were collected and reviewed of patients (pts) with metastatic or unresectable BRAF-mutant AM and mm hospitalized and administrated vemurafenib during January 2011 and January 2017. Responses were evaluated by RECIST v1.1, survival data were analyzed by Kaplan-Meier survival curve, and adverse effects were assessed by CTCAE v4.0. Results', ' 24 pts were identified, 13 (54.2%) with AM, 11 (45.8%) with mm (1 patient without available radiology data). All 13 AM pts harbored BRAF V600E mutation (1 with simultaneous C-KIT E861K mutation); 10/11 (90.9%) mm pts carried BRAF V600E mutation (1 with simultaneous PDGFRA V824I mutation), 1/11 (9.1%) had BRAF D594N mutation. Median PFS were 5.4 (95%CI 3.5-8.7) and 4.5 (95%CI 1.5-15.0) months, median OS were 11.7 (95%CI 8.1-23.6) and 7.9 (95%CI 4.6-26.2) months; ORRs were 61.5% (8/13) and 40.0% (4/10), DCRs were 92.3% (12/13) and 90.0% (9/10) in AM and MM, respectively. Vemurafenib was well tolerated. The most common adverse effects (AEs) were hand-foot syndrome in AM and elevation of total cholesterol in MM, with the incidence of 23.1% (3/13) and 18.2% (2/11), respectively. Grade 3/4 AEs have not been observed. No patient discontinued vemurafenib because of treatment related toxicity. Conclusions', ' Vemurafenib yields substantial response in pts with AM and MM. Compared with in CM, vemurafenib has similar efficacy and safety profiles in BRAF-mutant AM and MM.']",
        "Doc_id":"ASCO_188703-199",
        "Doc_title":" Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.",
        "_version_":1606188984387502080},
      {
        "Meeting_name":" Metastatic melanoma associated genes identified using the human tumor metastasis RT2 profiler PCR array",
        "Background":"['Metastatic melanoma is a complicated disease with growing rates of diagnosis and few clinical treatment options currently available. While melanoma results in only 5% of skin cancers, it is the cause of 75% of all skin cancer deaths. In 2008, the American Cancer Society (ACS) reported 62,480 new cases of melanoma. Of these individuals, 8,420 died, including 5,400 men and 3,020 women. According to the ACS for 2010, the 5-year survival rate for stage IV melanoma is 15% to 20% and the 10-year survival is 10% to 15%. To improve survival it is important to establish which genes are involved in the regulation of metastasis in melanoma as potential targets for prevention and/or treatment. Our laboratory compared the differences in the relative expression levels of metastasis genes from two human melanoma cell lines and a normal melanocyte cell line. The normal melanocyte cell line was assayed in duplicate and averaged as an inner plate control in order to validate the assay. Established melanoma, SK-mel-103 and SK-mel-147, were investigated. Template cDNA was prepared from total RNA from these lines using the Qiagen RNeasy Mini kit. The melanoma cell lines were both male and matched on GPR-30 and ER beta expression and B-RAF and N-RAS mutation status but they differed in G2 checkpoint and p16 mutation status. RT Array technology was utilized to compare the relative levels of mRNA from metastasis related genes expressed in SK-mel lines. The Human Tumor Metastasis RT2 Profiler PCR Array contains 84 primer pairs that amplify genes involved in human metastasis. Genes on this array include those that regulate cell adhesion, the extracellular matrix components, cell cycle, cell growth and proliferation, apoptosis, and transcription factors and regulators. The PCR array is a set of optimized real-time PCR primer assays on a 384-well plate for pathway focused genes and includes appropriate RNA quality controls. The quantitative PCR was run on the ABI 7900 HT using the real-time PCR cycling program. Total RNA from normal and melanoma tumors were characterized and the relative expression levels for each gene in the two melanoma samples were plotted against each other and against the normal cell line in scatter plots. Gene expression with controls samples was highly correlated. Genes involved in metastasis were up or down regulated in the melanoma cell lines compared to the normal cell lines. Upregulation of genes associated with DNA replication has previously been correlated with metastatic aggressiveness in melanoma cell lines. Conversely the down regulation of genes has been associated with an increase in cellular adhesion and melanocyte differentiation. This research identifies metastatic genes that contribute to the metastatic aggressiveness in the SK-mel metastatic melanoma cell lines. In the future we plan to examine the genes identified in this study for novel drug repurposing experiments.']",
        "Doc_id":"AACR_2012-5555",
        "Doc_title":" Metastatic melanoma associated genes identified using the human tumor metastasis RT2 profiler PCR array",
        "_version_":1606189021090807809},
      {
        "Meeting_name":" Data-driven computational modeling to identify biomarkers of response to lenvatinib (E7080) in melanoma.",
        "Background":"['Background', ' Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFR. Anti-tumor activity has been observed in melanoma patients in Phase I studies. We applied an integrative supercomputer-driven analysis approach to identify biomarkers of lenvatinib treatment response in melanoma patients.Methods', ' Clinical data sets including tumor response data (RECIST), progression free survival (PFS), pharmacokinetic parameters (PK) and molecular data sets including baseline tumor gene expression (Affymetrix U133Plus2) and BRAF and NRAS mutational status, were collected from 18 patients with metastatic melanoma who received lenvatinib 10 mg orally twice daily in 28-day cycles. These clinical and molecular data sets were used to generate computational models developed using REFS (Reverse Engineering and Forward Simulation) modeling platform, which utilizes Bayesian network inference and simulations. Simulations were performed to identify biomarkers of lenvatinib treatment response. These potential predictive biomarkers were then tested for their ability to predict response to lenvatinib in preclinical models.Results', ' Using a model comprising gene expression, mutational status and PK data, REFS identified a panel of 18 potential predictive biomarkers of lenvatinib treatment response. Identified biomarkers were able to predict up to 89% of the observed variance in the tumor response data. A total of 32 identified genes including 6 candidate predictive biomarkers (TARBP2, CACNA1, C7ORF, RAP2A, SHMT1, IL22RA2) were further validated in a preclinical melanoma model system (n=12) and tissue bank samples with matched normal adjacent tissue (n=21). Expression of 14 genes correlated with relative tumor volume (r>0.35 or r<-0.35) in the preclinical model and expression levels of 19 genes were found to be higher in tumor compared to normal tissue (FC>2).Conclusions', ' Potential predictive biomarkers of lenvatinib treatment response in melanoma patients were identified by computational modeling and validated in a preclinical model system and tumor tissue bank samples. The identified biomarkers will be tested for their predictive value in an ongoing Phase 2 trial.']",
        "Doc_id":"AACR_2013-4025",
        "Doc_title":" Data-driven computational modeling to identify biomarkers of response to lenvatinib (E7080) in melanoma.",
        "_version_":1606189001222389760},
      {
        "Meeting_name":" Enhancement of anti-melanoma effect of BRAF and MEK inhibition by metformin",
        "Background":"['Introduction', ' Metformin has been shown to inhibit human cancer cell growth via activation of MAP kinase with resultant inhibition of mTOR signaling pathway. Recent clinical evidence demonstrated the anti-melanoma effect of combined mutant BRAF inhibition and MEK inhibition. We determined the effect of metformin in combination with mutant BRAF and MEK inhibition on melanoma proliferation and the possible mechanisms.Methods', \" Human melanoma cells (SK-23, Mel888, Mel1861) were treated with Metformin (1-20 mM), PLX4032 (a mutant BRAF inhibitor, 1-20 uM), AZD6244 (a MEK inhibitor, 1-20 uM), or combination. Cell proliferation assay was performed using Cell Titer Blue assay. Western blotting was performed to determine the expression of PARP, caspases-9, LC3A/B,Beclin1, pERK, pMEK, AMPKa, p70S6, and p4E-BP1. GAPDH was used as internal control. Autophagy was further analyzed with immunofluorescence with LC-3 and NECN1 anti-antibody for visualization of lysosomal morphology and evaluated under the Nikon Eclipse Ti microscope (20). DAPI was used to counter stain the nucleus. Apoptosis was further analyzed with flow cytometry using FITC Annexin V Apoptosis Detection Kit (BD Biosciences). Data were presented as means  SD for the three separate experiments. For comparison between groups, the student's t test was used and p< 0.05 was considered to be statically significant.Results\", ' There was dose-dependent inhibition of melanoma cell proliferation with either metformin(M), PLX4032(P), and AZD6244(A). Addition of M to PA combination had synergistic effect on the anti-melanoma proliferative effect of PA. Significantly increased expression (p<0.05) of apoptosis markers (PARP and caspases-9) and autophagy markers (LC3B and Beclin1) were observed in cells treated with PAM compared with PA. Enhanced induction of autophagy with the triple drugs was confirmed by visualization of autophagosome and autolysosome formation on immunofluorescence. Synergistic effect on apoptosis was confirmed on Annexin V assay. The PAM combination treatment also lead to significant enhancement of AMPK activation and increased phosphorylation of AMPK at Thr-172 compared with metformin alone (p<0.01). The addition of M to PA combination resulted in inhibition of mTOR signaling with decreased phosphorylation of p70S6K and 4E-BP1 in treated cancer cells, when compared with PA or M alone.Conclusion', ' We have observed a synergistic effect on suppressing human melanoma proliferation with the addition of metformin to combined inhibition of mutant BRAF and MEK. The synergism is due to enhanced inhibition of mTOR signaling pathways.']",
        "Doc_id":"AACR_2015-1196",
        "Doc_title":" Enhancement of anti-melanoma effect of BRAF and MEK inhibition by metformin",
        "_version_":1606189041411162112},
      {
        "Meeting_name":" Targeting EZH2 in acral lentiginous melanoma (ALM).",
        "Background":"['Background', ' Efforts to identify targeted therapies that can improve treatment outcome in metastatic ALM have been unsuccessful. In a previous genomic screening, we identified copy number amplification of the histone methyltransferase EZH2 in 47% of ALM cases, a higher frequency than previously reported in cutaneous melanomas (CM) (5%). Here, we tested the hypothesis that increased EZH2 expression contributes to ALM progression and may confer selective sensitivity to EZH2 inhibition. Methods', ' EZH2 expression was examined by immunohistochemistry (IHC) in 51 primary (21 stage I, 13 Stage II and 17 Stage III) and 23 metastatic (11 in transit, 8 nodal and 4 visceral) ALM cases with extensive clinicopathological data and protocol-driven follow up. Colony formation and cell proliferation was assessed following treatment of ALM and CM cell lines with three EZH2 inhibitors, including GSK126, currently in clinical trials. The effect of GSK126 on H3K27me3 and downstream EZH2 targets was analyzed by western blotting. Results', ' EZH2 is commonly overexpressed in both primary (30/51; 65%) and metastatic (20/23; 87%) ALM cases, with a significant increase in mean IHC score between primary and metastatic tumors (1.9 vs. 2.7, respectively, p = 0.047). EZH2 expression increased in 6/10 metastatic ALM tumors compared to their matched primary tumors. ALM tumors with EZH2 gene amplification showed increased EZH2 protein expression; however more cases showed overexpression with no amplification suggesting a potential epigenetic component of EZH2 regulation. GSK126 significantly suppressed ALM colony formation at lower doses compared to CM (1 M vs. 5 M, respectively). EZH2 inhibition also increased expression of the downstream tumor suppressor E-cadherin in ALM but not in CM cell lines. Finally, ALM cell lines had significantly lower basal H3K27me3 levels than CM cell lines, suggesting an additional, histone methyltransferase-independent function of EZH2 in ALM. Conclusions', ' Our data demonstrate thatEZH2 upregulation is common in ALM, and suggest that it may play a role in ALMs metastatic progression that requires further investigation. Selective sensitivity of ALM cell lines to EZH2 inhibitors supports the therapeutic potential of EZH2-targeted therapy in ALM.']",
        "Doc_id":"ASCO_185888-199",
        "Doc_title":" Targeting EZH2 in acral lentiginous melanoma (ALM).",
        "_version_":1606188999692517376},
      {
        "Meeting_name":" Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma",
        "Background":"['Background', ' Recent progress in melanoma research identified a wide variety of different melanomas in term of biology, clinical behavior and chemosensitivity profiles. This phase I/II study of association of sorafenib (SOR) and temozolomide (TMZ) evaluates the safety and efficacy of this association in patients with metastatic melanoma and tries to correlate clinical responses to early biological and imaging parameters. We report the ph I results and preliminary results of the ph II (still recruiting pts). Methods', ' Safety was the primary objective of the phase I and three escalating dose levels were tested. Primary objective of the phase II is PFS at 12 weeks and 32 patients were recruited at the recommended (45 planned). Secondary objectives evaluate tumour vascularization by dynamic contrast enhanced ultrasonography (DCE-US), PK profile of TMZ, number and function of circulating lymphocytes, melanoma RNA expression profiles and mutational status (BRAF, NRAS, c-KIT, PTEN, PI3K, cat), circulating endothelial and progenitor cells. Results', ' 13 evaluable pts were included in the phase I. The recommended doses are SOR', ' 400 mg bid and TMZ', ' 150 mg/m2 /d every other week. Toxicity was manageable. SOR did not influence TMZ PK. RECIST evaluation showed 1 CR (+ 12 months), 1 PR (+ 13 months), 3 SD, 8 PD. Among the 23 evaluable pts included in the phase II, 1 PR, 11 SD and 11 PD were observed. Five pts presented rapid and massive metastases necrosis with obvious tumour cavitation on CT which is very unusual during the course of melanoma treatment. Devascularization seen on DCE-US after 1 month was predictive of tumour response. Integrated correlative biological parameters are being analyzed and will be presented. Conclusions', ' SOR+TMZ association is well tolerated and gives promising results in some patients with metastatic melanoma. Unexpected major tumour necrosis has been observed in 5 patients. Early tumour devascularization observed by DCE-US seems predictive for tumour response. Extensive biological studies are being performed and might give useful clues allowing the identification of melanoma subtypes that are sensitive to this treatment regimen.']",
        "Doc_id":"ASCO_34633-65",
        "Doc_title":" Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma",
        "_version_":1606188995248652288},
      {
        "Meeting_name":" The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.",
        "Background":"['Background', ' Studies of c-kit inhibitor imatinib for the treatment of acral melanoma emphasize the importance of delineating and targeting the unique pathways driving tumorigenesis of histologic subtypes. There are no agents specifically tailored to treat the two most common subtypes', ' superficial spreading (SSM) and nodular melanoma (NM). We integrated gene expression and SNP array data to identify genes and pathways that differentiate NM and SSM. Methods', ' Gene array (U133A 2.0 Affymetrix) and SNP array (6.0 Affymetrix) were performed on 18 melanoma cell lines (2SSM, 4NM, 12 MET) and 4 melanocyte controls. Gene lists and correlations between DNA copy number and mRNA expression were made using the Partek Genomics Suite. Array data were validated in an expanded group of NM and SSM lines using qRT-PCR, western blot, and an in silico analysis of a public melanoma data set (Jaeger CCR 2007). Immunohistochemistry (IHC) of candidate genes was performed using human tissues from the IMCG. Results', \" Principal component analysis of gene expression showed high variance among NMs, with all but one falling outside 2 standard deviations of the mean expression for all other melanomas (SSM and MET). mRNA array revealed 114 genes differentially expressed between NM and SSM (p < 0.05, Bonferroni correction). Integrative genomics yielded 14 genes in which expression was significantly correlated with copy number (p < 0.05, Spearman's rank). qRT-PCR verified differential expression between NM and SSM in 7/8 (88%) genes studied, and the same trend between NM and SSM expression of all 7 genes was observed in the external validation set of human tissue. Pathway analysis of the most differentially expressed genes between NM and SSM showed highest representation of metabolic processes (65 genes, 55.1%, p = 0.05). Metabolism-related proteins MTAP and ALDH7A1, and reported tumor suppressor EPB41L3 were assessed by western blot which verified higher expression in NM vs. SSM in all 3 proteins. IHC in human specimens also showed higher levels of ALDH7A1 in NM vs. SSM. Conclusions\", ' Integrative genomics revealed molecular differences between NM and SSM. Data suggest NM and SSM have distinct biology, which may justify different strategies of drug development.']",
        "Doc_id":"ASCO_47611-74",
        "Doc_title":" The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.",
        "_version_":1606188988476948481},
      {
        "Meeting_name":" Combined inhibition of protein kinase C and MEK is a rational therapeutic approach for melanomas with GNAQ or GNA11 mutations.",
        "Background":"['Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults. There currently is no effective treatment for metastatic UM. UM differs from cutaneous melanoma in that it lacks BRAF, NRAS, or KIT mutations but instead harbors mutations in the Gq family members GNAQ and GNA11 in over 80 to 90% of cases. Understanding the downstream effector pathways of these oncoproteins is of considerable interest to identify opportunities for targeted therapy. Using 293T cells, immortalized mouse and human melanocytes, we find that GNAQQ209L or GNA11Q209L induce activation of the protein kinase C (PKC) and MAPK pathways. ShRNA mediated knock-down of mutant GNAQ abrogates both PKC and MAPK activation in human melanoma cell lines or model systems. Using two different PKC inhibitors we found selective extinction of PKC and MAPK signalling and induction of G1 arrest in panels of melanoma cell lines carrying GNAQ or GNA11 mutations, whereas no such effect was observed in melanoma cell lines with other mutations. MAPK activation occurred downstream of activated PKC in cells with GNAQ or GNA11 mutations. In contrast to PKC inhibitors, which selectively inhibited the growth of melanoma cell lines with GNAQ or GNA11 mutations, the MEK inhibitor PD0325901 inhibited melanoma cell lines irrespective of their GNAQ/11 mutation status. In vivo the PKC inhibitor AEB071 slowed the growth of tumors in an allograft model of GNAQQ209L transduced melanocytes, but did not induce tumor shrinkage. Analysis of tumor lysates identified suppression of PKC signaling but not of MAP-kinase pathway signaling under chronic PKC inhibition. The rebound of MAP-kinase activation could be overcome using a combination of AEB071 with the MEK inhibitor PD0325901, which showed strong synergy in halting proliferation and in inducing apoptosis. Our data suggest that PKC is a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and indicate that a combination therapy with MEK inhibitor is superior to treatment with either approach alone.']",
        "Doc_id":"AACR_2013-2345",
        "Doc_title":" Combined inhibition of protein kinase C and MEK is a rational therapeutic approach for melanomas with GNAQ or GNA11 mutations.",
        "_version_":1606188995026354176},
      {
        "Meeting_name":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "Background":"['The p16-CyclinD1-CDK4-RB pathway regulates G1-S cell cycle transition. This pathway is deregulated in 90% of melanomas, through amplification or increased expression of CDK4 or Cyclin D1 (CCND1), or reduced expression of the CDK inhibitor p16INK4A (CDKN2A).To explore if CDK4 may be a viable target for the treatment of human melanoma we screened a panel of melanoma cell lines with the highly selective CDK4/6 inhibitor PD-0332991 (PD-991). A majority of cell lines were found to be sensitive to PD-991, although there was a distinct population of resistant cell lines. In sensitive melanoma cell lines, treatment with PD-991 resulted in loss of hyperphosphorylated RB and a concomitant G0/G1 cell cycle arrest. Treated cells displayed an enlarged flattened morphology and an increase in SA--galactosidase staining compared to vehicle controls, indicative of cellular senescence. RB-null cell lines were resistant to CDK4/6 inhibition, and did not display cell cycle arrest or senescence. Expression and mutational analysis was performed to identify additional genomic predictors of sensitivity and resistance. Loss of CDKN2A/p16 correlated with sensitivity to PD-991 (p<0.02), and this was confirmed at the level of protein expression. Mutation of p53 and the corresponding low expression of p53 targets p21 and MDM2 correlated with resistance (p<0.0001). There was no increase in p53 transcriptional targets or evidence of apoptosis in response to PD-991 treatment of sensitive cells, and senescence occurs in both p53 WT and mutant cells, indicating that this response does not require functional p53. However, in p53 WT cells, combination treatment with PD-991 and the p53 pathway activator Nutlin3a results in increased sensitivity to PD-991 compared to treatment with PD-991 alone. This additive effect is not observed in p53 mutant cells, suggesting there is a functional role for WT p53 in the response to PD-991.Conclusions', ' These preliminary data identify RB, p16 and p53 as predictors of response to PD-991, and support further evaluation of CDK4/6 inhibitors in melanoma.']",
        "Doc_id":"AACR_2015-3089",
        "Doc_title":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "_version_":1606189010637553664},
      {
        "Meeting_name":" Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon.",
        "Background":"['Background', ' Attempts to identify patients who benefit from adjuvant treatment with interferon alfa-2b (IFN) have been disappointing. The development of autoimmunity during adjuvant therapy with IFN cannot assist selection of patients for therapy at baseline. The FOXP3 is located at Xp11.23 within an area of autoimmune disease linkage and therefore is an excellent positional candidate gene for autoimmunity at this locus. Consequently we performed a microsatellite analysis of FOXP3 gene in the exon 0 region in high-risk melanoma patients enrolled in a study of two regimens of high-dose IFN. Methods', ' A fragment analysis was performed in the DNA of 259 stage IIb, IIc, and III melanoma patients. After amplification and electrophoresis run, data from each sample were analyzed using Genemapper software (Applied Biosystems), which objectively calls the fragments size. Results', ' Thirteen alleles were detected (size', ' 284, 286, 288, 290, 292, 298, 302, 304, 306, 310, 312, 314, 316). The tabular distribution of these alleles in melanoma patients is presented below. At a median follow-up of 71 months (range 7.1-138.7 months), 144 patients have recurred and 95 have died. There were no statistically significant differences in the incidence of FOXP3 alleles between melanoma patients who recurred and those with no evidence of recurrence. RFS did not differ significantly between patients with recurrence and those without for each of the alleles detected. Conclusions', ' No allele defined by the microsatellite analysis of the FOXP3 gene in exon 0 was correlated with improved RFS in this high-risk group of melanoma patients. GenesNo relapsen=115 (%)Relapsen=144 (%)p valueallele_2842 (1.74)2 (1.39)1allele_2862 (1.74)1 (0.69)0.586allele_28879 (68.70)90 (62.50)0.358allele_2904 (3.48)2 (1.39)0.411allele_2920 (0.00)1 (0.69)1allele_2981 (0.87)5 (3.47)0.231allele_3021 (0.87)3 (2.08)0.632allele_3041 (0.87)2 (1.39)1allele_3066 (5.22)11 (7.64)0.463allele_31016 (13.91)18 (12.50)0.853allele_3121 (0.87)5 (3.47)0.231allele_3142 (1.74)2 (1.39)1allele_3160 (0.00)2 (1.39)0.504']",
        "Doc_id":"ASCO_53356-74",
        "Doc_title":" Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon.",
        "_version_":1606189007549497344},
      {
        "Meeting_name":" Synergism between NEDD9 overexpression and loss of PTEN and INK4A/ARF in melanoma tumorigenesis",
        "Background":"['The fact that melanoma, the most aggressive form of skin cancer, is driven by multiple combinations of genetic lesions has supported the use of genetically engineered mouse (GEM) models in validating the etiological and biological roles of oncogenes and tumor suppressors. Most of the currently studied mouse melanoma models are driven by RAS/RAF/MAPK activation via activating RAS or RAF mutations in combination with loss of INK4A/ARF or PTEN; therefore, BRAF/NRAS wild-type melanoma remains less well characterized and the overall survival of patients with metastatic BRAF/NRAS wild-type melanoma remains poor.In this study, we investigated the hypothesis that NEDD9 could synergize with the loss of PTEN and INK4A/ARF in melanoma tumorigenesis. This hypothesis is based on our observation of an inverse correlation between PTEN expression and levels of NEDD9 gene expression in human melanoma samples. NEDD9 (neural precursor derived, developmentally downregulated gene 9) was previously identified by us as a target of a recurrent focal amplification, associated with acquisition of metastatic potential in the RAS-Ink/Arf model. We have shown that NEDD9 is up-regulated in 3550% of metastatic melanomas and enhances proliferation and invasion. First, we demonstrated that NEDD9 cooperated with PTEN loss in Ink4a/Arf-/- melanocytes to enhance cell proliferation, anchorage independent growth, and invasion in vitro. Additionally, when melanocytes were injected into nude mice either subcutaneously or intravenously, NEDD9 overexpression facilitated increased tumor growth and lung seeding, respectively. Further analysis showed that NEDD9 expression correlated with increased phosphorylation of ERK, SFKs (Src family kinases), AKT2, and STAT3. Of these pathways we have demonstrated through the use of small molecule inhibitors that both ERK and AKT2 signaling are required for the enhanced anchorage independent growth observed in NEDD9 overexpressing melanocytes. In addition, we generated a mouse model based on loss of PTEN and INK4A/ARF with or without NEDD9 upregulation. To do this, we generated a tet-inducible NEDD9 allele that carries a doxycycline-responsive, melanocyte-targeted NEDD9. These mice were crossed with a strain containing floxed PTEN and INK4A/ARF in combination with a melanocyte-targeted CreERT2. The development of cutaneous and ocular melanomas in these mice was enhanced by NEDD9 induction. This study will generate a body of knowledge for the in vivo roles of NEDD9 in melanoma tumorigenesis and identify signaling pathways that could be therapeutically targeted to treat patients with BRAF/NRAS wild-type melanoma']",
        "Doc_id":"AACR_2016-4164",
        "Doc_title":" Synergism between NEDD9 overexpression and loss of PTEN and INK4A/ARF in melanoma tumorigenesis",
        "_version_":1606189033260580864},
      {
        "Meeting_name":" Molecular and clinical correlates of PTEN expression in melanoma",
        "Background":"['The management of melanoma is being revolutionized due to an improved understanding of oncogenic events in this disease. Many prevalent genetic alterations in this disease implicate activation of the RAS-RAF-MEK-ERK and PI3K-AKT pathways in melanoma. While the detection of activating BRAF, NRAS, and KIT mutations is relatively standardized, evaluation of PTEN, a tumor suppressor that inhibits the PI3K-AKT pathway, is challenging due to its regulation by epigenetic mechanisms. In order to understand the molecular correlates of PTEN expression in clinical specimens, we performed immunohistochemistry (IHC) for PTEN in a CLIA-certified laboratory at the MD Anderson Cancer Center on a cohort of FFPE melanomas with mutational and proteomic data from frozen tissue from the same tumors. The expression of PTEN in the tumor tissue was compared to staining intensity in internal positive controls (i.e. endothelial cells), and was scored as Absent, Markedly Reduced, Mildly Reduced, or Normal/Increased. In a cohort of 93 tumors, Absent PTEN expression was observed in 21%, Markedly Reduced in 23%, Mildly Reduced in 36%, and Normal/Increased in 18%. PTEN expression was not evaluable in 1 tumor, and 2% of tumors showed clonality of PTEN expression in the tumors with distinct areas of Normal/Increased and Absent PTEN expression. Absent PTEN expression was detected in 38% of BRAF mutant, 0% of NRAS mutant, and 11% of Wild-type tumors. Quantitative proteomic data generated by reverse phase protein array (RPPA) analysis of the frozen tissue demonstrated that tumors with Absent PTEN by IHC had significantly lower PTEN (p<0.001), and higher levels of P-AKT Thr308 (p=0.004), P-AKT Ser473 (p=0.008) and P-P70S6K (p=0.01) than tumors with Reduced/Normal/Increased PTEN expression, consistent with increased activation of the downstream signaling by the PI3K-AKT pathway. In contrast, tumors with Markedly Reduced PTEN had lower levels of PTEN expression by RPPA than the Mildly Reduced and Normal/Increased PTEN tumors (p=0.046) but they did not exhibit significant differences in P-AKT or P-P70S6K. In light of these results, PTEN expression in subsequent samples was scored as Absent, Present, or Clonal. PTEN IHC of 323 distant metastases identified Absent PTEN expression in 18%, Clonal expression in 2%, and PTEN Present in 79% of resected stage IV melanomas. Among tumor sites with at least 15 samples available for analysis, the rate of Absent PTEN expression was relatively high in CNS (n=39; 28%) and intestinal metastases (n=76; 30%), but was lower in lung (n=147; 10%) and liver (n=18; 6%). Twenty six patients had tissue available from both CNS and extracranial metastases; the concordance rate of PTEN Absence in the paired specimens was 77%. These integrated analyses provide molecularly-defined parameters for the evaluation of PTEN expression in melanoma, and add to our understanding of its expression in this disease.']",
        "Doc_id":"AACR_2012-968",
        "Doc_title":" Molecular and clinical correlates of PTEN expression in melanoma",
        "_version_":1606189031742242817},
      {
        "Meeting_name":" Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.",
        "Background":"['Background', ' Sunitinib is a small molecule that inhibits several tyrosine kinase receptors, including VEGFR, PDGFR, c-KIT, FLT3 and RET. These kinases play a key role in neoangiogenesis and in tumour cell proliferation and survival. The effects of sunitinib in cancer treatment may be both anti-angiogenic or related to a direct anti-tumour effect of the drug through drug targets activated in the tumour cell. Treatment options for advanced melanoma after dacarbazine-based chemotherapy remain limited. We provide the results of a phase II study with sunitinib in advanced melanoma patients. Methods', \" Patients with locally advanced or metastatic melanoma who failed at least one line of dacarbazine-based chemotherapy were enrolled in a Belgian academic multi-centre phase II trial, following a Simon's two-stage design. Patients received treatment with sunitinib in 6 weekly cycles comprising of a 50 mg once daily dosing for 4 weeks, followed by a 2 week off-treatment period. The primary endpoint was RECIST-defined objective response. Angiogenic biomarkers were collected to study their potential predictive value for response. Serum VEGF, VEGFR-1, VEGFR-2 and PlGF were determined by ELISA and circulating endothelial cells were enumerated by FACS at baseline and biweekly during the first cycle. Results\", ' Thirty-six patients with metastatic melanoma were enrolled. Seven patients were not evaluable for response because of early discontinuation of sunitinib, due to adverse events. Three patients (8.3%) demonstrated a partial response with a mean duration of 6.5 months. Nine had stable disease (25%) with a mean duration of 4.1 months (range', ' 3-8.2 months) and 17 had progressive disease (47.2%). The most frequent grade 3/4 toxicities were asthenia, anorexia and thrombopenia. No correlation between response and baseline VEGF, VEGFR-1, VEGFR-2 or PlGF was observed. Further analysis is ongoing. Conclusions', ' The present phase II trial met its primary endpoint (3 partial remissions) and a clinical benefit rate of 33% was observed. In a minority of patients significant toxicity was observed. Data from angiogenic biomarker analysis and the correlation with response will be reported.']",
        "Doc_id":"ASCO_44018-74",
        "Doc_title":" Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.",
        "_version_":1606189005275136000},
      {
        "Meeting_name":" Molecular changes induced by the curcumin biphenyl analogue D6 in melanoma cells",
        "Background":"['Malignant melanoma (MM) is one of the most aggressive cancers that affect humans. It is the most common and fatal skin cancer, with an incidence that is critically increasing in Western populations (15 times in the last 40 years) and for which, in the advanced stages, there is no effective therapy. The search for new compounds able to control it is therefore essential. The hydroxylated biphenyl compound (3E,3E)-4,4-(5,5,6,6-tetramethoxy-[1,1-biphenyl]-3,3-diyl)bis(but-3-en-2-one), namely D6, a structural analogue of curcumin, showed a strong antitumor activity on MM cells both in vitro and in vivo, as we have recently described [1]. The mechanisms of action of this compound are not clear yet, but it inhibits cancer cells growth by inducing apoptosis without affecting normal fibroblasts growth. Firstly we investigated the ability of D6 to enter cells by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis. The LC-MS data showed a quick cellular uptake of D6 with a maximum peak after about 2 hours. To investigate on the effects of D6 treatment on the cell cycle progression in MM cells, we performed flow cytometry analysis, which evidenced a cell cycle arrest in the G2/M phase. Gene expression profiles analysis using Illumina high-density microarrays, was carried out on D6 treated MM cells and normal fibroblasts allowing the identification of 599 transcripts whose expression was modulated by D6 treatment in MM cells but not in normal fibroblast. The analysis of results, performed by Ingenuity Pathway Analysis software, showed the centrality of CDKN1A gene, encoding p21, a major negative cell cycle regulator, which was strongly over expressed, while cyclin B and cdc25 phosphatase, showed both to be down modulated. Other genes which expression interestingly appeared to be decreased by D6 activity were the oncogenes c-kit and PI3K, suggesting a down regulation of both c-kit mediated and PI3K/AKT signal transduction pathways driving to cell proliferation. Modulation of expression of these specific genes has been confirmed at a protein level by western blotting analysis. Moreover our results pointed out an upregulation of several heat shock family genes, which is probably due to a curcumin related anti inflammatory effect of D6. The preliminary results of these analysis show that D6 induces molecular changes in MM cells at both gene expression and protein levels, involving major cell proliferation regulatory pathways. [1] Marina Pisano et al. (2010).Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Molecular Cancer, 9', '137.']",
        "Doc_id":"AACR_2012-3804",
        "Doc_title":" Molecular changes induced by the curcumin biphenyl analogue D6 in melanoma cells",
        "_version_":1606189002354851840},
      {
        "Meeting_name":" The role of SOCS-1 in stimulating melanoma development through growth factor receptors and MAPK pathways",
        "Background":"['Knowledge on the regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now recognized that multiple signaling pathways that affect motility, growth control, invasion, metabolism, cytokine release and the ability to escape the immune response, regulate melanoma development. Silencing of SOCS-1 protein, a negative regulator of Jak/Stat pathway, leads to partial reversion of the tumorigenic phenotype of B16F10-Nex2 melanoma cells. SOCS-1 silencing with shRNAi inhibits in vitro growth by cell cycle regulation with S phase arrest and increased size of cells and nuclei. It also inhibited tumor cell migration and invasion. Down-regulation of SOCS-1 decreased the expression of epidermal growth factor receptor (mainly the phosphorylated-R), Ins-R, and fibroblast growth factor receptors. Based on the results of SOCS-1 silencing, the present work aims at analyzing the expression of proteins relevant to tumor development, searching for signaling pathways related with SOCS-1. A protein microarray analysis of murine melanoma cells silenced for SOCS-1 by shRNAi SOCS-1 lentivirus transduction was undertaken using as controls, cells transduced with the empty vector. Among the 614 differentially expressed genes some cytokine/growth factor receptors were down regulated, e.g. c-kit, met and EphA3. Western blotting of B16 shR-SOCS-1 cell extracts showed a significant decrease in the expression of these receptors, indicating that SOCS-1 positively regulates the MAPK pathways in these cells. We analyzed the main MAPK pathways that were up regulated in melanoma and observed a decrease in the phosphorylation of mediators of ERK1/2 and p38 pathways and of STAT3 (S727). These results demonstrate that SOCS-1 can play an important role in tumor development and progression up regulating a number of growth factor receptors in murine melanoma cells. Interestingly, p-CREB (S133) was up regulated in the SOCS-1-deficient B16F10-Nex2 cells. In vivo experiments showed that using a prophylactic protocol, the subcutaneous immunization of syngeneic mice with B16 shR-SOCS-1 viable cells, rendered a protective effect against subcutaneously grafted and metastatic murine melanoma, with significant reduction in tumor growth and metastates in the lungs. A flow cytometry assay showed decreased expression of PD-L1 at the surface of B16 shR-SOCS-1 cells. This might explain the protective effect of subcutaneous immunization with these cells, rather than with wild-type B16F10-Nex2 cells that overexpress PD-L1, which negatively regulates T-cell immune response. Down regulation of PD-L1 is compatible with inactive ERK. The present results show the important role of SOCS-1 in murine melanoma stimulating cell growth and migration, allowing for the invasive phenotype.']",
        "Doc_id":"AACR_2014-5296",
        "Doc_title":" The role of SOCS-1 in stimulating melanoma development through growth factor receptors and MAPK pathways",
        "_version_":1606189037506265088},
      {
        "Meeting_name":" Defining the role of Akt activation in melanoma development and progression",
        "Background":"['We have developed a somatic cell gene delivery mouse model of human melanoma that allows for rapid validation of genetic alterations identified in this disease. A major advantage of this system is the ability to model the multi-step process of carcinogenesis in immune-competent mice using retroviral-mediated gene delivery. Mutant BRaf has been demonstrated to cooperate with Pten loss to induce metastatic melanoma in mice but the role of Akt in this context has not been evaluated. This is relevant because 60% of human melanomas contain amplification and activation of AKT. In this study, we evaluated the role of mutant Braf in melanoma initiation in the context of Ink4a/Arf loss and Akt activation. Ink4a/Arflox/lox mice expressing the viral receptor TVA specifically in melanocytes under control of the dopachrome tautomerase (DCT) promoter were crossed to Ptenlox/lox mice and mice carrying a conditional BrafV600E allele, which can be activated by Cre expression (BrafCA). Cohorts of newborn mice were injected subcutaneously with retroviruses containing Cre recombinase. Melanoma developed in 100% (8/8) of the DCT-TVA/BrafCA mice following Cre mediated Braf activation combined with Pten and Ink4a/Arf loss; median survival was 62  6.7 days in this cohort. The incidence was reduced to 43% (6/14) if Pten was retained (Pten+/+ mice); median survival of tumor bearing mice in this group was 72  6.7 days. Kaplan Meier survival analysis revealed a highly significant difference between these cohorts (P = 0.01). Interestingly, Akt expression could substitute for Pten loss in this context. Melanoma developed in 88% (15/17) of the DCT-TVA/BrafCA mice following viral delivery of activated Akt and Cre, which mediated Braf activation combined with Ink4a/Arf loss; median survival of tumor bearing mice in this group was 60  6.6 days. Kaplan Meier survival analysis revealed that there was no significant difference between cohorts with Pten loss or Akt expression (P = 0.658). Expression of virally delivered Akt in the absence of Cre did not lead to tumor formation in control cohorts (0/7) and no uninfected mice developed melanoma (0/14). Histological examination of the tumors generated in the BrafCA mice with delivery of Cre and Akt viruses demonstrated that they were very similar to tumors lacking Pten. Importantly, the tumors were similar to human melanoma consisting primarily of short spindle cells exhibiting high grade nuclear features and prominent nucleoli. Mitotic figures were abundant, and some tumors possessed giant cells with epitheliod features. Occasional neoplasms exhibited regions of necrosis. Extensive lung metastases were evident following Pten loss or Akt expression, but not in tumors lacking activation of Akt, confirming a role of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in melanoma progression and metastasis. Our ongoing experiments seek to further characterize the role(s) of the PI3K/AKT pathway in melanoma progression.']",
        "Doc_id":"AACR_2012-2365",
        "Doc_title":" Defining the role of Akt activation in melanoma development and progression",
        "_version_":1606189014140846080},
      {
        "Meeting_name":" Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets",
        "Background":"['In cutaneous melanoma, the most lethal form of skin cancer, BRAF is mutated in 45% of cases and NRAS in a further 20% of cases. The lack of known drivers in the remaining proportion of samples represents a challenge for personalized medicine. We hypothesize that the BRAF/NRAS double wild-type (WT) samples are a heterogeneous group driven by multiple events that arise independently. We performed whole exome sequencing (WES) and complimentary RNA-seq of 23 tumor tissue samples from 21 patients. Six of these tumors were WT for BRAF and NRAS, so we studied these cases further. The SNV load in the WT samples is more variable than the BRAF or NRAS driven melanomas. The median number of SNVs/Mb ( SD) for BRAF mutant (n = 9), NRAS mutant (n = 7) and BRAF WT/ NRAS WT (n = 6) samples were', ' 12.2  8.0, 42.2  82.7 and 12.6  90.2 respectively. Next we analyzed the TCGA cutaneous melanoma cohort where there are 154 BRAF and 92 NRAS mutated and 76 BRAF WT/NRAS WT samples. The median numbers of SNVs ( SD) were 374  638.3, 577  518.3 and 146.5  1221.6 respectively. The p-value for the comparisons BRAF vs. WT and NRAS vs. WT were 0.087 and 0.002 respectively (two-tailed Mann-Whitney test). We identified the somatic mutations that are specifically enriched for double wild-type samples and observed that the top two hits, NF1 (30.2% in double WT vs. 5.7% otherwise) and KIT (15.8% in double WT vs. 0.8% otherwise) are known driver gene candidates for wild-type melanomas, but we also find other novel candidate driver genes. Thus, we present a framework for identification of driver mutations and therapeutic targets in double wild-type melanomas and integration of these types of data with other large datasets such as those derived from RNA-seq and RPPA will assist in the development of approaches to stratify double wild-type patients for targeted or immune-therapies.']",
        "Doc_id":"AACR_2015-1094",
        "Doc_title":" Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets",
        "_version_":1606189026025406464},
      {
        "Meeting_name":" Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas",
        "Background":"['Current staging of melanoma, as defined in 2009 by the American Joint Committee on Cancer (AJCC), is based mainly on histopathological criteria but is limited in predicting outcome. Complementary molecular markers are not available for routine prognostic assessment.We have previously identified and validated a prognostic nine-gene signature expressed in fresh-frozen (FF) primary cutaneous melanomas (training cohort', ' n=91; validation cohort', ' n=44). A signature-based risk score predicts patient overall survival (OS) independently of AJCC staging (multivariate regression analysis', ' p = 0.0004; hazard ratio', ' 3.8). However, clinical application requires adaptation to formalin-fixed, paraffin-embedded (FFPE) melanomas.Therefore, we have transfered signature expression analysis onto FFPE melanomas. From FFPE melanomas matching the training and validation cohorts of the above FF melanoma study (n=125), RNA was prepared and transcribed into cDNA. Following cDNA pre-amplification, expression of the 9 signature genes, 2 additional candidate genes, and 3 housekeeping genes was quantified by real-time PCR. Correlation of gene expression with OS was evaluated using Cox regression analysis. Expression of a signature of 8 out of 11 genes (risk gene', ' KBTBD10; protective genes', ' DCD, GBP4, COL6A6, PIP, SCGB1D2, SCGB2A2, KRT9) was associated with OS in univariate regression and Kaplan Meier analysis. A signature-based risk score predicted OS independently of AJCC staging (multivariate analysis', ' p=0.0059, hazard ratio 3.09). The misclassification rates were 20% overall, 13.8% for low risk, and 5.7% for double low-risk (combined with AJCC staging). The risk score complemented and refined conventional AJCC staging. Thus, the FF melanoma risk score was successfully transfered onto FFPE melanomas.In order to validate the FFPE melanoma risk score, we analyzed signature expression in an independent cohort of 130 selected FFPE melanomas, which were particularly difficult to classify by AJCC staging (misclassification rate 40.8%), in order to stringently test the performance of the risk score. The misclassification rate of the FFPE melanoma risk score was comparable, even slightly better (39.2%) than that of AJCC staging, confirming its prognostic performance.The FFPE melanoma risk score was also externally validated in a Molecular Diagnostics Lab (Dermatologikum Hamburg). The concordance of melanoma classification exceeded 85%, demonstrating technical robustness of the risk score.We have established and independently as well as externally validated a quantitative, robust prognostic FFPE melanoma risk score that is complementary to AJCC staging in predicting outcome. This demonstrates clinical applicability and allows retrospective risk assessment of melanomas. The score identifies patients at low risk, not identified by AJCC staging, and defines high-risk patients in need of adjuvant therapy.']",
        "Doc_id":"AACR_2014-2861",
        "Doc_title":" Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas",
        "_version_":1606189009300619264},
      {
        "Meeting_name":" The genetic landscape of clinical resistance to RAF inhibition in melanoma.",
        "Background":"['Background', '  Although single-agent RAF inhibition has proved effective in metastatic BRAFV600-mutant melanoma, most patients relapse and some are intrinsically resistant. While several genetic resistance effectors have been identified, a comprehensive assessment of the genetic resistance spectrum in a large patient cohort may further inform resistance patterns and treatment strategies.  Methods', '  Pre-treatment and post-relapse biopsies were obtained from BRAFV600melanoma patients treated with vemurafenib or dabrafenib. Whole exome sequencing of tumor and normal samples was performed to identify exome-wide mutations, insertion/deletions, and chromosomal copy number alterations. Since somatic allelic fraction comparisons across treatment time points must account for variable stromal admixture between biopsies, novel algorithms were applied to impute purity and tumor cell ploidy, thus determining the cancer cell fraction (CCF) of each alteration. Those with enriched CCF in post-relapse samples were nominated as potential resistance effectors.  Results', '  30 patients (towards a goal of 77) were sequenced to a mean depth of 145-fold coverage. In acquired resistance patients (on drug  12 weeks, n=18), NRAS Q61R (28%) and BRAF amplifications (6%) were observed. The remaining patients had multiple clonally enriched alterations in the post-relapse tumors that may drive resistance, including MEK1 mutations at residues previously noted in an in vitro mutagenesis screen for vemurafenib resistance. In the intrinsic resistance cohort (on drug < 12 weeks, n=12), multiple putative resistance mutations not previously observed in the setting of acquired resistance were identified.  Conclusions', '  In addition to reported genetic resistance mechanisms, we identified new MEK1 mutations in resistant samples. For the majority of patients (67%) without events in these genes, computational algorithms identified new candidate drivers of RAF inhibitor resistance. Alterations that predict intrinsic or acquired resistance may also inform new approaches to melanoma therapy. Future studies incorporating longitudinal biopsies and genetic profiling will underpin a robust assessment of clinical resistance in melanoma and other cancers.']",
        "Doc_id":"ASCO_115911-132",
        "Doc_title":" The genetic landscape of clinical resistance to RAF inhibition in melanoma.",
        "_version_":1606188998759284736},
      {
        "Meeting_name":" Epidemiological study to evaluate the prevalence of BRAF V600 mutation in patients (pts) diagnosed with advanced melanoma (AM) in routine clinical practice in Spain.",
        "Background":"['Background', '  Nearly 50% of pts with AM harbor mutations in the BRAF gene which result in activation of the MAPK pathway. BRAF V600 mutations confer sensitivity to BRAF-inhibitors. We aimed to evaluate the prevalence of BRAF V600 mutation and the clinical and anatomopathological characteristics of pts with AM and BRAF mutations in Spain.   Methods', '  Multicenter, cross-sectional study in adult patients diagnosed with AM (stage IIIc/IV).   Results', '  Between July 2013 and October 2014, 264 evaluable pts were enrolled', ' median (range) age 68 (56-77) years; male', ' 57%; family history of melanoma', ' 5.7%. Primary tumor', ' limbs (33%), trunk (30%), head and neck (15%), mucosa (6%), uveal (4%) and unknown (9%). AM stage', ' IIIc (14%), IV (86%). Metastatic sites', ' lymph nodes (57%), lung (36%), skin and soft-tissues (33%), liver (19%), brain (11%). Lactate dehydrogenase (LDH) at diagnosis of AM', ' normal (52%), high (20%) (unknown', ' 28%). Melanoma histology', ' superficial spreading (30%), nodular (23%), mucosal (5%), acral lentigious (5%), uveal (3%); ulceration in 42%; regression in 9.5%; vascular invasion in 8%. Breslow thickness', ' > 4 mm (27%), 2.01-4.0 mm (22%), 1.01-2.0 mm (14%),  1.0 mm (6%). All samples were analyzed for mutation testing, which was mainly performed using the Cobas 4800 mutation kit (96%) on formalin-fixed paraffin-embedded tissue block (74%). Sample source', ' metastases (63%) (lymph nodes', ' 37%),  primary tumor (34%). BRAF mutations were found in 41% of pts. Factors independently associated with BRAF mutations', ' Age (OR', ' 0.977; 95% CI', ' 0.959-0.995; p = 0.012) and melanoma histology (superficial spreading melanoma vs. nodular [OR', ' 0.434; 95% CI', ' 0.219-0.861; p = 0.017] and acral [OR', ' 0.060; 95% CI', ' 0.007-0.483; p = 0.008]). LDH levels and brain metastatases were not associated with BRAF mutations.   Conclusions', '  The prevalence ofBRAF mutation is 41%, and seems to be more frequent in younger pts and those with superficial spreading melanomas.']",
        "Doc_id":"ASCO_149329-156",
        "Doc_title":" Epidemiological study to evaluate the prevalence of BRAF V600 mutation in patients (pts) diagnosed with advanced melanoma (AM) in routine clinical practice in Spain.",
        "_version_":1606188971855970304},
      {
        "Meeting_name":" Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma",
        "Background":"['Background', ' Melanoma, a malignancy originating in pigment-producing melanocytes, is generally resistant to conventional treatments such as radiotherapy or chemotherapy. Molecular targeted therapeutics against BRAF and MEK have shown marked efficacy for patients with metastatic melanoma. However these targeted therapies have a limited duration of response. Palbociclib is a highly selective inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6) that has been shown to inhibit growth of malignant cell lines in vitro and in vivo by preventing the phosphorylation of Rb and stopping the progression G1/S of cell cycle. Cyclin D-CDK4/6-Rb axis has been shown to be dysregulated in 85-90% of melanomas and may represent a new therapeutic target. Our main goal in this study was to evaluate the therapeutic potential of palbociclib in a large panel of human melanoma cell lines to identify potential biomarkers of sensitivity and resistance. Material and Methods', ' We evaluated the response to palbociclib treatment in 48 melanoma cell lines. A comprehensive biomarker screen was performed using mutation and gene expression (Agilent) data. The mechanism of action of the drug was investigated by western blot (WB) analysis measuring phospho-Rb and senescence markers. Effects on the cell cycle and apoptosis were study by flow cytometry. Results', ' A marked differential response to palbociclib was observed across the melanoma cell lines with IC50s ranging from 28nM to over 1M. A subset (14/48) of cell lines were classified as sensitive at clinically achievable concentrations (IC50<150nM). BRAF and NRAS activating mutation did not correlate with sensitivity in vitro. Increased expression of genes correlating with cyclin D-CDK4/6 activation strongly predicted for palbociclib sensitivity. We also found that genomic and expression markers of activation of the hedgehog/smoothened (SHH) pathway strongly predicted for in vitro resistance to palbociclib. These markers included chromosomal amplification of SHH, and high baseline expression of SMO and GLI2. Protein analysis by WB showed a dramatic decrease in phospho-Rb protein only in sensitive cell lines and also it caused a decrease in FOXM1 protein, indicating palbociclib may partially act by inducing senescence in treated cells. Flow cytometry analysis confirmed that palbociclib induces a strong G1/S arrest, but not significant apoptosis. Conclusion', ' Nearly 30% of the melanoma cell lines evaluated were found to be sensitive to palbociclib in vitro. Response to palbociclib did not correlate with BRAF and NRAS mutational status. A gene expression signature for CDK 4/6 activation successfully identified those cell lines most sensitive to palbociclib. We also identified markers of hedgehog/smoothened/GLI activation that strongly predicted for resistance to palbociclib. These data support the development of CDK 4/6 inhibitors in melanoma and provide a hypothesis for patient enrichment in clinical trials.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-1321",
        "Doc_title":" Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma",
        "_version_":1606189012468367360},
      {
        "Meeting_name":" A digital sorting-based detection and isolation assay for single disseminated cancer cells from lymph nodes of melanoma patients",
        "Background":"['We recently showed that sentinel lymph node (SLN) disaggregation followed by immunocytology enables precise quantification of disseminated cancer cells (DCC). We demonstrated that this approach has a 20-fold higher sensitivity to detect melanoma DCCs than routine histopathology and that the DCC density (DCCD, defined as the number of DCCs per million lymph node cells) together with ulceration state and tumor thickness enables individual risk prediction superior to current AJCC guidelines (Ulmer et al., PLoS Medicine, 2014). Here, we present the adaptation of this method to a semi-automated workflow, including automated single cell detection and isolation by DEPArrayTM technology for subsequent molecular analysis of DCCs from SLN of melanoma patients.The developed workflow includes a mechanical disaggregation of lymph node tissue and collection of the mononuclear cells after Percoll density centrifugation. Several tumor cell enrichment methods were tested (CellSearch and size-based enrichment technologies), however, failed to process cell suspensions generated from lymph nodes due to clumping of cells during the enrichment procedure. Tumor cell enrichment using MACS depletion of CD45+ cells delivered approx. 50% of spiked-in cell line cells with a mean depletion rate of lymphocytes and erythrocytes > 98%. To prevent limitations in DCC detection caused by phenotypic heterogeneity of tumor cells, we established a double staining against two melanoma-associated markers gp100 and MCSP. Individual melanoma cells are then detected and isolated by DEPArrayTM technology enabling single cell whole genome amplification (Ampli1TM) for subsequent molecular analysis as assessment of copy number alterations (e.g. by arrayCGH) or sequence analysis for melanoma specific point mutations (e.g. BRAF or NRAS). We successfully applied the workflow to first SLN samples from melanoma patients.The established workflow enables a standardized detection of single DCCs from lymph nodes of melanoma patients applicable in clinical diagnostic labs. Automated single cell isolation and subsequent molecular analysis of DCCs is feasible within short time after SLN biopsy. In the future, this approach could help to select individualized therapies for melanoma patients.']",
        "Doc_id":"AACR_2016-472",
        "Doc_title":" A digital sorting-based detection and isolation assay for single disseminated cancer cells from lymph nodes of melanoma patients",
        "_version_":1606189007325102080},
      {
        "Meeting_name":" A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.",
        "Background":"['Background', '    Metastatic uveal melanoma represents an orphan disease area with a median survival of less than 6 months. There is currently no effective systemic therapy for metastatic uveal melanoma and few clinical trials have been conducted. In the absence of phase III data, many patients in the UK continue to receive single agent dacarbazine or best supportive care outside of the context of clinical trials. Uveal melanoma is characterized by activation of the MAP kinase pathway via functionally activating mutations in Gnaq/11. Evidence also suggests that dysfunctional c-Kit signalling and angiogenesis may both play a role in disease progression and a small single-arm phase II trial recently reported preliminary activity using the multi-targeted receptor tyrosine kinase inhibitor, sunitinib (Tijani et al, ASCO 2010).   Methods', '    The SUAVE trial aims to evaluate the Progression Free Survival (PFS) of good performance status patients treated with sunitinib or dacarbazine.  Secondary objectives include', ' Overall Survival (OS), Overall Response Rate (ORR), safety, crossover PFS and response and biomarker analyses. SUAVE is a CR-UK-funded, open-label, randomised, phase II trial that will include 124 patients.  Patients will be stratified according to their Helsinki Prognostic Index (ALP, largest diameter of largest metastasis, ECOG). Inclusion Criteria', ' good performance status patients with confirmed unresectable metastatic uveal melanoma, with at least one target lesion measurable by RECIST 1.1. Patients must not have received previous systemic therapy. At confirmed progression, good performance status patients may crossover to the other study treatment. The trial opened in Oct 2010 and as of 23 January 2012, had randomized 49 patients with at least 1 recruited from each of the 12 recruiting sites.  There will be a total of 13 sites. Completion of the recruitment phase is expected within 36 months. Prospective tissue and blood sample collection for translational biomarker analyses is also ongoing. The SUAVE trial represents one of the largest randomised trials in this rare disease area (Clinical trial registry number', ' 2008-008794-55).']",
        "Doc_id":"ASCO_98121-114",
        "Doc_title":" A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.",
        "_version_":1606189011572883456},
      {
        "Meeting_name":" Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells (CETCs) from blood of patients with malignant melanoma.",
        "Background":"['Background', ' Almost 50% of melanomas harbor mutations in BRAF, mainly V600E. The mutations are usually identified in the primary tumor. However, the primary tumor is often no longer available and metastases not always reflect the characteristics of the primary tumor. In melanoma it is not clear at what stage epithelial antigen is expressed. CETCs are present in peripheral blood in a significant proportion of patients with malignant melanoma. The aim of the present study was to analyze whether these cells belong to melanoma clone due to the presence of the BRAF gene mutation in these cells. For this reason, the analysis of multiple isolated CETCs from individual patients for BRAF gene mutations was performed.  Methods', ' Blood from patients with malignant melanoma was analyzed for cells positive for the EpCAM and Melan-A using the maintrac approach, avoiding cell selection and using an image analysis system for detection. Subsequently, between 8-20 EpCAM and Melan-A positive cells from each patient were isolated individually using a semi-automated capillary approach and deposited one by one into micro cups. The DNA of individual cells was amplified by whole genome amplification and assayed using the cobas BRAF V600 mutation test. Furthermore, we performed mutation analysis of cells after magnetic bead enrichment which is known to contain a mixture of CETCs and leukocytes.  Results', ' DNA could be amplified from all individually isolated cells. In addition, we analyzed the presence of V600 mutation after magnetic bead enrichment. A BRAF mutation was detected in 20 - 75 % of evaluable cells in patients with BRAF mutation in primary tumor. In advanced stage or metastatic patients under Vemurafenib therapy, we were not able to find mutated CETCs.  Conclusions', ' Individually isolated CETCs from the peripheral blood from patients with melanoma allow not only to detect mutations but also to determine the frequency of mutated cells. This proves that at least part of the CETCs is originated from the primary tumor. Furthermore, detection of BRAF mutation in CETCs may be crucial for a successful molecular-targeted therapy.']",
        "Doc_id":"ASCO_151547-156",
        "Doc_title":" Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells (CETCs) from blood of patients with malignant melanoma.",
        "_version_":1606189032962785280},
      {
        "Meeting_name":" Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.",
        "Background":"['Background', '   Traditionally, oncology biomarker discovery and development has required the use of material obtained from tissue biopsies. However, recent developments in the exosome field have allowed biomarker research in biofluids to evolve. Exosomes are highly stable microvesicles, approximately 30-200 nm in diameter, that are shed by cells into all biofluids, including blood, urine, and CSF, carrying a rich source of intact protein and RNA. RNA can be efficiently isolated and addressed using technologies such as RT-qPCR and NGS. Here we demonstrate the use of RNA extracted from these vesicles to monitor transcriptional changes in response to an immunotherapy treatment for malignant melanoma.   Methods', '  Exosomes were isolated, using exoRNeasy columns, from plasma collected from malignant melanoma patients treated with Ipilimumab. Patients were split in two groups, based upon either a positive or negative response to the therapy (15 patients in total). Plasma was collected pre-treatment (baseline) and at 3 time-points post initial treatment (2 and 4 weeks, and 4 months). RNA was extracted using exoRNeasy kit. We screened the levels of 586 mRNAs associated with inflammation and 21 mRNA controls by RT-qPCR using the OpenArray technology  Results', '   Over 450 genes were detected across all samples and time-points. A number of mRNA species showed differential expression in patients responding to the therapy compared to those that did not respond. These mRNAs have previously been linked to tumor progression or suppression; current candidate genes of interest include BMP2, PLCG1 and PDGFB. In addition, levels of a subset of mRNA were shown to continue changing as a response to the therapy. This indicates that the exosome RNA profile can be used for longitudinal monitoring of treatment response.  Conclusions', '   RNA expression profiling from circulating exosomes offers the ability to monitor changes in immune pathway genes serially during immunotherapy. Initial data suggest expression signature changes occur early during therapy, offering the potential for predicting response.']",
        "Doc_id":"ASCO_148929-156",
        "Doc_title":" Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.",
        "_version_":1606189028548280320},
      {
        "Meeting_name":" Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.",
        "Background":"['Background', ' The survival of patients with metastatic uveal melanoma remains poor; most patients ultimately die of hepatic metastasis. Tumor cell expression of insulin-like growth factor-I receptor (IGF-1R) is a marker of poor prognosis in primary uveal melanoma. IGF-1 is produced mainly in the liver, which may account for the hepatic tropism of uveal melanoma. Therefore, we investigated the importance of IGF-1/IGF-1R interaction in hepatic metastases.Methods', ' The expression pattern of IGF-1R in hepatic metastases of uveal melanoma was analyzed by immunohistochemistry in a series of archival samples from patients treated at Thomas Jefferson University Hospital. To investigate the biological role of exogenous and endogenous IGF-1 on the growth of a uveal melanoma, a long-term, cell line obtained from a hepatic metastasis (TJU-UM001) was evaluated concurrently.Results', ' All 24 metastases stained positive by IGF-1R. Tumors showed 80-95% of cellular staining while adjacent normal liver showed negative staining. IGF-1R was expressed in both the cytoplasm and the exterior membrane of uveal melanoma cells. As previously reported (AACR 2010, Abstract #359), more than 90% of TJU-UM001 cells expressed IGF-1R on their surface and did so at approximately 1.2 x 104 IGF-1R per TJU-UM001 cell. The cell proliferation assay (Quick Cell Proliferation Assay Kit II; BioVision, Mountain View, CA) showed that quiescent TJU-UM001 was induced to proliferate by 2.6-fold (p<0.001) in response to exogenous IGF-1 at 300 ng/ml. Conversely, anti-IGF-1R antibody completely blocked the exogenous IGF-1-induced growth of TJU-UM001. IGF-1 preferentially induced phosphorylation of Akt (S473) in quiescent TJU-UM001 cells and this was blocked by anti-IGF-1R antibody. Cell proliferation kinetics analysis showed TJU-UM001 grows briskly in serum-free medium (SFM) and anti-IGF-1R antibody significantly inhibited growth. Correspondingly, TJU-UM001 maintained in SFM expressed mRNA for IGF-1 and furthermore secreted IGF-1 protein. Both anti-IGF-1 and anti-IGF-1R antibodies independently inhibited the spontaneous proliferation of the cells in SFM (p<0.05) suggesting a critical role for endogenous IGF-1 expressed by TJU-UM001 cells.Conclusion', ' Although the strong and extensive expression of IGF-1R in archival tissue specimens suggests paracrine stimulation via IGF-1R as a major mechanism of the growth of uveal melanoma in the liver, cell proliferation in SFM and the endogenous production of IGF-1 by tumor cells indicate an autocrine mechanism via IGF-1R is also operative. The results underscore a key role of IGF-1 in promoting the growth of uveal melanoma. The present study shows autocrine and paracrine mechanisms underlay IGF-1-induced uveal melanoma growth and indicate how these mechanisms can be targeted to suppress metastatic growth and improve clinical outcome.']",
        "Doc_id":"AACR_2013-2815",
        "Doc_title":" Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.",
        "_version_":1606189008819322880},
      {
        "Meeting_name":" LMTK3 is a novel regulator of oncogenic KIT in KIT-mutant cancers",
        "Background":"['Multiple cancers, such as gastrointestinal stromal tumors (GIST) and melanoma, have been shown to be caused by somatic activating mutations in the receptor tyrosine kinase KIT. The major cause of death in patients with advanced KIT-mutant cancers is due to KIT tyrosine kinase inhibitor-resistant metastatic disease. Resistance develops almost exclusively because of secondary mutations within KIT, highlighting the importance of KIT in the proliferation and survival of these tumors. Therefore, strategies that affect KIT protein expression and maturation may be therapeutic. In order to identify regulators of KIT that may represent novel targets, we performed an siRNA screen in multiple KIT-mutant cancer cell lines. From these screens we identified lemur tyrosine kinase 3 (LMTK3) as a novel KIT regulator and potential target in KIT-mutant cancers. LMTK3 has been implicated as an important protein in multiple cancers, including leukemia, breast, and colon cancer. However, the oncogenic function of LMTK3 is not entirely clear. Despite its name, lemur tyrosine kinase 3 is, in fact, a serine/ threonine kinase. Beyond its enzymatic kinase function, LMTK3 has also been shown to have important scaffolding functions. LMTK3 has not been previously known to interact with KIT, but does regulate the stability of other receptors. We have found that LMTK3 silencing reduced the viability of all KIT-mutant GIST and melanoma cells tested to date, including those with ATP binding pocket and activation loop resistance mutations. Importantly, LMTK3 silencing decreased the viability of KIT-mutant cells specifically, as silencing of LMTK3 in cells lacking KIT mutations did not affect their viability. Further, we found the decrease in cell viability was due to induction of apoptosis, as seen by cleavage of PARP within 96 hours of LMTK3 silencing. Because these cells depend so heavily on KIT and loss of KIT signaling results in cell death, we hypothesized that LMTK3 silencing may be affecting this pathway. Indeed, with LMTK3 silencing there was a significant decrease in phosphorylated KIT (Y719), which was accompanied by decreased phospho-AKT (S473). We also observed a robust decrease in total KIT protein levels. However, there was no decrease in KIT transcript levels, suggesting that LMTK3 plays a role in regulating KIT at the protein level. While other KIT protein regulators, such as HSP90, have been suggested as therapeutic targets for GIST, the ubiquitous functions of these targets makes these treatments sub-optimal, often causing toxicity. Silencing of LMTK3, on the other hand, specifically kills KIT-mutant cancer cells. Furthermore, as a kinase, inhibition of LMTK3 by a small molecule may be possible, and we are in the process of identifying LMTK3 inhibitors. LMTK3 is a positive regulator of oncogenic KIT in GIST and melanoma and represents a novel, tractable target in KIT-mutant cancers.']",
        "Doc_id":"AACR_2016-191",
        "Doc_title":" LMTK3 is a novel regulator of oncogenic KIT in KIT-mutant cancers",
        "_version_":1606189040731684864},
      {
        "Meeting_name":" A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).",
        "Background":"['Background', ' There was no standard treatment for advanced mucosal melanoma patients. BEAM study have demonstrated the effectivity and safety of bevacizumab combined with carboplatin plus paclitaxel in patients with previously untreated metastatic melanoma. This study was to evaluate the activity of bevacizumab combined with carboplatin plus paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma. Methods', ' This study is an open-label, multicenter, randomized phase II trial. Eligible patients had metastatic, or unresectable mucosal melanoma without any systemic therapy. Additional inclusion criteria included  1 measurable diseaseECOG PS 0/1, and adequate organ functions. The patient with mutations in c-KIT or BRAF-V600E will be excluded from this study. Patients were randomly allocated in a 1', '1 ratio to receive bevacizumab (CPB arm, 5mg/kg every two weeks) or placebo (CP arm) with carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2), all by intravenous infusion. Treatment was continued for both groups until disease progression, unacceptable toxicity, death, or withdrawal of consent. The primary study endpoint is progress-free survival (PFS). Overall survival, disease control rate, and safety will also be assessed. Results', ' The first patient visit was December 1, 2013; ninety-four of a planned 182 evaluable pts have been enrolled; 63.8% female, median age was 59 years old, and randomly assigned to the CBP (n = 46) or CP arm (n = 48). The objective response rate was 10.9% and 4.1% respectively. The median progression-free survival was 5.0 months and 3.0 months respectively (p = 0.028). The median overall survival was 12.0 months and 11.5 months respectively (p = 0.754). Treatment emergent grade 3 or 4 adverse events were neutropenia (13.0%), hypertension (4.3%), proteinuria (4.3%) in the PCB arm; and neutropenia (10.4%) in the PC arm. Conclusions', ' This is the largest study about advanced mucosal melanoma which demonstrated that bevacizumab in combination with carboplatin plus paclitaxel is active and safe as first line therapy in advanced mucosal melanoma. Clinical trial information', ' NCT02023710']",
        "Doc_id":"ASCO_167532-176",
        "Doc_title":" A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).",
        "_version_":1606189026566471680},
      {
        "Meeting_name":" Regulation of the functional interface between nucleotide excision repair and transcription by MITF modulates melanoma growth",
        "Background":"['Nucleotide excision repair (NER) is an essential instrument to maintain genomic stability in eukaryotes especially towards ultraviolet radiation (UVR). There is profound knowledge of the mechanistic execution of NER, however its regulation is not well understood. Here we provide evidence that the lineage-dependent oncogene MITF regulates the functional interface between NER and transcription through transactivation of XPG and GTF2H1, which constitute core elements of the NER and general transcription factor machineries, respectively.For this purpose, flow cytometry and microscopy fluorescence assays were applied to evaluate the temporal repair kinetics of DNA lesions after UVR in the presence and upon depletion of MITF in human primary melanocytes and several melanoma cell lines. Moreover, ChIP and luciferase reporter assays were performed to show the in vivo occupancy and a MITF dependent transactivation of the XPG and GTF2H1 promoters. Transcriptome as well as tissue microarrays (TMA) analysis were used to demonstrate the relationship between MITF and TFIIH. Finally, in vivo experiments were performed utilizing a subcutaneous xenograft tumor model in SCID mice to confirm our hypothesis.Our results showed that the NER/TFIIH complex is controlled by MITF in the presence and absence of UVR mediated genotoxic attack resulting in nucleotide repair deficiency and breakdown of global transcription upon MITF depletion. Importantly, in primary human melanoma the TFIIH subunit GTF2H1, which is involved in NER and RNA transcription, is linked to MITF abundance and prognostic melanoma stage. Moreover, RNA-interference mediated repression of GTF2H1 led to a significant reduction in tumor formation in a melanoma xenograft model.Collectively, these results describe an unanticipated role of MITF in the regulation of intimately linked NER and transcription machineries in the melanocytic lineage, which is preserved upon transformation into melanoma. Through its control of the NER/TFIIH complex MITF might coordinately regulate repair and transcription processes, thereby optimizing the rapid resumption of transcriptional activity after completion of strand repair, which is vitally important for cellular survival. The very same mechanism may drive the genesis of melanoma and its progression in the context of aberrant transcriptional activity of MITF due to SUMOylation defective germline mutation or genomic amplification.']",
        "Doc_id":"AACR_2014-2950",
        "Doc_title":" Regulation of the functional interface between nucleotide excision repair and transcription by MITF modulates melanoma growth",
        "_version_":1606189042138873856},
      {
        "Meeting_name":" A novel selective Mcl-1 inhibitor exhibits in vitro and in vivo efficacy in melanoma.",
        "Background":"['Metastatic melanoma is the deadliest form of skin cancer that still has limited treatment options and dismal 5-year year survival rates as low as 15%. Only recently has there been significant progress in the treatment of metastatic melanoma, advent by molecular targeted drugs and immunotherapy, but their limitations are exposed as these cancers are quickly able to develop resistance. Dysregulation of apoptotic machinery in melanoma allows the cancer cells to evade cell death and contributes to treatment resistance. Up-regulation of Mcl-1, a member of the Bcl-2 family of anti-apoptotic proteins, has been correlated with melanoma progression and metastasis. Mcl-1 amplification is one of the most common genetic aberrations found in human cancers and has been labeled as a marker of aggressive oncogenesis and poor patient prognosis. Previous studies have pointed to Mcl-1 as a viable therapeutic target for the treatment of melanoma and conclude that small molecule Mcl-1 inhibitors may appeal this unmet medical need. We have discovered and characterized a new class of selective small molecule Mcl-1 inhibitors using various biochemical, functional, and cell based assays; further development of these compounds allowed us to achieve potent low-nanomolar binding affinity for Mcl-1 and more than 300-fold selectivity over Bcl-2/Bcl-xL. Our most potent inhibitor, 483-LM, was screened across a panel of human melanoma cell lines using a cell proliferation assay and revealed varying levels of sensitivity. A BH3 profiling assay demonstrates that C8161, the cell line most sensitive to our inhibitor, solely relies on Mcl-1 for survival. The Mcl-1 dependence of C8161 might contribute to the known metastatic nature of this cell line. Mechanistic studies revealed that 483-LM effectively engaged the endogenous Mcl-1 protein after treatment of C8161, as determined by a CETSA assay, and prompted disruption of protein-protein interactions between Mcl-1 and several pro-apoptotic proteins, including Bax, Bak and Bim. This was followed by induction of Bax/Bak dependent apoptosis and activation of hallmarks of the intrinsic apoptotic pathway, including mitochondrial outer membrane depolarization, caspase activation, and PARP cleavage. Importantly, treatment with 483-LM caused massive up-regulation of the pro-apoptotic BH3-only protein Noxa, an effect apparent after an 8 hour treatment, which contributes to the induction of cell death. The in vivo efficacy studies with 483-LM showed significant effect on tumor growth and caspase-3 activation in tumor samples. Overall, our data indicate that Mcl-1 inhibitors are a promising treatment option for aggressive metastatic melanoma and warrant further preclinical investigation of 483-LM as a promising selective Mcl-1 inhibitor to be used as a single agent and in combination with chemotherapy and immunotherapy.']",
        "Doc_id":"AACR_2017-1173",
        "Doc_title":" A novel selective Mcl-1 inhibitor exhibits in vitro and in vivo efficacy in melanoma.",
        "_version_":1606188981690564608},
      {
        "Meeting_name":" Cross-site reproducibility and orthogonal validation of copy number and somatic mutation calls of OncoScan FFPE Assay Kit in solid tumors",
        "Background":"['ObjectivesCopy number (CN) and somatic mutation (SM) analysis in tumors is rapidly gaining importance in cancer management as a tool for differential diagnosis, determination of prognosis, and selection of therapeutic. Genome-wide copy number and LOH detection as well as a panel of frequently tested somatic mutations can be detected with OncoScan FFPE Assay Kit. We report on a validation study of OncoScan FFPE Assay Kit CN and SM data by orthogonal technologies (FISH and NGS, respectively) to estimate the sensitivity and specificity parameters of the platform. In addition, we assessed the reproducibility of the platform across three different sites in the UK', ' Leeds Institute of Cancer and Pathology (LICP), West Midlands Regional Genetics Laboratory (WMRGL), and Almac Diagnostics (Almac).MethodsValidation of CN data was performed on a cohort of cancer samples identified as Her2 positive/ambiguous by FISH. The panel of SMs available was validated by a custom targeted amplicon NGS panel on a diverse collection of samples derived from multiple cohorts across several tumor types sourced from both LICP and WMRGL. For the reproducibility study, 162 samples encompassing six different tumor types (breast, colorectal, lung, melanoma, prostate, and ovarian) were collected from LICP and WMRGL. DNA was extracted and plated in triplicate and distributed to the three testing sites', ' LICP, WMRGL, and Almac. Data from all sites was analyzed for reproducibility of genome-wide CN/LOH calls and SM calls.ResultsCross-site comparisons of genome-wide CN and LOH profiles on 162 FFPE solid tumor samples showed greater than 95% average agreement between three sites (LICP, WMGRL, and Almac), while SM classification concordance between the sites averaged 97%. Initial orthogonal validation of Her2 amplification by FISH showed greater than 90% concordance, as did initial test samples used for validating OncoScan SM calls by a targeted amplicon NGS panel.ConclusionIn this study we validated both CN and SM calls using OncoScan FFPE Assay Kit and demonstrated a high degree of agreement with orthogonal methods in all aspects. Reproducibility of whole-genome CN, LOH, and SM data using OncoScan FFPE Assay Kit has also been demonstrated for a range of FFPE samples, including highly degraded samples. This study is a step forward in evaluating the potential clinical utility of a platform combining genome-wide copy number and somatic mutation calls within the national health service of the UK.']",
        "Doc_id":"AACR_2015-626",
        "Doc_title":" Cross-site reproducibility and orthogonal validation of copy number and somatic mutation calls of OncoScan FFPE Assay Kit in solid tumors",
        "_version_":1606189037532479488},
      {
        "Meeting_name":" Growth factor-mediated resistance to BRAF/MEK inhibitors in BRAF mutant melanoma",
        "Background":"['BRAF and MEK inhibitors induce striking tumor regressions in BRAF V600E melanoma patients. However, relapse occurs in the majority of patients within several months. Reported resistance mechanisms include acquisition of NRAS mutations, PDGFR or IGF1R activation, Cot amplification, or truncated BRAF upregulation. We report here that hepatocyte growth factor (HGF), neuregulin-1 (NRG1), and fibroblast growth factor-2 (FGF2) cause robust resistance in vitro to BRAF or MEK inhibitors in BRAF mutant melanoma cell lines. NRAS mutant lines were similarly resistant to MEK inhibition in the presence of these growth factors. By contrast other mitogenic factors such as PDGF, EGF, NGF, BDNF, MSP, MDK, GRO, and IGF1 did not maintain cell viability or growth. HGF, NRG1 and FGF2 prevented growth arrest and cell death and in some cell lines maintained cells in progressive growth. In addition, HGF and NRG1 could prevent growth arrest after dual treatment with BRAF and MEK inhibitors. Western analysis revealed that HGF and NRG1 reactivated Erk signaling and activated S6RP and AKT phosphorylation. Combined pharmacological inhibition mTor signaling and Akt signaling was required to fully block growth factor-mediated proliferation. In addition, small molecule Met inhibitors and an anti-HGF antibody blocked HGF-mediated resistance, while lapatinib and an anti-NRG1 antibody blocked NRG1-mediated resistance. While combined Akt and mTor inhibition potently inhibited cell line growth independent of BRAF or MEK inhibition, lapatinib and Met inhibitors had minimal effect on growth, suggesting potential for less adverse events with receptor inhibitors. In vitro co-culture experiments revealed that primary cells present in normal skin can cause resistance, and we have identified growth factors produced by these cells that contribute to resistance. We are analyzing receptor activation (Met and Erbb3) and FGF2 expression in wildtype, NRAS, and BRAF mutant primary melanoma samples. In future experiments we plan to test clinical samples from patients treated with BRAF/MEK inhibitors, and we hypothesize that HGF, NRG1, and FGF2 signaling is elevated in patients with poor initial responses or relapse to BRAF or MEK inhibitors.']",
        "Doc_id":"AACR_2012-1065",
        "Doc_title":" Growth factor-mediated resistance to BRAF/MEK inhibitors in BRAF mutant melanoma",
        "_version_":1606189027468247040},
      {
        "Meeting_name":" A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary (CUP) using circulating tumor cells",
        "Background":"['Metastasis is responsible for the majority of cancer-related deaths. A limiting step in metastasis is access to circulation, thus circulating tumor cells (CTCs) should be present in all patients with metastatic tumors, which may have both diagnostic and prognostic value. Accounting for only 2-3%, carcinoma of unknown primary (CUP) presents a challenge for clinicians in diagnosis and therapy. Tissue biopsy is the standard for diagnosis but there is need for improved methodology including a non-invasive blood test that may rely on CTC analysis. We have been developing a post-Veridex CTC analysis method using multiplexed Q-dot conjugated antibodies with the goal of detection of multiple markers in each single cell within a CTC population to aid in CUP diagnosis including tissue of origin. We have developed an immunofluorescence (IF) protocol with a minimal set of markers to predict the primary sites and provide prognostic information for common metastatic tumors', ' melanoma, lung, colorectal, upper gastrointestinal organs, and breast or prostate cancer. Two kits are available to isolate CTCs through Veridex CellSearch', \" melanoma kit (using melanoma antigen), and epithelial or carcinoma kit (using EpCam). A patient's blood is initially tested with both kits, and positive CTCs from the melanoma kit supports a diagnosis of melanoma, whereas positive CTCs from the epithelial kit supports carcinoma. For carcinomas, we use cytokeratin 7 (CK7), cytokeratin 20 (CK20), thyroid transcription factor 1 (TTF-1), estrogen receptor (ER) or prostate-specific antigen (PSA) as the minimal set of markers. IF has been optimized in cultured tumor cells, first with individual antibodies, then quantum dots (Q-dot) conjugated multiplex quadra-antibody set. We evaluated antibodies by IF specific to these 5 markers in lung, breast, colorectal, and prostate cancer cell lines. The CK7 and ER antibodies conjugated to Qdot 605 and 705 respectively demonstrated expression in the appropriate cell lines. CK7-Qdot 605 and ER-Qdot 705 expression in cells that were recovered after being spiked into normal blood samples and isolated by the Veridex CellSearch system was similar to that observed with unconjugated antibodies. Our data show that it is feasible to detect expression using Qdot-labeled multiplexed antibodies on tumor cells isolated from blood by Veridex CellSearch system. Successful application of this protocol to CTCs in patient samples is expected to provide a noninvasive, relatively quick and inexpensive blood test that can be both diagnostic and prognostic, which may be a valuable adjunct to routine biopsy.\"]",
        "Doc_id":"AACR_2012-3625",
        "Doc_title":" A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary (CUP) using circulating tumor cells",
        "_version_":1606188994365751296},
      {
        "Meeting_name":" Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by enhanced-ice-cold-PCR.",
        "Background":"['Background', '  Two BRAF inhibitors have been approved for patients with BRAF V600 activating mutation. However, to date the different tools developed for the detection of BRAF V600 mutations lack sensitivity and/or specificity or do not allow sequencing-based identification of the mutation. Enhanced-ice-COLD PCR  is a very sensitive assay, which enables a strong enrichment of the mutation during the PCR where mutant and WT alleles undergo exponential and linear amplification, respectively. Methods', '  Methods', ' Two melanoma-derived cancer cell lines harboring different heterozygous BRAF codon 600 mutations were used in this study for assay optimization. Molecular analyses were performed on 18 fresh frozen, 17 FFPE melanoma and 17 plasma samples from patients suffering from advanced melanoma were used. E-ice-COLD-PCR was performed using a 96-well real-time thermocycler followed by pyrosequencing and automatic mutation identification and quantification.  Results', ' This assay has a large dynamic range as 25 pg to 25 ng can be used as DNA input without any reduction in mutation enrichment efficiency and is ultra-sensitive as it can detect up to 0.01% of mutated alleles in a wild-type background. The assay has been validated on fresh frozen, FFPE and plasma samples of melanoma patients and has allowed the detection and identification of BRAF mutations present in the samples which appear as wild-type using standard pyrosequencing, endpoint genotyping or Sanger sequencing.  Conclusions', '  This BRAF V600 E-ice-COLD PCR assay is currently the most powerful molecular diagnostic tool for ultra-sensitive detection and identification of BRAF codon 600 mutations.']",
        "Doc_id":"ASCO_134616-144",
        "Doc_title":" Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by enhanced-ice-cold-PCR.",
        "_version_":1606188970959437824},
      {
        "Meeting_name":" Delta-tocotrienol and simvastatin induce cytotoxicity and synergy in BRAF mutant SK-MEL-28 but not in wild type BRAF SK-MEL-2 melanoma cancer cells",
        "Background":"['Targeting the mutant BRAF protein is an accepted approach to the treatment of metastatic melanoma. Potent and specific BRAF inhibitors like vemurafenib and dabrafenib are superior to chemotherapy in treatment of BRAF mutant melanomas which represent nearly 50% of all melanomas. Previous studies have shown that certain isoforms of vitamin E and statins can have synergistic anti-cancer activity. We determined whether a combination of delta-tocotrienol (DT3), an unsaturated vitamin E isoform, and simvastatin, an HMG-CoA reductase inhibitor, can exert an anti-neoplastic activity on BRAF-mutated SK-MEL-28 and BRAF-wild type SK-MEL-2 melanoma cell lines and whether a differential effect would be evident.MTS assays were used to analyze cytotoxicity. SK-MEL-28 and SK-MEL-2 cells were cultured in MEM media containing 10% serum and plated in 96-well culture plates for 24 hours then treated with DT3 (0-40 M), simvastatin (0-5 M), or a combination and dosed again at 48 hours. SK-MEL-28 and SK-MEL-2 cells grown in 60 mm plates and were treated with DT3 at concentrations of 40, 30, 20 M, simvastatin at a concentrations of 20, 10, 5 M or dissolution vehicle as a control for 6 h. Protein concentration of cell lysates was measured spectrophotometrically (GLO Max Multi+, Promega), using a BCA protein assay kit. The samples were run in SDS PAGE and blotted onto nitrocellulose membranes. Membranes were incubated with antibodies against Hsp 70 (Enzo Life Sciences, Farmingdale, NY), Hsp 90 (Santa Cruz, Dallas, TX), pS6 and pBAD (Cell Signaling, Danvers, MA).Using MTS assay, we found that DT3 (IC50 38.8 M) and simvastatin (IC50 22.7M) have cytotoxic effects on melanoma cell line SK-MEL-28, but on the SK-MEL-2 cells DT3 does not have an effect at the concentrations studied (10-40 M DT3) yet simvastatin (IC50 16.9 M) does have cytotoxicity. Further studies determined that combinations of these drugs display a synergistic effect on SK-MEL-28 by inhibition of pS6 and pBAD and subsequent apoptosis. However, these effects are not observed in SK-MEL-2 cells; treated SK-MEL-2 cells show over-expression of Hsp70 and Hsp90 suggestive of a rescue effect leading to lesser cytotoxic activity. The selective cytotoxicity observed in BRAF-mutated cells and not in wild type BRAF melanoma cell lines by both DT3 and simvastatin warrants further research into the potential therapeutic use of these combinations. This observation has added importance in the light of recent findings that show the acquisition of BRAF mutation is an early event in melanogenesis and hence these compounds may have a key role in chemoprevention approaches to melanoma.']",
        "Doc_id":"AACR_2016-3568",
        "Doc_title":" Delta-tocotrienol and simvastatin induce cytotoxicity and synergy in BRAF mutant SK-MEL-28 but not in wild type BRAF SK-MEL-2 melanoma cancer cells",
        "_version_":1606189023038013440},
      {
        "Meeting_name":" Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma",
        "Background":"['Background', ' Although remarkable progress has been made in the genomic characterization of cutaneous melanoma, the genetic alterations of primary mucosal melanoma (PMM) remain largely unknown. This study aims to investigate the recurrent mutations in PMM and to characterize the oncogenic potential of the newly identified ZNF767-BRAF fusion as well as its therapeutic implications in PMM.Methods', ' A total of 46 PMMs underwent exon-capture sequencing of 111 cancer-associated genes to identify somatic non-synonymous mutations, copy number alterations, and structural variations. A cancer cell with a novel ZNF767-BRAF fusion was established from a patient with PMM of the respiratory tract, who was refractory to vemurafenib. To characterize the oncogenic functions of the novel ZNF767-BRAF fusion, we performed western blot, soft agar growth assay and in vivo tumor. The inhibitory effects of vemurafenib, trametinib, buparlisib and LEE011 monotherapy and their combination treatment were measured in vitro and in vivo.Results', ' Targeted exon-capture sequencing of 46 PMMs revealed a total of 48 somatic non-synonymous mutations in 26 genes. Eight genes harbored recurrent mutations on NRAS (n = 6; 13%) and TP53 (n = 4; 9%) along with BRAF, KIT, MAP3K9, C8A, KRAS, FGFR3 (all observed in two cases; 4%). Of note, a novel ZNF767-BRAF fusion was identified in a PMM of the respiratory tract refractory to vemurafenib treatment. ZNF767-BRAF fusion was validated by Sanger sequencing. We show that ZNF767-BRAF encoded protein promotes the dimerization of RAF and potently activates mitogen-activated protein kinase pathway. The ectopic expression of ZNF767-BRAF fusion induced tumor formation as shown in colony forming assay and tumor xenograft model. The treatment of trametinib inhibited the growth of PMM cells harboring the ZNF767-BRAF fusion but vemurafenib showed no inhibitory effects. Compared with either agent alone, the combination of trametinib and buparlisib showed synergistic antitumor effects in vitro and in vivo.Conclusions', ' The genomic makeup of PMM is remarkably diverse and distinct from that of cutaneous melanoma. BRAF fusion defines a new molecular subset of PMM and can be therapeutically targetable by the combination of MEK inhibitor and PI3K Inhibitor.']",
        "Doc_id":"AACR_2015-3942",
        "Doc_title":" Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma",
        "_version_":1606189020769943553},
      {
        "Meeting_name":" Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition",
        "Background":"['Epigenetic changes in cancer are thought to contribute to regulation of invasion and metastasis. To study this at a genome-wide level in melanoma we analyzed the methylome of 44 cases of malignant melanoma with the HELP (HpaII tiny fragment enriched by LM-PCR) assay and compared it to melanocyte controls. We saw widespread demethylation in melanoma occurring preferentially outside of CpG islands. Comparison of primary and metastatic lesions demonstrated that demethylation occurs early during carcinogenesis with few additional alterations in advanced tumors. Parallel transcriptomic analysis revealed many known and novel oncogenic pathways aberrantly expressed and regulated by loss of DNA methylation.The colony stimulating factor-1 receptor (CSF1R) was aberrantly expressed and hypomethylated in nearly all cases. The expression of CSF1R was validated by immunohistochemistry on primary tumors and by Western blotting in BRAF V600E mutant and WT melanoma cell lines. Expression of its ligand IL34, but not of CSF1 was also shown in the melanoma cells by both ELISA and qPCR. The effects of a small molecule inhibitor, PLX3397 as well as shRNA-mediated knockdown of the receptor were investigated in traditional and 3D cell culture. We saw inhibition of cell growth, smaller colony size, increased apoptosis and decreased invasiveness - suggesting a functional role for CSF1R in melanoma.Treatment of melanoma with small molecule inhibitors of BRAF V600E is effective for a time, but resistance invariably develops. The feedback activation of EGFR, BRAF amplification, BRAF splice variants and others are known to aid in the acquisition of resistance and lead to rebound activation of the MAPK-pathway. In Western blotting experiments, the rebound of ERK phosphorylation after BRAF inhibitor treatment was accelerated with the addition of the CSF1R ligands CSF1 and IL34, or delayed with PLX3397, also attenuating AKT phosphorylation. Melanoma cells stably expressing CSF1R shRNA recapitulated the effects of the inhibitor. Assaying the cells at different time points during a long-term V600E inhibitory experiment, we saw increasing levels of the transcription factor RUNX1, followed by increasing levels of IL34 and of the CSF1R protein, as well as its maturation, evidenced by the appearance of the high MW form. Utilizing shRNA-mediated knockdown of RUNX1 resulted in lower levels of the CSF1R and IL34 transcripts and delayed the rebound. Analysis of primary RNA-Seq data showed an increase in RUNX1, CSF1R and IL34 expression as resistance was acquired. Co-inhibition of CSF1R and BRAF was also tested and resulted in synergistic blockade of cell growth in vitro and xenograft growth in vivo. The CSF1R inhibitor, PLX3397, is in clinical trials for breast and other cancers, and these data present a preclinical rationale for its study in malignant melanoma.']",
        "Doc_id":"AACR_2016-1885",
        "Doc_title":" Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition",
        "_version_":1606189017713344512},
      {
        "Meeting_name":" Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma.",
        "Background":"['Background', ' Temozolomide (TMZ) is an oral formulation of dacarbazine with improved central nervous system penetration. Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab is a monoclonal antibody targeted against VEGF. TMZ plus sorafenib has shown efficacy in advanced melanoma. The triple combination, chemotherapy plus the complementary inhibition of VEGF signaling, was hypothesized to have synergistic effects on acral metastatic melanoma. Methods', ' Eligible are refractory (previous one systemic regimen failed) acral advanced melanoma, measurable disease (RECIST). Treatment includes TMZ 200 mg/m2/d (days 1-5), bevacizumab 5 mg/Kg (days 1, 14) and sorafenib 400 mg/bid (days 1-28), repeated every 28days. VEGFR, PDGFR, EGFR and CD117 of tumor tissue were detected by Immunohistochemistry (IHC) assay and the DNA was abstracted and amplified by PCR assay and then sequenced to detect the mutation of C-KIT (exon11,13,17,18),B- RAF(exon11, 15) and N-RAS(exon1, 2). Progression free survival (PFS), overall survival (OS), response and toxicity were assessed. Correlation was analyzed between gene mutations, IHC results and clinical response. Results', ' 50 patients were planned to recruit. Till December of 2008, 11 patients all in M1c stage have been enrolled and evaluated. One patient has achieved complete response (CR) which has been lasting 5 cycles. One patient has achieved partial response (PR) with a 69% tumor reduction which has been lasting 3 cycles. One patient achieved PR with a 41% tumor reduction which has been lasting 6 cycles. 6 pts got stable disease (all tumor reduction, range', ' 4-21%) lasting > 2 cycles (range', \" 3-4 cycles); and 2 PD after 1 cycle. The toxicity was moderate. It's too early to assess survival. It seemed no correlation between positive IHC results and response. It could not be decided if there is correlation between gene mutation/IHC results and response/survival. Conclusions\", ' The triple combination (TMZ, sorafenib, and bevacizumab) regimen preliminary achieved durable clinical response especially the patients with CR or PR. The regimen is safe and well tolerated. More data will be presented in ASCO.']",
        "Doc_id":"ASCO_32514-65",
        "Doc_title":" Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma.",
        "_version_":1606188978664374272},
      {
        "Meeting_name":" A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma",
        "Background":"['Background', ' Metastatic  melanoma lacks effective therapy.  Pazopanib is a small-molecule inhibitor of VEGFR-1,2,3, PDGFR-B and c-KIT that has antiangiogenic activity in renal cell cancer as well as inhibition of melanoma tumor xenografts. We designed a phase II single arm, open label clinical trial evaluating pazopanib in combination with metronomic paclitaxel as first line therapy for subjects with unresectable stage III and stage IV melanoma. Methods', ' This protocol utilizes a Simon 2-stage Minimax design, with a planned interim analysis to confirm >3 responders to move to the second stage. To date, 20 eligible patients have been enrolled with 17 evaluable for response.  All subjects were treatment nave and received paclitaxel  at 80mg/m2 weekly for three weeks in a 4 week cycle and pazopanib at 800mg as a continuous daily oral dose. The primary endpoint is 6 month progression free survival. Exploratory endpoints include biomarker analysis that may be associated with treatment outcomes (serum VEGF, soluble VEGF R2, serum HIF, serum TSP1 and BRAF mutation status). An additional exploratory endpoint includes the in vitro activity of pazopanib and paclitaxel on patient biopsy material co-cultured with vascular endothelial cells.  RECIST criteria were used to define treatment response. Results', ' For the 17 evaluable patients treated to date the following results were seen', ' 1 CR, 6 PRs, 8 SDs and 2 PDs. The overall RR (CR+PR) was 40%. Total disease control rate was 80% (PR+SD). The most common AEs/lab abnormalities were nausea (71%), hypertension (57%), fatigue (57%) and vomiting (43%). Grade 3-4 AEs included hypertension (28%), transaminitis (21%) and neutropenia (14%).  One patient discontinued for grade 4 transaminitis which subsequently resolved completely. Dose reductions were required for pazopanib in 5 patients and for paclitaxel in one patient. Conclusions', ' Planned interim analysis of this phase II study demonstrated that pazopanib in combination with paclitaxel was well tolerated and resulted in a 40% response rate, indicating that this combination is of further interest. Accrual will continue to reach a goal of 60 patients.']",
        "Doc_id":"ASCO_95402-114",
        "Doc_title":" A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma",
        "_version_":1606189026273918976},
      {
        "Meeting_name":" Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.",
        "Background":"['Background', ' Agents blocking programmed death-1/ligand (aPD1) induce durable responses in many melanoma patients (pts). Greater numbers of somatic mutations have been linked to high aPD1 response rates (RR) in other cancers. We assessed whether number and/or type of mutations (mut) using HC NGS correlated with outcomes to aPD1 in melanoma. Methods', ' HC NGS on 236-315 genes was performed on archival samples from pts who received aPD1 (comprising ~1.25 megabases [MB]). A novel algorithm extrapolated genomic mutational load (ML) from this panel. Intratumoral T cell clonal expansion was determined by T cell receptor (TCR) sequencing. ML and TCR clonality were correlated with with aPD1 outcomes. Results', ' Responders to aPD1 had higher ML compared to non-responders in discovery (median 45.6 vs. 3.9 mut/MB; p=0.003, n=32), and validation cohorts (37.1 vs. 12.8 mut/MB; p=0.002, n=33). RR was superior in high ML pts compared to intermediate/low (Table) as was progression-free survival (PFS) (median not reached [MNR] vs. 89 days vs. 86 days, p<0.001) and overall survival (OS) (MNR vs. 300 days vs. 375 days, p<0.001). Responders had more C>T transitions than non-responders (median 33.5 vs. 3.0, p<0.001). Melanomas with NF1 mutations had high ML (median 62.7 mut/MB) and high RR (74%); whereas BRAF mutant (12.0 mut/MB), NRAS mutant (17.6 mut/MB), and BRAF/NRAS/NF1wild-type (2.2 mut/MB) melanomas had lower median ML. TCR clonality did not correlate with response in these archival samples, nor did PD-L1 gene amplification (<1% incidence). Conclusions', ' ML as determined by HC NGS effectively stratified patients by likelihood of response. This approach may provide a widely available, clinically feasible predictor of response to aPD1. CohortMutational load groupResponseNo ResponseP valueDiscoveryHigh (n=11)9 (82%)2 (18%)0.003Intermediate (n=11)4 (36%)7 (64%)Low (n=10)1 (10%)9 (90%)ValidationHigh (n=16)14 (88%)2 (12%)0.001Intermediate (n=13)3 (23%)10 (77%)Low (n=4)1 (25%)3 (75%)CombinedHigh (n=27)23 (85%)4 (15%)<0.001Intermediate (n=24)7 (29%)17 (71%)Low (n=14)2 (14%)12 (86%)High ML', ' >23.1 mut/MB; Intermediate', ' 3.2  23.1 mut/MB; Low', ' <3.2 mut/MB']",
        "Doc_id":"ASCO_163406-176",
        "Doc_title":" Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.",
        "_version_":1606188975965339648},
      {
        "Meeting_name":" Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target",
        "Background":"['Melanoma has seen a remarkable improvement in the treatment of advanced disease. However, the majority of patients still relapse with the emergence of resistant disease. This is especially true for BRAF inhibitors, were multiple mechanisms of resistance have been uncovered. However, the lack of dependable models to develop approaches to overcome resistance, poses a real challenge for clinical decisions on second line therapies. In addition, combination therapies necessary to achieve long term responses increase the number of possibilities to be assessed. In this study, we developed patient derived xenograft (PDX) models from BRAF inhibitor resistant patients and, after characterization, tested rational second line combination therapies in co-clinical trials.Fresh tumor tissue from 12 patients after progression on vemurafenib or dabrafenib was implanted into immune deficient NSG mice. Once the tumor grafts were established, mice were continually dosed with PLX4720 to approximate clinical plasma levels to preserve the resistant phenotype. Xenografts were then characterized for genomic alterations and pathway activation status using a targeted sequencing array and a reverse phase protein array, respectively. We found at least 2 and up to 9 known deleterious alterations in all samples, many of which have been described as conferring resistance. The protein array clustered into two major groups', ' MAPK pathway activated and PI3K pathway activated, again consistent with previous reports. Integrating these data allowed us to design rational combination therapies for in vivo testing. We treated a PDX model with MET amplification and high phospho c-Met with the BRAF inhibitor LGX818 20mg/kg QD, the MEK inhibitor MEK162 3mg/kg QD, and the c-Met inhibitor INC280 25mg/kg QD (all p.o.). Although INC280 alone led to significant decrease in tumor growth, only the LGX818/ MEK162/ INC280 triple combination led to complete and sustained tumor regression in all mice. Further, we tested a second PDX model with a MET amplification (albeit broader and lower) but baseline pMET on the protein level. In this model, INC280 did not show any antitumor effect confirming the specificity for c-Met and the importance of validating genomic data.In summary, using our BRAF inhibitor resistant PDX model pipeline we were not only able to identify actionable alterations in all models, but also to test rational second line combination therapies in pre-clinical in vivo trials. Genomic data alone might not be sufficient to accurately predict therapy responses and protein arrays were a valuable tool to validate deleterious alteration calls. This study represents an important step towards improving personalized medicine in melanoma, and highlights the potential use of c-Met inhibitors in melanoma combination therapy in a defined subset of patients.']",
        "Doc_id":"AACR_2015-2842",
        "Doc_title":" Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target",
        "_version_":1606189007099658240},
      {
        "Meeting_name":" Statin induced apoptosis in human melanoma cells is prevented by inhibition of caspase 2 and translational activity.",
        "Background":"['Background', ' Statins may trigger apoptosis in tumour cells in vitro and, particularly, melanoma cells are susceptible to statin induced apoptosis. Lipophilic statins (e.g. Atorvastatin, Simvastatin) induce strong caspase 3 activation after 48h of treatment, whereas hydrophilic statins (e.g. Pravastatin, Rosuvastatin) do not trigger caspase activation. Recently, we demonstrated the presence of an autocrine amplification loop which increases apoptosis by a caspase 8 dependent pathway after treatment with lipophilic statins (Minichsdorfer and Hohenegger, Br J Ph 2009). It is known that activation of caspase 2 may prime melanoma cells for death receptor induced apoptosis, however, although an association between caspase 2 activation and RhoB upregulation was shown, the significance of this interaction is still not clear.Methods', ' We investigated the activity of caspase 2, 3 and 8 in A375 and 518A2 human metastatic melanoma cells after statin treatment in the presence and absence of a caspase 2 inhibitor (Z-VDVAD-FMK) or cycloheximide by cleavage of specific fluorescent caspase substrates. Upregulation of RhoB after statin treatment as well as the influence of the co-treatment with the isoprenoids farnesylpyrophosphate (FPP) or geranylgeranylpyrophosphate (GGPP) was studied by Western blot.Results', ' Exposure of these cells to simvastatin led to increased caspase 2 activation which is abrogated by co-application of the caspase 2 inhibitor Z-VDVAD-FMK. Moreover, treatment with Z-VDVAD-FMK also prevented caspase 8 and caspase 3 activation. We could show that production of an autocrine factor needs an intact translation machinery. Inhibition of translation by co-administration of cycloheximide prevented apoptotic morphological changes as well as caspase 3 and caspase 8 activation in A375 and 518A2 cells. Since caspase 2 may interact with RhoB, we also investigated the effect of statin treatment on RhoB expression and observed an upregulation of RhoB which was inhibited by the addition of cycloheximide in both cell lines. However, isoprenoids were not able to reverse RhoB upregulation or PARP cleavage in 518A2 cells.Conclusion', ' Overall, our data provide evidence for an important role of caspase 2 in statin induced apoptosis of 2 human metastatic melanoma cell lines. These findings may help to understand the function of caspase 2 in the induction of apoptosis. Moreover, we observed upregulation of RhoB following statin treatment in these cell lines. However, additional experiments are necessary to fully understand the role of RhoB in statin induced apoptosis.']",
        "Doc_id":"AACR_2013-2940",
        "Doc_title":" Statin induced apoptosis in human melanoma cells is prevented by inhibition of caspase 2 and translational activity.",
        "_version_":1606188974322221056},
      {
        "Meeting_name":" DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models",
        "Background":"['Introduction', 'KIT kinase mutations are causative of a number of human cancers, including gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), mast cell leukemia (MCL), and subtypes of melanoma and acute myeloid leukemia (AML). DCC-2618 is a robust Type II switch pocket control inhibitor which potently inhibits exon 17 KIT mutations that are resistant to conventional TKIs.Experimental procedures', 'DCC-2618 was tested for inhibition of KIT isoforms using a standard PK/LDH coupled spectrophotometric assay. CHO cells were transiently transfected to express mutant KIT or PDGFR constructs. Transfected cells were treated with a range of DCC-2618 and levels of phosphorylated KIT or PDGFR in cell lysates were determined by ELISA or western blot. Cell proliferation of several cell lines was measured using the fluorescent dye resazurin. Experiments were performed in triplicate. In vivo xenograft models were performed at Molecular Imaging, Inc. (Ann Arbor, MI) or Molecular Response, LLC (San Diego, CA).Summary of results', 'DCC-2618 inhibited various forms of KIT with nanomolar potency', ' WT (IC50 4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V (14 nM). In CHO cells transiently transfected with both single and double (primary/secondary) KIT mutants, DCC-2618 robustly inhibited exon 17, exon 9/13, exon 9/14, and exon 9/17 KIT mutants, as well as exon 11/17 KIT mutants, including exon 17 D816V, D816G, D820A, D820E, D820Y, N822K, N822Y, N822H, and Y823D primary or secondary mutations.DCC-2618 inhibited wild type KIT phosphorylation in the MO7e cell line (IC50 36 nM). DCC-2618 potently inhibited KIT activation in human GIST cell lines, including GIST T1 (exon 11 deletion, IC50 2 nM), GIST 430 (exon 11 deletion/exon 13 V654A, IC50 7 nM), and GIST 48 (exon 11 V560D/exon 17 D820A, IC50 53 nM). In the murine mastocytosis P815 cell line expressing the exon 17 D816Y mutation, DCC-2618 potently inhibited cell proliferation (IC50 2 nM).In vivo, DCC-2618 administration at 50 mg/kg afforded an ED90 for inhibition of KIT phosphorylation in the GIST T1 xenograft model, corresponding to an EC90 concentration of  470 ng/mL. When give twice daily, this oral dose resulted in almost complete tumor stasis. This dose of DCC-2618 produced tumor regressions in a patient derived xenograft (PDX) GIST expressing KIT exon 11 delW557K558/exon 17 Y823D, and also in a KIT exon 17 N822K AML xenograft model.Conclusion', ' DCC-2618 is a potent inhibitor of singly and doubly mutated KIT characterized by primary exon 9 or exon 11 mutations paired with secondary mutations in exons 13, 14 or 17. DCC-2618 inhibits exon 17 mutations, including the D816V mutation refractory to currently marketed KIT inhibitors. DCC-2618 has the potential to treat KIT mutant-driven cancers including GIST, systemic mastocytosis, AML, or melanoma. DCC-2618 has been selected for formal IND-enabling clinical development.']",
        "Doc_id":"AACR_2015-2690",
        "Doc_title":" DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models",
        "_version_":1606189000645672961},
      {
        "Meeting_name":" OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.",
        "Background":"['Background', ' The liver is one of the most common metastases in melanoma pts and associated with extremely poor prognosis. However, effective treatment has not been found. The safety and efficacy of OrienX010, a herpes simplex virus type 1-derived oncolytic immunotherapy with expression of gene encoding human GM-CSF, was tested in phasec trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment. Methods', ' We studied safety and efficacy of OrienX010 (8107pfu/ml, 10ml per injection) q2w by ultrasound guided puncture. Efficacy was evaluated q8w by CT scan. The primary endpoint was toxicity. Secondary endpoints included Objective Response Rate (ORR), Disease Control Rate (DCR) as well as PFS time. Treatment continued until intolerance, or disease progression per Immune Related Response Criteria. Results', ' From May 2016, 15 pts received OrienX010 intralesional therapy. The median age was 47 y (32, 61), and 53.3% were female. The primary anatomic sites were', ' 40.0% (6 pts) from ocular, 33.3% (5 pts) from acral, 26.7% (4 pts) from mucosal. Only 1 patient with c-Kit mutation, 14 pts were wide-type in genotype. All pts had received at least one prior therapy, 53.3% (8 pts) had received transcatheter hepatic arterial chemoembolization. 73.3% (11 pts) had multiple liver metastases, 60.0% (9 pts) had extrahepatic metastases such as lung, bone, abdominal, distant lymph node. 60.0% (9 pts) had an elevation of serum LDH. Mean injection times were 6 (4-18). Mean size of all injectable lesions was 30.4mm (10.0-59.0). AEs were all grade 1/2, pyrexia 80.0%, fatigue 33.3%, injection site pain 26.7%, nausea/vomiting 20.0%, hepatotoxicity 20.0%, leucopenia 6.7%. 12 pts were eligible for evaluation till Jan 2017, and the median follow-up time was 6.0 months. ORR was 8.3% (1 PR), DCR was 41.7% (1 PR, 4 SD). Time to response was 8-16 wks, median PFS was 13.3 wks (95%CI 8.3-18.4), OS was not reached. Conclusions', ' This is the first trial for evaluating OrienX010 of intralesional injection in liver metastases among melanomas. It appears to be tolerable and with a potentially beneficial effect. Phase 2 and combination trial are pending.']",
        "Doc_id":"ASCO_191410-199",
        "Doc_title":" OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.",
        "_version_":1606189016431984640},
      {
        "Meeting_name":" Elucidation of c-KIT- dependent signaling to MITF",
        "Background":"['MITF, the master regulator of melanocytes, is a basic basic- helix- loop-helix- leucine zipper transcription factor that is essential for the development of melanocytes. MITF is also a lineage- survival oncogene in melanoma and recently, it has been shown that germline mutations in MITF predispose to this malignant disease. In melanoma, MITF has been proposed to act as a rheostat where high levels of MITF contribute to a proliferative phenotype whereas low levels result in a more invasive phenotype. The biological output generated by high or low levels of MITF is well characterized. However, how the activity of MITF is regulated to mediate these effects is less well known. It has been proposed that MITF is phosphorylated upon ligand induced activation of the receptor tyrosine kinase c- KIT. C-KIT engages the MAP kinase signaling cascade where ERK2 directly phosphorylates Ser73 of MITF and P90RSK phosphorylates the Ser409 residue of MITF. As a consequence, MITF activity increases and the protein is subjected to ubiquitin dependent degradation.Here, we show for the first time that c-KIT induces phosphorylation of MITF through the survival PI3 kinase- AKT pathway, the P38 stress pathway as well as the well-known MAP kinase-ERK signaling pathway. In addition, we show that the SRC kinase upstream of ERK is essential for c-KIT induced MITF activation. Moreover, we used several c-KIT phosphorylation site mutants to map the specific sites that are involved in the mediating transcription activation potential of MITF. These mutants also show less effects on MITF-mediated proliferation.We have generated phosphorylation specific antibodies against Ser73 and Ser409 of MITF and characterized the phosphorylation pattern of MITF using these reagents. Our results suggest that there is a particular relationship between Ser73 and Ser409 with subsequent effects on function. Based on our findings, we propose that phosphorylation of MITF might act as negative feedback mechanism that keeps MITF activity in check. Our model challenges the current knowledge of MITF modulation and provides insights that may have a profound impact on our understanding of the role of MITF in melanocyte and melanoma biology.']",
        "Doc_id":"AACR_2012-3093",
        "Doc_title":" Elucidation of c-KIT- dependent signaling to MITF",
        "_version_":1606189000479997952},
      {
        "Meeting_name":" Xkr5 negatively regulates KIT/D816V signaling.",
        "Background":"['D816V is the most often occurred mutation of type III receptor tyrosine kinase KIT in mastocytosis and CBF-AML. In attempting to identify specific downstream signaling pathways of KIT/D816V, we found that KIT/D816V but not wild-type KIT can bind to Xkr5 that was not studied previously. In addition to the association with KIT/D816V, Xkr5 is phosphorylated at Tyr 369, Tyr487 and Tyr 543 by KIT/D816V, and the phosphorylation is mediated by only mutations of Asp 816 in KIT but not by other KIT mutations that occurred in gastrointestinal stromal tumors and melanoma. Furthermore, the tyrosine phosphorylation of Xkr5 is not dependent on Src family kinases that play a crucial role in the activation of wild-type KIT. In KIT/D816V expressing mast cells, phosphorylation of Xkr5 inhibits KIT/D816V downstream signaling molecules Akt, Erk and p38. As a consequence, cell proliferation and colony formation are inhibited by the tyrosine phosphorylation of Xkr5 as well, indicating that Xkr5 is a negative regulator of KIT/D816V signaling.']",
        "Doc_id":"AACR_2017-2372",
        "Doc_title":" Xkr5 negatively regulates KIT/D816V signaling.",
        "_version_":1606188995781328896},
      {
        "Meeting_name":" Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition.",
        "Background":"['Epigenetic changes in cancer are thought to contribute to regulation of invasion and metastasis. To study this at a genome-wide level in melanoma we analyzed the methylome of 44 cases of malignant melanoma. We saw widespread demethylation in melanoma occurring preferentially outside of CpG islands. Comparison of primary and metastatic lesions showed demethylation occurs early during carcinogenesis with few additional alterations in advanced tumors. The colony stimulating factor-1 receptor was aberrantly expressed and hypomethylated in nearly all cases. The expression of CSF1R was validated by IHC on primary tumors and by qPCR and Western blotting in BRAF mutant and WT cell lines. CSF1R can be aberrantly expressed via an upstream LTR element in Hodgkins lymphoma. After analyzing our patient samples and the cell lines, we have found this aberrant transcript may be the dominant form in melanoma as well. Expression of one of its ligands IL34 was also shown in the cell lines by both ELISA and qPCR pointing to a potential autocrine regulatory loop. The effects of a small molecule inhibitor, PLX3397 as well as shRNA-mediated knockdown of the receptor were investigated in 2D and 3D cell culture. We saw inhibition of cell growth, smaller colony size, increased apoptosis and decreased invasiveness - suggesting a functional role for CSF1R in melanoma. Treatment of melanoma with small molecule inhibitors of BRAF V600E is effective for a time, but resistance invariably develops. The feedback activation of EGFR, BRAF amplification, BRAF splice variants and others are known to aid in the acquisition of resistance and the rebound activation of the MAPK-pathway. We are suggesting a role for CSF1R in this process. In Western experiments, the rebound of phospho-ERK after BRAF inhibitor treatment was accelerated with the addition of CSF1R ligands, or delayed with PLX3397, also attenuating AKT phosphorylation. Melanoma cells stably expressing shRNA against CSF1R recapitulated the effects of the inhibitor. Assaying the cells at different time points during a long-term V600E inhibitory experiment, we saw increasing levels of the transcription factor RUNX1, followed by increasing levels of IL34 and of the receptor, as well as its maturation, evidenced by the appearance of the high MW form. Utilizing shRNA-mediated knockdown of RUNX1 resulted in lower levels of the CSF1R and IL34 transcripts and delayed the rebound. Analysis of primary RNA-Seq data showed an increase in RUNX1, CSF1R and IL34 expression in resistant tumors. Co-inhibition of CSF1R and BRAF was also tested and resulted in synergistic blockade of cell growth in vitro and xenograft growth in vivo. The CSF1R inhibitor, PLX3397 is currently in clinical trials for glioblastoma, prostate, breast cancers and other cancers. These data present a preclinical rationale for its study in malignant melanoma.']",
        "Doc_id":"AACR_2017-3332",
        "Doc_title":" Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition.",
        "_version_":1606189003290181632},
      {
        "Meeting_name":" Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment",
        "Background":"['Introduction', ' Our group has been developing methods to quantitatively detect mutant BRAF DNA in the plasma of metastatic melanoma patients, with the aim of developing new biomarker assays. In this study we evaluated the potential of a probe-based, droplet digital PCR (ddPCR) assay to quantitatively measure copies of DNA encoding the mutant BRAFV600E and wild-type alleles in the plasma of patients undergoing treatment with a BRAF inhibitor. We previously showed this assay to be 100% specific with a sensitivity to detect 1 mutant copy among 10,000 wild-type copies when sufficient input DNA was used.Methods', ' Ten patients with BRAF-mutant stage IV melanoma were prospectively studied. At least 3 serially-collected plasma samples were available for each patient, corresponding to pre-treatment, best treatment response, and progression of disease as evidenced by PET/CT scan. DNA was extracted from plasma samples and concentrations were measured using a Qubit fluorometer. The relevant BRAF region was assayed using 24 to a maximum of 337 ng of DNA from each sample, using multiple replicate wells for dilute samples to maximize the probability of detecting BRAF mutant copies. Specific Taqman 5 hydrolysis probes for wild-type and mutant BRAF were employed along with common primers to measure the number of copies of each amplicon/reaction. The amount of amplifiable DNA was measured using RPP30 as a control gene.Results', ' All 10 patients had partial responses. We analyzed 35 plasma samples, of which 30 had a minimum of 4ml of plasma. Qubit-based DNA concentrations ranged from 6.9 to 1158 ng/ml. All samples yielded positive amplification of the BRAF and RPP30 amplicons. Total BRAF DNA concentrations ranged from 719 to 156,920 copies/ml plasma. Mutant BRAF DNA concentrations ranged from 0 to 13,028 copies/ml. The fraction of BRAFV600E amplicons ranged from 0 to 45%, with a minimal detected mutant fraction of 0.01%. In 8/10 patients, levels of mutant BRAF fell with clinical response and/or rose with disease progression. In 3 of these 8 patients, samples drawn 10 days to 2 months prior to imaging studies showed increased levels of BRAF mutant DNA prior to evidence of disease progression. In 1 of the remaining 2 patients levels of total BRAF DNA tracked with clinical outcome better than levels of mutant BRAF DNA. In 1/10 patients neither levels of mutant nor total BRAF DNA tracked with clinical responses.Conclusions', ' These results demonstrate that a ddPCR assay is able to quantitatively measure total and mutant BRAF DNA in the plasma of patients with stage IV melanoma. Levels of mutant and total BRAF DNA tracked with disease progression showing promise for this assay as a potential biomarker that may predict disease progression. Analyses of additional tumor-derived mutations in plasma DNA, and more precise assessments of disease response, are underway to determine optimal biomarkers to incorporate into melanoma clinical trial and patient care protocols.']",
        "Doc_id":"AACR_2014-2847",
        "Doc_title":" Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment",
        "_version_":1606188979761184768},
      {
        "Meeting_name":" Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.",
        "Background":"['Background', '  Uveal melanoma (UM) is a rare cancer with a propensity for metastasis. There are no effective systemic therapies for metastatic UM, although dacarbazine is commonly used in practice. Sunitinib is a tyrosine kinase inhibitor with activity against several targets including c-Kit and VEGF receptors, both of which have been implicated in the pathogenesis of UM.  Methods', '  In this randomized multicentre, phase II study (SUAVE), patients (pts) with metastatic UM, ECOG PS 0-2, and no prior systemic therapy for advanced disease, were randomized 1', '1 to sunitinib (50mg daily for 28 days, followed by a 14 day break), or dacarbazine (1000 mg/m2once every 21 days). Crossover was permitted on progression. The primary endpoint was PFS; secondary endpoints included response rate and OS. A sample size of 124 was planned, with a power of 0.9 to detect an increase in 3 month PFS from 0.2 to 0.4 (HR', ' 0.563) and a one-sided alpha of 0.05. A preplanned futility analysis was performed after 50% of events, and recruitment stopped early, due to low conditional power (0.17% under current trend). Presentation of results was approved by DMC.  Results', '  74 pts from 12 centres were randomized over 24 months. Overall response rates of 0% and 8% were observed in the sunitinib and dacarbazine arms; while stable disease was observed in 24% of pts on sunitinib, and 11% on dacarbazine. PFS and OS were not improved with sunitinib (see Table). 11 pts in the sunitinib arm and 23 in the dacarbazine arm underwent crossover on progression. No unexpected AEs were observed, and no deaths due to toxicity occurred.  Conclusions', '  In these preliminary results sunitinib did not have significant clinical activity in metastatic UM. This trial is one of the largest undertaken in metastatic UM and demonstrates that timely recruitment to collaborative multicentre randomized trials is achievable in this rare disease.  Clinical trial information', ' 75033520.']",
        "Doc_id":"ASCO_114030-132",
        "Doc_title":" Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.",
        "_version_":1606188983422812160},
      {
        "Meeting_name":" Controls to detect limit of detection for BRAF V600E as an actionable mutation of interest by NextGen Sequencing and qPCR",
        "Background":"['Background', \" Molecularly targeted therapy across tumor types has great potential to benefit cancer patients. In order to validate the assays being used to identify actionable mutations of interest, controls that establish an assay's limit of detection are needed. 40-60% of melanomas harbor a mutation in proto-oncogene BRAF, resulting in constitutive activation of the RAF/MEK/ERK signaling pathway; driving growth, differentiation and metastasis. Metastatic melanoma patients have a poor prognosis; 5 year survival after diagnosis is only 15%. BRAF mutations are also found in lymphomas, colorectal, thyroid and lung cancers. This study was undertaken to develop reference materials for establishment of the lowest limits of detection for identification of the BRAF V600E mutation with the cobas 4800 BRAF V600 Mutation test, the THxIDTM BRAF kit, the Ion AmpliSeqTM Cancer Hotspot Panel. Reference materials with a limit of detection below 5% are useful for validation and identification of patient tumors with an extremely low percentage of the V600E mutation across multiple types of tumors.Methods\", ' Melanoma cells containing the V600E allele, the V600D allele and the wild type allele were mixed at a range of allelic ratios from 50 to 1% in Histogel and embedded in FFPE. Genomic DNA was extracted from macro-dissected cells in 10M FFPE sections and analyzed for quality and concentration using the KAPA Biosystems hgDNA Quantification and QC Kit. Quality scores (Q-ratios) generated with the kit may be used to predict the outcome of NGS library construction, with scores close to 1.0 being ideal for sequencing applications. Samples with Q scores close to 1.0, were subsequently tested on an ABI 7500 real time PCR system with the TrimGen BRAF V600 mutation kit. The extracted gDNA and unprocessed FFPE blocks and sections were then sent to diagnostic testing laboratories for analysis on the the cobas 4800 BRAF V600 Mutation test, the THxIDTM BRAF kit, and the Ion AmpliSeqTM Cancer Hotspot Panel.Results', ' We were able to isolate high quality and quantity (>700ng per 2 10M curls, Quality scores 1.0) gDNA suitable in fragment size and concentration for use in V600 companion diagnostic and NGS analysis from FFPE at a range of allelic ratios. Our 50% and 10% V600E mutant samples were detected by the TrimGen BRAF V600 mutation kit. Testing of mutations below 10% is currently ongoing on companion diagnostic and NGS platforms in clinical diagnostic laboratories.Conclusions', ' Prototype FFPE and extracted genomic DNA process controls were generated for use in NGS and companion diagnostics for BRAF V600. The advantage of this material is that it contains the mutation of clinical significance at well defined, consistent low levels, at and below the current minimum detectable mutant allele ratio of 10%. These reference controls may allow laboratories to verify assay detection limits, establish run to run reproducibility, and monitor testing quality over time.']",
        "Doc_id":"AACR_2015-3394",
        "Doc_title":" Controls to detect limit of detection for BRAF V600E as an actionable mutation of interest by NextGen Sequencing and qPCR",
        "_version_":1606189026255044608},
      {
        "Meeting_name":" Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.",
        "Background":"['Background', ' Imatinib mesylate can induce rapid tumor regression, inhibit tumor immunosuppressive mechanisms, and release large amounts of antigenic debris from tumor cell death with subsequent increase in tumor antigen presentation. CTLA-4 blockade and imatinib combination therapy in mouse models of GIST synergistically reduces size of tumors mediated by imatinib-dependent intratumoral accumulation of CD8+ T-cells and suppression of Treg-cells. We hypothesized that combination therapy with imatinib and ipilimumab immunotherapy would be tolerable and may synergistically enhance anti-tumor T-cell activation in patients (pts). Methods', ' Primary objective of the dose-escalation study (3+3 design) was to establish the maximum tolerated dose (MTD) and recommended phase II dose of the combination. Eligible pts had metastatic or unresectable, solid tumors. In the expansion cohort, pts were required to have a known KIT mutation. Secondary objectives included evaluation of antitumor activity of the combination based on KIT mutation status and the predictive status of tumor-associated immune biomarkers. Results', ' 26 pts were dosed in the escalation portion of the study. No dose limiting toxicities were encountered. The most common grade 1 and 2 related adverse events (AEs) were nausea (57%), fatigue (50%), vomiting (46%), anorexia (35%), diarrhea, skin rash, and edema (each 27%). There were 4 (16%) grade 3 related AEs including fatigue, anemia, rash, and vomiting. There were no grade 4 AEs. The MTD was the highest planned dose level of Ipilmumab at 3mg/kg and Imatinib at 400mg twice daily. An additional 10 pts were treated at MTD. Among all pts, three responses were seen', ' one GIST (PR) and 2 melanoma pts (CR + PR). These responses were seen at higher dose levels. Stable disease was seen in 7 pts lasting an average of 6 months. Notably, both melanoma responders had KIT mutations; the GIST responder was wild type. Immune cell activity in tumor tissue biopsy specimens and serum is under analysis. Conclusions', ' In this phase I trial the combination was well tolerated. Responders in this trial suggest that this combination at MTD has antitumor activity in WT GIST and KIT-mutant melanoma and merits further investigation. Clinical trial information', ' NCT01738139']",
        "Doc_id":"ASCO_163383-176",
        "Doc_title":" Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.",
        "_version_":1606189008098951168},
      {
        "Meeting_name":" Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft",
        "Background":"['Bcl-2 and bcl-XL are anti-apoptotic proteins that promote drug resistance and enhance tumor cell survival. Bcl-2 gene amplification occurs in 90% of cutaneous melanomas implicating it as a potential target. PNT100 is a 24-mer unmodified DNA oligonucleotide complementary to a non-coding region of bcl-2. PNT2258, is comprised of PNT100 encapsulated in a unique pH tunable nuclear-targeted liposomes termed SMARTICLES. Preliminary studies demonstrated fluorescently-labeled PNT100 in a SMARTICLE is delivered to the cell nucleus and that PNT2258 produces dramatic tumor regression in a diffuse large cell lymphoma xenograft, prolonging survival with a coincident decrease in bcl-2 protein. PNT2258 activity in the A375 melanoma model was assessed as a single agent or in combination in two separate studies. Study 1', ' PNT2258 alone, IV, 5 days/week for 3 weeks, to mice bearing A375 produced growth delays of 10.4, 7.8, and 7.8 days at 12.5, 8.3, and 5.6 mg/kg/dose, respectively. Docetaxel alone, IV weekly x3, produced growth delays of 19.4 (1/10 TFS), 14.8 (1/10 TFS), and 11.5 days at 30, 20, and 13.3mg/kg/dose. Combination therapy produced growth delays of 45.3 (5/10 TFS), 18.9, 28.1 (2/10 TFS), and 25.0 (3/10 TFS) days at 12.5+30, 12.5+20, 5.6+30, and 5.6+20 mg/kg/dose, respectively. Study 2', ' PNT2258 alone produced a growth delay of 12 days at 15mg/kg/dose. Dacarbazine alone was ineffective at 80 mg/kg/dose IP. Combination therapy was not superior to PNT2258 alone. In contrast, vemurafenib alone (37.5 mg/kg/dose, PO, BIDx18 days) was highly active producing a growth delay in excess of 30 days, as did the combination of PNT2258+vemurafenib. PNT2258 is currently being evaluated for safety and tolerability in a phase Ia clinical trial. Preliminary mouse and human pharmacokinetics suggest that exposure levels in humans are similar to those producing anti-tumor efficacy in mice. Overall, 1) PNT2258+docetaxel produced a greater than additive effect compared to single agents, 2) PNT2258+dacarbazine was not superior to PNT2258 alone, 3) PNT2258+vemurafenib while highly active, was not superior to vemurafinib therapy alone, and 4) therapeutic PNT2258 exposures have been attained in patients.']",
        "Doc_id":"AACR_2012-2764",
        "Doc_title":" Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft",
        "_version_":1606189029423841280},
      {
        "Meeting_name":" Analysis of the University of North Carolina (UNC) and the Cancer Genome Atlas Project (TCGA) next generation sequencing (NGS) datasets to identify somatic mutations (SM) with prognostic significance in cutaneous melanoma (CM).",
        "Background":"['Background', ' Genotyping for therapy selection is now standard of care in advanced melanoma. The prognostic significance of genome-wide SM has not been adequately explored. Methods', ' Patient (pt) data (clinical followup, DNA and RNA sequencing) were obtained from large NGS projects, including pts enrolled in the UNC trial LCCC1108, pt with brain metastases, and the TCGA. SM were then characterized by the ANNOVAR software and filtered for functional significance. Only genes with SM variants in > 2% of samples were considered. We investigated the association between functional SM and overall survival (OS), using time-dependent linear regression models within an otherwise clinically similar risk pt group (AJCC stage III/IV). Detection of all relevant variant alleles was validated by RNA expression using the UNCeqR method. Results', ' To date, 267 pts met all above criteria (108 and 159 of pts were censored or dead, respectively). Median follow-up was 53.6 months. 19,753 of 274,466 SM showed potential functional importance and > 80% SM were validated by UNCeqR. 18 of 618 genes, which met the inclusion criteria were significantly associated with OS. Genes demonstrated both favorable [e.g. WHSC1, TPTE, STAG2, PPP6C with hazard ratios (HR) 0.29, 0.30, and 0.30, 0.45, respectively] and unfavorable (e.g. KIT, FGFR1, DNAH10, PLCB4, CNTN1, POU5F1, DBC1, CDX2 with HR 1.96, 2.04, 2.35, 2.62, 3.43, 3.71, 3.97, 5.93, respectively) associations with OS. Most SM were suggestive of a loss-of-function pattern consistent with tumor suppressor genes. Genes coding for proteins involved in non-MAPK mediated signal transduction pathways (KIT, FGFR1, PLCB4, CNTN1), motility (DNAH10), cell cycle progression (DBC1), and transcription embryologic control (POU5F1, CDX2) tended to associate with worse OS. Genes coding for proteins involved in m phase (STAG2, PPP6C) demonstrated a protective effect. Conclusions', ' Clinicians currently offering SM panels to pts for clinical decision making may consider including these genes for prognostic implications. Updated analysis will be reported at the time of presentation.']",
        "Doc_id":"ASCO_170836-176",
        "Doc_title":" Analysis of the University of North Carolina (UNC) and the Cancer Genome Atlas Project (TCGA) next generation sequencing (NGS) datasets to identify somatic mutations (SM) with prognostic significance in cutaneous melanoma (CM).",
        "_version_":1606189033051914240},
      {
        "Meeting_name":" Performance comparison of BRAF V600E detection assays in malignant melanoma and colorectal cancer specimens",
        "Background":"['Personalized cancer care requires reliable biomarkers. One already implemented in the clinic is the BRAF V600E mutation. We present a comprehensive comparison of three detection methods including immunohistochemistry (IHC) using a mutation specific monoclonal antibody (VE1), Sanger sequencing and a probe-based high resolution melting assay, in melanoma and colorectal cancer specimens. Genomic DNA (gDNA) from fresh frozen tissue from 389 liver metastases and 6 primary tumors from 141 metastatic colorectal cancer (mCRC) patients as well as gDNA from 125 tumors from 75 malignant melanoma (MM) patients was available. Tissue microarrays (TMAs) containing formalin fixed paraffin embedded (FFPE) tissue from 285 of the CRC metastases from 123 patients were made. BRAF, exon 15 was amplified using the DyNazyme EXT polymerase system and sequenced by Sanger sequencing. IHC staining with the BRAF-VE1 antibody was performed on a Ventana BenchMark XT immunostainer. The intensity of staining was graded as 0 (no visible staining), grade 1 (weak diffuse background staining), 2 (moderate diffuse and granular) and 3 (strong granular staining). Grade 2 or 3 was regarded as positive. For high resolution melting analysis of V600-status, we used the LigthMix Kit BRAF V600E/K on a LightCycler 480 instrument.To establish the detection limits for the DNA-based methods used in this comparison, we analyzed a dilution series containing a ratio of 1', '1- 1', '107 BRAF V600E mutated DNA in BRAF wild-type DNA. We found the detection limit for the LightMix assay to be 1', '1000 mutated alleles while it was 1', '10 for Sanger sequencing. Among 125 samples from 75 MM patients, we found 60 samples from 31 patients to be positive for BRAF mutations by Sanger sequencing. By the LigthMix assay, we found 75 mutated samples from 37 patients. Among 395 samples form 141 mCRC patients, we found 22 samples from 7 patients to be BRAF V600E mutated by Sanger sequencing. 127 tumors from 42 of these patients were analyzed by the LigthMix assay and the BRAF V600E mutation was detected in 24 samples from the same 7 patients. IHC was performed on TMAs including tissue from 285 metastases from 123 of the mCRC patients. By this method 25 samples from 15 patients were found to be BRAF V600E mutated. These 15 patients included 5 of the 7 patients identified by DNA-based mutation analyses. Thus 8 patients revealing no mutation by either of the DNA-based methods showed positive immunostaining. Two patients found to carry the mutation by sequencing and melting point analysis were not identified by IHC.Our data show differences in sensitivity and specificity between the three methods. Compared to the LigthMix, assay Sanger sequencing showed inferior sensitivity. Further, we observed a large discrepancy between IHC and the two DNA-based methods, indicating IHC with the current antibody not to be recommendable for clinical tests alone.']",
        "Doc_id":"AACR_2014-1878",
        "Doc_title":" Performance comparison of BRAF V600E detection assays in malignant melanoma and colorectal cancer specimens",
        "_version_":1606188990373822465},
      {
        "Meeting_name":" Monitoring of melanoma therapy with quantitative tissue cytometry of a panel of apoptosis markers",
        "Background":"['Background', ' Monitoring of the apoptosis is a critical part of determining whether certain therapeutic agents are effective. However, given the complexity of the up- and down-regulation of AKT and ERK pathways, it can be difficult to determine the state of each cell in a solid tumor section using single-marker staining methods. Tissue cytometry (or in situ cytometry) is a means of obtaining quantitative, per-cell, multi-marker antigen expression data from a tissue section. While determining the per-cell, multi-marker phenotype of samples containing whole cells has become a common, if not ubiquitous, part of flow cytometry and high-content screening, the same multi-marker analysis on samples such as solid tumors, bone or other solid tissues, which are not easily broken down into individual cells, are not easily performed. Immunohistochemical (IHC) and immunofluorescence (IF) methods have been developed for labeling such samples; however, in order to obtain quantitative multi-marker results from IHC and IF samples there are several challenges that must be overcome to give analogous tissue cytometry results. Methods', ' To address this, a tissue cytometry platform was developed that integrates', ' a) multiplexed immunofluorescence staining protocols; b) a multispectral imaging system (Vectra or Nuance) that to isolate IHC or IF marker signals from one another and, for IF, from tissue autofluorescence; and c) a new pattern-recognition-based image analysis package (inForm) for automatically performing morphologic segmentation and extracting data from cells-of-interest; and d) easy-to-use, optimized staining kits for panels of markers. For this study, a staining panel was developed targeting phosphoepitopes of AKT, ERK, and S6, using antibodies of three different isotypes, with secondaries conjugated to Alexa fluorophores (A488, A555, and A647). DAPI was used as a counterstain. Proof of principle of the suitability of the marker panel and imaging and analysis methods was done in cell lines, monitoring the down regulation of pS6 by a PI3 Kinase Inhibitor and the down regulation of pERK by a Raf inhibitor. Clinical samples pre- and post-case for treatment of a melanoma with a PIK3CA inhibitor were analyzed and both nuclear and cytoplasmic signal levels for all three markers obtained. Results', ' Results from cell lines matched expected down regulation. In the clinical samples, downregulation of pERK in melanoma was observed following treatment with the PLK3CA Kinase inhibitor. Conclusions', ' Tissue segmentation accuracy was estimated at greater than 90%, based on visual review by pathologists. Performance of the platform for automated multiplexed tissue cytometry analyses supports its application to routine clinical studies and works for both IHC and IF staining methodologies. In this particular example, the monitoring of apoptosis in these clinical samples was effective and easy to perform.']",
        "Doc_id":"AACR_2012-4050",
        "Doc_title":" Monitoring of melanoma therapy with quantitative tissue cytometry of a panel of apoptosis markers",
        "_version_":1606189010264260609},
      {
        "Meeting_name":" Analyses of the immunologically relevant gene transcript by qRT-PCR in primary cutaneous melanoma by the young and the elderly.",
        "Background":"['Background', ' To understand the dynamics of anti tumor immune responses (IR) in the setting of the ageing immune system, we examined immunologically relevant gene transcripts in formalin fixed paraffin embedded (FFPE) primary cutaneous melanoma (PCM) samples derived from  five young (age <50 years) and five elderly (age >or=70 years) patients by qRT-PCR. Methods', ' A total of 10 FFPE tumor blocks were collected between 2004-2007 of patients with PCM at the University of Connecticut Health Center. Total RNA was extracted from FFPE tissue sections and random primed cDNA was generated.  Pre amplification using pooled Taqman assays and Universal PCR Master Mix (Applied Biosystems, USA) was performed for 14 cycles to ensure an adequate amount of starting material for qPCR.  Using 15 ng total RNA, the quantification of human IR genes (IL-2, INFg, TNFa, TGFb1, IL-10, Foxp3, and IDO-1) and transcripts of succinate dehydrogenase (SDHA) (as endogenous control) was accomplished by qRT-PCR amplification of a cDNA using TaqMan Universal PCR Master Mix and TaqMan gene expressions assay probes. All reaction assays including that of SDHA were performed in triplicate on an ABI 7500 Fast system (Applied Biosystems). Cycle threshold (Ct) values for each mRNA were normalized to SDHA (DCT) and represented as RQ=2-DCT. The average RQ was calculated for all ten samples in both cohorts and Students T-test was performed to evaluate the statistical significance of the IR gene expression. Results', ' While no significant difference of expression of Th1 cytokines (IL-2, IFNg, TNFa) or Th2/3 cytokines (IL-10, TGFb) could be detected within the two groups, FOXp3 expression was significantly decreased in PCM in the elderly. Conclusions', ' Our results suggest ageing may be associated with less regulatory responses in situ in PCM and that more expanded analyses of the nature of the IR in PCM are likely to provide information with implications on prognosis and  immune based treatment options for elderly PCM subjects.']",
        "Doc_id":"ASCO_98696-114",
        "Doc_title":" Analyses of the immunologically relevant gene transcript by qRT-PCR in primary cutaneous melanoma by the young and the elderly.",
        "_version_":1606189032314765312},
      {
        "Meeting_name":" Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML",
        "Background":"['c-Kit is an attractive target for the treatment of a variety of solid tumors [gastrointestinal tumors (GIST), small cell lung cancer (SCLC), melanoma] and acute myelogenous leukemia (AML) due to its role as an oncogenic driver and high level of expression. Several targeted therapies, such as imatinib, sunitinib and regorafenib, bind to c-Kit and are approved for clinical use. However, due to their insufficient activity on cancers expressing wildtype c-Kit or insensitive forms of mutant c-Kit, the clinical response has been quite varied. Moreover, despite initial anti-cancer benefits in c-Kit mutant settings (such as in GIST), resistance to c-Kit inhibitor therapies emerges due primarily to the development of additional mutations in c-Kit.In an attempt to broaden the treatment of patients whose cancers express c-Kit (wildtype and mutant) and to enhance potency with comparable or better tolerability than the current therapeutics, we developed a c-Kit-targeting antibody-drug conjugate (ADC) that disrupts tumor growth through anti-mitotic activity. Hybridomas from mice immunized with the c-Kit extracellular domain (ECD) were screened for selective c-Kit binding and degradation. A humanized lead antibody (Ab) was identified, which rapidly internalized upon binding cell-surface c-Kit, but did not block binding to the c-Kit ligand (SCF). The Ab exhibited minimal-to-no cytotoxicity against c-Kit+ cell lines in vitro. To generate cytotoxic activity and to potentially overcome resistance to current c-Kit-targeting therapies, the Ab was conjugated to the maytansinoid DM1, a powerful anti-tubulin agent, via a non-cleavable linker, SMCC (technology licensed from ImmunoGen, Inc.). The ADC demonstrated robust anti-proliferative activity against cell lines expressing mutant c-Kit (GIST) and wildtype c-Kit (SCLC, AML) in vitro. The ADC also demonstrated potent anti-cancer activity in GIST and SCLC tumor xenograft models in vivo.In summary, the anti-c-Kit ADC is highly selective and active against cancers with elevated c-Kit expression regardless of their mutational status, thus representing a promising novel therapeutic approach for the treatment of c-Kit+ solid tumors, such as GIST and SCLC, as well as hematological malignancies such as AML and aggressive systemic mastocytosis (ASM).']",
        "Doc_id":"AACR_2015-1695",
        "Doc_title":" Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML",
        "_version_":1606188970868211712},
      {
        "Meeting_name":" Combination therapy to target KIT mutant cells.",
        "Background":"['Purpose', ' Gastrointestinal stromal tumors (GIST), the most common abdominal sarcoma, arise from the interstitial cells of Cajal in the wall of the gut. Eighty percent of GISTs harbor activating mutations in the receptor tyrosine kinase KIT. Despite progress in medical treatment of GIST, advanced disease remains incurable. In addition to GIST, activating KIT mutations are found in cases of mast cell neoplasms, AML, melanoma and seminoma. Therefore, there is a compelling need to identify new targets whose inhibition is synergistic when combined with biochemical inhibition of KIT. Based on shared oncogenic kinase mechanisms with CML, we hypothesized that combined inhibition of KIT and a novel Wnt/Ca++/Calcineurin/NFAT pathway would synergistically inhibit the proliferation of KIT mutant cells.Experimental methods', ' We sequentially combined four different calcineurin inhibitors with five different KIT inhibitors and measured cell proliferation and caspase 3/7activity in nine unique KIT mutant cell lines. Using the Chou and Talalay method we calculated combination indices to quantify drug-drug interactions. Changes in NFAT phosphorylation and localization in KIT mutant cells were assessed by immunoblotting. Finally, we measured NFAT transcriptional activity using an NFAT-responsive reporter cell line.Results', ' In contrast to other cellular models, NFAT appeared to be constitutively active and localized in the nucleus in many KIT mutant cell lines. We observed synergy when we combined a calcineurin inhibitor with a KIT inhibitor in all KIT mutant cell lines where NFAT was constitutively active. Combination index (CI) values for the different KIT mutant cell lines ranged from 0.3-0.5. To investigate whether NFAT was required for this synergy, we combined NFAT specific inhibitors with KIT inhibitors and found synergistic inhibition of cell proliferation. We created a KIT-mutant reporter cell line where NFAT binding drives the expression of luciferase. As expected, NFAT transcriptional activity decreased when our promoter-reporter cell line was treated with calcineurin inhibitors and increased with TPA and ionomycin treatment. Unexpectedly, we also found that KIT inhibitors decreased NFAT transcriptional activity in this cell model.Conclusions', ' These data indicate that combination therapy using a calcineurin phosphatase inhibitor and a KIT kinase inhibitor results in synergistic killing of KIT mutant cells. Additionally, the constitutive activation of NFAT in these cell lines indicate aberrant signaling in the Wnt/Ca2+/calcineurin/NFAT pathway, which has not been previously reported in KIT mutant cell lines. The observed synergy between NFAT inhibitors and KIT inhibitors suggests this effect is mediated by NFAT rather than other calcineurin targets. Finally, the fact that KIT inhibitors modulated NFAT transcriptional activity suggests crosstalk between KIT and NFAT signaling pathways.']",
        "Doc_id":"AACR_2013-3281",
        "Doc_title":" Combination therapy to target KIT mutant cells.",
        "_version_":1606189006354120704},
      {
        "Meeting_name":" Cytotoxic effects of a novel BRD4 inhibitor in uveal melanoma cells with Gnaq/11 mutations",
        "Background":"['Uveal melanoma (UM) is an aggressive intraocular malignancy with high tendency to metastasize to the liver. The majority of UM harbor activating mutations in the G proteins Gnaq/11, and amplification of the oncogene c-Myc. Currently available drugs have shown limited response in patients with UM and there is an urgent need for new effective therapies. Recent findings from our laboratory demonstrated that UM cells with Gnaq/11 mutations are dependent on BRD4 activity. BET proteins are epigenetic readers involved in chromatin remodeling and transcriptional regulation. BRD4 inhibitors consist of small molecules that competitively displace BRD4 from acetylated histones, resulting in the suppression of the MYC transcriptome and other BRD4-dependent genes. Here, we report that a novel clinical BRD4 inhibitor from Plexxikon (Berkeley, CA), PLX51107, induces high cytotoxic activity in UM cell lines at nanomolar concentrations. In cells with Gnaq/11 mutations, PLX51107 showed an IC50 of 250nM, similar to the pre-clinical compound JQ1. In contrast, PLX51107 did not have a significant effect (IC50>3000nM) in cells without the mutations. PLX51107 induced marked apoptosis in Gnaq/11 mutant cells, as detected by Annexin V staining and induction of cleaved PARP. It also suppressed the expression of BRD4 targets, i.e c-Myc, Rad51, and induced the pro-apoptotic protein Bim. In mouse xenograft models of UM PLX51107 significantly inhibited tumor growth. Since the MAPK pathway plays a major role in UM, we explored the combination of PLX51107 with a MEK inhibitor, and found increased activity in vitro and in vivo. All together, these observations support the idea that this clinical BRD4 inhibitor represents a novel therapeutic intervention against UM with Gnaq/11 mutations, and clinical development is planned.']",
        "Doc_id":"AACR_2016-4462",
        "Doc_title":" Cytotoxic effects of a novel BRD4 inhibitor in uveal melanoma cells with Gnaq/11 mutations",
        "_version_":1606189001648111616},
      {
        "Meeting_name":" Functional killer-immunoglobulin-like receptor variation and risk of non-melanoma skin cancer.",
        "Background":"['Natural killer (NK) cells of the immune system are the first line of defense against transformed and infected cells. NK cell action is determined through binding of killer immunoglobulin-like receptors (KIR) with specific human leukocyte antigen (HLA) class I ligands on target cells. The KIR gene family is diverse and highly polymorphic, is poorly covered on GWAS platforms, and exhibits significant functional copy number variation. The KIR locus has been primarily studied in the context of HCV, HIV, and transplant outcomes. Here, we have tested the hypothesis that KIR genotypes are associated with Non-Melanoma Skin Cancer (NMSC) etiology. These are among the most prevalent malignancies worldwide with rising incidence. In addition, they are highly antigenic tumors, with a possible viral etiology, making NMSC an ideal model to test KIR as a cancer susceptibility trait. A random subset of a population-based case-control study in New Hampshire was selected for the study', ' 422 basal cell carcinomas (BCC) (1 BCC=243, 2 BCC=131, 3 BCC=48), 132 squamous cell carcinomas (SCC), and 222 controls. KIR genotyping was performed with Lifecodes KIR-SSO typing kit on Luminex using buffy coat derived genomic DNA, capturing KIR loci', ' 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 2DP1, 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DS1, and 3DL2. Cutaneous HPV status was assessed using serum samples and established Luminex detection assays covering 16 genus beta HPV types.The KIR2DL2/3 locus was associated with a significantly increased risk of BCC (OR=2.65, 95% CI', ' 1.08-6.48), which was particularly strong for cases with 3 or more tumors (OR=5.77, 95% CI', ' 1.30-25.66). For SCC, the KIR3DL1 gene was associated with a significantly increased risk of malignancy (OR=3.73, 95% CI', ' 1.51-9.22). Next we investigated the association of KIR and SCC within HPV strata. The KIR3DL1-SCC association was strongest among those with no evidence of HPV infection (OR=6.81, 95% CI', ' 1.78-26.12). In contrast, the non-functional KIR2DS4 variant related to an increased risk and the KIR2DL2 gene related to reduced risk of SCC among those with multiple -HPV infections. Our results implicate a strong role for KIR in the etiology of NMSC. KIR2DL2/3 may be particularly important in the development of multiple BCC, and KIR3DL1 in the pathogenesis of SCC. Finally, we identified a pattern of KIR-SCC associations that supports a potential etiologic role of cutaneous HPV in SCC occurrence.']",
        "Doc_id":"AACR_2013-1332",
        "Doc_title":" Functional killer-immunoglobulin-like receptor variation and risk of non-melanoma skin cancer.",
        "_version_":1606189029777211392},
      {
        "Meeting_name":" Potential survival benefit of adjuvant sunitinib in high risk uveal melanoma.",
        "Background":"['Background', '  Patients with high-risk uveal melanoma have up to 70% chances of developing distant metastases. There is no US FDA-approved adjuvant treatment able to reduce that risk and prolong survival. We aimed to compare overall survival (OS) in high-risk patients who received adjuvant sunitinib with institutional historical controls.   Methods', '  A cohort of patients who received adjuvant sunitinib for at least 6 months was compared with institutional historical controls patients who had similar demographic as well as high-risk features, including', ' A)  monosomy-3 and 8q amplification (M3-8qA) in the primary tumor by cytogenetic analysis or class II by molecular analysis; B)  monosomy-3 and large tumor size (T3 or 4 by AJCC TNM). Patients in the control group were diagnosed during the same period of time (2007 - 2013) but did not receive any adjuvant treatment. Primary endpoint was OS and was evaluated using Kaplan-Meier survival curves and Cox proportional hazards model.  Results', '  A total of 105 Caucasian patients were included; median follow-up was 34.5 months (range 0.25  82 months). There were 50 patients who received sunitinib. Median age was 55 (29  69 years old) and 46% were males. Fifty five historical controls, with the same high risk factors, were found in our database. The median age was 58 (21  70 years old) and 51% were males. Patients in the sunitinib group had worse cytogenetic features (M3-8qA 78% vs. 47%; P = .001) but smaller tumor sizes (T3-4 56% vs. 80%; P = .01). There were a total of 19 deaths; 3 (6%) in the sunitinib and 16 (29%) in the control group, respectively. Estimated 5-year survival rate was 91% (95% CI', ' 82 100%) in the sunitinib group and 61% (95% CI', ' 47  79%) in the non-adjuvant control group. OS was significantly longer in the sunitinib group (HR = 0.267, 95% CI', ' 0.077  0.925, P = 0.037) and this remained significant after being individually adjusted by cytogenetic status, tumor size, age and gender. No meaningful interactions were detected.   Conclusions', '  In this retrospective study, the use of sunitinib in the adjuvant setting was associated with better OS. Current ongoing clinical trials are testing this hypothesis.']",
        "Doc_id":"ASCO_151013-156",
        "Doc_title":" Potential survival benefit of adjuvant sunitinib in high risk uveal melanoma.",
        "_version_":1606189039130509312},
      {
        "Meeting_name":" Tyrosine 823 in the activation loop of c-Kit regulates the transforming capacity of the oncogenic mutant D816V and its sensitivity to kinase inhibitors",
        "Background":"['Oncogenic mutations in c-Kit have been shown to lead to ligand-independent receptor activation and contribute to transformation. A substitution of an aspartate for a valine at position 816 (D816V) is one of the most commonly found oncogenic c-Kit mutation and is found in more than 90% of cases of mastocytosis and in a subgroup of germ cell tumors, core-binding factor acute myeloid leukemia and mucosal melanomas. Previous studies have shown that the D816V mutation causes a structural change in the activation loop resulting in weaker binding of the activation loop to the juxtamembrane domain, leading to a release of the negative constraint it poses on kinase activity. Here we have investigated the role of Y823 in the activation loop of c-Kit and its role in oncogenic transformation by c-Kit/D816V. Although dispensable for the kinase activity of c-Kit/D816V, the presence of Y823 was shown to be crucial for cell proliferation and survival. Furthermore, mutation of Y823 selectively down-regulated the Ras/Erk and Akt pathways. It also led to decreased phosphorylation of STAT5 and reduced the transforming capacity of D816V/c-Kit in vitro. The sensitivity to kinase inhibitors, such as dasatinib and nilotinib, was decreased in cells expressing c-Kit/Y823F/D816V compared to cells c-Kit/D816V. Mice injected with cells expressing c-Kit/D816V/Y823F displayed significantly reduced tumor size as well as tumor weight compared to controls. Finally, microarray array analysis, comparing c-Kit/Y823F/D816V cells with cells expressing c-Kit/D816V, demonstrate that mutation of Y823 causes up-regulation of pro-apoptotic genes whereas genes of survival pathways are down-regulated. Thus, phosphorylation of Y823 is not necessary for kinase activation, but essential for the transforming ability of the c-Kit/D816V mutant.']",
        "Doc_id":"AACR_2015-128",
        "Doc_title":" Tyrosine 823 in the activation loop of c-Kit regulates the transforming capacity of the oncogenic mutant D816V and its sensitivity to kinase inhibitors",
        "_version_":1606189040545038336},
      {
        "Meeting_name":" Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition.",
        "Background":"['Background', '  E7080 is a TKI targeting VEGFR1-3, FGFR1-4, KIT, RET and PDGFR. Anti-tumor activity has been observed in melanoma patients in phase I.  The objective of this study was to examine the effect of E7080 alone and in combination with PLX-4032 on tumor response, gene expression and tumor microvasculature in BRAFmu melanoma.  Methods', '  BRAF mutant (mu) cell lines were created by transfection of BRAF V600E constructs into BRAF wild type (wt) cell lines. Anti-tumor activity of E7080 alone or in combination with the selective BRAF inhibitor PLX-4032 was examined in xenografted models bearing mock and BRAFmu transfectants.  Results', '  The ratio of ANGPT1/2 expression was significantly higher in BRAFmu/ PTENwt compared to BRAFwt/PTENwt and BRAFmu/PTENmu among 14 melanoma cell lines. ANGPT1 expression was up-regulated in BRAFmu by 330%, and ANGPT2  in PTENmu by 290% compared to wt. PLX-4032 decreased ANGPT1 expression and pericyte coverage of tumor vessels in BRAFmu/PTENwt A375 melanoma. Similarly, overexpression of BRAF V600E in BRAFwt SK-MEL-2 melanoma resulted in increased ANGPT1 expression along with increased pericyte coverage. E7080 at 3, 10, 30 to 100 mg/kg showed significant anti-tumor activity against mock transfectants, but only at 100 mg/kg against BRAF V600E transfectants. Combination of E7080 at 10 mg/kg with PLX-4032 at 100 mg/kg showed synergistic anti-tumor activity against A375 melanoma and caused tumor regression, not observed by either single agent E7080 or PLX-4032. E7080 alone increased pericyte coverage of tumor vessels, but in combination with PLX-4032 resulted in marked decreased in pericyte coverage and microvessel density.  Conclusions', '  The BRAFmu/ PTENwt melanomas studied demonstrate high pericyte coverage and resistance to E7080.   Combination of E7080 with PLX-4032 achieves synergistic antitumor effect with enhanced reduction of pericyte coverage. These data provide a mechanistic basis for clinical study of BRAF inhibitors in combination with VEGFR and FGFR targeted agents.']",
        "Doc_id":"ASCO_78660-102",
        "Doc_title":" Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition.",
        "_version_":1606189026744729600},
      {
        "Meeting_name":" Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility.",
        "Background":"['Background', '   Analysis of genomic alterations in advanced malignant disease is quickly becoming the standard of care in oncology. Biopsies are risky, often costly and may not capture genetic changes that can emerge over time or in response to therapy. In contrast, GUARDANT360, a blood-based liquid biopsy approach that analyzes circulating tumor DNA (ctDNA), offers a simple and comprehensive tool for real-time tumor genetic profiling in advanced refractory cancer patients.  Methods', '  We studied the performance of GUARDANT360 in five prevalent cancers', ' colorectal, melanoma, lung, breast, and prostate. Over 500 plasma samples and 100 matched tumors from a total of 300 unique patients were analyzed using GUARDANT360, a single-molecule next-generation digital sequencing assay with ability to detect somatic mutations and copy number variations with exquisite sensitivity. The assay covers sequences across a total of 54 actionable genes covering approximately 80 kbps. Select patients were treated on the basis of ctDNA alterations detected by GUARDANT360.    Results', '  The overall detection rate of somatic alterations in ctDNA approached 85% for all indications (the range of detectable ctDNA mutations was 0.03%-87%). The concordance of tumor mutations to GUARDANT360 ranged from 67% (blood draw > 6 months post biopsy) to 93% (concurrent blood draw at time of biopsy). The dominant genetic mutations observed were similar to those previously reported for solid tumors. About 60% of cases with colorectal, breast and lung cancers had actionable mutations. The select patients treated on the basis of observed ctDNA alterations exhibited significant positive clinical outcomes (PR) suggesting strong potential for clinical utility of ctDNA sequencing.  Conclusions', '  Advances in single-molecule sequencing and bioinformatics make possible the ultra-sensitive detection of somatic mutation and amplifications. Comprehensive profiling of ctDNA shows reasonable concordance to tumor profiles and illustrates the potential to improve the care of advanced refractory cancer patients.']",
        "Doc_id":"ASCO_135280-144",
        "Doc_title":" Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility.",
        "_version_":1606189028195958784},
      {
        "Meeting_name":" Companion testing using next-generation sequencing as compared with FDA-cleared kits.",
        "Background":"['Background', ' Companion diagnostic tests are currently recommended for the prescription of multiple therapeutic agents in oncology. Most of these companion tests are FDA-cleared kits. We compared the mutations detected in large number of solid tumors using next generation sequencing (NGS) and confirmation by Sanger sequencing with FDA-cleared testing kits. Methods', ' Samples from 822 patients were submitted for routine clinical testing for mutations in EGFR, BRAF, and KRAS. This included 442 lung cancers, 168 colorectal, 29 (4%) brain tumors, 33 melanomas, 14 thyroid cancers, and others. All samples were tested by NGS, then confirmed by Sanger sequencing. LNA was used to increase sensitivity of Sanger for EGFR T790M mutation, codons 12/13 for KRAS, and V600 for BRAF mutations. We compared our results with listed detectable mutations in the FDA-approval labeling for EGFR, KRAS and BRAF for cobas tests (Roche, Indianapolis, IN) and Therascreen tests (Qiagen, Germantown, MD). Results', ' We detected 55 unique EGFR mutations in 99 patients. Of all 99 patients with EGFR mutations, 39 patients (39%) had mutations in codons not covered in the commercial cobas v2 kit and 63 (64%) were not covered by the older cobas v1 kit. Therascreen test also did not cover 64 (65%) mutations detected in EGFR. We detected mutations in BRAF in 114 patients, but only 61 patients had mutations involving codon V600 and 53 (46.5%) patients had mutations involving other codons. These mutations would have been missed if tested using FDA-cleared tests. We detected mutations in KRAS in 320 patients, of which 284 mutations (89%) involved codons 12 and 13. Sixteen (5%) mutations involved codon 61 and 20 (6%) mutations involved other codons. Therefore 6% of patients with KRAS mutation would have been missed if the cobas KRAS test (P = 0.00002) is used and 11% if Therascreen is used. Conclusions', ' Currently available FDA-cleared kits for testing for mutations in EGFR, KRAS, and BRAF genes are not comprehensive enough and miss significant number of mutations. GenesDetected mutationsMissed cases by FDA-Cleared kitsTotalUniqueCobas V1Cobas V2TherascreenEGFR995563 (64%)39 (39%)64 (65%)BRAF1144253 (51%)NA53 (51%)KRAS32030NA20 (6%)36 (11%)']",
        "Doc_id":"ASCO_166832-176",
        "Doc_title":" Companion testing using next-generation sequencing as compared with FDA-cleared kits.",
        "_version_":1606189014347415552},
      {
        "Meeting_name":" Pan-cancer analysis of programmed death-ligand 1 (PD-L1) amplifications",
        "Background":"['PD-L1, located in the chromosomal region 9p28, is a ligand of programmed cell death protein 1 (PD-1) and has been described as immune checkpoint regulator that allows cancers to evade the host immune system. To stratify patients for treatment with PD-1 inhibitors, PD-L1 expression is currently intensively studied on RNA and protein levels. However, no comprehensive study of PD-L1 amplifications including many cancer types has been performed so far.We investigated PD-L1 amplifications in eighteen cancer types that were copy number profiled, gene expression profiled and clinically characterized by the TCGA consortium', ' Acute Myeloid Leukemia (LAML), Bladder Urothelial Carcinoma (BLCA), Brain Lower Grade Glioma (LGG), Breast invasive carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Colorectal adenocarcinoma (COADREAD), Glioblastoma multiforme (GBM), Head and Neck squamous cell carcinoma (HNSC), Kidney renal clear cell carcinoma (KIRC), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD) and Uterine Corpus Endometrial Carcinoma (UCEC).We found a diverse landscape of focal PD-L1 amplification, 9p chromosome arm amplifications and polysomy 9. Focal amplifications had the highest incidence in OV (10.7%), LUSC (9.8%), HNSC (8.6%), BLCA (8.3%), SARC (8.2%), CESC (7.1%), STAD (6.8%) and BRCA (5.3%). 9p amplifications were most frequently found in OV (12.6%), BLCA (7.4%), BRCA (6.8%) and LUAD (5.2%). Polysomy 9 had the highest incidence in COADREAD (14.0%), HNSC (13.6%), CESC (11.2%), SARC (9.4%) and STAD (7.2%), BLCA (5.9%) and GBM (5.5%). In a pooled analysis of focal and non-focal alterations, PD-L1 amplifications positively correlated with gene expression in nine cancer types and significantly (p < 0.05) shortened overall survival in five cancer types.In summary, PD-L1 amplifications represent a frequent genetic alteration that occurs in many cancer types and could potentially be exploited for patient stratification and immune therapy.']",
        "Doc_id":"AACR_2016-2652",
        "Doc_title":" Pan-cancer analysis of programmed death-ligand 1 (PD-L1) amplifications",
        "_version_":1606189034603806720},
      {
        "Meeting_name":" A novel ATP-competitive MEK/Aurora kinase inhibitor BI-847325 reverses acquired BRAF inhibitor resistance through suppression of Mcl-1 and inhibition of MEK expression",
        "Background":"['BACKGROUND', ' BRAF/MEK inhibitors have shown promising levels of response in melanomas harboring the BRAF V600E mutation, however responses tend to be short-lived and resistance is a major clinical problem. In the current study, we evaluated the pharmacological activity of BI847325, a dual inhibitor of MEK and Aurora kinases against multiple melanoma cell line models.METHODS', ' The cytotoxic effect of BI847325 was evaluated in vitro in a panel of selected BRAF-mutant vemurafenib resistant cell lines by Alamar blue and Annexin V binding assay. 3D spheroid model systems and colony formation assays demonstrated the long-term growth inhibitory effect of BI847325. Western blot analysis and qRT-PCR studies were carried out to evaluate the mechanism underlying BI5-mediated cytotoxicity. In vivo studies in Balb SCID mice were performed to assess the suppression of BRAF-mutant xenografts on treatment with BI847325.RESULTS', ' BI847325 potently reduced the growth and survival of BRAF-mutant melanoma cell lines with acquired and intrinsic BRAF inhibitor resistance (NRAS mutations, BRAF splice forms, Cyclin D1 amplification, RTK upregulation, PTEN loss, COT amplification). We confirmed that BI847325 induced apoptosis through decrease in Mcl-1 mRNA and protein expression and increase in BIM expression. The effects of BI847325 upon BIM and Mcl-1 expression could not be mimicked by the combination of other MEK and aurora kinase inhibitors. For the first time we demonstrated that BI847325 reverses the acquired vemurafenib resistance by inhibiting MEK expression at mRNA and protein level. A strong suppression of MEK expression was observed without recovery following 72 h of washout. In vivo studies revealed complete tumor suppression with no recurrence over a period of 65 days of treatment with 70mg/kg/week dose of BI847325. In contrast, treatment with vemurafenib analog PLX4720 in the same mouse model was associated with tumor relapse after 30 days of treatment. BI847325 also successfully suppressed the long-term growth of xenografts with acquired vemurafenib resistance. Analysis of tumor samples complied with in vitro results demonstrating inhibition of phospho-ERK, phospho-Histone3, Mcl-1 and total MEK.CONCLUSION', ' In conclusion we report for the first time that BI847325, a novel ATP-competitive MEK/ Aurora kinase inhibitor effectively inhibits BRAF-mutant melanoma and overcomes vemurafenib-resistance by decreasing expression of MEK and Mcl-1; in vitro and in vivo. Further preclinical and clinical investigations towards this would open new avenues in treatment of melanoma.']",
        "Doc_id":"AACR_2015-703",
        "Doc_title":" A novel ATP-competitive MEK/Aurora kinase inhibitor BI-847325 reverses acquired BRAF inhibitor resistance through suppression of Mcl-1 and inhibition of MEK expression",
        "_version_":1606189005456539649},
      {
        "Meeting_name":" Quantitative digital PCR analysis of cancer gene promoter methylation using low amounts of input DNA.",
        "Background":"[\"Silencing of tumor suppressor and tumor-related gene transcription by hypermethylation at promoter CpG motifs is a significant mechanism at work in human tumorgenesis. Various methods have been developed to analyze DNA methylation levels, both across the genome and at specific loci, in order to discover and interrogate disease relevant loci for methylation-based transcriptional control. Methods able to quantitatively measure differences in DNA methylation between normal and cancer cells provide promising sources for biomarker identification and assessment.Here we report on the use of a methylation assay (Zymo Research's OneStep qMethyl) and digital PCR counting (RainDrop dPCR) to enable quantitative measurements of DNA methylation at specific genomic loci using small amounts of non-bisulfite converted DNA. MGMT promoter methylation measurements are used to illustrate the method's robust quantification of small percent methylation changes using low amounts of input DNA.Zymo Research's OneStep qMethyl Kit is used for the detection of region-specific DNA methylation via the selective amplification of methylated cytosines after digestion with methylation-sensitive restriction enzymes. RainDance Technologies RainDrop dPCR system is a highly sensitive tool for precise quantification of nucleic acids using probe-based qPCR reagents. RainDrop offers unique analytical advantages for clinical diagnostics due to its exceptionally high sensitivity for absolute quantification and capability to multiplex assays, using a wide dynamic range of input DNA in a contamination-free and simple workflow. The combination of both technologies enables a novel, fast, and robust method for quantitative methylation analysis of small amounts of DNA.The DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) removes mutagenic alkyl adducts from DNA, and its epigenetic silencing by promoter methylation confers susceptibility to DNA-damaging alkylating agents in glioblastomas, melanomas, and lung cancer cell lines, and is increased in cancers including advanced gastric carcinomas, colorectal tumors, and triple-negative breast cancers. A sensitive, quick, and cost-effective quantitative method for assessing MGMT promoter methylation would greatly enhance the diagnostic potential for this candidate cancer biomarker.Here we show digital quantification of MGMT promoter methylation across the range from 0 to 100%, demonstrating a linear correlation that enables less than 15% methylation changes to be robustly measured using less than 20 nanograms of input DNA. This method provides a sensitive count of region-specific methylation percentages using an easy workflow. Continuing work will make use of RainDrop's unique ability to multiplex assays to enable combining MGMT methylation analysis with additional cancer relevant methylation biomarkers in a single assay.\"]",
        "Doc_id":"AACR_2013-808",
        "Doc_title":" Quantitative digital PCR analysis of cancer gene promoter methylation using low amounts of input DNA.",
        "_version_":1606189001579954176},
      {
        "Meeting_name":" Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling blockade.",
        "Background":"['Introduction', ' Lenvatinib (LEN) selectively inhibits the kinase activity of VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, which are involved in tumor angiogenesis and tumor cell proliferation in several cancer types. Currently, Phase 1b/2 clinical trials of the combination of LEN and pembrolizumab (a monoclonal antibody [mAb] that blocks the interaction between PD-1 and its ligands) are ongoing for selected types of cancer including renal cell carcinoma, melanoma and non-small cell lung carcinoma. We have reported that tumor associated macrophage and regulatory T cell population were downregulated by treatment of LEN. In this study, mechanism of LEN and PD-1 mAb combination was investigated by flow cytometory and RNA-seq analyses.']",
        "Doc_id":"AACR_2017-4614",
        "Doc_title":" Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling blockade.",
        "_version_":1606188997786206208},
      {
        "Meeting_name":" BRAF inhibitor acquired resistance",
        "Background":"['Background', '  Acquired resistance (AR) to BRAF inhibitors (BRAFi) in melanoma is a near-universal phenomenon driven by numerous genetic and non-genetic alterations. Clinical implications of these AR mechanisms have not been described in a large cohort. We assessed the spectrum of BRAFi AR mechanisms and their associated timing of onset, pattern of disease progression (DP), and clinical outcomes.  Methods', '  We compiled clinical and genetic data from 100 patients (pts) with 132 melanoma samples obtained at BRAFi DP from three previously published studies of BRAFi resistance. Whole exome sequencing and/or PCR-based genetic testing were performed on all samples. Associations between AR mechanisms and clinical features/outcomes were assessed with multivariate logistic regression models.  Results', '  In 132 DP samples, putative AR mechanisms were identified in 58%, including NRAS or KRAS mutations (20%), BRAF splice variants (16%), BRAFV600E/K amplifications (13%), MEK1/2 mutations (7%), and non-MAPK pathway alterations (11%). Marked heterogeneity was observed within tumors and patients. BRAFV600E/K amplifications and non-MAPK alterations often co-occurred with other genetic changes, whereas NRAS mutations, MEK1/2 mutations, and BRAF splice variants largely arose in isolation (p = 0.02). Of 19 pts with  2 DP biopsies, identified AR mechanisms were concordant in only 1 pt (5%). NRAS mutations were associated with vemurafenib use (p = 0.045) and baseline intracranial metastases (p = 0.036). Progression-free survival and patterns of DP were similar across AR mechanisms. The median survival after DP was 6.9 months, and subsequent responses to combined BRAF/MEK inhibition were uncommon (2/15; 13%); no patients responded to ipilimumab (0/24). Post-progression outcomes did not correlate with specific BRAFi AR mechanisms.   Conclusions', '  This is the largest study of acquired BRAFi resistance in pts with BRAF mutant melanoma. Despite marked heterogeneity of AR mechanisms within pts and tumors, NRAS mutations were associated with vemurafenib use and intracranial disease. Further investigation into non-genetic AR mechanisms and immune features of BRAFi progression is warranted.']",
        "Doc_id":"ASCO_146700-156",
        "Doc_title":" BRAF inhibitor acquired resistance",
        "_version_":1606189014756360192},
      {
        "Meeting_name":" The neoantigen landscape underlying clinical response to ipilimumab.",
        "Background":"['Background', '   Ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), prolongs overall survival and can produce durable tumor regression in patients with advanced melanoma.  Ipilimumab activates cytotoxic T-lymphocytes and enables them to destroy tumor cells. However, the molecular determinants of response to ipilimumab are unknown.  Methods', '   Fresh frozen tumor DNA (and matching blood) from 25 melanoma patients treated with ipilimumab was subjected to whole exome sequencing.  Exon capture was performed using the SureSelect Human All Exon 50MB kit (Agilent). Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to a mean coverage of 103X.  Somatic mutations and candidate somatic neoantigens generated from these mutations were identified and characterized.  Results', '   Our cohort included complete responders (CR) and nonresponders (NR). Mutational burden ranged from 1-1121 mutations per tumor.  Mutational load was significantly associated with clinical response (p=0.028, CR vs. NR, Fishers Exact Test), but alone was not sufficient to predict response. Using genome-wide somatic neoepitope analysis, we defined candidate tumor neoantigens and identified a neoantigen landscape that is specifically present in tumors with complete responses to ipilimumab.  These somatic neoepitopes share consensus sequences with experimentally validated antigens from a variety of pathogens.  Furthermore, in four of six CR patients, a mutation led to the generation of a consensus amino acid sequence previously identified as necessary for T-cell recognition of melanoma antigen recognized by T-cells (MART-1).  Conclusions', '   Somatic mutations and concomitant generation of neoepitopes in melanoma tumors confers enhanced antigenicity and response to the immune checkpoint modulator ipilimumab. Our study defines the neoantigen landscape in responders to ipilimumab, provides a rationale for examining the exomes of patients for whom ipilimumab is being considered, and builds a foundation for understanding the molecular determinants of response to cancer immunotherapy.']",
        "Doc_id":"ASCO_129838-144",
        "Doc_title":" The neoantigen landscape underlying clinical response to ipilimumab.",
        "_version_":1606189021641310209},
      {
        "Meeting_name":" MELADIAG",
        "Background":"['Background', ' Genetics of melanoma (MM) has greatly progressed in the last decades by the discovery of mutations in BRAF, NRAS and KIT. However, there is a large genetic variability not only of a tumor to another but also depending on the stage of the disease. In order to deepen our knowledge about this and for a purpose referred to therapeutic and prognosis we studied 118 MM tumors and 73 nevi by target next generation sequencing. Methods', ' After extraction, tumor DNA of 118 tumors (44 metastatic tumors, 46 SSM, 11 ALM, 5 nodular, 2 Dubreuilh and 3 spitzoid) and 73 nevi (50 benign nevi, 18 dysplastic nevi and 5 spitzoid nevi) were sequenced using a panel of 15 genes (ALK, BRAF, CDKN2A, CTNNB1, GNA11, GNAQ, KIT, NOTCH1, NOTCH2, NRAS, RAC1, RAF1, SF3B1, TERT and TP53) on a new generation sequencer (PGM Ion Torrent) using chips 318 with a depth > 51000x . The analysis of the variants was made by dedicated software (Ion Reporter, wAnnovar) and we selected only those which had a sufficient quality score. Results', ' The results of the sequencing showed the presence of very large number of mutations. In the begnin nevi, excepting BRAF mutations (V600E and V600K, present in 86%) there were no other mutations. At the opposite, the percentage of mutations in many other genes (ALK, KIT,CDKN2A,TP53...) in MM tumors range from 55% (Breslow < 1mm) to 90% in metastatic tumors. More than 80% of mutations were transitions C > T reflecting the UV-induced mutagenesis. Interestingly, in 33% of atypical and Spitz nevi, we also found at least one mutation in one of these genes (40% of these mutations were reported in Cosmic databases). Comparison of the proportion of somatic mutations between the different types of nevi, tumors with low thickness and metastatic tumors clearly showed an accumulation of somatic mutations during tumor development. Conclusions', ' This chip dedicated to MM is interesting', ' high sensitivity, allowing a better tumor classification and rapid identification of therapeutic targets. In addition, it could help for MM diagnosis in case of pigmented lesions with atypical component or uncertain diagnosis. In a second step, this panel of markers will be used to detect circulating tumor DNA in plasma of patients and to correlate their presence with melanoma prognosis.']",
        "Doc_id":"ASCO_167776-176",
        "Doc_title":" MELADIAG",
        "_version_":1606188995637673984},
      {
        "Meeting_name":" NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation",
        "Background":"['FLT3 (FMS-like tyrosine kinase 3) and KIT are both members of the class III receptor tyrosine kinase family characterized by an autoinhibitory juxtamembrane (JM) domain that docks with the kinase domain to stabilize a catalytically inactive conformation. Therefore, mutations or deletions in this or in adjacent regions cause constitutive activation of these kinases as observed in 30% of AML patients for FLT3 and in 70% of adult GIST and a subset of melanoma patients for KIT.NMS-P088 is a member of a novel indazole sub-series, which selectively targets both FLT3 and KIT kinases, with different mutations, both primary and secondary, some of which involved in resistance to inhibitors clinically used to target these kinases, such as quizartinib for FLT3 and imatinib for KIT.The compound is able to arrest in vitro growth of human cell lines (AMLs and GISTs) which bear constitutively activated FLT3 or KIT, with IC50s in the low nanomolar range and with high selectivity towards cell lines, including AMLs, which are not dependent on these kinases. When tested against a panel of BA-F3 cells engineered to be driven by different FLT3 or KIT mutants, NMS-P088 compared favorably with reference compounds, both in vitro and in vivo. For example, comparative in vivo tumor inhibition values against BA-F3_FLT3-ITD(F691L) model were 85% for 15 mg/kg NMS-P088 vs. 14% for 40 mg/kg quizartinib.In vivo studies conducted on nude mice bearing the human MOLM-13 AML model revealed that repeated oral administration of NMS-P088 was able to significantly inhibit tumor growth and to increase survival time and that strong inhibition of FLT3 signaling is sustained for at least 48 h after a single treatment.Preclinical profiling of the compound showed a good oral bioavailability in all species, indicated a good therapeutic window in 7-day repeated toxicological studies in rat and in dog and excellent BBB penetration. The low myelotoxicity observed in exploratory toxicological studies suggests that NMS-P088 is potentially well-suited to combination with myelotoxic chemotherapeutic agents and this point is currently subject of preclinical evaluation. Furthermore, no adverse effects on cardiac parameters were observed in a canine telemetry study in which animals were exposed to Cmax levels several fold higher than those required for efficacy in the mouse. NMS-P088 is currently undergoing advanced preclinical development activities.']",
        "Doc_id":"AACR_2015-798",
        "Doc_title":" NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation",
        "_version_":1606189019619655680},
      {
        "Meeting_name":" 6-Phosphofructo-2-Kinase (PFKFB3)",
        "Background":"['Targeted cancer therapies that block the growth and spread of cancer by interfering with specific onco-proteins are limited by signaling mechanisms that drive intrinsic and acquired resistance. In particular, the MAPK and the PI3K/AKT pathways have been found to both reduce response rates to these agents and to mediate the acquisition of resistance via mutations that activate both pathways. For example, two recently approved BRAFV600E inhibitors, vemurafenib and dabrafenib, cause dramatic clinical responses in 50% of BRAFV600E + melanoma patients but universally become ineffective within 5-6 months as a result of genetic alterations that activate the MAPK and PI3K-AKT pathways, including amplifications in BRAFV600E, loss of PTEN, and activating mutations in NRAS and KRAS, MEK, AKT1/3, PIK3CA and PIK3CG. Several of these mutated signaling proteins stimulate glucose metabolism, required for survival and proliferation, in part by increasing the expression and activity of 6-phosphofructo-2-kinase (PFKFB3). For example, PFKFB3 transcription is induced by HIF-1 (which is increased by BRAFV600E, RAS and MEK), loss of PTEN, and PFKFB3 activity is stimulated by AKT via phosphorylation of serine 461. We postulated that PFKFB3 is an essential downstream target of targeted cancer therapies and that the multitude of mutations and amplifications in signaling pathways that cause resistance to these agents activate PFKFB3. In new studies, we demonstrate that BRAFV600E, estradiol and epidermal growth factor each regulate PFKFB3 expression in melanoma cells, breast cancer cells and NSCLC cells, respectively. Moreover, we find that simultaneous inhibition of these oncoproteins or their co-ligands (i.e. the estrogen and EGF receptors) and PFKFB3 using a novel PFKFB3 inhibitor currently in a phase 1 trial, PFK-158, causes a synergistic increase in apoptosis and cytotoxicity in vitro, suggesting that PFK-158 can overcome the intrinsic resistance to these agents. We then decided to determine if these significant synergies would translate in vivo by investigating them in the A375 and A2058 melanoma preclinical models, and in the MCF-7 ER-dependent breast model. For instance, we compared the anti-tumor effects in A375 melanoma xenograft-bearing mice of', ' (i) the BRAFV600E inhibitor vemurafenib; (ii) PFK-158; or (iii) the combination of vemurafenib and PFK-158. Although we observed significant tumor growth inhibition with both monotherapies (>80%), we only observed tumor regression with the combination therapy (>50%). Results in these different models will be presented. Taken together, these data demonstrate that the PFKFB3 inhibitor PFK-158 may be able to universally overcome resistance to targeted cancer therapies. Furthermore, we predict that phase 1/2 trials of PFK-158 in combination with targeted cancer agents will yield improvements in objective response rates as well as improvements in progression-free survival.']",
        "Doc_id":"AACR_2015-4478",
        "Doc_title":" 6-Phosphofructo-2-Kinase (PFKFB3)",
        "_version_":1606189004691079168},
      {
        "Meeting_name":" Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel",
        "Background":"['NVP-BYL719 is a p110 isoform-specific small molecule inhibitor that is currently in a Phase I clinical trial. To identify cancer populations that most likely to respond to BYL719 treatment, we initiated a comprehensive in vitro pharmacologic profiling screen across a large panel of cancer cell lines that have been previously characterized at the molecular level as part of the Cancer Cell Line Encyclopedia (CCLE) effort. We found that BYL719 responsive cell lines are enriched in indications such as Her2 positive and luminal breast cancer, while lacking in other indications such as Glioblastoma and Melanoma. Further exploration of the underlying genetic and pathway aberrations revealed that BYL719 sensitivity is positively associated with PIK3CA mutation, ERBB2 amplification and PIK3CA amplification/copy number gain. PTEN and BRAF mutations on the other hand, are associated with BYL719 insensitivities. KRAS mutation alone is neither associated with enhanced sensitivity nor insensitivity, however, co-commitant PIK3CA and KRAS mutants are more likely to be insensitive to BYL719 treatment. These findings will help to guide our clinical development plan.']",
        "Doc_id":"AACR_2012-3749",
        "Doc_title":" Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel",
        "_version_":1606189003624677377},
      {
        "Meeting_name":" Potential biomarkers of Smac mimetic tumor sensitivity",
        "Background":"['The inhibitor of apoptosis (IAP) family of proteins block programmed cell death and promote survival signaling. Birinapant (TL32711) is a bivalent Smac Mimetic that antagonizes multiple IAPs to promote efficient apoptosis and is currently in clinical trials as a single agent and in combination with multiple chemotherapeutics. However, to enrich for patient populations that will maximally benefit from each specific treatment regimen, it is critical to identify predictive biomarkers to achieve maximum response. Based on multiple individual studies, members of IAPs have been reported to be overexpressed in multiple cancers. Therefore, the main focus of this study was to evaluate DNA copy number alterations of different IAPs in a variety of cancer cell lines, and to evaluate their association with birinapant sensitivity. Our initial analysis of the Cancer Cell Line Encyclopedia (CCLE) database revealed that approximately 41% (397/972) of the cancer cell lines carried DNA amplification of different IAPs. Detailed analysis showed copy number amplification of ML-IAP in 214 cell lines (22%), cIAP1/2 in 85 cell lines (9%), NAIP (BIRC1) in 37 cell lines (4%), BIRC8 (ILP-2) in 39 cell lines (4%) and XIAP in 22 cell lines (2%). Tumor-type evaluation indicated that 50% pancreatic, 25% melanoma, 35% colorectal, 40% ovarian, and 7% AML cancer cell lines carried DNA amplification of different IAPs, indicating that IAPs are frequently amplified in cell lines of various cancer types. To understand the association of IAP amplification and birinapant sensitivity, we analyzed 94 cell lines present in the CCLE for birinapant sensitivity with or without TNF, and with or without TRAIL. Our analyses indicated that approximately 20% (19/94) of cancer cell lines were birinapant single-agent sensitive, and 80% (75/94) were single resistant cell lines. Furthermore, 50% (37/75) of the birinapant single resistant cell lines showed synergistic induction of apoptosis when birinapant was combined with either TNF or TRAIL (\"synergy-positive\"). Our analysis showed that the frequency of cIAP1/2 amplification in birinapant single-agent sensitive cell lines was 3-fold higher (4/19, 21%) than in single-agent resistant cancer cell lines (5/75, 7%). However, there was no difference in IAP gene amplification between birinapant \"synergy-positive\" and \"synergy-negative\" resistant cell lines. This lack of correlation with the synergistic response observed with the combination of birinapant plus either TNF or TRAIL implies the involvement of additional pathways that we are attempting to define. We will present a comprehensive dataset for the role of IAP gene amplification in birinapant tumor sensitivity.']",
        "Doc_id":"AACR_2013-599",
        "Doc_title":" Potential biomarkers of Smac mimetic tumor sensitivity",
        "_version_":1606189006009139200},
      {
        "Meeting_name":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "Background":"['MET amplification has been implicated in signaling pathways that promote cell proliferation, invasion, and survival. It has been identified as an oncogenic driver in various malignancies and is currently being investigated as a potential therapeutic target. To date, MET exon 14 skipping by sequencing and MET amplification by FISH have been found to have potential clinical utility in predicting those patients who may derive benefit from MET-targeted therapy. However, little research has been conducted on alternative technologies to FISH such as CISH, which does not require a dark room and can be interpreted by a board-certified pathologist. The purpose of this study is to report our experience with MET amplification across solid tumors using CISH.A retrospective analysis was done on 26,619 specimens analyzed for MET amplification by CISH at a CLIA-certified lab (Caris Life Sciences). The validated CISH assay, previously validated against a FISH assay, utilized a gene copy number > 5 to assess amplification. Concordance and correlative studies were done in MET-amplified, non-small cell lung cancer (NSCLC) specimens analyzed using a cMET IHC (SP44, 2+ or 3+ staining intensity in 50% or more tumor cell membrane) analyzing protein expression. Correlative studies involving co-existing aberrations, including PD-L1 (SP142, any intensity in at least 50% of tumor cells), in this MET-amplified, NSCLC cohort were also performed.MET amplification utilizing CISH was 0.7% (188/26,619) overall. MET-amplified solid tumors included carcinomas such as NSCLC (3.1%, 87/2767), gastric adenocarcinoma (3.8%, 11/293), esophageal and esophagogastric junction adenocarcinoma (3.3%, 11/338), and endometrial carcinoma (0.4%, 9/2020) along with non-carcinomas, including glioblastoma multiforme (1.0%, 5/510), uterine sarcoma (1.3%, 5/400), melanoma (0.4%, 2/538), and rare tumors such as placental-site trophoblastic tumor (100%, 1/1) and prostatic neuroendocrine tumor (100%, 1/1). A sub-analysis of MET-amplified, NSCLC specimens demonstrated co-occurring protein overexpression in 92.6% (75/81) of cases. These same MET-amplified, NSCLC specimens were found to have EGFR pathogenic/presumed pathogenic mutations (19.7%, 15/76), ALK rearrangements (2.5%, 2/80), and PD-L1 overexpression (27.5%, 14/51). ROS1 rearrangements were not detected in this NSCLC cohort (0%, 0/76).Our data suggest MET amplification detection utilizing CISH is a viable option for identifying MET-driven cancers. The presence of MET across various solid tumors contrasts with biomarkers like HER2, which are exclusive to carcinomas. A sub-analysis of our NSCLC population shows MET-amplified tumors contains a similar molecular distribution to the general NSCLC population. Future studies should incorporate MET CISH in clinical trials utilizing MET-targeted agents to determine its potential as a predictive test for evaluating who may derive the most benefit.']",
        "Doc_id":"AACR_2016-396",
        "Doc_title":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "_version_":1606188983115579392},
      {
        "Meeting_name":" Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors",
        "Background":"['Background', '  Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFR. Two phase 3 trials in differentiated thyroid cancer [DTC] and hepatocellular cancer [HCC] are ongoing. Baseline levels (BL) of circulating cytokines and angiogenic factors (CAFs) were evaluated across multiple phase 2 trials in 6 different types of solid tumors.  Methods', \"  BL serum or plasma samples from a total of approximately 500 patients were analyzed for about 50 CAFs using ELISA and multiplex assay platforms* in 5 phase 2 trials of lenvatinib for thyroid cancer (DTC and medullary thyroid cancer [MTC]), HCC, glioblastoma, endometrial cancer (EC), and melanoma (with or without BRAF V600E). Correlation with clinical outcomes (objective response rate [ORR], overall survival [OS]) was performed using Wilcoxon signed-rank test and univariate Cox proportional hazard model, respectively, whereas correlation with tumor size prior to lenvatinib treatment was performed using the Spearman's rank correlation test.  Results\", '  Among 50 CAFs, BL angiopoietin-2 (Ang-2) correlated with tumor size (p) in DTC (0.004), MTC (0.004), EC (<0.001), melanoma [WT (<0.001), MU (<0.001)] and HCC (0.046) among multiple phase 2 trials. BL Ang-2 levels showed consistent correlation with clinical outcomes per tumor types across trials and with OS (p/hazard ratio per standard deviation) in DTC (0.001/3.2), MTC (<0.001/3.2), EC (<0.001/1.8), and melanoma [WT (0.001/1.5), MU (<0.001/2.0)]. Correlation with ORR was observed only for a minor subset of analyzed CAFs; only BL Ang-2 levels correlated with ORR in >1 tumor type, specifically in DTC (0.034*), MTC (0.025) and EC (0.001). In EC, almost 50% of BL CAFs showed a significant correlation with tumor size, potentially suggestive of an EC-specific tumor micro-environment and the contribution of Ang-2 to tumor angiogenesis in EC.   Conclusions', '  BL Ang-2 levels correlated with tumor size and OS across majority of solid tumors in multiple lenvatinib phase 2 trials. Only BL Ang-2 levels also correlated with ORR in a subset of tumors including EC. Clinical trial information', ' NCT00784303,NCT01111461,NCT01136967,NCT00946153,NCT01433991,.']",
        "Doc_id":"ASCO_132299-144",
        "Doc_title":" Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors",
        "_version_":1606189016061837313},
      {
        "Meeting_name":" Copy number changes are associated with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenib",
        "Background":"['Copy number alterations, both gains and losses, have been shown to be involved in melanoma pathogenesis and may provide novel targets for treatment. Previous observations have additionally suggested that specific copy number profiles may be associated with BRAF, NRAS and WT/WT status. The randomized, phase III clinical trial E2603', ' carboplatin, paclitaxel, +/- sorafenib (CP vs. CPS) offers the largest available collection of tumor samples from patients with well annotated clinical outcome to evaluate these associations. We evaluated copy number variants (CNVs) using array Comparative Genomic Hybridization in melanoma tumor samples from patients treated on this trial. Genomic DNA was hybridized on SurePrint G4 human CGH microarrays 2 x 440 K (Agilent). Copy number gains and losses were  0.3 or  -0.3 on a log2 scale, respectively (Nexus BioDiscovery, Inc). In 119 melanoma tumor samples, 45% had BRAF mutations, 24% NRAS mutations, and 24% without either (designated WT), CNVs were evaluated in an initial set of 26 genes known to be involved in melanoma pathogenesis. Overall genomic instability, as measured by number of genes with CNVs, was associated with poor ECOG performance status (P=0.007) and marginally significant for more organs with metastatic involvement (P=0.06), and is consistent with other studies suggesting that genomic instability is a predictor of worsened outcome. We further explored the association between copy number and somatic mutation status. Not surprisingly, BRAF gene amplification was observed in 91% of BRAF mutant melanoma tumor samples (P<0.001, as compared to 66% of NRAS/WT samples). The average value of BRAF copy number was higher in tumor samples with BRAF V600K mutations compared to samples with BRAF V600E mutations (1.11 v 0.55, P<0.001). MET, also on chr 7, was found to be amplified in 59% of BRAF mutated melanoma tumor samples. The average value of MET copy number was also higher in BRAF V600K mutant compared to BRAF V600E mutant melanoma (0.53 v 0.27, P=0.04), which may contribute to the differing clinical behaviors of melanomas with the two mutations. Patients with BRAF copy number gain had a trend towards lower overall response rate to either treatment compared to diploid (15.2% v 29.6%, OR=0.37, P=0.08). Patients with NRAS copy number gain receiving CPS had significantly improved overall survival compared to patients receiving CP alone (HR=0.35, P=0.03) in multivariable Cox model. We had previously found a trend suggesting an improved clinical response and PFS in patients with NRAS mutant melanoma treated with CPS as compared to CP. Our present study demonstrates an association between CNVs and treatment response to CP or CPS, as well as an association with somatic mutations. In addition, distinct cooperating genomic events identified in somatic mutation cohorts, such as MET and BRAF V600K gain, may contribute to the pathogenesis of melanoma tumors.']",
        "Doc_id":"AACR_2014-933",
        "Doc_title":" Copy number changes are associated with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenib",
        "_version_":1606188970661642240},
      {
        "Meeting_name":" Liquid biopsy using the ion AmpliSeq v2 cancer panel",
        "Background":"['Introduction', 'Plasma cell-free circulating tumor DNA (ctDNA) has the potential to serve as a noninvasive surrogate to determine tumor genotype and monitor treatment response. Here we report the analytical validation of the Ion AmpliSeq v2 Cancer Panel (ACP) in plasma ctDNA samples.Methods', 'Mutations were assessed using the ACP, designed to survey 2800 mutations in 50 cancer-related genes. TruQ reference standards were used to determine LOD. Healthy donor and cancer patient plasma samples were used for other studies. Eight libraries were barcoded and sequenced with PGM sequencing 200 kit v2 on a 318 v2 chip. The sequencing data were analyzed with a combination of Torrent Suite 3.4.2, VarScan, our proprietary analysis pipeline and IGV. The background noise level of hotspot nt positions was calculated from multiple runs of known wild type DNA. In order to increase the sensitivity of the assay to detect low-level mutation, a custom program was developed to detect variants clearly different from background noise (95% confidence) and not reported by the two variant callers. PCR methods were used for concordance testing.Results', 'The performance characteristics of the AmpliSeq v2 Cancer Panel were demonstrated in 1) Minimum DNA input and LOD', ' With 10 ng DNA input, 43/43 and 42/43 expected mutations were detected at 2.5% or 1%, respectively. With 1 ng DNA input, 42/43 and 40/43 expected mutations were detected at 2.5% and 1%, respectively. 2) Coverage', ' The mean library coverage for 40 plasma libraries was 2912x with only 5 non-critical regions below 250x coverage. 3) Baseline error rate', ' 95% of 2290 hot-spots for SBS showed <0.5% background error frequency assessed in 10 healthy control ctDNA samples. The mean background error frequency plus two folds of SD falls below 0.5% for 91% of SBS hot-spots. 4)Precision', ' All mutations expected for TruQ6 were detected in 4 independent runs at observed allele frequencies with 0.6% mean SD and 0.1% mean deviation from the true value. A 2% TP53 mutation R174W was reproducibly detected in a lung cancer plasma sample in 2 independent runs. 5) Concordance study', ' Consistent results were observed for 3 positive (Allele Freq 40%, 3% and 0.2%, respectively) and 3 negative melanoma plasma samples previously genotyped by AS-PCR for Braf V600E/K mutations. Additional cancer patient ctDNA samples are being assessed for concordance in the detection of other mutations.Conclusions', 'The ACP offers a useful tool for comprehensive somatic mutation profiling in ctDNA. The limit of detection is 1-2% mutation frequency for most mutations with slight variation across different nucleotide positions. The low concentration of ctDNA obtained from plasma samples can present a challenge. Less than 10 ng DNA input may result in allele drop out for low level mutations due to the inefficient amplification of multiplex PCR compared with PCR methods using a short length single amplicon. Higher DNA input to rescue allele drop-out is under evaluation.']",
        "Doc_id":"AACR_2015-4925",
        "Doc_title":" Liquid biopsy using the ion AmpliSeq v2 cancer panel",
        "_version_":1606188992402817024},
      {
        "Meeting_name":" Co-amplification of FGF receptors and ligands in FGFR inhibitor-sensitive cell lines",
        "Background":"['The fibroblast growth factor receptors (FGFR) play a key role during development and in adult function. FGFRs belong to a family of receptor tyrosine kinases which are single-pass transmembrane receptors with extracellular ligand binding domains and an intracellular tyrosine kinase domain. Upon binding of the ligand the kinase domain activates intracellular signaling networks that coordinate cellular processes such as proliferation, growth, differentiation, migration and survival. Fibroblast growth factors (FGFs) are a family of 18 ligands which are able to bind and activate distinct FGFRs. Deregulated FGFR activity, through mutations or translocations, is often associated with oncogenic events. Overexpression of FGFR or FGF may lead to increased cell proliferation, growth, differentiation, migration or survival, thus making it an interesting target.In this study we optimized a TaqMan qRT-PCR-based approach to evaluate the copy number variation for several FGFRs (FGFR1, FGFR2, FGFR3 and FGFR4) and several FGF ligands (FGF1, FGF2, FGF3, FGF4, FGF10, FGF12, and FGF19) on a panel of 23 cell lines. The cell types covered a variety of diseases including bladder, breast, endometrial, gastric, kidney, liver, lymphoma, melanoma, sarcoma, small cell lung carcinoma and squamous cell carcinoma. These cell lines had been tested for sensitivity to the JNJ FGFR small molecule inhibitor JNJ42541707 which is a pan-FGFR inhibitor. We observed in the sensitive (IC50<100nm) and moderately sensitive (IC50 100 nM - 1000 nM) cell lines a co-amplification of FGF receptor and ligand. Two of the most sensitive cell lines to FGFR inhibitor treatments had the greatest amplification of FGFR2 with a copy number value greater than 100. This finding that co-amplification occurs in receptor and ligand offers a new potential biomarker for patients that may be sensitive to small molecule FGFR inhibitors.']",
        "Doc_id":"AACR_2015-4326",
        "Doc_title":" Co-amplification of FGF receptors and ligands in FGFR inhibitor-sensitive cell lines",
        "_version_":1606189018697957376},
      {
        "Meeting_name":" Identifying cancer driver mutations in clinical sequencing data",
        "Background":"['BackgroundCancer therapy is challenged by diverse molecular implementations of oncogenic processes and by variations in therapeutic responses. So far, whole genome sequencing (WGS) and whole exome sequencing (WES) has been implemented in both research and clinical settings to identify oncogenic events in cancer genomes. However, a large number of passenger mutations have been identified and true driver mutations have been disguised. Distinguishing driver events from passenger events will be a key challenge for the realization of targeted therapy. To elucidate driver mutations that are clinically actionable, the Institute for Personalized Cancer Therapy at MD Anderson cancer center has developed a NGS clinical sequencing platform, T200, to sequence 202 cancer-related genes at high depth in thousands of cancer patients at MD Anderson.Materials and MethodsThe T200 mutation data, including single nucleotide variants (SNV, variant allele frequency >=1%) and copy number variations (CNV), of more than 500 cancer patients treated in MD Anderson Cancer Center were utilized in our study.Results1. By analyzing the SNV data, we identified several sets of co-occurring genes across all cancers. Some sets such as KRAS/APC/SMAD4 contain driver genes from multiple signaling pathways, which may indicate essential mechanisms for tumor development and nominate targets for combinational therapy.2. We elucidated mutual-exclusive mutations that were from genes in the same or different pathways. Several sets of well-known mutual-exclusive SNVs were verified in our analysis such as BRAF/NRAS SNVs in melanoma. We also illustrated novel sets of mutual-exclusive mutational events, such as IDH1/PTEN/PPP1R3A SNVs in brain tumors and EGFR/FGFR3/GNAS/NOTCH4 CNVs in all cancers.3. SNVs of more than 10 genes were enriched in specific cancer types, such as IDH1 and NF1 in brain tumor, BRAF and MITF in melanoma. CNVs of more than 50 genes were found enriched in one cancer type, such as PDGFRA amplifications in brain tumors and IL6R amplifications in breast cancer. We observed not only expected cancer specific mutations such as BRAF SNVs but also novel mutations such as NF1 SNVs and PDGFRA amplifications.4. We performed mutual-exclusivity and cancer type enrichment analysis on SNV hotspots. More than 20 SNV hotspots were elucidated, such as BRAF(V600E) in melanoma, IDH1(R132H) in brain tumors, KRAS(G12D) in colorectal cancer, and PIK3CA(H1047L) in breast cancer. In addition, multiple SNV hotspots were found to occur mutual-exclusively, such as BRAF(V600E)/IDH1(R132H)/MPL(L532V) in brain tumors.ConclusionDeep target sequencing enables us to systematically determine the potential driver mutation events (including low allele frequency SNVs), which not only help us characterize the landscape of cancer genomic alterations, but also provide comprehensive patient molecular profile to facilitate clinical decision-making and novel clinical trial design.']",
        "Doc_id":"AACR_2014-4275",
        "Doc_title":" Identifying cancer driver mutations in clinical sequencing data",
        "_version_":1606188979656327168},
      {
        "Meeting_name":" Genomic analysis and 3-y efficacy and safety update of COMBI-d",
        "Background":"['Background', ' Previous analysis of COMBI-d (NCT01584648) showed that D+T compared with D monotherapy improved ORR (69% [95% CI, 62%-75%] vs 53% [95% CI, 46%-60%]; P = 0.0014), reduced risk of progression (HR, 0.67 [95% CI, 0.53-0.84]; P = 0.0004) and death (HR, 0.71 [95% CI, 0.55-0.92]; P = 0.0107), and increased 2-y OS rate (51% vs 42%) in BRAFV600mutant melanoma. Methods', ' In this phase 3, randomized, double-blind study, pts with histologically confirmed unresectable stage IIIC or IV, BRAF V600E/Kmutant melanoma were randomized 1', '1 to receive frontline D 150 mg twice daily (BID) + T 2 mg once daily or D 150 mg BID only. The primary endpoint was PFS; secondary endpoints were OS, ORR, duration of response, and safety. Whole-exome sequencing was used to assess somatic mutations and copy number changes in pretreatment tumor (mean target coverage [MTC], 170) and matched normal blood samples (MTC, 100) collected from > 140 pts to further characterize BRAF V600mutant melanoma and explore whether individual gene changes or genetic profiles were associated with treatment benefit. Results', ' A total of 423 pts were randomized to D+T (n = 211) or D (n = 212). As expected, initial genetic analysis of 130 pts showed that BRAF was the most frequently mutated gene (V600E, 83%; V600K, 15%). Additional mutations were observed in genes related to tumor suppression (TP53, PTEN, CDKND2A) and resistance to MAPK pathway inhibition (MEK1, MEK2, NRAS, NF1, RAC1), and amplifications were observed in BRAF and MITF. Overall mutation rate was higher in V600K vs V600E pts (median mutations per sample, 1701 vs 419; P< 0.0001). Updated genomic analysis, including OS and mutation rate association, and efficacy and safety results, including 3-y OS, will be presented. Conclusions', ' Preliminary genetic analyses showed additional mutations related to tumor suppression and MAPK inhibitor resistance were present in pts with BRAF-mutant melanoma, with a higher overall mutation rate in V600K-mutant tumors. Updated genetic analysis and 3-y efficacy and safety analysis will be presented. Clinical trial information', ' NCT01584648']",
        "Doc_id":"ASCO_168199-176",
        "Doc_title":" Genomic analysis and 3-y efficacy and safety update of COMBI-d",
        "_version_":1606189036992462848},
      {
        "Meeting_name":" Targeted agents matched with tumor molecular aberrations",
        "Background":"['Background', ' Identification of activating mutations in melanoma has increased the number of novel targeted agents for this disease. Methods', ' Weretrospectively reviewed clinical outcomes of 160 consecutive metastatic melanoma patients (pts) treated in the Dept of Investigational Cancer Therapeutics (Phase I program) at M. D. Anderson since 2008, and compared their median progression free survival (PFS) to their first and last standard systemic therapy PFS. In addition, we compared those pts outcomes tested for tumor molecular aberrations on a phase I trial with a matched targeted agent with those of pts who were treated without regard for their molecular profiles. Results', ' Of 160 pts treated on 35 different phase 1 clinical trials, 110 pts (69%) had  1 molecular aberration. Of those pts who had adequate tissue for molecular analysis, 63% (85/134) pts had BRAF mutation, 20% (22/109) NRAS mutation, 20% (1/5) GNAQ mutation, 11% (1/9) P53 mutation, 2.5% (1/39) PIK3CA and 1.3% (1/76) had KIT mutation. 77 (48%) pts were treated on a phase I trial with a matched targeted agent and 83 (52%) pts were treated on a non-matched phase 1 trial. The overall response rate was 39% (complete response [CR], 9%; partial response [PR], 30%) in the 77 pts treated with matched therapy and 9% (all PRs) in the 83 pts treated without matched therapy (P = 0.0018). 139 (87%) pts received at least one systemic therapy before referral to phase I, median PFS was longer on phase 1 therapy than on last line standard therapy prior to referral to phase 1 (4.2 vs. 2.8 months, P = 0.002). Median PFS was greater for pts on matched vs. non-matched therapy (5.3 vs. 3.7 months, log rank P = 0.004). Also, median PFS was longer on phase 1 matched trial than on first standard treatment (5.3 vs. 3.9 months, log rank P = 0.045).PFS did not differ between first standard and non-matched phase 1 study. Univariate analyses with the log rank test revealed that matched therapy (P = 0.004) was positively associated with longer PFS on phase I clinical trials. Conclusions', ' Matching melanoma pts with targeted drugsbased on specific molecular aberrations in the phase I setting can be associated with superior outcomes compared to prior standard systemic therapies.']",
        "Doc_id":"ASCO_95941-114",
        "Doc_title":" Targeted agents matched with tumor molecular aberrations",
        "_version_":1606189025221148672},
      {
        "Meeting_name":" Oncomine focus assay",
        "Background":"['Introduction', ' The Oncomine Focus Assay (OFA) is aimed to simultaneously detect and report hotspot mutations, Copy Number Variants (CNVs) and gene fusions in 52 oncogenes clinically relevant to solid tumors. With minimal DNA/RNA input, OFA employs AmpliSeq library preparation chemistry to enrich target regions for Ion Torrent Next Generation Sequencing. Variants are annotated for actionability by Oncomine Knowledgebase. Here we report an analytical validation of OFA.Methods', ' DNA and RNA, extracted from the FFPE processed GM12878, was used as the negative control to evaluate the specificity of OFA. A RNA sample containing multiple oncogenic gene fusions and a DNA sample containing multiple hotspot SNV and indels were used as the positive controls. Fresh DNA from cancer cell lines (HCC1143 or NCI-H2122) along with DNA from matched normal cell lines, HorizonDx NGS standards TruQ-1, TruQ-2, several engineered FFPE samples with gene fusions or copy number changes, and 43 clinical FFPE samples of a variety of solid tumor types (non-small cell lung cancer, colorectal cancer, gastrointestinal stromal tumor, ovarian cancer, pancreatic cancer, and melanoma) were used to evaluate the OFA performance. The analysis of the sequencing data was primarily performed with the OFA pipeline integrated with the Oncomine Knowledgebase. Only the genetic alterations with clinical utility were selected as the final output from the data pipeline. The SBS and indels detected by OFA were confirmed by Sanger sequencing. Any CNVs detected were confirmed by FISH, if possible, and detected fusions were confirmed by RT-PCR or FISH.Results', ' No clinically relevant genetic alterations were detected from the negative control FFPE-GM12878, indicating the high specificity of the OFA. The LOD for SBS and short indel detection was 5%, as assessed by TruQ-1 and TruQ-2, each containing 9-10 variants. The assay can detectgene fusion RNA present as 0.1%-1% of the total RNA, and gene amplifications are detected with a minimum of 50% tumor cell content. A known 12X CCND1 amplifications in HCC1143 and a 13X MYC amplification in NCI-H2122 were detected. In addition, a 13X EGFR amplification and 11X CDK4 amplification were detected in a lung cancer FFPE sample and confirmed by FISH. The analytical specificity for detection of SBS and indels was 100% (25/25). The analytical specificity for detection of CNV gain and gene fusions, and the assay sensitivity are currently under assessment.Conclusions', ' These results demonstrate the high sensitivity and specificity of OFA. With as little as 10 ng RNA and 10 ng DNA, OFA provides biomarker analysis of patient FFPE tumor specimens focusing on the detection of genetic alterations that have been targeted by oncology drugs or supported by published clinical evidence.']",
        "Doc_id":"AACR_2016-1397",
        "Doc_title":" Oncomine focus assay",
        "_version_":1606188990251139072},
      {
        "Meeting_name":" A highly sensitive, repaid and reliable assay for detection of human B-raf (V600) mutations",
        "Background":"['BackgroundThe most common activating B-raf mutations (T1799A point mutation) lead to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. This oncogenic mutation in the B-raf gene constitutively activates the MAPK signaling pathway which results in increased proliferation and inhibition of apoptosis. B-raf V600E mutation was described in approximately 8% of all solid tumors (43% melanomas, 39-67% papillary thyroid carcinomas and 12% colorectal adenocarcinomas). Currently, the gold standard to identify B-raf mutations is sequencing of the tumor DNA. However this method is not practical for routine clinical detection due high risk of contamination and low sensitivity. Recent development of therapeutic intervention using B-raf inhibitors requires an accurate and rapid detection system for B-raf mutations.MethodsHere we developed a new methodology for the rapid and reliable detection of B-raf (V600) mutations by combination of the modified real-time PCR primers, peptide nucleic acid (PNA) clamping and MGB probe, named of PM-PCR method. In this assay, the mutant gene is selectively amplified by the modified PCR primers and the amplicon extending signals are collected by the taqman-MGB probe in a real-time fashion, while the amplification of wild-type B-raf DNA is completely blocked by the specifically designed PNA with a higher annealing temperature. The assay procedure includes only one step of sample loading to avoid potential contamination. The PM-PCR method can detect 3-10 copies of the mutant gene stably in somatic cells with background of a total of 10ng wild-type genomic DNA.Tumor samples from 97 patients with malignant melanoma (N=20) and papillary thyroid carcinoma (N=78) were evaluated for the B-raf V600mutation. Genomic DNA was extracted from FFPE tissue sections and analyzed by PCR amplification followed by Sanger sequencing for comparison.ResultsAmong the 97 tested samples, 74% (72/97) of them were positive for B-raf V600 mutation detected by our ARMS-PM assay, while 60.8% (59/97) were detected positive by Sanger sequencing. All the 25 negative cases detected by our assay were confirmed by Sanger sequencing with a concordance rate 100% (25/25). The overall concordance between our assay and Sanger sequencing was (87%) .ConclusionWe have developed a new method for detection of B-raf V600 mutation by combination of the modified real-time PCR primers, PNA and MGB probes (PM-PCR method). The new assay demonstrates significantly improved sensitivity and feasibility for clinical application. <!EndFragment>']",
        "Doc_id":"AACR_2014-1511",
        "Doc_title":" A highly sensitive, repaid and reliable assay for detection of human B-raf (V600) mutations",
        "_version_":1606189015913988096},
      {
        "Meeting_name":" Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.",
        "Background":"['Background', '  ARQ 087 is a novel, orally bioavailable, ATP-competitive inhibitor of multiple kinases, including FGFR1-3. It has potent in vitro and in vivo inhibitory effects on a variety of human tumor cell lines and xenograft models dependent on FGFR signaling.   Methods', '  This first-in-human 2-step study was initiated in pts with advanced solid tumors. Step 1', ' dose escalation/food-effect to characterize PK, safety, maximum tolerated and recommended Phase 2 Dose (RP2D; unselected for FGFR aberration). Step 2', ' expansion cohort to to assess safety and clinical activity of ARQ 087 in selected tumor types, including FGFR gene amplification, translocation and mutation. Assessments included tumor molecular status, response by RECIST v.1.1 every 8 weeks (wks), plasma concentrations of FGF19, 21, 23, fasting glucose and phosphate.   Results', '  61pts were treated (dose range 25-425mg QOD or QD) in Step 1; the majority were female (61%), mean age 64 yrs (34 -78). The RP2D was defined as 300 mg QD continuous dosing. Dose-limiting toxicities included increased liver enzymes (reversible Grade (G) 3 AST increase). Common drug-related adverse events (AEs; mostly G  2) were fatigue (53%), elevated LFTs (45%), nausea (45%), vomiting (20%) and diarrhea (20%). Only 2 pts (3%) experienced G1 drug-related hyperphosphatemia. Drug t1/2 was 2-11 days, PK was unaffected by food. FGF 19/21/23 concentrations post-treatment were increased 1.5-6 fold.   Ten pts in Step 1 had confirmed stable disease (SD)  16 wks (adrenocortical [2], endometrial, ovarian, NSCLC, choroidal melanoma, carcinoid, sarcoma [3]). A squamous NSCLC pt with Src amplification had SD (24% tumor reduction) for 32 wks. One adrenocortical carcinoma pt with FGFR1 amplification remains on study > 22 months. Two ongoing pts with intrahepatic cholangiocarcinoma with FGFR2 fusions demonstrated a partial response and SD > 24 wks with 26% decrease in target lesions, respectively.   Conclusions', '  ARQ 087 has manageable, mostly G  2 AEs. It has demonstrated preliminary antitumor activity in pts with FGFR-pathway aberrations. Further evaluation of ARQ 087 in pre-defined tumor types is ongoing. Clinical trial information', ' NCT01752920']",
        "Doc_id":"ASCO_149025-156",
        "Doc_title":" Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.",
        "_version_":1606188981934882816},
      {
        "Meeting_name":" Distribution of PD-L1 expression in diverse cancer types",
        "Background":"['Background', ' Blocking the programmed death-1 (PD-1) pathway has clinical benefit in metastatic cancer and has led to the approval of two mAbs for several cancer types. Expression of PD-1 ligand (PD-L1) on the tumor cell surface is associated with a higher likelihood of response to PD-1 blockade in multiple studies. We analyzed the distribution of PD-L1 in a wide variety of tumor types, studied the underlying mechanisms of expression, and compared methods of detection. Methods', ' 10,187 tumor samples were tested for expression of PD-L1 (SP142 antibody, Spring Biosciences). Expression (IHC) of PD-L1 in a selected number of cases was compared to 3 additional mAbs (SP263, Ventana; 22c3 and 28-8 DAKO). PD-L1 gene amplification was calculated using next generation sequencing (NGS) data. Results', ' Using the  2+ intensity and  5% IHC threshold, PD-L1 was detected with the highest frequency in thymic carcinoma (63%), followed by lymphomas (42%), head and neck squamous carcinoma (35%), anal carcinoma (31%), non-small cell lung cancer (30%), thyroid carcinoma (29%), bladder carcinoma (22%), cervical carcinoma (20%), melanoma (19%), and esophageal and GE junction carcinoma (15%). Significant differences between genomically defined cancer subtypes were observed (e.g. 4-fold more frequent PD-L1 expression in MSI-H colorectal and endometrial carcinomas vs. MSS counterparts). Analytical comparison of 4 different, yet well-defined Abs used in numerous clinical trials showed overall concordance of > 90%, irrespective of the thresholds employed. High copy number (  8) of PD-L1 gene was identified in 1/2 DLBCL, 1/3 thymic carcinoma and additionally in a small percentage of breast carcinoma (4%), non-small cell lung cancer (2%) and ovarian carcinoma (1%). Conclusions', ' Targetable PD-L1 protein expression was identified in numerous cancer types, including some rare but highly overexpressing types not previously recognized. Threshold determination for predictive purposes remains challenging, but concordance between 4 antibodies was superb. High PD-L1 gene amplification (alone or co-amplification with JAK2 gene) is detected in a minority of carcinomas, and additional methods of detection (e.g. in-situ hybridization) may be needed.']",
        "Doc_id":"ASCO_170639-176",
        "Doc_title":" Distribution of PD-L1 expression in diverse cancer types",
        "_version_":1606189005188104192},
      {
        "Meeting_name":" Integrating molecular profiling into cancer treatment decision making",
        "Background":"['Background', '  Molecular profiling of both common and rare cancer types provides for the identification of actionable targets for chemotherapy with many unexpected associations.  Methods', '  Caris Life Sciences database of >35,000 profiled cancers was reviewed for well-established driver gene mutations and copy number alterations, and protein expression patterns that are relevant for selection of targeted therapy.  Based on the published literature, these tumor characteristics were then associated with potential benefit or no benefit to the specific therapeutic agents.  All relevant published studies were evaluated using the USPSTF grading scheme for study design and validity. Assay methodologies included sequencing (Sanger, pyrosequencing), PCR, FISH, CISH, and immunohistochemistry.  Results', '  All common malignancies (10 most common cancer types in men and women) and 10 rare cancer types were well represented (minimum of 100 cases in each individual cancer type). Well established driver mutations and protein expression in common cancers were all identified with expected frequencies (e.g. HER2 amplification in breast, PIK3CA mutations in ER+ breast cancer, EGFR mutations in NSCLC, etc.). Importantly, unexpected new and potentially actionable targets were identified in common (e.g., 6.7% HER2 amplification in NSCLC, 1.6% KRAS mutation in prostatic adenocarcinoma) and rare cancers (e.g., 8.3% ALK alteration in soft tissue sarcomas, 10.5% c-MET and 26.4% EGFR gene amplification in melanomas, 16.3% KRAS mutation in cholangiocarcinomas, 10% AR expression in STS), as well in cancers of unknown primary site (approximately 4% of all tested cases).  Conclusions', '  This review of the large referral cancer profiling database provided an unparalleled insight in the distribution of common and rare genetic and protein alterations with direct and potential treatment implications. Numerous targets were discovered that had a potential to be treated by the conventional chemotherapy as well as targeted therapy not usually considered for the cancer type. Comparison between an individual patient tumor profile and database for the matched cancer type provides additional level of support for targeted treatment choices.']",
        "Doc_id":"ASCO_110052-132",
        "Doc_title":" Integrating molecular profiling into cancer treatment decision making",
        "_version_":1606189019414134784},
      {
        "Meeting_name":" Comparative oncogenomics",
        "Background":"['The elucidation of core networks driving tumorigenesis is greatly enhanced by studying tumors from multiple species. A comparison of tumors between evolutionarily distant organisms such as humans and fish offers a particularly powerful method to identify such core functionalities. In the past several years, the zebrafish has emerged as an important vertebrate model of cancer because it develops tumors that are histologically and functionally similar to the human disease. Overexpression of the BRAFV600E oncogene under the melanocyte-specific mitf promoter leads to a 100% penetrant melanoma in the context of p53 loss of function. We have previously shown that these zebrafish tumors exhibit characteristics of neural crest progenitors, rather than differentiated melanocytes, similar to many human melanomas which also overexpress the neural crest markers sox10 and ednrb. To identify the genomic lesions that are common to both species, we are performing RNA and DNA-sequencing of the zebrafish tumors and comparing them to human melanoma resequencing samples to identify common driver events. To facilitate this, we have developed technologies for both short and long term culture of zebrafish melanoma cell lines, along with normal tissue from each individual animal. One such melanoma line, ZMEL1, has been comprehensively characterized. RNA-seq demonstrated upregulation of neural crest genes such as ednrb, and pathway analysis indicated enrichment for ERK/MAP kinase and PI3K/AKT signaling pathways, and these tumors are sensitive to inhibition by the BRAF inhibitor PLX4720. Whole-genome sequencing (WGS) was performed on tumor cell line and matched normal tissue to a depth of 39X coverage on the Illumina platform. A total of 5193 single basepair mutations were identified, of which 2% were found in the coding region, 41% in intronic regions and 56% in the intergenic DNA. Within the coding region, 25% were G>C and 18% T>C substitutions, with approximately equal number of non-synonymous to silent mutations. Coding mutations in several genes such as rps6kb1b and plb1 are of particular interest because of their reported mutation in human cancer as well. 35 regions of copy number changes were found, comprising over 600 genes, and these include amplification of known oncogenes such as SETDB1. Functional analysis of the genomic changes common to both zebrafish and human tumors is now being undertaken using in vitro and in vivo melanoma models. In summary, comparative oncogenomics between zebrafish and human melanoma provides a powerful method for filtering the vast number of changes down to a list of manageable, testable hypotheses. This method can be broadly applied to other tumors types.Citation Format', ' Richard M. White, Erin Langdon, Charles Kaufman, Ellen van Rooijen, Jennifer Yen, Peter Van Loo, Leonard Zon. Comparative oncogenomics', ' identifying melanoma drivers from zebrafish to humans. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 3234. doi', '10.1158/1538-7445.AM2013-3234']",
        "Doc_id":"AACR_2013-3234",
        "Doc_title":" Comparative oncogenomics",
        "_version_":1606188976650059776},
      {
        "Meeting_name":" Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance",
        "Background":"['Purpose', ' To evaluate the association between the immunoreactivity of the immune inhibitory ligand PD-L1 with tumour infiltrating lymphocytes (TILs) and known mechanisms of MAPK inhibitor (MAPKi) resistance in tumor biopsies resected at the time of MAPKi disease progression.Experimental Design', ' 23 patients with disease progression on MAPKi (vemurafenib, dabrafenib, and combination dabrafenib and trametinib) each had a progressing tumor biospied. All tumors underwent MAPKi resistance screening including RNA expression profiling. Morphological features, PD-L1 immunohistochemical immunoreactivity, and RNA expression profile were correlated with mechanisms of resistance (including mutations in NRAS and MEK, and amplification and aberrant splicing of BRAF).Results', ' PD-L1 immunoreactivity was significantly higher in tumors that harbored an aberrant BRAF splicing variant (n = 8) or MEK mutations (n = 5) than those with BRAF amplification (n = 4), NRAS mutations (n = 2) or those with unknown resistance mechanisms (n = 4) (mean 27% vs 1%, p = 0.049). Additionally, the PD-L1 immunoreactivity in tumors with known MAPK-reactivating mechanisms (n = 19) tended to be higher than those with unknown resistance mechanisms (n = 4) (mean 17% vs 0%, p = 0.283). The immunoreactivity of PDL1 in progressed lesions was independent of BRAFV600 genotype, RECIST response and type of MAPK inhibitor. Correlations with TIL subsets, RNA expression, and response to subsequent anti-PD-1 therapy are underway.Conclusions', ' The induction of PD-L1 immunoreactivity following MAPKi treatment in human melanoma is variable, however specific mechanisms of MAPKi resistance may confer increased expression of the inhibitory ligand. Further study is underway examining the association of the above with TIL infiltration, the RNA expression profile, and the response to subsequent anti-PD1 therapy.']",
        "Doc_id":"AACR_2015-5025",
        "Doc_title":" Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance",
        "_version_":1606189041574739968},
      {
        "Meeting_name":" Meta-iodo-benzylguanidine (MIBG) is a MYCN/MYC destabilizer that specifically targets neural crest derived tumors",
        "Background":"['Melanoma and malignant pheochromocytoma are known for high MYC expression. MYCN amplification and its over-expression are associated with the worst neuroblastoma disease outcome. Meta-iodo-benzylguanidine (MIBG) is a norepinephrine analogue and a mitochondrial respiration inhibitor. 131I-MIBG has been used for scintigraphic detection of neural crest derived tumors (neuroblastoma, pheochromocytoma and melanoma) that specifically uptake MIBG by norepinephrine transporters (NET). 131I-MIBG is also used for targeted radiotherapy of neuroblastoma and pheochromocytoma. Non-radiolabeled MIBG had been reported to be cytotoxic to neuroblastoma cells in vitro and in vivo. However, the molecular mechanism of its growth suppressive effect was not elucidated. Our previous studies showed that FCCP, a well-known mitochondrial respiration inhibitor, destabilized MYCN and MYC in neuroblastoma cells and caused growth suppression. In this study we confirmed that MIBG suppressed growth of neuroblastoma cell lines (SKNBE(2)C, IMR5, Nb69, and SKNAS), and its growth suppressive effect in each cell line correlated with NET expression in these cells. In addition, MIBG suppressed growth of neuroblastoma stem cells derived from SKNBE(2)C. MIBG treatment of SKNBE(2)C and SKNAS resulted in an increase expression of growth suppressive gene (GADD45B) and genes encoding for biomarkers of favorable neuroblastoma (CD44, EPHB6, EFNB2, EFNB3, NTRK1). Treatment of MYCN amplified (SKNBE(2)C, IMR5) and non-MYCN amplified (Nb69, SKNAS) neuroblastoma cells with MIBG resulted in marked reduction of MYCN and MYC expression, respectively in dose and time dependent fashions. Collectively, our studies suggest that MIBG not only targets neural crest derived tumors, but also is a MYCN/MYC destabilizing agent.']",
        "Doc_id":"AACR_2012-2875",
        "Doc_title":" Meta-iodo-benzylguanidine (MIBG) is a MYCN/MYC destabilizer that specifically targets neural crest derived tumors",
        "_version_":1606189018100269056},
      {
        "Meeting_name":" A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein",
        "Background":"[\"Members of the ETS transcription factor family have been implicated in several cancers, where they are often dysregulated by genomic derangement. ETS variant 1 (ETV1) is an ETS factor gene that undergoes chromosomal translocation in prostate cancers and Ewing's sarcomas, amplification in melanomas, and lineage dysregulation in gastrointestinal stromal tumors. Pharmacologic perturbation of ETV1 would be appealing in these cancers; however, oncogenic transcription factors are often deemed undruggable by conventional methods. Here, we used small-molecule microarray (SMM) screens to identify and characterize drug-like compounds that modulate the biological function of ETV1. We identified the 1,3,5-triazine small molecule BRD32048 as a top candidate ETV1 perturbagen. BRD32048 binds ETV1 directly, modulating both ETV1-mediated transcriptional activity and invasion of ETV1-driven cancer cells. Moreover, BRD32048 inhibits p300-dependent acetylation of ETV1, thereby promoting its degradation. These results point to a new avenue for pharmacological ETV1 inhibition and may inform a general means to discover small molecule perturbagens of transcription factor oncoproteins.Note\", ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-2519",
        "Doc_title":" A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein",
        "_version_":1606189039689400320},
      {
        "Meeting_name":" BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers",
        "Background":"['Oncogenic B-RAF, which drives cell transformation and proliferation, has been detected in approximately 70% of human malignant melanomas and 5-15% of colorectal cancers (CRC). B-RAFV600E mutation, which gives rise to constitutive MAPK signaling, accounts for at least 90% of oncogenic B-RAF mutations. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating B-RAFV600E metastatic melanoma, their clinical efficacy in B-RAFV600E CRC is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon B-RAF inhibition contributed to the intrinsic resistance of CRC to the first generation B-RAF inhibitors. This report represents the first characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigations. BGB-283 is a potent and selective pan-RAF and EGFR inhibitor with IC50 ranging from 5 to 47 nM on RAF and EGFR kinases. In vitro, BGB-283 potently inhibits B-RAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harbouring B-RAFV600E and EGFR mutation/amplification. In B-RAFV600E CRC cell lines, BGB-283 effectively inhibits the reactivation of EGFR and achieved sustained inhibition of MAPK pathway. In vivo, BGB-283 is highly efficacious in inhibiting tumor growth accompanied by partial and complete tumor regressions in both BRAFV600E mutant cell derived CRC xenograft models, including HT29, Colo205, WiDr, as well as two primary human CRC xenograft models. In particular, BGB-283 shows compelling efficacy and potent inhibition of EGFR/MAPK signaling in WiDr xenograft model where EGFR reactivation occurs upon B-RAF inhibition. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating CRC harboring B-RAFV600E mutation.']",
        "Doc_id":"AACR_2015-4692",
        "Doc_title":" BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers",
        "_version_":1606188981824782336},
      {
        "Meeting_name":" Breast cancer patients stratification by microarray-based gene expression profiling from FFPET samples.",
        "Background":"['Background', ' Microarrays have been used to monitor global genes expression and have aided the identification of novel biomarkers for patients stratification and drug response prediction . To date there has been limited application of microarray- based gene expression analysis to formalin fixed paraffin embedded tissues (FFPET). FFPE tissues are the most commonly available clinical samples with documented clinical information for retrospective clinical analysis. However, FFPET RNA has proven to be an obstacle for microarray analysis because of low yield and compromised RNA integrity. Methods', ' Using a novel RNA amplification method, Single Primer Isothermal Amplification (SPIA, NuGEN Inc, San Carlos, CA), we amplified FFPET RNA, hybridized amplified, and labeled cDNA onto Affymetrix HG U133plus2 GeneChips. Results', ' We found that SPIA amplification successfully overcomes the problems of poor quality of FFPET RNA, and produced informative biological data. Comparing the gene expression data from 5 different types of FFPET archival cancer samples (breast, lung, ovarian, colon, and melanoma), we demonstrated that gene expression signatures clearly distinguish the tissue of origin. Further, from an analysis of 91 FFPET samples comprised of ER+, HER2+, triple negative breast cancer patients, and normal breast tissue, we have identified a 103 gene signature that distinguishes the intrinsic sub-types of breast cancer. Finally, the accuracy of gene expression measured by microarray was verified by real time PCR quantitation of the ERBB2 gene, resulting in a significant correlation (R = 0.88). Conclusions', ' We have demonstrated the feasibility of global gene expression profiling using RNA extracted from FFPET and have shown that a gene expression signature can stratify patient samples into different subtypes of disease. This study paves the way to identify novel molecular biomarkers for disease stratification and therapy response from archival FFPET samples, leading to the goals of personalized medicine.']",
        "Doc_id":"ASCO_35138-65",
        "Doc_title":" Breast cancer patients stratification by microarray-based gene expression profiling from FFPET samples.",
        "_version_":1606188988291350528},
      {
        "Meeting_name":" A primary cell-based assay to identify initiating oncogenic events in neuroblastoma",
        "Background":"['The pediatric cancer neuroblastoma (NBL) forms from immature cells of the sympathetic nervous system (SNS). A prominent category of high-risk NBL is MYCN amplification with loss of heterozygosity (LOH) at 1p36. This LOH includes the chromatin remodeling factor, CHD5, a proposed tumor suppressor of NBL and can include ARID1A, a component of the SWI/SNF chromatin remodeling complex.To identify genetic changes that cooperate with MYCN amplification in initiating NBL we developed an assay based on oncogenic transformation of neural crest cells (NCCs), the progenitors of the SNS. Isolation of NCCs from E9.5 mouse embryos resulted in a population that was 90% positive for the NCC markers p75, Sox10, and Ascl1, suggesting a highly enriched population.Next, we tested the ability of N-Myc infected NCCs to form tumors in vivo. In pilot experiments using NCCs with compromised p53, we obtained subcutaneous tumors following injection of NCCs in nude mice. Resulting tumors were diffusely positive for neuronal markers such as synaptophysin, MAP2, and Tyrosine hydroxylase (TH). Tumors also contained focal areas of divergent differentiation characteristic of melanoma, Schwannoma, and osteosarcoma, all cancers that can arise from NCC lineages. To our knowledge, this is the first report of cancer from transformed primary neural crest cells.To more closely model NBL genetics, we replaced loss of p53 with shRNA to knockdown CHD5 and ARID1A prior to N-Myc infection. Injection of the resulting NCCs also resulted in tumor formation in nude mice. Tumors were uniformly positive for neuronal markers including TH and Ascl1, as well as Phox2B, a marker of undifferentiated NBL, and with no evidence of other cancers. Future studies in understanding the interactions of N-Myc overexpression with loss of these chromatin remodeling factors should further increase our understanding of NBL development.']",
        "Doc_id":"AACR_2015-3955",
        "Doc_title":" A primary cell-based assay to identify initiating oncogenic events in neuroblastoma",
        "_version_":1606189000008138752},
      {
        "Meeting_name":" Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.",
        "Background":"['Background', '    Median survival of MBM pts is significantly shorter than pts with extra-cranial metastases. However, a subset of MBM pts exhibit extended survival. Radiation therapy (RT - radiosurgery and whole-brain radiation) is used to treat MBM pts and recent data by several groups including ours demonstrate that RT may potentiate response to immunotherapies by inducing an immunological tumor cell death. In this study, we investigate the immunomodulator effect of RT on MBM tissue and attempt to identify an immunological profile associated with improved post-MBM survival.  Methods', '    Expression of 560 immunoregulatory genes was assessed in 32 MBM tissues (10 post radiation and 22 no radiation) using a customized NCounter GX Human Immunology Kit (Nanostring) comprising of 24 immunology-related gene networks compiled from the Gene Ontology Consortium List of immunologically important genes. We also compared expression of the immunoregulatory genes in long term survivors ( > 1 year) compared to short term survivors ( < 1 year). We then verified the data using RT-PCR and IHC in an expanded cohort of 47 MBM tissues.  Results', '    Irradiated MBM had higher expression of genes involved in', ' (1) autophagy/apoptosis (ATG12, BCL2L11 and CASP8); (2) adhesion (CD209, ICAM2; ITGA4 , ITGB1 and PECAM-1); (3) immune cell development and activation (IFNAR2, IKZF2, MAP4K2, NFATC3, POU2F2 and TCF4) (p < 0.05). In addition, RT induced upregulation of PD-L1 (transmembrane protein involved in immunoinhibitory signals) and TGF-b (immunosuppressive cytokine and cell cycle regulator) at the gene expression level, as determined by Nanostring and confirmed by RT-PCR, and protein level of PD-L1 by IHC. Genes involved in lymphocyte activation such as CD44, CD81 and IL16 were significantly overexpressed in long term survivors (p < 0.05).  Conclusions', '    Our data demonstrate that RT induces both lymphocyte activation and  upregulation of immunosuppressive signals. Our data also suggest that MBM pts with prolonged survival host an immunologically distinct subset of tumors with upregulated lymphocyte activating genes. Identification of MBM pts with enhanced immunogenicity may aid in prognostication and prediction of response to immunotherapy.']",
        "Doc_id":"ASCO_152729-156",
        "Doc_title":" Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.",
        "_version_":1606189022041866240},
      {
        "Meeting_name":" BRAF",
        "Background":"['Background', ' A series of reports demonstrating the successful use of BRAF and MEK inhibitors in clinically advanced non-melanoma cancers has recently emerged. BRAF alterations in metastatic breast cancer (mBC) are rare and BRAF is not currently considered a target for the disease. Methods', ' DNA was extracted from 40 microns of FFPE sections from a series of 10,428 cases of metastatic breast cancer (mBC). Comprehensive genomic profiling (CGP) was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of > 550X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. Results', ' 135 (1.2%) of the mBC featured alterations in BRAF. The median age of the 135 female patients was 66 years (range 27 to 83 years). The primary tumor was used for CGP in 50 (37%) and from metastatic sites including lymph nodes, liver, bone, lung, brain, adrenal and soft tissue in 85 (67%). Using CDH1 mutation as the definition of lobular mBC, 126 (93%) were ductal and 9 (7%) were lobular histology. Activating BRAF alterations included amplifications (48%), SV mutations (39%) and rearrangements (13%). No (0%) mBC had multiple BRAF GA in the same case. 34% of BRAF SV were V600E and 66% were a wide variety of non-V600E GA. 10 (7.4%) of 135 BRAF mutated mBC featured ERBB2 amplification with 1 (1%) having an ERBB2 SV mutation and 1 (1%) having both ERBB2 amplification and SV GA. Of the 115 BRAF GA cases with known hormone receptor status 71 (62%) were ER negative, 44 (38%) were ER positive and 63 (55%) were triple negative (TNBC). Other targetable genes enriched in mBC with BRAF GA included CDK6 (p = 0.001), HGF (p < 0.001) and MET(p < 0.001). The median TMB was 4.5 with 17 (13%) of cases with TMB > 10 mut/Mb and 7 (5%) of cases with > 20 mut/Mb. Conclusions', 'BRAF alterations, although uncommon in mBC representing only 1.2% of cases, are enriched in TNBC and feature both targetable base substitutions and rare fusions. BRAF GA may be a rare cause of anti-HER2 therapy resistance in a subset of ERBB2 driven mBC. Targetable genes co-altered with BRAF in mBC include CDK6, HGF and MET. The TMB in BRAF altered mBC is significantly higher than that for mBC in general and indicates potential role for immunotherapy for these patients.']",
        "Doc_id":"ASCO_182196-199",
        "Doc_title":" BRAF",
        "_version_":1606189009205198848},
      {
        "Meeting_name":" Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.",
        "Background":"['Background', '   The unresponsiveness to anticancer drugs in patients outlines the need to identify novel and robust biomarkers of response to therapy. The recent release of large molecular cell line datasets labeled for drug sensitivity enables the development of such predictors. Cell line based models poorly reflect the extent of molecular heterogeneity existing at the patient level. We aimed to overcome this limitation by combining cell line with patient data to uncover novel molecular traits associated with drug response at the patient level.  Methods', '  We used both patients and cell lines data from the following publicly available datasets', '  CCLE (1057 cell lines, 24 drugs), Sanger (790 cell lines, 130 drugs) and TCGA (patients', ' breast cancer, colorectal cancer, lung squamous carcinoma, lung adenocarcinoma, ovarian cancer, endometrial cancer and melanoma). A two-step Elastic Net approach was used to model the drug sensitivity using gene-expression, copy-number alteration, and somatic mutation data. As validation, we used the dataset of 420 cancer patients prospectively enrolled in the ongoing MOSCATO molecular screening program (Gustave Roussy, France).  Results', '   As positive control, we were able to recover all of the recognized landmark biomarkers across drug - tissue combination (e.g. Erlotinib', ' EGFR mutation in lung adenocarcinoma; Lapatinib', ' ERBB2 amplification in breast cancer; Vemurafenib', ' BRAF mutation in melanoma, etc). We uncovered novel molecular traits (copy, number mutations) associated (FDR<20%) with drug response (e.g. erlotinib', ' CDKN2A deletion in lung adenocarcinoma, lapatinib', ' CDH1 deletion in breast cancer, etc.). The validation of our framework in the MOSCATO patients cohort will be presented.   Conclusions', '   We provide a comprehensive annotation of mutations and copy-number events predicted to be associated with sensitivity and resistance in 142 anti-cancer drugs and across 7 tumor types. This approach is likely to exert a major impact on precision medicine programs in oncology.']",
        "Doc_id":"ASCO_133297-144",
        "Doc_title":" Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.",
        "_version_":1606189032474148864},
      {
        "Meeting_name":" Analysis of structural mutations in cancer genomes",
        "Background":"['In our group, we have extensively sequenced various cancer genomes (breast cancer, ovarian cancer and melanoma) using a range of genome-wide sequencing approaches, including DNA-PET, RNA-SEQ and exome-capture sequencing. Taking each tumor as a system of its own, we aim to integrate the different outputs of these technologies to explore the composite of hard-wired changes that drive tumorgenesis in different cancers. One type of hard-wired changes is copy number alterations, where the cancer genome tends to gain oncogenes and lose tumor suppressors by DNA amplifications and deletions respectively. While copy number variation data are now a standard output of the DNA-PET pipeline, the accurate prediction of copy number gains and losses is further complicated by several issues, including normal tissue contamination, tumor heterogeneity and aneuploidy. I will present my current work to deconvolute the contribution of these factors to the copy number profile. I will also discuss the classification of our sequenced cancer genomes into various chromotypes based on their unique copy number signatures. I will show how different chromotypes are enriched in specific types of structural variations, which may underlay alternative mechanisms of genomic instability promoting cancer evolution.']",
        "Doc_id":"AACR_2012-4947",
        "Doc_title":" Analysis of structural mutations in cancer genomes",
        "_version_":1606189008384163840},
      {
        "Meeting_name":" COSMIC",
        "Background":"['COSMIC, the Catalogue Of Somatic Mutations In Cancer (http', \"//cancer.sanger.ac.uk) is the world's largest and most comprehensive online resource for exploring the impact of somatic mutations in human cancer. Live since 2004, the 71st release (Nov 2014) describes over 2 million mutations in more than 1 million tumour samples across most human genes. To emphasise depth of knowledge on known cancer genes, mutation information is curated manually from the scientific literature, allowing very precise definitions of disease types and clinically relevant patient details. Combination of over 20,000 published studies gives substantial resolution of how mutations and phenotypes relate in human cancer, providing insights into the stratification of populations and new diseases behind known biomarkers. Conversely, our curation of over 15,000 cancer genome studies emphasises knowledge breadth, driving discovery of new unrecognised cancer-driving hotspots and molecular targets. Our high-resolution curation approach is globally unique, giving substantial insight into molecular biomarkers in human oncology. For example, BRAF is well characterized in skin melanoma, transiently treatable with inhibitors such as Vemurafenib. It is also well known in colorectal cancer, which is largely non-responsive to BRAF inhibitors. COSMIC's unique approach demonstrates the impact of BRAF mutations in much less well-known cancers, for instance, Hairy Cell Leukaemia (89% of samples mutated) and Langerhans Cell Histiocytosis (49%), both of which respond remarkably well to BRAF inhibitors. Converse to skin melanoma, our curations suggest BRAF has a minimal role in Uveal melanoma (6% of Uveal tumors mutated for BRAF), with higher mutation rates in other genes (particularly GNA11, BAP1 and GNAQ), suggesting different mechanisms behind this disease.In addition to describing over two million coding point mutations across cancer, COSMIC also details more than six million non-coding mutations, 10,567 gene fusions, 61,232 genome rearrangements, 702,652 abnormal copy number segments, and more than 6 million abnormal expression variants. All these types of somatic mutation are annotated to both the human genome and each affected coding gene, then correlated across disease and mutation types. As increasing amounts of genetic data are gathered into COSMIC across human cancer, our annotations are beginning to emphasise events with a higher impact in cancer, highlighting the more functional coding mutations and major amplifications and deletions. This concept of high-impact data is being extended across the entire COSMIC system, much more strongly defining genes and mutations which drive oncogenesis.\"]",
        "Doc_id":"AACR_2015-62",
        "Doc_title":" COSMIC",
        "_version_":1606189014888480769},
      {
        "Meeting_name":" Personalizing cancer treatment of combined targeting of PI3K/AKT and MAPK pathways in advanced cancer patients harboring simultaneous oncogenic alterations in both signaling pathways.",
        "Background":"['Background', '  Frequent coactivation of both PI3K/AKT and MAPK pathways has been seen in a number of different tumor types. Preclinical studies also provide a clear rationale for the co-inhibition of these, \"semi-parallel\" pathways.  Methods', '  We reviewed the records of 1,672 consecutive advanced cancer patients (pts) in our Phase I Clinical Trials Program and investigated the clinical impact of simultaneous blockade of both PI3K/AKT and MAPK pathways in patients with oncogenic alterations in both signaling pathways from 317 pts who received PI3K pathway inhibitor and/or MAPK pathway inhibitor.  Results', '  163 of 317 pts (51.4%) were tested for comprehensive tumor genomic analysis using DNA array-based CGH/PCR-based DNA sequencing. PI3K pathway genetic alterations (PIK3CA mutation, n=3; PTEN deletion, n=18; AKT amplification, n=10) were detected in 29 of the 163 (17.8%) pts. RAS/RAF pathway genetic alterations (KRAS mutation, n=33; HRAS mutation, n=4; BRAF mutation, n=6) were detected in 43 of the 163 (26.4%) pts. Simultaneous oncogenic alterations in both PI3K/AKT and MAPK pathways were detected in 12 pts (colorectal cancer, n=7; pancreatic cancer, n=2; melanoma, n=2; non-seminomatous germ cell tumor, n=1). Six of 8 (75%) pts treated with personalized treatment based on dual pathways inhibition had tumor regression with prolonged duration of time to treatment failure compared to that of pts treated with single pathway inhibition. A pt with pancreatic cancer harboring simultaneous KRAS mutation and AKT2 amplification treated with combination MEK1/2 inhibitor and AKT inhibitor showed central cavitations of numerous lung metastatic lesions along with a decrease in CA19-9, which may reflect treatment effect.  Conclusions', '  These data could serve as a platform for therapeutic decision making. The strategy of targeting parallel pathways may be especially important in pts with coexisting PI3K/AKT and MAPK pathway genetic alterations. The data also suggest the need to further investigate the role of molecular profiling and matching pts with targeted drugs for personalized treatment.']",
        "Doc_id":"ASCO_93337-114",
        "Doc_title":" Personalizing cancer treatment of combined targeting of PI3K/AKT and MAPK pathways in advanced cancer patients harboring simultaneous oncogenic alterations in both signaling pathways.",
        "_version_":1606189000172765184},
      {
        "Meeting_name":" Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.",
        "Background":"['Background', ' Biomarkers capable of predicting response to checkpoint inhibitor therapies represent a significant clinical need. Increased tumor neo-antigenic burden has been linked to PD1/PD-L1 therapeutic response in several conditions including metastatic melanoma, non-small cell lung carcinoma and microsatellite instable (MSI-H) colorectal cancer (CRC). However, the challenges and high cost associated with neo-antigen discovery has shifted focus towards more efficient methods of response stratification. As such, mutational burden determination from whole exome sequencing and comprehensive genomic profiling (CGP) has emerged as a potential solution. In CRC, MSI-H may serve as a predictive biomarker for activity of PD1/PD-L1 therapy, reflecting an unquantified immunogenic mutational burden. Herein, we explore the ability to quantify tumor mutational burden (TMB) as a potential predictive biomarker of PD1/PD-L1 therapy in CRC. Methods', ' Formalin-fixed, paraffin embedded tissue sections from 2013 cases of CRC were sequenced with CGP (FoundationOne assay). MSI status and PD-L1 gene amplification were determined as previously described. TMB was calculated by counting mutations across a 1.25Mb region spanning 315 genes. Patients were classified as TMB high or low using the top quartile threshold and microsatellite instable (MSI-H) or stable (MSS) using a computational algorithm developed by Foundation Medicine. Results', ' MSS tumors were observed in 1934 of 2013 (95.2%) cases and MSI-H tumors were observed in 79 of 2013 (3.9%) cases. 79 of 79 (100%) MSI-H cases were TMB high (range 16.8-72.7 mut./Mb) and 1510 of 1934 (78.1%) MSS cases were TMB low (range 0.0-8.0 mut./Mb). Consequently, 424 of 1934 (21.9%) MSS cases were confirmed as TMB high (range 8.8-43.1 mut./Mb). Of note, less than 0.1% of cases featured PD-L1 gene amplifications. Conclusions', ' Tumor mutational burden as estimated by CGP, as opposed to MSI assessment alone, significantly increases the number of patients with metastatic CRC who may benefit from checkpoint inhibitor based therapeutic approaches. Investigations to validate this biomarker are ongoing.']",
        "Doc_id":"ASCO_165676-176",
        "Doc_title":" Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.",
        "_version_":1606189021873045504},
      {
        "Meeting_name":" Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations",
        "Background":"['Background', ' Massively parallel sequencing studies have demonstrated that there are few highly recurrently mutated genes in tumors and that there are vast numbers of mutations found in a minority of cancers from a given anatomical site. Numerous bioinformatics tools to predict the effect of a given amino acid substitution on protein function are available, and there is no consensus as to which prediction algorithms are the most appropriate for the identification of driver mutations. Here we sought to compare the performance, as standalone or in combination, of nine algorithms predictive of the impact of a mutation on protein function, when challenged against mutations whose pathogenic role is supported or refuted by in vitro or in vivo experiments, or have been shown to be pathogenic in the context of familial cancer syndromes.Methods', ' We mined the literature and databases and compiled known mutations for six oncogenes (BRAF, KIT, PIK3CA, KRAS, EGFR, ERRB2) and three tumor suppressors (TP53, BRCA1, BRCA2). We applied Boolean logic to identify experimental and clinical evidence of functional effects for each mutation. A total of 3072 missense mutations were subjected to analysis using nine mutation impact predictor algorithms, namely CHASM lung/breast/melanoma, FATHMM cancer/missense, Mutation Assessor, MutationTaster, PolyPhen-2, Condel, Provean, VEST and SIFT. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated and the agreement between predictors evaluated. Furthermore, predictions made by combinations of algorithms were assessed.Results', \" The PPV of all predictors was relatively high (median 0.941, range 0.909-0.989). Their sensitivity, specificity and NPV, however, varied widely. The median sensitivity was 0.854 (range 0.632-0.987), with the best performers being FATHMM cancer, CHASM lung and melanoma. The median specificity was 0.667 (range 0.482-0.939), with CHASM breast performing best. Inter-predictor agreement was only fair-to-moderate for most pair-wise comparisons (kappa scores ranging from 0.187 to 0.826). Finally, 358/4653 combinations performed better than each of the algorithms tested alone; 163/358 displayed higher NPVs and 131/358 improved sensitivity than the highest single algorithm's NPV and sensitivity, i.e. FATHMM cancer. The combination CHASM/FATHMM cancer/MutationTaster showed excellent performance, with sensitivity, specificity, PPV and NPV of 0.988, 0.824, 0.974 and 0.913, respectively.Conclusions\", ' Our results revealed discrepancies in performance of mutation impact predictors. No algorithm, on its own, was able to distinguish accurately driver from passenger events. Combining algorithms that provide orthogonal information likely results in substantial improvements in the functional predictions.']",
        "Doc_id":"AACR_2014-4258",
        "Doc_title":" Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations",
        "_version_":1606189027762896896},
      {
        "Meeting_name":" IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues",
        "Background":"['Introduction', ' NY-ESO-1 is a cancer testis antigen frequently expressed in a broad range of tumors', ' lung, breast, ovarian, bladder, liver cancer, melanoma, sarcoma and myeloma. CDX-1401, a fully human monoclonal antibody linked to full length NY-ESO-1, binds to dendritic cell (DC) receptor DEC-205 to stimulate NY-ESO-1 specific CD4 and CD8 responses. Immunohistochemistry (IHC) and quantitative RT-PCR (qRT-PCR) assays were developed to determine NY-ESO-1 expression in human tumors and normal adjacent tissues (NAT). A qRT-PCR assay for the detection of LAGE-1, a cancer testis antigen with significant DNA homology to NY-ESO-1, was also developed but no commercially specific antibody was available for IHC.Methods', ' Formalin fixed, paraffin embedded tumors and NAT were procured from a commercial source or obtained from Mosaic Laboratories; split anonymized samples were analyzed for NY-ESO-1 by IHC at Mosaic and for NY-ESO-1 and LAGE-1 by qRT-PCR at MolecularMD (OR) under IRB-approved protocols allowing in vitro analysis of remnant human samples. The study included', ' 18 each melanoma and ovarian cancers; 13 each colorectal (CRC), head & neck (H&N), and non-small cell lung cancers (NSCLC); and 38 NAT. HT1080 fibrosarcoma and SKOV3 ovarian cancer cell lines (ATCC, VA) and normal testis were used as controls. The qRT-PCR assays were validated using in vitro transcribed RNA on NY-ESO-1 and LAGE-1 kits provided by Life Technologies and the NY-ESO-1 IHC was developed using a mouse monoclonal antibody (Sigma, MO).Results', ' The NY-ESO-1 and LAGE-1 qRT-PCR assays had a linear range of 100-1,000,000 copies/reaction with limit of detection between 1-10 copies. An excess of LAGE-1 copies did not impact the specificity of the NY-ESO-1 assay and vice-versa. NY-ESO-1 protein was detected by IHC and NY-ESO-1 transcripts and LAGE-1 transcripts were detected in 9 (12%), 12 (16%) and 16 (21.3%), respectively, of the 75 tumor tissues while only 2 of the 38 normal samples were positive for LAGE-1. When stromal staining was considered in addition to epithelial staining, 16 (21.3%) tumor samples were positive by IHC. NY-ESO-1 protein was more prevalent in NSCLC (38%), ovarian cancer (11%) and melanoma (11%) vs. other tumor types. Positive staining by IHC was achieved in tumor tissues shown positive for NY-ESO-1 and negative for LAGE-1 transcripts. In general, tumor tissues obtained from Mosaic were of better quality, as assessed by the pathologist, and more positive than commercially procured samples.Conclusions', ' Two qRT-PCR assays were developed to specifically quantify NY-ESO-1 or LAGE-1 mRNA without cross reaction. The antibody used in IHC assay seemed specific to NY-ESO-1. Inadequate sample quality impacted target prevalence. Implementing these assays in clinical trials may aid in prospectively identifying patients with NY-ESO-1 positive malignancies who could derive benefit from investigational NY-ESO-1 vaccines designed to induce anti-tumor immunity, such as CDX-1401.']",
        "Doc_id":"AACR_2016-1373",
        "Doc_title":" IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues",
        "_version_":1606189003181129728},
      {
        "Meeting_name":" Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.",
        "Background":"['Background', '   Mutational testing has become standard of care in melanoma, lung, and colorectal cancers. The advent of Next Generation Sequencing (NGS) and increasing availability of new targeted therapeutics raise the question of how broader use of testing will impact care in the community setting.  Methods', '   We conducted a retrospective chart review of patients (pts) seen at a network of community oncology practices whose tumors were tested with NGS for actionable mutations in AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, FGFR1/3, GNA11, GNAQ, MAP2K1, HRAS, KDR, KIT, KRAS, MET, NF1, NRAS, NTRK1/2/3, PIK3CA, PIK3R1, PTEN, RET, STK11, TSC1, and TSC2. Under IRB approval, data were collected on diagnosis, date of testing, treatments, mutational results, treatment outcomes, and survival.  Results', '   632 pts had NGS, of whom 360 harbored actionable mutations (57%). Of these, 301 were included for review', ' 59 were excluded based on disease stage or insufficient clinical data. There were 26 different cancer types; lung, colorectal and breast cancers represented over half.  As of December 2013, 45% of pts had started new therapies after NGS results were available. Mutational testing guided treatment in 34% of these pts, with over half enrolling on clinical trials targeting specific mutations.  A minority (6.6%) was treated off label with FDA approved medications targeting the mutations. Conclusions', '   When performed in a timely manner, NGS had a clinically meaningful impact on treatment planning in one third of pts. The availability of molecularly targeted clinical trials played a significant role in the importance of the testing. Our data provide an initial view of how NGS can impact treatment decision making in the community setting.']",
        "Doc_id":"ASCO_128879-144",
        "Doc_title":" Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.",
        "_version_":1606188985397280768},
      {
        "Meeting_name":" Analysis of mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples from two phase II clinical trials using a Sequenom-based approach.",
        "Background":"['Background', '  Analysis of tumour samples for biomarker discovery, personalised health care and disease stratification is becoming increasingly important.  Methods to detect somatic mutations are often limited by the requirement for a significant amount of input DNA, low sensitivity or low sample throughput.  The aim of this work was to obtain a comprehensive mutation profile of tumour samples taken from patients enrolled on two Phase II clinical trials.  A Sequenom based approach was used to determine mutation profiles for the samples so that these could be correlated with response at some future date.   Methods', '  After successfully piloting the Sequenom MassArray 4 platform on formalin fixed paraffin embedded (FFPE) tumour samples and tumour cell line admixes, we ran an exploratory analysis of 177 melanoma and 230 non small cell lung cancer (NSCLC) FFPE samples collected from two phase II clinical trials.  DNA was extracted from the FFPE samples using the QIAmp DNA FFPE Tissue Kit (Qiagen).  We designed a panel of 86 assays in 14 genes covering approximately 160+ mutations.  Mutations were chosen based on mutation frequency and biological significance in these tumour types.    Results', '  Using this approach we were able to detect concomitant mutation profiles in a significant percentage of samples using only approximately 20uL of FFPE DNA (500 copies/L average).  Mutation status concordance was over 97% in BRAF and KRAS when compared to data generated via other approaches (sequencing, ARMS).    Conclusions', '    Using Sequenom to screen tumour material, collected during clinical trials, is a feasible, rapid and comprehensive approach.  Such an approach can be used to identify mutation profiles which correlate with patient response, potentially identify further patient stratification and help generate new hypotheses for further exploration.']",
        "Doc_id":"ASCO_98465-114",
        "Doc_title":" Analysis of mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples from two phase II clinical trials using a Sequenom-based approach.",
        "_version_":1606188987093876736},
      {
        "Meeting_name":" Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers",
        "Background":"['Background', ' Plasma cell-free (cf) DNA from cancer patients offers an easily obtainable and repeatedly applicable source of DNA for mutation analysis, which provides attractive alternative to tumor tissue testing. Novel ultrasensitive multiplex technologies using small amounts of DNA are needed for further implementation of plasma cfDNA testing in personalized therapy.Methods', ' We have developed an ultra-deep next-generation sequencing method for somatic BRAF mutation detection in 5 ng of cfDNA with high sensitivity and specificity, which was expanded to include 30 (full exon tiling', ' ERBB2, TP53, FGFR1, PTEN, MET, KRAS, ALK, CTNNB1, KIT, NRAS, BRAF, PIK3CA, EGFR, MAP2K1, PIK3R1, DDR2, NF1, MITF, AKT3, PHLPP1, HGF, HOXD8, MEK2, hotspot containing exons', ' AKT1, HRAS, GNA11, GNAQ, RAC1; copy number variations', ' ERBB2, FGFR1, MET, BRAF, EGFR, MITF, HGF, HOXD8; gene fusions', ' RET1, ROS, and ALK) and then 58 common cancer related genes (previous panel + APC, AR, FGFR2, FGFR3, FGFR-4, SMO, FBXW7, NOTCH1, CDKN2B, IDH1, IDH2, GNAS, KDR, STK11, ESR1, VHL, ATM, CDH1, TRKA, TRKB, TRKC, TSC1, TSC2, Fltr3, FOXL2, CDKN2A, PDGFRA, IGF1R). Each cfDNA fragment was uniquely barcoded and amplified prior to Illumina target enrichment workflow, followed by ultra-deep sequencing (>10,000X). Proprietary data processing and analysis tools were developed to enable sensitive detection of rare mutant molecules over high wild-type background (detection of 1 in 1,000 - 10,000 molecules). Results were compared to mutation analysis of archival primary or metastatic tumor tissue obtained at different points of clinical care from a CLIA-certified laboratory.Results', ' Initially, cfDNA was extracted from plasma samples of 24 patients with advanced cancers (melanoma, n = 9; colorectal, n = 5; non-small cell lung, n = 2; papillary thyroid, n = 2; other cancers, n = 6) and 5ng were used for BRAF mutation analysis. BRAF mutations were detected in 71% (17/24) of plasma samples and in 88% (21/24) of archival tumor samples, resulting in concordance in 87% (20/24) of cases. Subsequently, we extracted plasma samples from additional 13 patients with advanced cancers (colorectal, n = 4; melanoma, n = 3; other cancers, n = 6) and tested 14-30ng of cfDNA for the presence of alterations in 30 to 58 cancer related genes. Both ultra-deep sequencing of plasma cfDNA and standard tissue sequencing detected median of 2 alterations per patient and dominant oncogenic alterations previously detected in the tumor tissue were also found in plasma cfDNA. Additional 80 samples are being analyzed and results will be presented at the meeting.Conclusions', ' Detecting common oncogenic alterations using ultra-deep sequencing of plasma cfDNA is feasible with an acceptable level of concordance with testing of tumor tissue and should be further investigated for testing in patients with advanced cancer.']",
        "Doc_id":"AACR_2015-2414",
        "Doc_title":" Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers",
        "_version_":1606189008548790272},
      {
        "Meeting_name":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "Background":"['Detection of low abundant alterations in oncogenes from circulating cell free DNA (cfDNA) samples or formaldehyde fixed-paraffin embedded samples (FFPE) has been a challenge for the community. Additionally, cfDNA and FFPE samples are typically limited in the amount of material that can be obtained, and often the FFPE samples are highly degraded, compounding the ability to sequence them and to perform accurate variant calling. To overcome these challenges, we have developed a single tube, multiplexed amplicon sequencing technology that employ hundreds of primer pairs for amplification of targeted loci, producing ready-to-run libraries for Illumina sequencing platforms. The resulting amplicons are less than 150 bp in length, enabling amplification and sensitive detection of mutations from cfDNA-sized DNA fragments or highly damaged DNA. A 200+ amplicon panel across 55 genes was developed to target known clinically relevant oncological mutations. The panel design encompasses single exons (e.g. BRAF) as well as comprehensive exon coverage of entire genes (e.g. TP53).DNA was extracted from FFPE, and cfDNA was extracted from fresh plasma. DNA was quantified by qPCR using 2 primer pairs targeting ALU repeat regions. 10ng of DNA input was used to perform the multiplexed PCR. Libraries were quantified by qPCR and sequenced with MiSEQ V2 reagents, paired end reads. Alignment was performed using Burrows-wheeler Aligner (BWA) and variant calling was performed with at least two validated publicly available tools and confirmed manually by IGV. A variety of tools were used to validate allele technology was used to validate the sequencing data.We interrogated 80 FFPE samples using our amplicon technology.The percent of on-target bases was over 95% and the coverage uniformity was over 98%, where uniformity is the percent based covered over 20% of the mean coverage. Out of the 40 colorectal cancer samples tested, 17 showed mutations in KRAS. Out of the 20 melanoma samples (Cure line) also analyzed, 9 were positive for BRAF V600E. The presence of those mutations was confirmed using myTprimerTM KRAS and BRAF qPCR assay. The limit of detection of the assay was set at 3% due to the inherent noise caused by the damage from the FFPE samples. For cell lines with known mutations, the sensitivity was 0.5%. No false positive or false negative were reported. 20 FFPE samples from different cancer types were also assessed. Mutations were identified in ERBB2 (cervical cancer), ALK (lung cancer) and TP53 (colon cancer) genes, as well as MET amplification (lung cancer).Cell free DNA provides a non-invasive tool to monitor cancer progression and treatment efficacy. Tumor DNA, matching blood DNA and cfDNA from 10 cancer patients will be subjected to our multiplex PCR oncology panel. Data of this study will be presented.Our results show that this unique multiplex PCR panel is an excellent tool to assess multiple oncogenes in limiting clinical samples, enabling high throughput, cost effective NGS analysis.']",
        "Doc_id":"AACR_2015-4902",
        "Doc_title":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "_version_":1606188971681906688},
      {
        "Meeting_name":" AIP1 suppresses tumor metastasis by regulating tumor microenvironment and metastatic niche",
        "Background":"['AIP1 (also called DAB2IP, a new member of RAS-GAP family protein) is downregulated in a variety of human cancer tissues. We and others have recently reported that AIP1 functions as a tumor suppressor in prostate cancer models. However, the role of AIP1 in regulating tumor microenvironment and metastatic niche is not known. In the present study, we implanted tumor cells with the same genetic background into C57BL/6 wild type (WT) and AIP1-deficient (AIP1-KO) mice to address this question. In subcutaneous (SQ) allograft models using B16 melanoma and LLC Lewis lung carcinoma, tumor growth and metastasis to multiple organs including lymph node, lung, liver, spleen and bone marrow were significantly enhanced in AIP1-KO host, suggesting AIP1 in tumor microenvironment limits tumor metastases. However, a direct intravenously injection of tumor cells resulted in no differences in tumor metastasis between WT and AIP1-KO mice, indicating AIP1 in host regulates tumor metastasis at steps prior to extravasation to target tissues. We examined effects of AIP1 deletion on the induction of local inflammation, tumor cell epithelial-mesenchymal transition (EMT), generation of metastatic routes (formation of new blood and lymphatic vessels) and establishment of pre-metastatic niche in distance tissues. SQ tumors in AIP1-KO host showed more profound increases in macrophage infiltration, tumor cell EMT, intratumoral angiogenesis and peri-tumoral lymphangiogenesis as well as lymphangiogenesis in lymph nodes prior to the detection of metastatic tumor cells. Finally, SQ tumor induced an establishment of pre-metastatic niche in lung as indicated by increased immunostaining for fibronectin and accumulation of VEGFR1, c-Kit and CXCR-positive cells which were augmented in AIP1-KO mice. Importantly, WT recipient with AIP1-KO bone marrow-derived cells showed similar phenotype to AIP1-KO mice in tumor growth and metastasis. Taken together, our data suggest that AIP1 functions as tumor metastasis suppressor by regulating tumor microenvironment, metastatic routes and pre-metastatic niche.']",
        "Doc_id":"AACR_2014-129",
        "Doc_title":" AIP1 suppresses tumor metastasis by regulating tumor microenvironment and metastatic niche",
        "_version_":1606189005739655168},
      {
        "Meeting_name":" Phenformin is a MYCN/MYC destabilizer that can specifically target neural crest derived tumors.",
        "Background":"['We have been interested in identifying MYCN/MYC destabilizers that can specifically target neural crest derived tumors (neuroblastoma, melanoma, and malignant pheochromocytoma). MYCN amplification and its over-expression are associated with the worst neuroblastoma disease outcome. Non-MYCN amplified neuroblastomas express high-levels of MYC, and prognosis of these neuroblastomas is very poor. Melanoma and malignant pheochromocytoma are also known for high MYC expression. Interestingly, these neural crest derived tumors characteristically express the norepinephrine transporter (NET). This feature can be used to specifically target the tumor cells with agonists of NET, such as Meta-Iodo-BenzylGuanidine (MIBG). In the previous AACR meeting, we presented our finding that non-radio-labeled MIBG can suppress growth of neuroblastoma cells in vitro, and this effect is in part related to its ability to destabilize MYC and MYCN. We have also shown that FCCP, a well-known mitochondrial respiration inhibitor, destabilized MYCN and MYC in neuroblastoma cells and caused growth suppression. Recently, it has been reported that Phenformin, a Type II diabetic drug, binds NET, suggesting that NET positive cells preferentially uptake Phenformin. It is also known that Phenformin inhibits the mitochondrial electron transfer system. In this study, we have investigated a possible effect of Phenformin on growth and MYC/MYCN stability in neuroblastoma cells in vitro. SKNBE(2)C and CHP134 neuroblastoma cell lines were treated with various doses (0-2.5mM) of Phenformin for two days. MTS assay was used to assess the effect of Phenformin on growth of the cells. There was a dose-dependent growth suppression of the NB cell lines tested. Phenformin was more effective against growth of SKNBE(2)C than CHP134 cells. The effect of Phenformin on MYC/MYCN expression in four neuroblastoma cell lines [SKNBE(2)C, CHP134, SKNAS, and SY5Y] was also examined by Western blot assay. SKNBE(2)C and CHP134 express MYCN, whereas SKNAS and SY5Y express MYC at high levels. Treatment of these cells with Phenformin at the dose of 1mM for 24 hours resulted in destabilization of MYCN/MYC, suggesting that the growth suppressive effect of Phenformin on neuroblastoma cells was in part due to reduction in MYC/MYCN expression. We are currently examining whether the above observations made in neuroblastoma are also applicable to other neural crest derived tumors. In addition, we are investigating how Phenformin-related mitochondrial dysfunction causes destabilization of MYC/MYCN in neuroblastoma cells.']",
        "Doc_id":"AACR_2013-766",
        "Doc_title":" Phenformin is a MYCN/MYC destabilizer that can specifically target neural crest derived tumors.",
        "_version_":1606188981480849408},
      {
        "Meeting_name":" Monitoring anti-PD-1 therapy efficacy by circulating tumor DNA",
        "Background":"['Background', ' Initial flare-ups of cancer deposits have been observed under nivolumab and pembrolizumab therapy, making imaging evaluations uneasy. In that setting, we hypothesized that circulating tumor DNA (ctDNA) levels during PD1 blockade could reflect the tumor burden and may even differentiate lymphocytic infiltrates of tumor deposits from true tumor progressions. Methods', ' All patients (pts) starting a therapy with on-label nivolumab or pembrolizumab at Institut Curie were eligible for this ethically approved prospective study. After signed informed consent, patients had up to four blood draws', ' (i) before therapy; (ii) after 2 months; (iii) at tumor progression; (iv) in case of toxicity. Optimized pre-analytical procedures were applied on EDTA tubes. Circulating DNA was extracted using the QIAamp kit and quantified by Qubit. ctDNA was then quantified by detecting either (subgroup A) previously characterized point mutations for which ddPCR or biPAP-PCR (Madic, Clin Cancer Res 2012) probes were available or (subgroup B) previously unknown mutations discovered by a targeted massively parallel sequencing of cancer-related genes in plasma (Lebofsky, Mol Oncol 2015). Results were correlated with prospectively registered radiological evaluations (RECIST & irRC) and clinical outcomes. Results', ' Thirty-six pts (N = 23 NSCLC, N = 11 melanoma, N = 2 MSI-H GI cancers) have been included from July to November 2015. ddPCR and biPAP-PCR was performed in the first seven pts with known KRAS, BRAF, GNAQ or GNA11 mutations in (subgroup A). The only pt with rising ctDNA levels in the first two months of therapy (50 to 1200 copies/ml of plasma) experienced a tumor progression. The two other pts with confirmed tumor progression had stable (600 to 500 copies/ml) or undetectable (0 to 0 copy/ml) ctDNA levels. As expected, stable disease and partial responses (N = 4) were associated with decreased (210 to 0) or undetectable (0 to 0) levels. Mutation discovery by targeted massively parallel sequencing (subgroup B) is ongoing and will be presented at the meeting. Conclusions', ' This first proof of concept study suggests that early ctDNA levels changes may be a tool to manage anti-PD1 therapy efficacy.']",
        "Doc_id":"ASCO_170077-176",
        "Doc_title":" Monitoring anti-PD-1 therapy efficacy by circulating tumor DNA",
        "_version_":1606188979009355776},
      {
        "Meeting_name":" Emerging findings in the Cancer Research UK stratified medicine program.",
        "Background":"['Background', '  Molecular analysis of tumours may be used to identify those predicted to benefit from novel targeted therapies. The Cancer Research UK programme is piloting plans to apply such testing broadly across the UK healthcare system, linking molecular phenotype to clinical outcomes.   Methods', '  The Stratified Medicine Programme (SMP) aims to develop a model for high quality, large-scale molecular characterization of cancer specimens through an initiative developed in partnership with AstraZeneca, Pfizer, the UK Department of Health and academic researchers. Phase One of the SMP is a two year feasibility study. It aims to demonstrate the submission of consented blood samples and sections of surplus diagnostic formalin-fixed paraffin-embedded tumour tissue from 9,000 patients at centres across the UK to one of three technology hubs for mutation testing of genes of potential clinical interest (KRAS, BRAF, NRAS, PIK3CA, TP53, PTEN, TMPRSS2-ERG, EGFR, EML4-ALK and KIT) in six selected tumour types. The tests are technically validated and will be completed in clinically relevant timescales.  Data including pathological and treatment information and clinical outcome is also collected for the recruited patients, linked to the genetic data and stored in a central data repository hosted within the National Cancer Registration Service.  The study opened in September 2011 at 7 sites across the UK and by the end of 2011, 760 patientswith breast, lung, prostate, colorectal, ovarian cancer or metastatic malignant melanoma had consented to participate.  142 sets of molecular results had been returned to clinical teams. Updated figures will be presented at the meeting, by which time the programme is projected to have accrued 4000 subjects.  By 2013, we hope to have developed a scalable model for routine, high quality, prospective molecular characterisation of tumours for NHS cancer patients, with consent for the collection, storage and research use of population-scale genetic and clinical outcome data. We will report the emerging results from the Stratified Medicines Programme and early insights into implications for wider implementation across the UK healthcare system.']",
        "Doc_id":"ASCO_99103-114",
        "Doc_title":" Emerging findings in the Cancer Research UK stratified medicine program.",
        "_version_":1606188992689078272},
      {
        "Meeting_name":" A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).",
        "Background":"['Background', '  E7080 is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFR.   In phase I studies of E7080 partial responses (PR) were observed in thyroid as well as melanoma, endometrial, and renal cancers.   Methods', '  Between Oct 2, 2008 and Feb 5, 2010, patients (pts) with advanced, RAI-refractory DTC (papillary, follicular or Hurthle Cell) and disease progression demonstrated by RECIST during the prior 12 months were enrolled.  Pts may have received prior VEGFR targeted therapy.  Pts were treated with a starting dose of E7080 24 mg once daily in 28 day cycles until disease progression or development of unmanageable toxicities.  Primary end point was Response Rate (RR) by RECIST.    Results', '   58 pts were enrolled (med age', ' 62; M', '59%, F', '41%) and are evaluable for response.  35% of pts required dose reduction for management of toxicity, and 23% were withdrawn from therapy due to toxicity.  The most common adverse events were hypertension 64% (Gr 3', ' 4%), fatigue 55% (Gr3', ' 7%), diarrhea 45% (Gr3', ' 5%), decreased appetite 44% (Gr3', ' 2%), weight loss 43% (Gr3', ' 4%), and proteinuria 39% (Gr3', ' 7%).  5 pts (8.6%) experienced Gr 4 events.  Confirmed PRs were observed in 29 pts (RR', ' 50%, 95% CI', ' 37-63) based on investigator assessment.  65% of responses were identified at first on-therapy imaging at ~8 wks.  For pts who received prior VEGFR-directed treatment (n=17) RR=41%; with no prior VEGFR-directed treatment (n=41) RR=54%. Median PFS is 12.6 mo (95% CI', ' 10.4-14.1) (based on minimum 8 mo. f/u, with only 34% events observed).  Updated PFS will be reported.    Conclusions', '  E7080 administered orally at a dose of 24 mg once daily to patients with RAI refractory DTC is associated with manageable toxicity and a RR of 50%, identifying E7080 as a promising new potential therapeutic agent for treating patients affected with this disease which has very limited therapeutic options at present.']",
        "Doc_id":"ASCO_73708-102",
        "Doc_title":" A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).",
        "_version_":1606189034477977600},
      {
        "Meeting_name":" Correlation of sorafenib plasma concentrations and clinical toxicity",
        "Background":"['Background', ' Sorafenib is an angiogenesis inhibitor recently approved for the treatment of metastatic renal cell carcinoma and hepatocarcinoma. This oral multi-targeted kinase inhibitor blocks the VEGF, PDGF receptors, BRAF and c-kit. In clinical trials, severe toxicities included rash, hand-foot syndrome and diarrhea. We investigated the relationship between severe toxicity and sorafenib plasmatic exposure. Patients and methods', ' From February 2008 to December 2008, 32 patients (pts) were treated with sorafenib (800 mg given daily). Clinical and blood exams were performed at baseline and every 2 weeks. Toxicity events were graded according to National Cancer Institute Common Toxicity Criteria 3.0. The sorafenib area under the plasma concentration-time curve over 12 hours (AUC0-12) was determined every 2 weeks by gradient elution liquid chromatography, data analysis with one-compartment disposition and a population approach using NONMEM software. Grade 3 toxicity free survival was estimated by Kaplan-Meier method. Results', ' Pts (23 males), ECOG 0-1 (27 pts), median age 62.8 years (range 37-78), with metastatic hepato-carcinoma (11), melanoma (6), thyroid cancer (8), renal cell carcinoma (7), received a median treatment duration of 94 days (range ', ' 7-330). 20 pts experienced grade 3 toxicities with 33 events', ' hand-foot hyperkeratosis (14), diarrhea (5), cutanous rash (4), asthenia (2), anorexia (2), dyspnea (1), scrotal toxicity (1), post surgical complication (1), hypertension (1), increase creatinine level (1), digestive hemorrhage (1). The median AUC0-12 was 62.4 mg/L.h, ranging from 28.7 to 202.2 mg/L.h. Amongst pts experiencing grade 3 toxicity, two groups of 16 pts were defined with the median AUC0- 12 as cut off', ' low exposure (Lw) and high exposure (Hi). Six Lw pts experienced grade 3 toxicity versus 14 Hi pts (exact Fisher Test p=0.009). The probability of free grade 3 toxicity survival was higher for Lw (Logrank test p=0.004). Conclusions', ' These results show that grade 3 toxicity occurrence may be related to high plasma sorafenib exposure. This supports the need for therapeutic drug monitoring to prevent toxicity grade 3 occurrence and therefore optimize the clinical management of patients under sorafenib.']",
        "Doc_id":"ASCO_35284-65",
        "Doc_title":" Correlation of sorafenib plasma concentrations and clinical toxicity",
        "_version_":1606189034655186945},
      {
        "Meeting_name":" Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.",
        "Background":"['Background', ' Blood-based liquid biopsies offer easy accessible genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from dying cells. In contrast exosomal nucleic acid (exoNA) originates from living cells, which can better reflect underlying cancer biology. Methods', ' We isolated exoNA (EXO52) and cfDNA (QIAamp Circulating Nucleic Acid kit) from plasma of patients with progressing advanced cancers and tested for BRAFV600, KRASG12/G13, and EGFRexon19del/L858R mutations using next-generation sequencing (EXO1000), droplet digital PCR (ddPCR, QX200) and BEAMing digital PCR. The results were compared to clinical testing of archival tumor tissue and correlated with survival. Results', ' Of the 43 patients (colorectal cancer, 20; melanoma, 8; non-small cell lung cancer, 6; ovarian cancer, 2; papillary thyroid cancer, 2; other cancers, 5) 41 had a mutation in the tumor tissue (20 [47%] BRAF mutation, 17 [40%] KRAS mutation and 4 [9%] EGFR mutation). Mutation testing of plasma exoNA from all 43 patients detected 39 (95%) of 41 mutations present in tumor tissue with 100% specificity. Mutation testing of plasma cfDNA from 39 patients using ddPCR detected 33 (89%) of 37 mutations present in tumor and testing of plasma cfDNA from 37 patients using BEAMing detected 34 (97%) of 35 mutations present in tumor tissue; however, both cfDNA methods reported an additional KRAS mutation not present in tumor tissue. Patients with high mutation allele frequency (MAF, > median) had shorter median survival compared to patients with low MAF ( < median) when using exoNA (5.9 vs. 11.8 months, P= 0.006), but not cfDNA ddPCR (6.0 vs. 7.4 months, P= 0.06) or cfDNA BEAMing (6.5 vs. 7.4 month, P= 0.07). High MAF in exoNA was an independent prognostic factor for survival in multicovariate analysis (HR 0.13, P= 0.017). Conclusions', ' Mutation testing of plasma exoNA for common BRAF, KRAS, and EGFR mutations has high sensitivity compared to clinical testing of archival tumor tissue and better specificity than PCR testing of plasma cfDNA. High MAF in exoNA is the independent prognostic factor for shorter survival.']",
        "Doc_id":"ASCO_184715-199",
        "Doc_title":" Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.",
        "_version_":1606189041204592640},
      {
        "Meeting_name":" Elevated expression of Fn14 in non-small cell lung cancer correlates with c-MET and promotes tumor cell invasion and metastasis.",
        "Background":"['Tumor invasiveness and therapeutic resistance strongly contribute to the low (<10%) five-year survival rate for advanced stage lung cancer; thus, identification of novel interventions targeting metastasis and therapeutic resistance is a necessity. Hepatocyte growth factor receptor (c-Met) and fibroblast growth factor-inducible 14 (Fn14) are two cell surface receptors known to be associated with lung cancer invasiveness and cell survival. Our lab recently demonstrated that Fn14 was over-expressed in non-small cell lung cancer (NSCLC), correlated with activated epidermal growth factor receptor, and that expression of Fn14 modulated NSCLC cell invasiveness and metastasis. We hypothesize that elevated Fn14 expression can be maintained by c-Met activation, and that blockade of Fn14 can suppress NSCLC invasiveness driven by c-Met. Here we demonstrate that Fn14 protein expression significantly correlated with c-Met expression in primary NSCLC patient tumors. Fn14 and c-Met were more highly expressed in metastatic tumors compared to patient-matched primary NSCLC tumors, suggesting a role in the metastatic phenotype. To further elucidate the relationship between Fn14 and c-Met in NSCLC invasiveness, we employed two cell lines derived from a primary tumor (H2073) and metastatic lymph node (H1993) of the same patient. H1993 cells (c-Met receptor amplification) expressed significantly elevated protein levels of Fn14 compared to H2073 (low c-Met), which were significantly diminished in H1993 cells upon c-Met inhibition through SU11274 treatment. Moreover, exposure of H2073 cells to HGF induced the protein expression of Fn14. The elevated expression of Fn14 through HGF stimulation (H2073) or c-Met receptor amplification (H1993) was attenuated by pretreatment of the cells with U0126, a potent MEK inhibitor, suggesting that c-Met-induced Fn14 expression may depend on MAPK signaling. To further elucidate the effect of Fn14 on global c-Met-induced expression, genome-wide expression analysis was employed to determine genes both over-expressed in H1993 compared to H2073 and subsequently suppressed in Fn14 depleted H1993 cells. RALGPS2, a gene over-expressed in lung tumors that induces of c-fos and OPRL1, a gene elevated in metastatic melanoma, were elevated in the metastatic cell line and subsequently suppressed with Fn14 depletion. In addition, shRNA-mediated depletion of Fn14 in H1993 cells attenuated cell migration and invasion by 45% and 40%, respectively. This work demonstrates that c-Met and Fn14 may play a critical role in NSCLC metastasis, and suggests that targeting Fn14 may impact c-Met-driven NSCLC invasiveness. Successful targeting of NSCLC invasiveness would have significant clinical impact on a disease that is deadly in its advanced stages.']",
        "Doc_id":"AACR_2013-3785",
        "Doc_title":" Elevated expression of Fn14 in non-small cell lung cancer correlates with c-MET and promotes tumor cell invasion and metastasis.",
        "_version_":1606189039942107136},
      {
        "Meeting_name":" Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US",
        "Background":"[\"Commercial genomic and protein-based profiling was performed on tissue from pancreatic cancer patients who enrolled in the Pancreatic Cancer Action Network's Know Your Tumor (KYT) service. The service offers molecular profiling for patients with resectable or metastatic disease, in preparation for their next treatment plan. Patients are eligible to enroll at any institution, clinic, or cancer center in the US. Biopsies, tissue retrieval and testing is coordinated by Perthera, Inc.From 6/2014 to 11/2015 tumor biopsies, resected or archived tissue was obtained from 152 (53% male) pancreatic cancer patients and profiling including NGS/FISH (144 patients) and IHC (143 patients) was performed. The median age at biopsy or resection was 63 (25-83), 55% of the tissue came from liver, 16% from pancreas, 7% lung, 4% peritoneum, and 18% from another type of tissue. 87% of the patients were diagnosed with pancreatic ductal adenocarcinoma and the remaining with another form of confirmed or suspected pancreatic cancer.The most identified pathogenic mutations were KRAS (85%), TP53 (72%), CDKN2A (47%), CDKN2B (24%), SMAD4 (22%), ARID1A (10%), STK11 (7%), and BRCA2 (5%). The average number of genomic alterations (likely but not confirmed to be somatic) detected was five per patient from a panel of 320 genes. Molecular modifications that are linked to a treatment option were observed in 44% of patients. Twenty four of 144 patients (17%) had mutations in at least one DNA repair gene potentially benefiting from platinum or PARP inhibitor-based therapies, including BRCA2 (5%), ATM (4%), BAP1 (4%), SMARCA4 (3%), FANC (1%), CHEK2 (1%), and PALB2 (<1%). Other actionable molecular phenotypes observed include anti-HER2 therapies targeting ERBB2 amplifications (3%) and mTOR inhibitors suitable for patients with mutations in STK11/LKB1 (7%), PTEN (3.5%), PIK3R1 (<1%), or PIK3CA (3%). Actionable alterations identified with a low frequency (<2%) include RET fusions, amplifications of FGFR, CRKL, AXL, and mutations in NTRK3, MEN1 (PNET), and BRAF. One patient harbored the BRAF V600E mutation, prompting consideration of off label melanoma-approved therapy. Overexpression of ALK by IHC was observed in one patient who chose to enroll in a ceritinib clinical trial. Six percent of patients were PDL-1 positive, and 22% were positive for PD-1 from tumor infiltrating lymphocytes, suggesting possible activity from immune checkpoint inhibitors.To date, 7 of the 152 patients have enrolled in a clinical trial, 4 were treated with an off label treatment, 67 have yet to make their next treatment decision, and 53 are known to be deceased. KYT has successfully profiled tumors and presented targeted treatment options to patients and physicians in 33 states regardless of a patient's socioeconomic background and geographic location, moving the field a step closer towards a democratized, personalized approach to treating pancreatic cancer.\"]",
        "Doc_id":"AACR_2016-93",
        "Doc_title":" Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US",
        "_version_":1606189020780429312},
      {
        "Meeting_name":" Sensitive, specific and highly multiplexed mutation detection for cancer management",
        "Background":"['Mutations in RAS, RAF, EGFR and PIK3CA genes are present in a number of cancers including colon, lung and breast cancers. Importantly, many of these mutations are predictive biomarkers of clinical outcomes for targeted therapies. This has led to a growing demand for detection of multiple mutations simultaneously. Multiplex formats allow a greater amount of information to be obtained from each sample.PASS primer technology can sensitively and specifically identify the presence of SNPs and somatic DNA changes (point mutations, deletions and insertions) with sensitivity up to 1 in 1,000 (0.1%). PASS primers selectively amplify nucleic acid variants and create amplicons that are markedly different from the parent sequence. The method is superior to ARMS PCR for multiplexing, particularly when mutations are present at the same, adjacent or nearby loci.PASS primers consist of two target specific regions separated by an insert sequence (IS) which is not complementary to the target. A long 5 target-specific region anchors the primer and a short 3 region targets the variant base/s thus directing highly specific binding and extension. During amplification, the IS sequences are incorporated into amplicons, introducing 10 base difference between the starting single base variant and the resulting amplicon. This reduces competition between primers during amplification and facilitates robust discrimination between amplicons during detection.MNAzyme qPCR is a robust alternative to other probe based real-time qPCR protocols such as TaqMan and Beacons. MNAzymes are bi-specific, catalytic oligonucleotide complexes which form in the present of target and cleave universal reporter probes. The bi-specificity, and the use of well-characterised universal probes sets (suitable for use with any group of targets), makes MNAzyme qPCR more amenable to multiplexing. When combined with PASS, MNAzyme qPCR easily discriminates between amplicons since MNAzymes are tailored to specifically detect both the distinct IS and the original mutation.PASS MNAzyme qPCR has been used to facilitate multiplex detection of RAS, RAF, EGFR and PIK3CA mutations. As many as eight mutations located at codons 12 and 13 of RAS have been successfully detected in a single well using three channels on a standard PCR machine. The technology is even more powerful when combined with newer instruments with higher multiplex capabilities such as Biocartis Idylla automated platform. A multiplexed KRAS/BRAF assay, which detects 18 mutations, was evaluated using colon cancer and melanoma FFPE samples. The results showed >96% concordance with sequencing and significantly specificity compared to the singleplex Therascreen KRAS test.Since PASS MNAzyme qPCR affords greater multiplex capacity, along with high specificity and sensitivity, it provides a superior tool for ascertaining mutations from tumour tissues and is particularly well suited for use with liquid biopsies.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-4910",
        "Doc_title":" Sensitive, specific and highly multiplexed mutation detection for cancer management",
        "_version_":1606189032768798720},
      {
        "Meeting_name":" Novel, simplex and multiplex assays for BRAF mutation detection.",
        "Background":"['Background', ' BRAF gene mutations play key roles in colorectal cancer (CRC) and in malignant melanoma (MM). In CRC, BRAF mutation is associated with poorer prognosis and may be a marker for new targeted therapies. In MM, BRAF mutations are predictive of the efficacy of BRAF-targeted therapies. In CRC, only the V600E change is observed regularly, while in MM different BRAF mutations may occur. To improve the identification of BRAF mutations, we developed novel simplex and multiplex real-time PCR-based assays (SensiScreen) and compared them with Direct Sequencing (DS), Mutant-Enriched PCR (ME-PCR) and Cobas. Methods', ' SensiScreen assays (PentaBase, Denmark) comprise SuPrimers (DNA primers with increased specificity), BaseBlockers (suppressing amplification of wild-type genes) and HydrolEasy probes (hydrolysis probe with increased S/N ratio and sensitivity). Sensitivity studies on plasmids and extracted cell line DNA were performed. Two cohorts of patients were analysed', ' 100 CRC patients used for comparison of the V600E SensiScreen assay, DS and ME-PCR; and 100 MM patients used for comparison between SensiScreen assays (simplex and multiplex) and Cobas. Results', ' Our sensitivity studies gave superimposable results for both simplex and multiplex assays. In plasmids and cell lines experiments, DS had a limit of detection of 10%, ME-PCR of up to 0,5% and SensiScreen of < 0,1%. In 100 CRC cases, we found 7 (7%) BRAF mutated patients by DS, 9 (9%) by ME-PCR and 10 (10%) by SensiScreen. In 100 MM patients, we found 51 (51%) BRAF mutations by Cobas and 55 (55%) by SensiScreen. Simplex and multiplex SensiScreen assays identified the same mutations. Conclusions', ' SensiScreen simplex and multiplex assays are novel, rapid, easy-to-use and highly sensitive methods for BRAF mutation analysis in CRC and in MM. Indeed, it enables the detection of additional BRAF alterations in CRC and MM patients compared with widely used methodologies.']",
        "Doc_id":"ASCO_167916-176",
        "Doc_title":" Novel, simplex and multiplex assays for BRAF mutation detection.",
        "_version_":1606188970912251904},
      {
        "Meeting_name":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "Background":"['Background', ' Predictive biomarkers for response and resistance to immune checkpoint blockade targeting programmed death 1 (PD-1) are incompletely characterized, and the utility of anti-PD-1 therapy for uterine leiomyosarcoma (ULMS) is unknown. Methods', ' A 49 yo woman with ULMS developed rapidly progressive metastatic disease 4 months after R1-resection of the primary tumor and was enrolled on a phase 1b study of pembrolizumab (10 mg/kg every 2 wks) (KEYNOTE-028). Tumor regression at multiple metastatic sites occurred within 2 months. A single pre-existing metastasis increased in size and was resected at 9 months. IHC, whole exome/transcriptome sequencing, and neoantigen analysis was performed on primary pretreatment (preRx) and treatment-resistant tumors (postRx). Results', ' Responsive tumor sites revealed complete pathologic response at time of surgery. Progressive tumor demonstrated viable ULMS. IHC showed tumor cells negative for PD-L1 and positive for PD-L2 both preRx and postRx. Degree of PD-1+ lymphocyte infiltration decreased significantly postRx compared to preRx. PreRx harbored exomic focal MYC amplification, TP53 nonsense mutation, and heterozygous PTEN deletion. PostRx maintained these genomic alterations and acquired a loss-of-function mutation in PTEN that resulted in biallelic PTEN inactivation. PreRx tumor expressed tumor-specific neoantigens (TSNs) that were immunogenic to patient-derived peripheral blood mononuclear cells; expression of TSNs decreased postRx. Conclusions', ' This patient exhibited complete pathologic response to pembrolizumab at all but one metastatic ULMS site. Genomic analysis of the resistant tumor revealed acquired bialllelic PTEN loss - recently implicated in resistance to PD-1 inhibition in melanoma and glioblastoma  reduced infiltration of PD-1+ lymphocytes, and diminished expression of neoantigens. To our knowledge, this is the first report of exceptional response to PD-1 inhibition in ULMS, and highlights biallelic PTEN loss and neoantigen downregulation as potential mechanisms of acquired resistance to immune checkpoint blockade across cancer types.']",
        "Doc_id":"ASCO_166429-176",
        "Doc_title":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "_version_":1606189008174448640},
      {
        "Meeting_name":" Characterization of cell-free circulating tumor DNA in patients with brain metastases.",
        "Background":"['Background', ' Brain metastases are the most common malignant brain tumor and a significant cause of morbidity and mortality. As patients live longer from more effective systemic therapies, they are at increased risk of developing brain metastases. Genetic profiling of tumor tissue allows for targeted therapy, though biopsy of brain metastases is not always feasible. Cell-free circulating tumor DNA (ctDNA) testing carries diagnostic potential for targeted therapy without the need for repeat biopsies, and the ability to rapidly respond to changes in the molecular profile. Methods', ' 37 patients with brain metastases (15 lung, 12 breast, 5 ovarian, 3 renal, 2 melanoma) were tested prospectively with the Guardant360 ctDNA panel at a CLIA-certified, CAP-accredited clinical laboratory. Samples were analyzed for amplifications in 18 genes, single nucleotide variants in 68 genes, and select fusions, rearrangements and indels. Results', ' 29/37 (78.4%) patients tested harbored at least one detectable genomic alteration. The median number of alterations was 3 (range, 1-12). The most frequently detected alterations were in EGFR (19), TP53 (18), APC (6), NF1 (6), PIK3CA(6). The median ctDNA concentration was 0.50% (range, 0.10-43.80%). 11/37 patients had a subsequent test. 4/11 patients were tested within 50 days of initial testing; the median number of new alterations detected was 0.5 (range, 0-1). 7/11 patients were tested greater than 50 days of initial testing; the median number of new alterations detected was 2 (range, 0-4). Conclusions', ' CtDNA testing was able to detect alterations in a majority of patients with brain metastases. An increasing number of alterations were observed with time, suggesting the utility of ctDNA analysis in monitoring changes in tumor biology, response to therapy, and the ability to refine treatment plans with changes in the molecular profile.']",
        "Doc_id":"ASCO_171553-176",
        "Doc_title":" Characterization of cell-free circulating tumor DNA in patients with brain metastases.",
        "_version_":1606189026680766464},
      {
        "Meeting_name":" Loss of imprinting of KCNK9 in breast cancer",
        "Background":"['KCNK9 (TASK-3) encodes a two-pore potassium channel that functions in tumor growth and survival. The potassium channel function is necessary for tumor proliferation and survival, by enhancing resistance to hypoxia and apoptosis. KCNK9 overexpression is observed in melanoma, colorectal cancer, and breast and brain tumors, but with no associated mutations found. Rather, the overexpression is often the apparent result of gene amplification of KCNK9, but any other mechanism that increases expression would presumably have a similar effect on tumorigenesis. This importance of gene dosage and expression levels is particularly relevant, as KCNK9 has been demonstrated to be a maternally expressed imprinted gene, which, in effect, reduces copy number. Monoallelic expression of KCNK9 was originally found in brain tissue, but our work has found that it is also imprinted in breast tissue. Thus, we hypothesized that loss of imprint control would be similar to a gene duplication, increasing the effective copy number, and therefore KCNK9 gene expression. To study the regulation of KCNK9 imprinting in tumors, we have screened for differentially methylated regions that may function as imprint control regions (ICRs), and examined the expression status of KCNK9 in breast tumor samples relative to the methylation state of the putative ICRs. Approximately 40-50% of breast tumor samples analyzed show loss of imprinting, seen as expression of both alleles of an exonic polymorphism. Additionally, loss of methylation at a putative ICR upstream of the transcription start site is observed in combination with loss of imprint regulation. This correlated loss of methylation and imprint control is seen most commonly in tumors of the triple negative subtype - tumors negative for expression of estrogen receptor, progesterone receptor, and HER2/neu. These novel findings regarding KCNK9 imprint regulation and its disruption in a subset of tumors may lead to new approaches in diagnosis and targeted therapy of breast cancer.']",
        "Doc_id":"AACR_2012-4043",
        "Doc_title":" Loss of imprinting of KCNK9 in breast cancer",
        "_version_":1606189038019018752},
      {
        "Meeting_name":" TCR use and cytokine response in PD-1 blockade.",
        "Background":"['Background', '   PD-1 blockade releases effector T-cells in the tumor microenvironment, but little is known on the effects in peripheral blood. We used T cell receptor (TCR) sequencing and multiplex serum cytokine analysis to assess treatment-induced changes and correlation with clinical response.  Methods', '    Patients with metastatic melanoma were administered PD-1 inhibitor pembrolizumab (MK-3475) across three clinical trials at UCLA (NCT01295827, NCT01704287, NCT01866319). Among those consenting to blood collection (UCLA IRB#10-000870), we selected cases with paired samples (baseline and at second dose), yielding 19 responders and 22 non-responders per irRECIST. Peripheral TCRs were sequenced by immunoSEQ assay (Adaptive Biotechnology). Serum cytokines were analyzed by Milliplex 38 Cytokine kit (HCYTMAG-60K-PX38). Mann-Whitney and Wilcox signed-rank tests evaluated group differences and treatment effects.  Results', '    Unlike previous reports with CLTA4 blockade, anti-PD-1 treatment itself did not cause a net expansion in unique TCR repertoire size (p = 0.42). However, post treatment samples in responders had significantly more unique TCRs compared to non-responders (p = 0.022). Fold change in the number of clones comprising the top 25% of total TCR reads, a metric which minimizes noise from rare clonotypes, differed significantly between groups (p = 0.015, MW), showing a net decrease in non-responders but no net change in responders (p = 0.013 vs p = 0.77, WSR).  Among serum cytokines, higher FGF-2 (p < 0.01) and eotaxin (p = 0.04) levels at baseline correlated with response, as did a post treatment decrease in relative levels of IL-8 (p < 0.01), MCP-1 (p < 0.01) and FGF-2 (p = 0.01). Changes in FGF-2 correlated with IL-8 and MCP1 (Spearman rho  = 0.35, p = 0.03 and  = 0.70, p < 0.0001). Among all study patients there was a mean increase in IP-10 (p < 0.001), IL-12.p40, IL-10, and TNF-a (all p < 0.05), and decrease in MDC (p = 0.037).  Conclusions', '    Greater diversity of post-treatment peripheral T-cell repertoire favorably correlates with response to PD-1 inhibition, and differs from the non-specific increase observed with CTLA4 blockade. Of 38 circulating cytokines analyzed, 8 showed treatment induced changes, of which a decrease in FGF-2, MCP1, and IL-8 correlated with response.']",
        "Doc_id":"ASCO_152330-156",
        "Doc_title":" TCR use and cytokine response in PD-1 blockade.",
        "_version_":1606188977976508416},
      {
        "Meeting_name":" Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors.",
        "Background":"['Background', '  Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase and multiple members of the Eph receptor family as well as c-Kit and Ron, based on isolated kinase assays. Golvatinib showed preclinical evidence of anti-tumor activity. This phase 1 study was performed to determine the MTD, safety, PK, PD and preliminary activity of golvatinib.  Methods', '  Patients (pts) with advanced solid tumors, ECOG PS 0-1,  18 years (yrs) and adequate organ function were eligible. Golvatinib was administered orally, once daily (QD), continuously. Blood samples for PK and PD analysis were collected at multiple time-points. Mandatory tumor biopsies for PD analysis were taken pre and post Cycle 1 in an expanded MTD cohort.  Results', '  34 pts (M/F', ' 21/13; median age 63.5yrs [range 32-78]) were treated at 6 dose levels', ' 100, 200, 270, 360, 450 and 400 mg. Tumor types were colorectal (n=15), lung (n=4), renal (n=4), esophageal (n=2), melanoma (n=2) and others (n=7). Three DLTs were observed', ' Gr3 GGT and alkaline phosphatase (n=1; 200mg) and repeated Gr2 (n=1) and Gr3 (n=1) fatigue, both at 450mg. The MTD was determined to be 400 mg QD. Frequently occurring adverse events ([AEs]; all grades) were fatigue', ' 68% (Gr3', ' 15%), diarrhea', ' 65%, nausea', ' 62%, vomiting', ' 53%, decreased appetite', ' 47% (Gr3', ' 9%), ALT increase', ' 38% and AST increase', ' 23%. No Gr4 AEs were observed. Best response was stable disease in 6 pts lasting >84 days. PK showed high variability and plasma concentration increased with dose. The Cmax was reached within a median time of 4 hours. Plasma PD analysis showed an increase in soluble c-Met and Ang 2 levels after golvatinib treatment. Tumor PD analysis in 5 pts  at 400 mg demonstrated a baseline elevated MET  gene copy number, with c-Met overexpression and post treatment decline in phospho(p)-c-Met expression in 1 pt; post-treatment decline in p-c-Met in a 2nd pt,  and post-treatment decline in p-ERK in a 3rd pt.  Conclusions', '  Golvatinib at an MTD of 400 mg QD has manageable toxicity. Preliminary PD analysis demonstrated evidence of c-Met target modulation. Further evaluation will continue in phase 2 combination studies.']",
        "Doc_id":"ASCO_97955-114",
        "Doc_title":" Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors.",
        "_version_":1606188978349801472},
      {
        "Meeting_name":" Cancer MET at the metastatic lesion preserves the malignant features acquired via EMT.",
        "Background":"['Purpose', ' Cancer EMT is one of the mechanisms to acquire malignant features including invasiveness, drug resistance and stemness. However, the subsequent mechanism after EMT toward progression has not been fully understood yet. Based on the EMT-centered theory, it is simply thought that the reversal event of EMT, MET,\" is caused in the tumor cells at the distant metastatic lesions. However, the molecular mechanism still remains unclear. In this study, we attempted to clarify the post-EMT mechanism in tumor cells.Results', ' Firstly, we prepared tumor cells harvested from metastatic lesions of mice after tumor implantation provisionally as post-EMT tumor cells. Murine metastatic melanoma B16-F10 cells were transduced with a neo resistant gene, and were subcutaneously (s.c.) implanted in many C57BL/6 mice to obtain spontaneous tumor metastasis. Three weeks later, various tissues including bone marrow were harvested from the mice, and the single-cell suspensions were cultured in G418-supplemented medium for tumor selection. To characterize the post-EMT tumor cells, RT-PCR, immunostaining and cellular functional assay were conducted. As compared to the primary tumor cells harvested from s.c. tumor tissues, these tumor cells proliferated extremely slowly, and were resistant to chemotherapeutics, but rapidly grew in vivo after implantation. However, these tumor cells were very adhesive accompanied by increase of epithelial markers such as E-cadherin, but not mesenchymal markers such as Snail, indicating epithelial features. In addition, its chemoresistance and in vivo tumorgenesis activity of these tumor cells were superior to those of even Snail-transduced B16-F10 tumor cells, which were harvested from the metastatic lesions in a similar way. DNA microarray analysis revealed the significant upregulation of epithelial markers and drug resistant genes such as c-kit and GDF15 in the post-EMT tumor cells, as compared to those of the Snail transfectant. These imply that MET may not be just a reversion of EMT.Conclusions', ' These results suggest that tumor cells revert into an epithelial state preserving malignant features acquired via EMT even after Snail lost at the metastatic lesions toward progression. We are now attempting to elucidate the molecular mechanism specific for the unique transition utilizing DNA microarray data.']",
        "Doc_id":"AACR_2013-283",
        "Doc_title":" Cancer MET at the metastatic lesion preserves the malignant features acquired via EMT.",
        "_version_":1606188981760819201},
      {
        "Meeting_name":" Melapred",
        "Background":"['Background', ' Melanoma (MM) has a dramatically poor prognosis in case of late diagnosis, emphasizing the critical role of early detection and prevention. We have developed a predictive algorithm calculating an individualized mm risk by combining clinical and genetic factors (test Melapred). We evaluated the acceptability of this test in a pilot study of patients seen in dermatology at hospital or in liberal exercise. Methods', ' The Melapred test allows the custom calculation of a personnalized mm risk score using an algorithm incorporating clinical risk factors and genetic mm risk factors. From April to October 2014, 261 patients were proposed to have the Melapred test, and results were given during a second clinical consultation, with explanations provided on the impact of the test result on clinical management and behaviour towards UV exposure. A survey was given to the patients, evaluating the service and potential impact of the Melapred test result. A questionnaire to physicians was also performed evaluating the usefulness of Melapred for high-risk mm patients in their daily exercise. An agreement of the local ethic committee has been obtained. Clinical data were collected on data sheet, and salivary DNA was collected by Oragene kit after information, signature and informed consent. Results', ' The Melapred test classified 64% of patients at high risk, 26% of patients at intermediate risk and 10% at low risk. The survey for the first 163 patients showed a positive evaluation with perception of its usefulness (90%), a clear desire to follow the recommendations of the physicians and to adapte their UV exposition to their mm score, a lack of anxiety generated by pending the result of the test. The physicians also had a very good evaluation of the test in terms of easy logistic, and help to survey and monitoring their patients. Therefore, the Melapred test is very well received and considered useful by patients and physicians, and is not cause of concern. Conclusions', ' Melapred test is well accepted and perceived by patients and physicians. Indications are the identification of high-risk patients and improved screening. Melapred is commercialized since july 2015 (www.melapred.com) under dermatogical prescription.']",
        "Doc_id":"ASCO_165975-176",
        "Doc_title":" Melapred",
        "_version_":1606189013294645248},
      {
        "Meeting_name":" A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).",
        "Background":"['Background', '  Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFR. In phase I studies of lenvatinib partial responses (PR) were observed in thyroid as well as melanoma, endometrial, and renal cancers.   Methods', '  Patients (pts) with unresectable MTC and disease progression demonstrated by RECIST during the prior 12 months were enrolled.  Pts may have received prior VEGFR targeted therapy.  Pts were treated with a starting dose of lenvatinib 24 mg once daily in 28 day cycles until disease progression or development of unmanageable toxicities.  Primary end point was Response Rate (RR) by RECIST. Tumor genetic analysis and circulating cytokine and angiogenic factors (CAF) analysis were performed.  Results', '  59 pts were enrolled (med age', ' 52; Male', ' 63%;) and are evaluable for response.  54% of pts required dose reduction for management of toxicity, and 22% were withdrawn from therapy due to toxicity.  The most common treatment-related adverse events were proteinuria 58% (Gr3', ' 2%), diarrhea 56% (Gr3', ' 5%), hypertension 48% (Gr3', ' 7%), fatigue 44% (Gr3', ' 5%), decreased appetite 41% (Gr3', ' 5%), nausea 34% (Gr3', ' 0), and weight decreased 32% (Gr3', ' 3%).  No Gr4 events were reported for these event categories. Confirmed PRs were observed in 21pts (RR', ' 36%, 95% CI', ' 24-49) based on independent imaging review (IIR) and 29 pts (RR', ' 49%, 95% CI', ' 36-62) based on investigator assessment.  For pts who received prior VEGFR-directed treatment (n=26) RR=35% (IIR); with no prior VEGFR-directed treatment (n=33) RR=36 % (IIR).  Median PFS by IRR is 9.0 mo (95% CI', ' 7.0-) (based on minimum 8 mo. f/u, 46% events observed).    There was no clear difference in treatment response between RET-mutant (RET-mu) and RET-wild type (RET-wt) patients. Low baseline levels of ANG2, sTie-2, HGF and IL-8 were associated with greater tumor shrinkage and prolonged PFS whereas high baseline levels of VEGF and sVEGFR3 were associated with greater tumor shrinkage.    Conclusions', '  Lenvatinib administered orally at a dose of 24 mg once daily to patients with MTC is associated with manageable toxicity and a RR of 36%, identifying lenvatinib as a promising new potential therapeutic agent for treating patients affected with this disease.']",
        "Doc_id":"ASCO_100784-114",
        "Doc_title":" A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).",
        "_version_":1606189041649188864},
      {
        "Meeting_name":" Sensitive detection of BRAF V600E mutation by bridged nucleic acid (BNA)-mediate real-time PCR assay",
        "Background":"['BRAF is a human gene encoding a serine/threonine protein kinase in the RAS-RAF-MEK-ERK signal pathway, which is important in regulating cellular responses to extracellular signals. Frequent mutations on BRAF gene have been detected in various types of human cancer, including malignant melanoma, non-small cell lung cancer, colorectal cancer, papillary carcinoma of the thyroid, ovarian cancer and hairy cell leukemia. Among all, a single point 1799T>A (V600E) transversion, the most common mutation on BRAF, results in increased kinase activity. It serves as a driver mutation in several types of cancer and confers increased sensitivity to tyrosine kinase inhibitors. Thus, detecting the BRAF V600E mutation may offer valuable information for cancer diagnosis, treatment selection, and prognosis. Here we report a rapid, highly sensitive method for the detection of BRAF V600 mutation using a bridged nucleic acid (BNA) clamp technology associated with quantitative PCR (qPCR). Due to the feature of enhanced affinity for hybridization template, BNA clamp is able to selectively block PCR reactions on the perfect match DNA sequence, while leaves the mismatch template unaffected. In this study several BNA clamps that bind to BRAF V600 wild-type (WT) template was designed, synthesized, and characterized. As compared to DNA clamp counterparts, these BNA clamps increased Tm values for the BRAF V600 WT by greater than 30C. In addition, BNA clamps efficiently distinguished BRAF WT (perfect match) from V600E (mismatch) templates (deltaTm >12C). In qPCR assays BNA clamps could suppress amplification of WT by >1,000-fold, while had little or no effects on the V600E mutant. Such BNA clamps allowed us to detect 1.0% or lower levels for the BRAF V600E mutant in a wild-type background. These results indicate that BNA clamp-based qPCR technology offers a new tool for rapid, sensitive detection of BRAF V600E mutation. The technology may be adapted for detection of mutations of a variety of biomarker genes.']",
        "Doc_id":"AACR_2016-411",
        "Doc_title":" Sensitive detection of BRAF V600E mutation by bridged nucleic acid (BNA)-mediate real-time PCR assay",
        "_version_":1606189002639015936},
      {
        "Meeting_name":" In vivo circulating tumor cells in blood, lymph and cerebrospinal fluid",
        "Background":"[\"We introduced a new platform of multicolor multi-fluid in vivo flow cytometry for real-time ultrasensitive molecular detection and counting of circulating tumor cells (CTCs) and their subpopulations the blood, lymph and cerebrospinal fluid's (CSF) flows. To achieve these goals we integrated multicolor photoacoustic (PA), photothermal (PT) and fluorescent flow cytometry, and combined this technical platform with multiplex molecular targeting strategy using low-toxicity, gold-based functionalized nanoparticles as PA/PT high-contrast agents or genetically encoded proteins (e.g., green fluorescent protein [GFP]) as fluorescent labels. This platform can provide also label-free detection mode using intrinsic (e.g., melanin) molecular labels. The advantages of this new generation of flow cytometries are (1) improving sensitivity by at least a two-order of magnitude compared to available CTC-assays, and (2) significantly extending biomedical applications compared to existing in vivo flow cytometries.Using preclinical tumor-bearing mouse models of metastatic melanoma and breast cancer, and spiked human blood samples, we demonstrated that our technology can overcome great challenge in cancer research related to monitoring lymph, CSF and blood CTCs at single-cell levels in the natural environment in vivo over the long-term period of metastatic disease development from an early micrometastatic stage to deadly multiple macro-metastases. The obtained results allowed us to estimate in vivo cross-correlations between lymph, CSF and blood CTC counts, size of primary tumor and metastasis (micrometastasis) progression. We also showed that the presented approach can break some important diagnostic limitations of existing methods (e.g., low sensitivity) and potentially permits prevention, or at least inhibition, of metastatic progression. Taking into account the safe nature of the PA technology, we anticipate its quick translation for use in humans.Citation Format\", ' Ekaterina I. Galanzha. In vivo circulating tumor cells in blood, lymph and cerebrospinal fluid', ' dynamic cross-correlations and amplification for cancer diagnosis. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 1455. doi', '10.1158/1538-7445.AM2013-1455']",
        "Doc_id":"AACR_2013-1455",
        "Doc_title":" In vivo circulating tumor cells in blood, lymph and cerebrospinal fluid",
        "_version_":1606189003654037504},
      {
        "Meeting_name":" Comprehensive analysis of potential immunotherapy genomic biomarkers by profiling paired tumor/normal exome of 1,000 Chinese cancer patients.",
        "Background":"['Background', ' With the broadening landscape of immunotherapy use, it is important to identify patients who are likely to benefit from the therapy. We reported the comprehensive analyses of potential predictive biomarkers for PD1/PD-L1 inhibitors based on Chinese patients exome profiling data. Methods', ' Over 1,000 cancer patients from 70 hospitals across 20 provinces in China were recruited and the whole exome of tumor/normal samples of each patient were sequenced. Four potential genomic biomarkers', ' tumor mutation burden (TMB), mismatch repair deficiency (MMR), microsatellite instability (MSI), and PD-L1 (CD274) amplification (PD-L1 AMP) were analyzed in this Chinese cohort and compared with the mainly Caucasian cohort in TCGA database. Results', ' At least one of the four preselected genomic biomarkers was identified in 40.8% of this Chinese cancer patient cohort by clinical whole exome sequencing (CWES) analysis. Similar to TCGA cohort, the top 3 high TMB tumor types are lung, esophagus and colorectal cancer. Chinese hepatocellular carcinoma (HCC) patients showed higher TMB than the TCGA cohort (Median', ' 106 vs. 65 non-synonymous mutations per tumor NMT), which might be due to different etiologies. Five late stage cancer patients (3 lung, 1 melanoma and 1 gallbladder) using PD1/PD-L1 blockade with high TMB showed durable clinical benefit (SD6months/PR/CR). Comparing with TCGA data, Chinese colorectal cancer cohort (252 patients) had relative lower MSI-high or MMR related mutations (8.33% vs. 12.5%, and 3.97% vs. 10.0% respectively). PD-L1 AMP most frequently occurred in lung squamous (14.3% VS 9.8% TCGA), HER2-positive breast cancer (8.8% VS 6.8% TCGA with unknown HER2 status) and sarcoma (6.0% VS 9.4%TCGA). One Chinese renal cell carcinoma patient with PD-L1 AMP received anti-PD-1 treatment and on-going PFS is 7 months by far. Conclusions', ' Our CWES analysis and limited clinical follow-up observations suggested that about 40% Chinese cancer patients had at least one of the 4 potential immunotherapy predictive biomarker mutations. Long-term follow-up is needed to verify the validity of those markers.']",
        "Doc_id":"ASCO_188568-199",
        "Doc_title":" Comprehensive analysis of potential immunotherapy genomic biomarkers by profiling paired tumor/normal exome of 1,000 Chinese cancer patients.",
        "_version_":1606189031886946304},
      {
        "Meeting_name":" Whole-exome sequencing analysis across 23 histotypes of patient-derived tumor xenografts reveals their similarities with TCGA patient tumors",
        "Background":"['Cell lines insufficiently recapitulate the genomic structure and diversity of its parent tumor. Consequently, results from in-vitro experiments can often not be reproduced in the clinic. In contrast, patient derived xenograft models (PDX) more closely mimic the molecular characteristics of patient tumors. In the present study, we analyzed a large part of our collection of patient derived xenografts by means of whole-exome sequencing (WES) to investigate whether their genomic alterations were consistent with those observed in patient tumors from The Cancer Genome Atlas (TCGA).Exonic regions from 268 Oncotest PDX were targeted using Agilent SureSelect Human all exon kits 38MB or 51MB. Enriched genomic DNA was sequenced with Illumina HiSeq2000 in 100bp paired-end (PE) reads with expected mean coverage of 100X. The WES data was analyzed for concordance with a) Sanger and Sequenom OncoCarta panels b) patient tumor mutational signatures described by Alexandrov et al. (Nature 2013) and c) gene mutation frequencies from publically available data of TCGA tumors.In the present study, we show that most of the mutations previously determined by Sequenom or Sanger sequencing were also detected by WES analyses. The mutations in our models were distributed as follows', ' 86% non-synonymous SNVs, 8% small indels (1 nucleotide), 3% splicing site and 3% start/stop gains or losses. The number and the type of mutations varied significantly across tumor types. Similar to the findings of Alexandrov et al., who analyzed TCGA tumors, most of our PDX were characterized by [C>T] transitions that correlated with the patient age. High mutation rates were observed in tissues typically exposed to mutagens, such as melanomas (UV radiation) or lung PDX (tobacco smoke), associated with specific mutation signatures such as increased rates of [C>T] or [C>A] mutations, respectively.Furthermore, we found an association between the presence of mutations in DNA repair genes such as MLH1 and increased mutation levels in some tumor types including colon, gastric and pancreatic cancer. Interestingly, in PDX with high mutation levels, frameshift mutations were increased two-fold, and represented 14% of all mutations. Analyzing our PDX gene mutation profiles and those of the TCGA dataset revealed comparable gene alteration patterns across the tumor types, with some exceptions possibly attributed to the enrichment of aggressive tumors in our collection.This study demonstrates that our PDX tumor collection shows typical signatures of mutational processes and gene alteration patterns similar to patient tumors of the TCGA database. These results confirm the relevance of using PDX models to evaluate anticancer agents in preclinical settings.']",
        "Doc_id":"AACR_2014-1203",
        "Doc_title":" Whole-exome sequencing analysis across 23 histotypes of patient-derived tumor xenografts reveals their similarities with TCGA patient tumors",
        "_version_":1606188988556640256},
      {
        "Meeting_name":" Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs).",
        "Background":"['Background', ' S is a tyrosine kinase inhibitor (TKI) of PDGFR, VEGFR and KIT. As combinations of VEGFR-TKI with cytotoxic therapy are promising, this phase I study aimed to determine the recommended phase II dose (RP2D) of S in combination with 2 different I schedules. Methods', ' Pts with progressive STs, good PS, organ function, and no standard therapy available, were eligible. I (3 g/m2/day, 72h CIV (I*3), every 3 wks) was combined with continuous S. S was started at 12.5 mg/day and to be escalated in serial cohorts of 3-6 pts. RP2D was exceeded if  1/3 pts experienced dose-limiting toxicity (DLT) within the 1st cycle. After establishing the RP2D of S with I*3, feasibility of this S dose with I at 1.2 g/m2/day for 5 days CIV (I*5) every 3 wks was assessed without further scheduled dose-escalation. At RP2D, additional patients were enrolled to assess PK. Circulating endothelial cells (CECs) were measured prior to the 1st, 3rd and 6th cycle. Results', ' 26 pts (36-68 yrs) were accrued. 12.5 mg S was not feasible with I*3 due to neutropenia > 7 days in 2/6 pts. After protocol amendment, pegfilgrastim 6 mg (P) was given to all subsequent patients after each I-cycle. Using P, the RP2D was I*3 plus 12.5 mg S (in 1/9 pts DLT', ' febrile neutropenia), while I*3 plus 25 mg S was not feasible due to febrile neutropenia in 2/5 pts and hypertension & cardiac chest pain in 1/5 pts. 12.5 mg S was also feasible using I*5 as 1/6 pts had a DLT', ' encephalopathy. Most frequent drug related adverse events (all grades/grade 3-4) were', ' neutropenia (77%/62%), thrombocytopenia (73%/31%), elevated transaminases (65%/0%), renal (42%/4%), nausea (77%/0%), vomiting (58%/0%) and alopecia (62%/0%). 4/22 pts evaluable for response had PR', ' 1 CUP, 1 small cell carcinoma (SCC) and 2 sarcoma pts. 7 pts had SD for  3 months', ' 1 CUP, 1 uveal melanoma, 1 SCC, and 4 sarcoma pts. The AUC ratio of I and its metabolites in cycles I*3 without versus with S ranged from 0.72 to 1.36. No consistent change in the number of CECs during treatment was observed. Conclusions', ' S at 12.5 mg/day with I*3 or I*5 every 3 weeks supported by P is tolerable in pts with advanced STs. S does not affect I-PK. Antitumor activity was observed in pts with diverse tumor entities including sarcoma.']",
        "Doc_id":"ASCO_30415-65",
        "Doc_title":" Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs).",
        "_version_":1606189005536231425},
      {
        "Meeting_name":" Implementing an automated clinical next generation sequencing analysis pipeline - assuring accurate and robust results.",
        "Background":"['Introduction', ' There is unmet clinical need for automated data processing of deep sequencing in heterogeneous sample populations in molecular oncology specimens. We have developed clinical assays using Next Generation Sequencing (NGS) for deep sequencing in both solid tumor and hematological indications. We have targeted five genes (ASXL1, RUNX1, EZH2, ETV6, and TP53) involved in myelodysplastic syndrome (MDS) and three genes (BRAF, c-KIT, NRAS) in late stage melanoma. We designed and implemented a data processing pipeline that integrates novel and commercial analysis software to provide automated rules-based filtering and annotation of variants.Methods', ' We used a targeted resequencing approach with the Fluidigm Access Array system for library creation and molecular barcoding for sample multiplexing. Samples were processed in duplicate to filter out potential false positives. Libraries were sequenced using the Ion Torrent Personal Genome Machine (PGM) (Life Technologies, Carlsbad, CA) and the Illumina MiSeq (Illumina Inc., San Diego, CA) systems. Raw data in FastQ format was preprocessed using Windows batch commands and Perl programs that were integrated with NextGENe (SoftGenetics, State College, PA) analysis software for quality trimming, alignment and variant calling against NCBI curated references. Variant calls were compared between duplicate samples and annotated using a separate Perl program that queried databases containing known germline and somatic variants.Results', ' Quality control was implemented by trimming all downstream reads that contained specified Q-scores (Phred, Q16 or above) as well as requiring a minimum coverage depth of 500X per exon. Only variant calls confirmed at greater than 5% in both duplicate samples and with a balanced ratio of forward and reverse reads were considered reportable in a clinical setting. Variants appearing in only one of the duplicates were consistent with systematic errors. Variant calls were annotated with existing database information or were saved in a database of novel mutations by the annotation pipeline. The pipeline removes all systematic errors in known cell line samples by filtering metrics.Conclusions', ' We have developed a robust and automated pipeline for NGS data analysis in the clinical lab that is independent of sequencing platform. The implementation of an automated processing pipeline increases the efficiency and consistency of analysis. Hands-on time for data analysis has been decreased from 30 minutes per sample to less than 5 minutes per sample. Carrying duplicates through the entire multiplexing and sequencing process also helps reduce test based false-positive errors (e.g. PCR errors) while robust analytical metrics remove other sources of error (e.g. strand bias). We have found an average of 6-10 false positive calls in both sample types, all of which were filtered out by the pipeline presented here.']",
        "Doc_id":"AACR_2013-5137",
        "Doc_title":" Implementing an automated clinical next generation sequencing analysis pipeline - assuring accurate and robust results.",
        "_version_":1606189041938595840},
      {
        "Meeting_name":" DNA methylation in SYK, GSTP1, & FHIT genes",
        "Background":"['Introduction', ' Breast cancer risk is transiently increased following pregnancy; these tumors, referred to as pregnancy associated breast cancer (PABC) have poorer prognosis. As more women delay pregnancy until older age this increase in risk following pregnancy is projected to mean increased numbers of PABCs. Epigenetic events are important in the development and progression of cancer. Methylation status of specific genes may potentially be useful as screening targets in clinical practice. We examined DNA methylation for three genes of interest, Spleen tyrosine kinase (SYK), a non-receptor protein tyrosine kinase expressed in hematopoietic and non-hematopoietic breast epithelial cells, exhibiting tumor suppressor qualities, Fragile histadine triad (FHIT), encoding a protein involved in cell differentiation and apoptosis, and Glutathione S-transferase P1 (GSTP1), a phase II detoxification enzyme in most cell types acting on carcinogens, environmental pollutants, and drugs. We compared DNA methylation in these genes in breast tissues from healthy premenopausal women by parity status and time since last birth (nulliparous, <5 years, >10 years) to understand changes in methylation associated with recent pregnancy.Methods', ' DNA samples were obtained from fresh frozen tissues of 81 premenopausal women undergoing reduction mammoplasty with no prior history of cancer except non-melanoma skin cancer. Genomic DNA was modified using EZ DNA Methylation Gold Kit and sequenced using Pyro Q-CpGTM Software. Two-sample t-tests and 1-way Analysis of Variance were used to examine differences in mean methylation in the three genes by parity status and time since last birth. Generalized linear regression models were used to compare mean methylation levels adjusted for age, race, menopausal status, and family history of breast cancer.Results', ' Parous healthy premenopausal women had a higher adjusted mean methylation in all three genes than their nulliparous counterparts. Mean percent methylation of SYK (0.98 vs. 0.87; P=0.56) and FHIT (2.08 vs. 1.85, P=0.50) were 12% higher in parous versus nulliparous women. Methylation of GSTP1 was 7% higher among parous versus nulliparous women (0.70 vs. 0.65; P=0.82); however, differences were not statistically significant. For GSTP1, there was a suggestion of higher mean percent methylation among women who gave birth more recently (<5 years', ' 0.93) versus births in the more distant past (>10 years', ' 0.64) or nulliparous women (0.69; P=0.64). There were no clear differences by recency of birth for FHIT or SYK.Conclusions', ' Mean percent methylation of SYK, GSTP1, and FHIT may be suggestive of changes in methylation among parous women, and for GSTP1, particularly higher DNA methylation among women who gave birth more recently. Given the small sample size, these findings are preliminary, and additional studies are needed to better understand methylation in PABC risk.']",
        "Doc_id":"AACR_2013-3639",
        "Doc_title":" DNA methylation in SYK, GSTP1, & FHIT genes",
        "_version_":1606189042083299328},
      {
        "Meeting_name":" Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)",
        "Background":"['Cancer is a heterogeneous disease with various molecular lesions and drug response profiles within the same tumor type. Patient stratification in clinical trials based on molecular features has contributed to recent success of several targeted cancer drugs on molecular aberrations such as BCR-ABL translocation in CML, Her2 amplification in breast and gastric cancers, EGFR mutations and ALK fusions in lung cancer and BRAF mutation in melanoma. However, in most cancers, the molecular features which can be used for patient stratification are not as simple as a single genetic aberration. Multiple drug resistance mechanisms caused by various mutations in cancer signaling pathways can also increase the uncertainty of clinical outcomes.To increase the chance of success in human clinical studies, patient-derived xenograft (PDX) clinical trials (PCTs) have increasingly been used for predictive biomarker validation, resistance mechanism investigation and combination therapy selection. PDX tumor models have been demonstrated to have high correlations with human patients in tumor pathology, molecular characteristics and drug responses. Large scale PCTs have also shown consistency in results when compared to related human clinical trials.At GenenDesign, we have established over 1000 PDX tumor models and more than 100 resistance models against various cancer drugs. Many of these PDX models have been characterized at RNA/Exome sequence, gene expression, gene copy number and hot-spot mutation levels. We carried out our PDX clinical trials by testing multiple approved drugs and clinical drug candidates such as targeted inhibitors against FGFRs, c-Met/ALK, HER2, EGFR, cell cycle regulators, Ras/Raf pathway, PI3K/Akt pathway, as well as chemotherapy drugs in biomarker-driven multi-drug multi-arm expanded PDX clinical trials. So far, we have accumulated more than 3000 efficacy data sets and associated PD samples.Analysis of drug response and associated genomic information from PDX clinical trials yielded rich information for predictive biomarker identification and validation. At the same time, many potential resistance mechanisms were also revealed. These information can make human clinical trial better prepared, more efficient and focused. More importantly, testing of a targeted drug with multiple chemotherapies in the same models can also provide guidance on future combination selection strategy.']",
        "Doc_id":"AACR_2016-395",
        "Doc_title":" Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)",
        "_version_":1606188982216949760},
      {
        "Meeting_name":" The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study",
        "Background":"['Background', ' The dual targeting strategy involving PI3K and MAPK pathways is compelling, as it has become increasingly clear that both pathways are interconnected. Nevertheless, the clinical impact of this strategy remains uncertain. Methods', ' A pooled analysis of advanced cancer patients (pts) treated with phase I study drugs targeting PI3K/MAPK pathways from 06/07 to 11/10 was conducted. Pts treated with either single pathway inhibition (S) or dual pathway inhibition (D) were evaluated for safety, efficacy, and correlations between tumor genetic alterations and response. Response was assessed by using waterfall plot analysis (WPA) which included both average enlargement in tumor burden (AETB) and median enlargement in tumor burden (METB). Tumor genetic alterations were analyzed using DNA array-based CGH/PCR-based DNA sequencing. Results', ' A total of 225 pts in 11 first-in-human phase I clinical trials were analyzed; 66 pts (30%) received D, while 122 (54%) and 37 (16%) received inhibitors of either PI3K or MAPK pathways (S); 159 (71%) had measurable disease. The rates of drug-related grade 3/4 adverse events (AEs) were 17% (28/159) for S and 46% (30/66) for D (p<0.0001); rates of DLTs were 10% (16/159) for S and 17% (11/66) for D (p=0.17). The most frequent grade 3/4 AEs were rash and transaminase elevation. WPA displayed AETB(%) / METB(%)', ' 21/17(S) and 13/14(D). Ninety-two of the 225 (41%) pts had available tumor genomic profiling data. PI3K pathway genetic alterations were detected in 17 of the 92 pts (18%; PTEN deletion, n=11; Akt2 amplification, n=5; PIK3CA mutation, n=1). Nine of the 17 (53%) pts with PI3K pathway genetic alterations had simultaneous KRAS or BRAF mutations (colorectal, n=8; melanoma, n=1). Of these 9 pts, all 5 pts who treated with D had tumor regression ranging from -2% to -64%. Conclusions', ' These preliminary results suggest that D of PI3K/MAPK pathways exhibits favorable efficacy compared to S of either pathway, at the expense of higher rates of Gr 3/4 AEs. This strategy may be especially important in pts with coexisting PI3K pathway genetic alterations and KRAS/BRAF mutations. Validation in the context of larger studies is recommended.']",
        "Doc_id":"ASCO_78544-102",
        "Doc_title":" The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study",
        "_version_":1606188987544764416},
      {
        "Meeting_name":" Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma",
        "Background":"['Background', '  The combination of dabrafenib (D) and trametinib (T) has demonstrated clinical responses in a subset of metastatic melanoma (MM) patients (pts) with BRAF V600 mutations after progression on BRAF inhibitor (BRAFi) monotherapy. We conducted a phase II study to identify clinical and molecular markers that predict response to D+T combination treatment in these pts.  Methods', '  MM pts with BRAF V600 mutations that had progressed after BRAFi monotherapy were treated with D (150 mg twice daily) and T (2 mg daily). Treatment response was assessed by RECIST v1.1 every 2 cycles (8wks). Tumor samples were collected prior to starting D+T and were analyzed by next generation sequencing (NGS) for mutations, RT-PCR for BRAF splicing, and by IHC. Blood samples were collected at baseline (BL), C1D8, C1D15, C2D1, C4D1, and off-study. Level of mutant BRAF RNA in circulating tumor cells isolated with peripheral blood mononuclear cells was assessed by RT-PCR.   Results', '  Twenty pts were evaluable for response. The overall response rate was 10%, disease control rate (DCR) was 45%, and median progression free survival (PFS) was 13 wks. PFS and DCR did not correlate significantly with age, gender, LDH, or stage. Pts with duration of prior BRAFi monotherapy > 6 months had better PFS (median 16 vs 8 wks, HR 0.29, p = 0.01) and DCR (73% vs. 11%, OR 21.3, p = 0.015). NGS and RT-PCR analysis on tumors with sufficient material for both analyses (n = 15) identified 5 pts (33%) with molecular changes predicted to reactivate the MAPK pathway (2 NRAS mutations, 2 BRAF amplifications, 2 BRAF splice variants, 1 MAP2K1 mutation). There was no significant difference in PFS (p = 0.36) or DCR (p = 0.73) between pts with and without such molecular events. Decreases in circulating BRAF V600 were detected by C1D8 in pts who achieved disease control (p = 0.06) or PFS > 13 wks (p = 0.06) compared to pts who did not.   Conclusions', ' In pts who have progressed on BRAFi monotherapy, clinical benefit from D+T correlates with duration of prior BRAFi therapy, but not the presence of resistance mechanisms in the MAPK pathway. Changes in levels of circulating mutant BRAF may be an early predictor of clinical benefit. Clinical trial information', ' NCT01619774']",
        "Doc_id":"ASCO_148111-156",
        "Doc_title":" Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma",
        "_version_":1606188989977460736},
      {
        "Meeting_name":" Genotype concordance between archival tumor DNA (atDNA) and circulating tumor DNA (ctDNA) in advanced solid malignancies",
        "Background":"['Background', ' ctDNA is a potentially superior means of classifying tumor genotype but predictors of Con with atDNA are not well established. We conducted a prospective multicenter study to determine the feasibility of atDNA genotyping on a Next-Generation Sequencing (NSG) platform and ctDNA genotyping among patients with advanced solid malignancies. ctDNA genotyping was concurrently performed and variables associated with Con were investigated. Methods', ' Patients at 5 BC Cancer Agency Centers were enrolled over 14 months. atDNA genotype was performed using NSG and high-throughput multiplex amplification of a 27 gene panel (Raindance). ctDNA genotyping was done with Boreal Genomics OnTarget on 4cc plasma from blood collected in Streck tubes processed within 96 hours. Con was determined in clinical gene subsets for Colorectal (CR) (KRAS, NRAS, BRAF), Lung (L) (EGFR, KRAS) and Melanoma (M)(BRAF). Results', ' Of 300 patients, tumor origin was CR (46%), L (28%), M (M) (7.7%), and Other (18%). The number of metastatic sites was 1 in 39% and >1 in 54% and 64% had resected primary tumors. 50% of patients had received systemic or radiation therapy within 3 months (median 18 d of ctDNA) and 48% had 1 elevated tumor marker. In multivariate analysis, higher Con was seen in CR compared to L (OR 2.5; 95%CI 1.2, 5.2) and when time between atDNA and ctDNA was 1 year versus >1 year (OR 2.4; 95%CI 1.03, 5.5). Con was not affected by # or type of metastasis, receipt of prior therapy, resection of the primary tumor or elevated tumour marker. ctDNA analysis was completed on the initial 181 cases. Conclusions', ' Concordance between atDNA and ctDNA was lower in L cancer and higher concordance was associated with shorter time interval between surgical and liquid biopsy. It was not associated with extent of metastatic disease and other measured variables. Discordance was more frequently related to variants not found in ctDNA. Updated results for the full cohort will be presented. Clinical trial information', ' NCT02171286ColorectalLungMelanomap-valueKRASNRASBRAFEGFRKRASBRAFConcordance77%94%91%74%75%79%+ atDNA - ctDNA17%0%5%24%14%21%- atDNA +ctDNA6%6%4%2%11%0%Overall Concordance59/83 (71%)30/57 (53%)11/14 (79%)0.043']",
        "Doc_id":"ASCO_165717-176",
        "Doc_title":" Genotype concordance between archival tumor DNA (atDNA) and circulating tumor DNA (ctDNA) in advanced solid malignancies",
        "_version_":1606188994985459712},
      {
        "Meeting_name":" Detection of IFN induced PDL1 expression by combined in situ RNA analysis and protein profiling from a single FFPE slide",
        "Background":"['PD1 ligands (PDL1) are often upregulated on the cell surface of many different tumors. The primary role of PDL1 in cancer is to inhibit T-cell mediated immune response. Two general mechanisms for PDL1 expression on tumor cells have been proposed. Innate immune resistance, in which PDL1 expression is induced by the constitutive oncogenic signaling, and adaptive immune resistance, in which PDL1 expression is induced by T-cells releasing interferon- (IFN) and activating the STAT signaling pathway. In order to differentiate between these two mechanisms, IFN mRNA expression is measured as an effective alternative to detecting IFN protein. Detection of cytokines by IHC is challenging as secreted proteins are widely diffused and the associated staining pattern appears to lack cellular specificity. RNAscope RNA in situ hybridization (ISH) assay is utilized to measure Interferon- (IFN) mRNA expression, and MultiOmyxTM multiplexed assay (demonstrated to stain up to 60 protein biomarkers) is utilized to measure CD3, CD4, CD8, CD56, CD68, PD1, and PDL1 protein expression. In this study, combined MO and RNAscope ISH assays, enabled identification of individual cells with characteristic mRNA and protein expression profile.The MultiOmyx assay utilizes a pair of directly conjugated Cyanine dye-labeled (Cy3, Cy5) antibodies per round of staining. Each Cy-dye conjugated antibody recognizes different target proteins. Each round of staining is imaged and followed by novel dye inactivation chemistry, enabling repeated rounds of staining. RNAscope is a novel RNA ISH assay capable of single-molecule detection in individual cells, utilizing hybridization mediated signal amplification. The assay utilizes a pair of RNA target specific oligonucleotide probes, which sequentially hybridize to preamplifier, amplifier, and fluorophore label probes.Utilizing MultiOmyx and RNAscope assays, this study proposed to profile both RNA and protein expression in lung, breast, melanoma, colorectal, esophageal, and prostate cancer samples.Differentiating PDL1 expression induced in response to inflammatory signals produced by an activated T-cell, from PDL1 expression induced by constitutive oncogenic signaling, has potential implications in effectiveness of PD1 blockade therapy. According to the proposed mechanisms, PD1 blockade as a mono therapy may only benefit individuals with strong endogenous immune response. In individuals with weak endogenous immune response, combinational therapies consisting of both immune activation and PD1-pathway blockade may be more effective than either mono therapy alone.']",
        "Doc_id":"AACR_2016-5135",
        "Doc_title":" Detection of IFN induced PDL1 expression by combined in situ RNA analysis and protein profiling from a single FFPE slide",
        "_version_":1606188995038937088},
      {
        "Meeting_name":" A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
        "Background":"['Background', ' About 50% of tumors harbor inactivating mutations in TP53. Aberrant MDM2 signaling is an alternate mechanism to inactivate wild type (WT) p53. In preclinical studies, DS-3032b disrupted the MDM2-WTp53 interaction resulting in cell cycle arrest, senescence and/or apoptosis. We characterized the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetic and pharmacodynamic (PD) profiles and efficacy of DS-3032b in a phase 1 trial. Methods', ' Using accelerated and Bayesian design in the dose-escalation phase of this 2-part study (part 1), we escalated DS-3032b from 15 to 240 mg orally once daily (QD) on a continuous or interrupted (QD 21/28 days) schedule. Results', ' Thirty-one of 34 pts enrolled in part 1 were evaluable for dose-limiting toxicities (DLTs). Median age was 59.5 years, 44% male, and 62% had  3 prior therapies. The majority of pts (79%) had wt TP53 and the most frequent tumor type was well/de-differentiated liposarcoma (LPS; n = 15). MTD was 120 mg (interrupted) and 90 mg (continuous) schedule. The most common drug-related adverse events were hematologic and gastrointestinal. Six pts had DLTs, 5 were due to thrombocytopenia alone or with neutropenia. Of 26 pts evaluable for efficacy, none had an objective response but 77% had stable disease (SD); consistent with cell cycle arrest/senescence seen in preclinical studies. Tumor shrinkage was seen but did not meet RECIST criteria. Two pts with previously progressing LPS and carcinoid remain on study for 26+ mos and tumor sequencing showed MDM2 gene amplification. Exposures of DS-3032b were significantly higher in pts with lower body weight. Induction of MIC- 1 (PD biomarker of WT p53 reactivation) correlated with drug exposure. Conclusions', ' DS-3032b has an acceptable safety profile at the MTD of 120 mg (QD 21/28). Clinical benefit with durable SD was seen in tumors with aberrant MDM2 signaling and WT p53. MDM2 is universally amplified in LPS and TP53 is the most commonly mutated gene in cancer; warranting further investigation of DS-3032b. Pts with melanoma or diffuse large B-cell lymphoma (DLBCL) are being enrolled in 2 dose-expansion cohorts (part 2) at the tentative recommended phase 2 dose 120 mg QD 21/28. Enrollment is ongoing (NCT01877382). Clinical trial information', ' NCT01877382']",
        "Doc_id":"ASCO_166204-176",
        "Doc_title":" A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
        "_version_":1606189031103660032},
      {
        "Meeting_name":" Genomics of Drug Sensitivity in Cancer (GDSC)",
        "Background":"['The Genomic of Drug Sensitivity in Cancer (GDSC; www.cancerRxgene.org) resource facilitates development of targeted cancer therapies through pre-clinical identification of therapeutic biomarkers. GDSC is the largest public resource for information on drug sensitivity in cancer cells and links these data to extensive genomic information to identify molecular features that influence anticancer drug response.There is compelling evidence that alterations in cancer genomes strongly influence clinical responses to anticancer therapies. There are several examples where genomic changes are used as molecular biomarkers to stratify patients most likely to benefit from a treatment (e.g. BRAF in melanoma). Despite these successes, the majority of cancer drugs have not been linked to specific molecular features that could be used to direct their clinical use to maximize patient benefit. We are using pharmacogenomic profiling in cancer cell lines as a biomarker discovery platform by systematically linking pharmacological data with genomic information in cancer cells. The GDSC database contains drug sensitivity data generated from high-throughput screening performed by the Cancer Genome Project at the Wellcome Trust Sanger Institute and the Center for Molecular Therapeutics at Massachusetts General Hospital using a collection of >1,200 cancer cell lines. GDSC release v3 (November 2012) contains drug sensitivity data for almost 80,000 experiments, describing response to 142 anticancer drugs across over 700 cancer cell lines. To identify molecular markers of drug response, cell line drug sensitivity data are integrated with large genomic datasets obtained from COSMIC (Catalogue of Somatic Mutations in Cancer), including information on somatic mutations in cancer genes, gene amplification and deletion, tissue type and transcriptional data. Analysis of GDSC data is through a web portal based on queries of specific anticancer drugs or cancer genes. Interactive graphical representations of the data are used throughout with links to related resources, and all datasets are freely available and downloadable. The GDSC database will undergo significant expansion in coming years as drug sensitivity and genomic datasets increase in size and complexity. GDSC provides a unique public resource incorporating large drug sensitivity and genomic datasets to facilitate discovery of new therapeutic biomarkers for cancer therapies.']",
        "Doc_id":"AACR_2013-2206",
        "Doc_title":" Genomics of Drug Sensitivity in Cancer (GDSC)",
        "_version_":1606189041283235840},
      {
        "Meeting_name":" Jak3 mutations in colorectal neoplasia- Preliminary data on a not so silent minority.",
        "Background":"['As a tumorigenesis model, colorectal cancer is associated with multiple gene mutations accumulating progressively but also has mutations that may alter disease course and provide a therapeutic target. Good examples of this are EGFR and VEGF. In melanoma, PD-1 interactions involving the immunobiome are therapeutically important. We conducted a study to detect potential mutations that might enhance therapy in colorectal cancer guided by expression of p87, a product of innate immune system Paneth cells. Methods', ' Adnab-9 immunohistochemistry or ELISA was used to define significant p87 Adenoma-associated antigen field effects (FE) in 10 patients with >1cm large high grade dysplastic adenomas (LHiGDA) and 3 with smaller high grade dysplastic adenomas (SHiGDA). We postulated that SHiGDA are not immunologically recognized by host defenses leading to negative outcomes. We used Ion Torrent sequencing (ITS) to find mutations in DNA (QiaAmp kit) extracted from 4 normal-appearing colonic segments taken from 1 patient in each group. Novel mutations found on ITS would then be sought using PCR with appropriate primers and subsequent sequencing of the PCR product circulating DNA extracted from available serum samples. These samples were taken from the Large- and SHiGDA groups described above and from 17 patients undergoing colonoscopy for diverse indications. Results', ' p87 FE were found in 40% of 10 LHiGDA and 0% of 3 SHiGDA patients. The ITS in the 2 representative patients showed unique mutational fields in', ' KRAS, APC, p53 in the LHiGDA and Jak3, PIK3Ca, p53, APC in the SHiGDA patient, both of whom lacked p87 FE. PCR using the Jak3 primers used in the ITS and subsequent sequencing revealed the same non-synonymous mutation in the serum of a FAP patient after colonic resection and an additional colonic segment of the selected ShiGDA patient but not in his serum. Other Jak3 mutations were found in 1 of 8 LHiGDA, 1 (the selected patient) of 3 SHiGDA, 1 of 7 patients with FAP and 1 of 10 colonoscopy patients with a family history of colorectal cancer with a FE and an untoward outcome. The selected SHiGDA patient subsequently contracted and died of NSCLC adenocarcinoma. The positive LHiGDA and FAP patients had a severely dysplastic anal condyloma and severe pancreatitis, respectively. Overall, the non-synonymous mutation occurring in the non-FAP SHiGDA patient occurred in the absence of p87 FE. Conclusions', ' In this pilot study we demonstrate the presence of Jak3 mutations likely associated with the lack of p87 expression in patients with high grade dysplastic adenomas and 1 FAP patient. Most of these patients had a clinical course which may have differed from their group members suggesting an altered immune system milieu. If confirmed in SHiGDA and FAP, Jak 3 mutations, associated with the SCID and late onset combined immunodeficiency, may allow for intervention with currently available medications to potentially avert a deleterious clinical outcome.']",
        "Doc_id":"AACR_2017-3689",
        "Doc_title":" Jak3 mutations in colorectal neoplasia- Preliminary data on a not so silent minority.",
        "_version_":1606189035155357696},
      {
        "Meeting_name":" Analysis of copy number and LOH in germline samples from different tumor types in The Cancer Genome Atlas (TCGA) project.",
        "Background":"[\"Using data from The Cancer Genome Atlas (TCGA) project and HapMap consortium, we examined the hypothesis that existing copy number polymorphisms might predispose individuals to cancer and if different common CNVs bias toward different cancer types. This analysis was performed using a subset of the TCGA data, obtained from blood derived normal samples of cancer patients. All the data was generated using Affymetrix SNP 6.0 arrays (Affymetrix, Inc.) and processed using Nexus Copy Number ver. 6.1 (BioDiscovery, Inc.). The project contained 451 Glioblastoma (GBM), 353 Colon cancer, and 245 Skin cancer samples in addition to 211 HapMap samples which we used as reference since these individuals were supposed to be healthy. Using Fisher's Exact test, we compared each different cancer types to the HapMap samples to identify regions of copy number change with FDR corrected p-value of less than 0.05 and difference in frequency between each population of at least 10%. Many of the regions found in this process encompass regions identified as common CNV polymorphisms as reported in the Database of Genomic Variance (DGV). For example, a polymorphic region on 8p23.1 containing a number of genes from the Beta defensin family involved in defense response to bacterium were seen significantly gained in germline samples obtained from cancer patients as compared to the HapMap samples (11% in HapMap, 42% in Colon Cancer, 28% in GBM, and 32% in Skin cancer). Additionally, some interesting regions were identified that were not seen as polymorphic in the general population, did not show up in the HapMap samples or reported in DGV, but had high prevalence in the blood derived normal samples from cancer patients. Using gene enrichment analysis on genes discovered in these regions we identified a number of known cancer specific pathways that were highly enriched (e.g. KEGG Glioma and Melanoma pathways being statistically significantly enriched). Looking at the effected genes in these pathways we identified small focal and recurrent events that often only spanned a small portion of a gene covering a few exons. This included genes such as PIK3CA where a focal gain covering exons 10-14 were observed in none of the HapMap samples but in 21% of the germline of patients with Colon cancer, 9% of GBM and 14% of Skin cancer patients. A similar focal and recurrent gain was observed in KIT covering exons 2-7 with no gains in the HapMap samples and 55% in Colon, 15% in GBM, and 50% in Skin cancer patients. Similar observations were also made for other well-known cancer genes such as RAF1 and EGFR but to a lesser extent. We are in a process of comparing matched tumor/normal cases to further investigate possible evolution of these changes from the germline to the surrounding tissue (also available from the TCGA database) to the primary tumor samples.\"]",
        "Doc_id":"AACR_2013-3171",
        "Doc_title":" Analysis of copy number and LOH in germline samples from different tumor types in The Cancer Genome Atlas (TCGA) project.",
        "_version_":1606189035853709312},
      {
        "Meeting_name":" Spliceosome-targeted antitumor drug discovery.",
        "Background":"['Over the last several years there has been a remarkable convergence of research related to oncogenic aberrations of the spliceosome, which has linked the identification of recurrent spliceosome mutations in tumors to medicinal chemistry. We designed synthetic natural product analogs (the sudemycins) that modulate the activity of the spliceosome and show potent and selective antitumor activity. We hypothesized that splicing gene mutations cause alterations in splice isoforms, which provide a selective advantage to tumor cells, and that perturbation of this environment with spliceosome modulators may cause a selective disadvantage for tumors. To test this hypothesis, we generated MSCV-based retroviruses encoding the wildtype or S34F mutant U2AF1 alleles. We infected c-kit+ primary C57BL/6J murine bone marrow cells with these recombinant retroviruses and cultured them in vitro with cytokine-supplemented media. Vehicle-treated cells expressing the mutant allele had reduced growth over 5 days, compared to cells expressing the wildtype allele or empty vector (P<0.0001, n=5 technical replicates, two experiments). At doses of 10-150 nM, sudemycin D1 (but not the inactive analog sudemycin E-OH) induced a reproducible dose-dependent decrease in cell growth and increase in apoptosis, as measured by Annexin V, in cells expressing the mutant, compared to the wildtype allele or empty vector. To study the effect of the U2AF1 mutation and sudemycin exposure on splicing, we analyzed RNA isoforms of Fmr1, a gene known to undergo alternative splicing. After retroviral transduction, GFP+ cells were sorted and RNA was isolated for RT-PCR analysis at baseline or 2h-6h after exposure to sudemycin D1 (75 nM) or vehicle. The U2AF1 S34F mutation increased the abundance of Fmr1 transcripts utilizing a cryptic splice acceptor, compared to cells transduced with empty vector or wildtype U2AF1 (P<0.05, n=3 technical replicates). These experiments provide proof-of-concept that cells expressing mutant U2AF1 have increased sensitivity to spliceosome modulators. The sudemycins show a short half-life (<15 min) when dosed IV via a bolus tail vein injection. So we have developed a jugular continuous infusion model to achieve therapeutic drug levels, and found that sudemycin D6 is tolerated at doses up to 200 mg/kg/h in mice. Additionally we have investigated numerous drug combinations and found significant cytotoxic co-treatment synergism with the experimental dual mTOR and PI3K inhibitor BEZ235, which suggests opportunities for multi-agent animal studies as a prelude to the design of human clinical trials. In this presentation we will also report in vitro and in vivo data on new sudemycin analogs along with additional work on the pharmacology, pharmacokinetics, toxicity and in vivo efficacy. Our results indicate a maturing therapeutic potential for sudemycin D6, which is in preclinical development for the treatment of subsets of MDS, melanoma and numerous other human cancers.']",
        "Doc_id":"AACR_2013-1125",
        "Doc_title":" Spliceosome-targeted antitumor drug discovery.",
        "_version_":1606189042101125120},
      {
        "Meeting_name":" AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model.",
        "Background":"['Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) play important non-redundant roles in negatively regulating T cell immune responses. Therapeutic blockade of CTLA-4 or PD-1 pathways has been demonstrated to enhance T cell reactivity to tumor-specific antigens, translating to a significant improvement in overall survival. This anti-tumor effect can be further augmented when PD-1 and CTLA-4 antagonist antibodies are co-administered. The therapeutic impact of this combination is exemplified by the approval of this combination for advanced melanoma, as well as clinical benefit of the combination observed in NSCLC, mRCC, and most recently, mUC. AGEN1884, a human IgG1 antibody directed against CTLA-4, potently inhibits CTLA-4 binding to CD80 and CD86, resulting in enhanced T cell responsiveness in vitro, as well as in a vaccination model in non-human primates. A Phase 1 clinical study (NCT02694822) is currently ongoing to evaluate the safety and pharmacokinetic (PK)/pharmacodynamic (PD) relationships in patients with advanced solid tumors. AGEN2034 is a human IgG4 antibody that binds selectively to PD-1 with high affinity and potentiates T cell responsiveness via the blockade of PD-L1 and PD-L2 binding to PD-1. Here we evaluated the pharmacologic effect of combining AGEN1884 with AGEN2034, and other molecules targeting the PD-1/PD-L1 pathway, on primary human T cell immune responses. AGEN1884 combined effectively with AGEN2034, and other antibodies targeting the PD1/PD-L1 pathway, to promote superior T cell immune responses compared to monotherapies. Consistent with these in vitro findings, the co-administration of AGEN1884 with an anti-PD-1 antibody in cynomolgus monkeys (Macaca fascicularis) induced a dynamic PD effect, including a proliferative T cell response in peripheral blood, as compared to animals receiving either antibody alone. Finally, co-administration of an anti-mouse CTLA-4 antibody together with Agenus tumor-specific neo-epitope-based vaccine (AutoSynVax) in mice induced effective amplification of vaccine-driven T cell responses, compared to animals that received the vaccine alone. These data further exemplify the versatility of harnessing antibody-mediated CTLA-4 blockade to influence apical events involved in T cell priming by antigen presenting cells. Taken together, these in vitro and in vivo findings demonstrate that the combination of AGEN1884 with PD-1 pathway blockade or with neo-epitope-based vaccines has the potential to provide therapeutic activity that is superior to that of either checkpoint- or vaccine-based monotherapies.']",
        "Doc_id":"AACR_2017-3654",
        "Doc_title":" AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model.",
        "_version_":1606188973316636672},
      {
        "Meeting_name":" Inhibiting glyoxylase 1 as a strategy to target highly glycolytic cancer cells",
        "Background":"['Cancer cells typically display altered glucose metabolism characterized by a preference of aerobic glycolysis (Warburg effect) resulting in higher levels of glycolytic waste including methylglyoxal (MG). GLO1 (Glyoxalase 1) functions in the detoxification of MG', ' MG reacts with glutathione to form hemithioacetal, which is converted into S-D-Lactoylglutathione by GLO1 and further metabolised into D-lactate by GLO2. When not detoxified, MG acts as a cytotoxic reagent by forming DNA- and protein-adducts (advanced glycation end products = AGEs) that subsequently lead to cell death. Therefore, GLO1 has been discussed as a potential anti-tumor target for highly glycolytic cancers.We confirmed previous reports that GLO1 expression is elevated in several tumor entities as compared to normal tissue. Tumor cells with high GLO1 expression levels are proposed to be highly dependent on GLO1 for removal of toxic MG. Therefore sensitivity to GLO1 inhibition was probed in a panel of cell lines covering lung, colon, breast, prostate and skin cancer with varying GLO1 amplification and expression levels. siRNA-mediated knock down of GLO1 did neither cause significant reduction of cellular proliferation nor significant induction of apoptosis in any of the tested tumor cells. Furthermore, treatment of these cells with a potent GLO1 inhibitor (Chiba et al. Bioorg Med Chem Lett. 2012, IC50=11 nM) did not affect proliferation or induce apoptosis at sub-M concentrations. In addition, no increase in AGEs upon GLO1 inhibition could be detected by western blot. Activity of the GLO1 inhibitor was further tested under conditions expected to increase endogenous MG levels such as hypoxia and elevated glucotriose (via GAPDH inhibition). Furthermore, a spheroid assay was developed to test the GLO1 inhibitor in a 3D assay system, better reflecting in vivo tumor growth. Even under hypoxic or spheroidal assay conditions, proliferation of cancer cells could not be reduced upon GLO1 inhibition. We could demonstrate however that GLO1 inhibition in A375 melanoma and SW620 colon adenocarcinoma cells sensitized the cells to exogenous MG.Taken together we could not confirm earlier published data that GLO1 inhibition leads to reduced proliferation and induction of apoptosis in cancer cells that have elevated GLO1 expression levels. Being aware that cellular systems may not reflect the situation in vivo, we speculate that GLO1 function alone may be redundant in detoxifying MG. Other possible enzymes which have been linked to MG removal include aldose reductase. Simultaneous inhibition of both enzymes might be a strategy to target highly glycolytic cancers in the future.']",
        "Doc_id":"AACR_2014-3355",
        "Doc_title":" Inhibiting glyoxylase 1 as a strategy to target highly glycolytic cancer cells",
        "_version_":1606188980616822784},
      {
        "Meeting_name":" PDK1 regulates cell migration and 3D invasion of breast tumor cells by a kinase independent mechanism",
        "Background":"[\"3-Phosphoinositide Dependent Kinase 1 (PDK1) is the kinase that phosphorylates the activation loop of several protein kinases such as Akt, PKC, RSK or SGK. In melanoma, breast and prostate carcinomas PDK1 was found amplified and overexpressed and this event correlates with a more aggressive phenotype.The purpose of our study is to unveil the mechanism by which PDK1 regulates cell migration and invasion with the aim to rationally target it in order to prevent tumor cell dissemination.Combining PDK1 stable silencing and PDK1 stable overexpression, we studied PDK1 role in different assays of breast tumor cells migration and invasion.Our data showed that PDK1 silencing in T47D, MDAMB231, MCF10A and MCF10DCIS breast tumor cells determined a potent reduction of chemotactic ability towards different chemoattractants, including serum, Epidermal Growth Factor (EGF) and Hepatocyte Growth Factor (HGF). Complementary, PDK1 exogenous overexpression, a condition that mimics PDK1 amplification and overexpression in tumors, significantly increased directional migration of MCF10A and MCF10DCIS cells. Surprisingly, the overexpression of a kinase dead mutant of PDK1 was equally able to increase cell migration, suggesting a kinase independent mechanism. We further confirmed this result by treating cells with an ATP competitive small molecule which inhibits PDK1 kinase activity but failed to impair cell migration. Moreover, we found that the kinase dead PDK1 overexpression was able to potently increase the ability of MCF10DCIS cells to invade through a basement membrane layer and to induce the formation of 3D invasive spheroids when cultured embedded in basement membrane matrix. We found that the molecular mechanism underlying the PDK1-mediated regulation of cell migration and invasion is the activation of Myotonic dystrophy kinase-related CDC42-binding kinase alpha (MRCK). This kinase protein is an important regulator of myosin contraction and cytoskeletal dynamics. According to our data, PDK1 is able to increase the kinase activity of MRCK. Moreover, we confirmed the MRCK role by silencing it, resulting in a complete abolition of the effects of PDK1 overexpression.The widespread role of PDK1 in the regulation of tumor cells migration and invasion together with its overexpression status in different tumors, makes it an appealing target for precision medicine. However the simple inhibition of PDK1 kinase activity by ATP competitors couldn't be effective on invasive properties of tumor cells. Future strategies to target PDK1 should take in account these findings by developing allosteric PDK1 inhibitors able to block its kinase independent functions.\"]",
        "Doc_id":"AACR_2015-530",
        "Doc_title":" PDK1 regulates cell migration and 3D invasion of breast tumor cells by a kinase independent mechanism",
        "_version_":1606188991924666368},
      {
        "Meeting_name":" Blockade of tumor expression of PD-1 promotes lung cancer growth in a murine model.",
        "Background":"['Lung cancer remains one of the most prevalent and fatal malignancies worldwide. There are substantial evidences that immunotherapies offer significant benefits among lung cancer patients. Pembrolizumab, a humanized programmed death receptor-1(anti-PD-1) antibody is now approved by FDA as a first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). Recent data demonstrate that PD-1 is not only expressed by immune cells, but also by human melanoma cells. However, little is known about the biological significance of PD-1 pathway in cancer including NSCLC. Thus, we examined PD-1 expression in a series of established murine lung cancer cell lines. RT-PCR amplification and sequencing of the full coding sequence of the murine PD-1 (PDCD1) gene revealed the presence of PDCD1 mRNA in the M109 lung cancer cells. Flow cytometry and immunofluorescence analysis demonstrated PD-1 protein expression in these murine lung cancer cells. To determine the molecular function of tumor PD-1 in lung cancer survival, we treated M109 cells in culture with either anti- mouse PD-1(100ug/ml) or isotype control antibody and found that PD-1 inhibition significantly enhanced cancer cell viability as measured by MTT and clonogenic assay. Alternative PD1 inhibition by either knockdown of PDCD1 via siRNA or knockout of PDCD1 by CRISPR-Cas9 all lead to increased survival of M109 cells. Furthermore, PDCD1-knockout M109 cells had no survival difference in the presence of anti-PD1 compared to its PD1-expressing parental cells. Conversely, treatment with recombinant PD-L1 fusion protein exhibited significantly increased apoptotic rates (7.53.2% vs 2.11.2%) suppressing the tumor cell growth in the wild-type M109 in culture. To validate these results in in vivo models, NSG mice were used to determine the direct impact of anti-PD1 on M109 xenografts without the interplay of host immune system. M109 xenografts treated with antiPD-1 (10mg/kg i.p.) antibodies showed accelerated growth compared to those treated by IgG control (2487473 vs 1499292mm3 at days 21 after tumor inoculation, p=0.013). M109 subcutaneous tumors in the PD-1 knockout mice also manifested more rapid growth than the same tumors implanted in wild-type mice. Taken together, our results uncover a novel function of PD-1/PD-L1 axis in lung cancer survival and implicate possible tumor-promoting effects from anti-PD-1 therapy upon PD1-expressing lung cancer in the absence of effective immune response. We plan to interrogate bio-specimens collected through NRG trials to establish the translational potential of these findings.']",
        "Doc_id":"AACR_2017-610",
        "Doc_title":" Blockade of tumor expression of PD-1 promotes lung cancer growth in a murine model.",
        "_version_":1606189032269676544},
      {
        "Meeting_name":" Investigation of RasGRP3 expression and function in human breast cancers and breast-derived ductal adenocarcinoma cell lines.",
        "Background":"['RasGRP3 is a member of the Ras guanine nucleotide releasing protein (RasGRP) family of the Ras-specific guanine nucleotide exchange factors. These proteins play role in the regulation of the activity of Ras signaling pathway which constitutive activation is demonstrated in many cancer types. The RasGRP3 protein has potential oncogenic effect, the amplification of the gen of the protein is observed in many malignant cancer types. Recent investigations have highlighted that RasGRP3 plays a role in tumorigenesis, hence it exerts effect on the proliferation, migration, survival and tumorigenecity of prostate adenocarcinoma-derived and melanoma cells. In light of this potential oncogenic effect we have examined the change of expression and potencial function of RasGRP3 in breast-derived ductal adenocarcinoma.The RasGRP3 and phosphoRasGRP3 expressions were examined in human ductal adenocarcinoma-derived samples from different grades and in 1 primary ductal adenocarcinoma-derived cell line called BT-474 and 5 different metastatic', ' JIMT-1, MCF7, SK-BR-3, MDA-MB-453 s T-47D cell lines both in mRNA (Q-PCR) and protein levels (Western blot; immunhisto-and cytochemistry). To explore the biological function of the protein RasGRP3 knockdown cultures were created on MCF7 and T-47D cell lines. To examine the role of RasGRP3 in the viability of cells annexin-V/PI staining was performed. To clarify the function of the protein in cell proliferation and in the developement of resistance against chemotherapeutic drugs Tamoxifen and Herceptin CyQuant assay was performed. To observe the RasGRP3 function in tumor formation and maintance SCID mouse model was used.According to our results the expression of RasGRP3 and the active phosphoRasGRP3 were elevated at protein level on the human ductal adenocarcinoma samples. This expression was increased in the tumor samples compared to the normal. RasGRP3 was found typically in the cytoplasm of the cells, while the phosphoRasGRP3 showed strong nuclear reaction. The RasGRP3 expression of the BT-474 cell line was lower then in the metastatics. The downregulation of RasGRP3 induced apoptosis, inhibited cell proliferation and sensitizied the T-47D cells to killing by Tamoxifen and Herceptin. In vivo tumor growth in mouse xenografts of both cell lines were decreased. Suppression of RasGRP3 expression inhibited downstream RasGRP3 responses AKT and ERK1/2 phosphorylation were reduced.Our results suggest the RasGRP3 may have an importante role in the regulation of cell growth, chemotherapeutic resistance, and tumor formation in breast cancer.']",
        "Doc_id":"AACR_2013-4399",
        "Doc_title":" Investigation of RasGRP3 expression and function in human breast cancers and breast-derived ductal adenocarcinoma cell lines.",
        "_version_":1606189033866657792},
      {
        "Meeting_name":" Comparative molecular analyses of BRAF-V600E mutant tumors",
        "Background":"['Background', ' Little is known about the molecular characteristics of BRAF mutant (mt) CRC. It is unknown whether BRAF mt CRC have molecular and biological profiles similar to BRAF mutant melanomas (Mel). Methods', ' A total of 5139 tumor samples (CRC, 4007 and Mel, 1132) submitted to Caris Life Sciences for IHC (protein expression), ISH (gene amplification), and NGS sequencing between 2009 and 2015 were retrospectively studied. Chi-square tests determined differences. Results', ' The rate of BRAF-V600E mutation was 7% in CRC (n = 270), and 30% in Mel (n = 334). Most frequently co-mutated genes in BRAF mt CRC were TP53 (56%), APC (26%), and PIK3CA (19%), and most frequently overexpressed proteins were TOP2A (90%), EGFR (77%), and cMET (57%). Most frequently co-mutated genes in BRAF mt Mel were CDKN2A (28%), ROS1 (19%), and TP53 (13%), and most frequently overexpressed proteins were PD1+ TILs (75%), and TS (71%). When compared with BRAF mt Mel, BRAF mt CRCs had a greater frequency of TP53 (56% vs. 13%), APC (26% vs. 3%), PIK3CA (19% vs. 1%), and SMAD4 (18% vs. 0%) mutations (all p-values < 0.01); however, mutations in CDKN2A (28% vs. 19%) and ROS1 (19% vs. 12%) appeared at higher rates in mt Mel (statistical significance not reached). BRAF mt CRC had a higher frequency of P-glycoprotein (PGP) (52% vs. 9%), cMET (57% vs. 13%), EGFR (77% vs. 6%), and HER2 (4% vs. 0%) overexpression (all p-values < 0.001), but lower PD1+ TILs (61% vs. 75%; p = 0.012) and ERCC1 (17% vs. 41%; p = 0.004) when compared with mt Mel. Co-occurring RAS mutations were rare, seen in 3 CRC and 2 Mel pts. MEK1 (1/31) and MEK2 (1/31) mutations were detected only in Mel. Mismatch repair deficiency and MSI were seen in 34% of BRAF mt CRC. On examining PD1+ TILs and PDL1 tumor expression in MSI-high (H) and MSIstable (S) CRC, and comparing with Mel, PD1+ TILs were found in 75% of Mel, 80% of MSI-H CRC, and 56% of MSI-S CRC (Mel or MSI-H CRC vs. MSI-S CRC; p < 0.01). PDL1 was positive in 10% of MSI-H and 15.8% of MSI-S CRC and 15% of Mel. Conclusions', 'BRAF mt CRCmay carry molecular alterations that are distinct from BRAF mt Mel, suggesting different carcinogenic pathways, and potential resistance mechanisms. Drug combinations that target these alterations (e.g., cMET, EGFR) may warrant further investigation.']",
        "Doc_id":"ASCO_169294-176",
        "Doc_title":" Comparative molecular analyses of BRAF-V600E mutant tumors",
        "_version_":1606189034023944192},
      {
        "Meeting_name":" Cancer immunotherapy biomarker profiling assay",
        "Background":"['Selecting patients predisposed to respond to existing and novel immunotherapy treatments requires the development of novel prognostic and predictive biomarkers. Recent reports have identified several gene expression signatures specific for immunity status and immune contexture in solid tumor microenvironments, and these enable predictions of efficacy of a number of chemo- and immunotherapeutics. Robust methods for molecular characterizations of the immune mechanism in the tumor microenvironment are essential to meet the imminent need for diagnostic approaches that identify patient populations responsive to the growing number of immunotherapeutic treatments. Toward this goal, we developed the Cancer ImmuneNet 2500 (CIN2500) assay for profiling cellular composition in the tumor microenvironment and discovery of novel prognostic and predictive immune response biomarkers.The CIN2500 panel provides signatures for approximately 400 immunity-related genes from 16 predictive and prognostic core genes that have been validated in recent chemo- and immunotherapy clinical trials across several tumor types, including melanoma, colorectal, breast, and lung cancers. In addition, using computational analysis of an immunotherapy network model, we predicted and included in the assay approximately 300 key nodes in pathways specific for antigen presentation and recognition, inhibition, activation and motility of immune cells, and adhesion and apoptosis of cancer cells. The CIN2500 panel also includes a comprehensive set of 1,700 genes specific for detection and quantitative profiling in the tumor microenvironment of different types of activated immune cells of adaptive and innate immunity, and stromal, fibroblast, cancer, endothelial and adipose cell types.The CIN2500 assay quantitatively profiles the expression levels of approximately 2,500 key cancer genes from 10-100ng of total RNA using multiplex RT-PCR amplification followed by Next-Generation Sequencing (NGS). Built-in standards for each gene target enable sample-to-sample calibration of the NGS data and provide a reference to adjust for background noise that often depends on the quality of samples. Control studies have shown that the CIN2500 assay quantifiably measures 4 orders of magnitude variation in the expression levels of 2,500 immune-related genes from as few as 100 cells in whole lysate, and profiles from frozen biopsies, surgically-removed tumor samples, PBMCs, and FFPE clinical samples show a comparable range and sensitivity. We will present profiling data from infiltrating immune cells and key intact and deficient immune mechanisms in the tumor microenvironment of breast cancer samples to demonstrate the performance and utility of the CIN2500 assay.']",
        "Doc_id":"AACR_2016-744",
        "Doc_title":" Cancer immunotherapy biomarker profiling assay",
        "_version_":1606189037420281856},
      {
        "Meeting_name":" A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.",
        "Background":"['Acquired drug resistance is a long-standing problem of cancer therapeutics. The issue has become even more vexing with the development of highly selective agents; resistance to gefitinib or erlotinib is acquired frequently in lung adenocarcinomas. Thus, anticipating acquired resistance and understanding its basis may help us develop strategies to prevent or circumvent occurrence. Through its receptor tyrosine kinase Met, hepatocyte growth factor (HGF) regulates mitogenesis, motogenesis, and morphogenesis during development and adulthood. HGF/Met signaling also contributes to cancer progression in many malignancies, including glioblastoma. Rilotumumab is a fully human neutralizing monoclonal antibody against HGF tested in multiple Phase 2 clinical trials, including mono therapy in renal cell carcinoma and glioblastoma, as well as combination trials in gastric, colorectal, small cell lung cancers and castrate resistant prostate cancer.To generate a cellular model of acquired resistance to rilotumumab, an HGF/Met dependent human glioblastoma-derived cell line (U87-MG) was grown in rilotumumab (600 nM) for 120 days. Growth rate, HGF secretion, Met content and Met activation state were 10-fold, 10,000-fold, 10-fold and 80-fold higher than the parental cell values, respectively. The HGF and MET coding sequences were normal in both parental and resistant cells. Quantitative PCR studies to determine mRNA levels of all HGF isoforms revealed a dramatic increase in full-length HGF transcript. CGH array studies indicated amplification within both HGF and MET genes. Xenograft studies confirmed that tumor growth was resistant to rilotumumab, however the resistant cell line and tumors remained sensitive to a highly selective Met tyrosine kinase inhibitor, suggesting that resistance was achieved via increased HGF/Met signaling rather than mutation or activation of alternate pathways. Microarray expression analysis demonstrated transcript profiles that were consistent with HGF/Met pathway activation. Thus the molecular basis of acquired resistance in this model differs from those prevalent in', ' [1] lung cancers treated with EGFR inhibitors and medulloblastomas treated with hedgehog inhibitors, where most cases acquire secondary mutations in the targeted kinase; [2] breast cancers treated with HER2 inhibitors, where PTEN loss, p27 downregulation, and activation of other receptors are primary causes; or [3] malignant melanoma treated with BRAF inhibitors, where increased signaling via multiple pathways lead to PI3K- and/or MEK-mediated reactivation of the MAPK pathway. In addition to the importance of HGF/Met pathway activity in selecting glioblastoma patients for HGF-targeted therapeutics, our results suggest that monitoring Met pathway activity could provide early indications of acquired resistance to these agents, and that Met kinase inhibitors may still be efficacious when resistance occurs.']",
        "Doc_id":"AACR_2013-5637",
        "Doc_title":" A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.",
        "_version_":1606189011878019073},
      {
        "Meeting_name":" Evaluation of BRAF(V600E) mutation by immunohistochemical staining with anti-BRAF V600E (VE1) antibody",
        "Background":"['Background', ' The most common of all activating BRAF mutations (T1799A point mutation) leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. This oncogenic mutation in the BRAF gene constitutively activates the MAPK signaling pathway and results in increased proliferation and inhibition of apoptosis. BRAF V600E mutation was described in approximately 8% of all solid tumors (43% melanomas, 39-67% papillary thyroid carcinomas and 12% colorectal adenocarcinomas). However, it is challenging to identify patients with this mutation. Currently, the gold standard is sequencing of the tumor DNA, but this method is not practical for routine practice. In contrast, immunohistochemistry (IHC) is a relatively easy diagnostic tool to detect proteins in paraffin-embedded tissues. The major goal of this study was to compare detection of BRAF V600E by sequencing and IHC using anti-BRAF V600E (VE1) antibody. This clone is mutation specific and can distinguish the V600E mutation in BRAF from the wild type BRAF protein.Methods', \" Tissues from sixty-nine patients with colon cancer (N=40) and thyroid cancer (N=29) were evaluated for the BRAF V600E mutation. Genomic DNA was extracted from 20 m tissue sections and analyzed by PCR amplification followed by Sanger sequencing. Primers were designed to cover the BRAF coding sequences at mutation site and a few nucleotides in the intron on both ends (BRAF-ex15F-TGCTTGCTCTGATAGGAAAATG; BRAF-ex15R-AGCATCTCAGGGCCAAAAAT). Both forward and reverse strands were sequenced on an Applied Biosystem's 3730xl DNA Analyzer. Immunohistochemical staining using anti-BRAF V600E (VE1) antibody was done on VENTANA BenchMark XT platform with OptiView DAB IHC Detection Kit.Results\", ' All cases (22/22, 100%) that were negative for BRAF V600E mutation by IHC were confirmed to be BRAF V600E negative by sequencing. Out of 47 cases staining positive for BRAF V600E (VE1) 43 cases were confirmed by sequencing. Of the four discordant cases, one case was weakly positive by IHC (score 1), two cases that were negative by sequencing showed stronger BRAF V600E (VE1) staining (score 2) and one case contained a different mutation at codon 600 (V600K). Overall, there was high concordance between IHC and DNA sequencing. Using the sequencing as the reference standard, negative predictive value was 100%, positive predictive value was 91% with a sensitivity of 100% and specificity of 85%. Overall percentage agreement across all cases was 94% (65/69 cases). Next-generation sequencing will be used to evaluate discordant cases for BRAF V600 mutation status.Conclusion', ' Detection of the BRAF V600E mutation is emerging as an important biomarker with diagnostic, prognostic, and predictive potential. Importantly, our data suggests that there is high concordance between sequencing and IHC using anti-BRAF V600E (VE1) antibody.']",
        "Doc_id":"AACR_2013-42",
        "Doc_title":" Evaluation of BRAF(V600E) mutation by immunohistochemical staining with anti-BRAF V600E (VE1) antibody",
        "_version_":1606189014471147520},
      {
        "Meeting_name":" Subtyping of pancreatic cancer patient-derived xenograft tumors and implications for anticancer agent testing",
        "Background":"['Despite improvements in treatment, pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a continuous increase in incidence emphasizing the need for further research and therapeutic development. In recent years, we have developed a collection of >40 patient-derived xenograft (PDX) models from PDAC. In order to determine their relevance for anticancer agent testing, we extensively characterized our models for histology features, whole exome mutations (Hiseq 2000), chromosome rearrangements, gene copy number variations (Affymetrix SNP6) and gene expression (Affymetrix U133 Plus2.0).PDAC from 65 patients were implanted into immuno-compromised mice, resulting in the development of 42 PDX models (success rate 65%). The PDAC from which models were established included moderate and poorly differentiated tumors and were heterogeneous for stroma content. In patient tumors, we showed fibroblast activation but not stroma content predicted poor patient outcome (p<0.0001) and success of PDX establishment (p<0.01). Correlating with those of the parental tumors, the resulting PDAC_PDX also showed heterogeneity for stroma content and for murine fibroblast activation. As seen in patient tumors, the PDAC_PDX were characterized by frequent chromosomal instability, with 38% of the models presenting a moderate hypoploidy while the 62% remaining ones showed a hyperploidy. Two models showed hypermutation due to mismatch repair deficiency while the others had on average a lower mutation load when compared to other histotypes such as colon, lung or melanoma tumors. In total, we identified more than 9000 genes altered by homozygous deletions, high gene amplifications and/or mutations, most of the models showed alterations in KRAS (81%), TP53 (67%), CDKN2A (64%) and TGFBR2/SMAD4 (64%) genes. Next, PDAC_PDX profiles were merged with those of patient tumors to determine PDAC_PDX subtypes and were found to be of the classical (61%), quasi mesenchymal (QM) (34%) and exocrine like subtype (5%) according to the 62 gene expression signature established by Collisson et al. 2011. Preliminary biomarker analysis revealed certain associations between genomic alterations and transcriptome subtypes, such as more frequent alterations in the TGFB pathway in classical PDX (80%) compared to QM (47%). Further detailed biomarkers analyses also addressing questions of molecular determinants of stroma content, of fibroblast activation and of sensitivity toward anticancer agents will be presented.Extensive characterization of our PDAC_PDX collection revealed similarities with patient tumors with regards of histology features including stroma content and fibroblast activation. At molecular level, the models showed similar genomic and transcriptomic patterns as those reported for patient PDAC, altogether, proving the value of this collection for drug development investigations.']",
        "Doc_id":"AACR_2016-639",
        "Doc_title":" Subtyping of pancreatic cancer patient-derived xenograft tumors and implications for anticancer agent testing",
        "_version_":1606189027478732800},
      {
        "Meeting_name":" Snail+ bone-metastatic cancer cells impair CTL induction via induction of immunoregulatory MSCs",
        "Background":"['Purpose', ' Immunosuppressive mechanism in cancer patients is still unintelligible due to its complexity including various immunoregulatory members such as MDSCs, Treg cells and mesenchymal stem cells (MSCs). Particularly, the phenotype markers and the functional role of MSCs are not fully defined yet in tumor immunology, although demonstrated in regenerative medicine fields. We recently found that Snail+ tumor cells undergoing EMT preferentially metastasized into bone marrow (BM) than other organs such as spleen and lymph node, accompanying increase of MSC-like cells. In this study, we elucidated the molecular mechanism and the MSC features for the further understanding of immunosuppressive mechanism in host with cancers. Results', ' When BM cells of C57BL/6 mice were cultured with supernatant of murine snail-transduced melanoma B16-F10 cells for 7-14 days, CD45-Vimentin+ mesenchymal cells were significantly increased as compared with the control with mock transfectant. These cells showed the ability to differentiate into adipocytes, chondrocytes and osteocytes, indicating MSC generation by Snail+ tumor cells. CD45- MSCs were also increased in BM of the mice 2-3 weeks after Snail+ tumor implantation. These Snail-induced MSCs (sMSCs) showed much higher suppressive activity on T-cell proliferation followed by Treg increase than the MSCs stimulated with mock-transfected B16-F10 supernatant. When B16-F10 cells were subcutaneously co-injected with the sMSCs in mice, tumor growth and metastasis was significantly promoted in C57BL/6 mice, but not in immunodeficient mice, implying requirement of other immune cells for the sMSC efficacy. Utilizing EGFP+ mice or GFP+ B16-F10 tumor cells, we found that the co-injected sMSCs mainly migrated and accumulated in lymphatic organs such as spleen. In the spleen, CD11b+Gr1+ MDSCs and Foxp3+ Treg cells were increased, and CD8+ T cells were disabled for IFN induction and tumor-killing, indicating CTL impairment following accumulation of various immunoregulatory cells. The sMSCs also significantly suppressed T-cell proliferation in vitro. On the other hand, the co-injected tumor cells rapidly metastasized into BM of the mice, suggesting EMT induction by the sMSCs. We identified the sMSC markers and the sMSC inducers that produced from Snail+ tumor cells. Blocking of the sMSC inducer with the specific siRNA resulted in decrease of the sMSCs and tumor cells in BM, accompanying improvement of anti-tumor immune responses in the mice. Conclusions', ' These results suggest that Snail+ bone-metastatic tumor cells increase sMSCs that induce MDSCs and Treg cells leading to systemic spread of immunosuppression in host. The sMSCs also stimulate noninvasive tumor cells to migrate into BM, resulting in further amplification of the immunosuppressive cascade. Elimination of the sMSCs would be an useful strategy for treatment of cancers.']",
        "Doc_id":"AACR_2012-5403",
        "Doc_title":" Snail+ bone-metastatic cancer cells impair CTL induction via induction of immunoregulatory MSCs",
        "_version_":1606189028862853121},
      {
        "Meeting_name":" Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity",
        "Background":"['Dysregulation of ERK signaling is a common event in malignancy. Receptor activation of RAS leads to dimerization and activation of RAF kinase, which in turn activates ERK. Physiologic activation of the pathway is limited by ERK dependent feedback inhibition of RAS activation and other components of the pathway. Oncogenic mutations and translocations of RAF family members have been identified in many human tumors and serve as drivers of tumor growth. We now show that these mutants are active despite feedback inhibition of RAS and that this is associated with dysregulated ERK output. All translocations and almost all of the RAF mutants tested so far form RAS-independent constitutive dimers, the activity of which is dependent on their dimerization. Mutations at one site, V600E and V600K allow RAF to function as a monomer in cells with low RAS activity and as a RAS-dependent dimer in cells with adequate RAS activity. In tumors expressing any of these mutants, RAF/MEK/ERK activity is elevated despite feedback inhibition of RAS. Currently available RAF inhibitors bind to one protomer of the RAF dimer and cause negative cooperativity of binding to the second site. This is sometimes associated with transactivation of the unbound protomer. These inhibitors cannot be used to inhibit ERK signaling in tumors in which ERK is driven by RAF-dimers (those with mutant RAS, NF1 loss, atypical RAF mutations, RAF translocations.) In contrast, in tumors with V600E BRAF mutations, ERK causes strong feedback inhibition of RAS and V600E BRAF exists as a monomer that is inhibited by these drugs. Acquired resistance to RAF inhibitors usually results from a molecular lesion that causes RAS-dependent or independent dimerization of V600E (NRAS mutation, V600E BRAF amplification, V600E aberrantly spliced isoform.) Current RAF inhibitors inhibit V600E BRAF dimers at concentrations 10-100 fold greater than those required to inhibit the corresponding monomer in cells. We take this as a provisional measure of the degree of negative cooperativity of binding to the second site. We have now identified inhibitors that inhibit V600E dimers at concentrations close (1-3 fold higher) than those required to inhibit the monomer. They do not cause dissociation of dimers and their inhibition is abolished by gatekeeper mutations. Phenotypically, therefore, binding of these compounds to dimers is associated with only minimal negative cooperativity. These drugs inhibit ERK signaling and the proliferation of tumor cells with atypical BRAF mutations and translocations as well as V600E melanoma models with acquired resistance to Vemurafenib. However, they are much less active in cancer cells with KRAS mutation or receptor-dependent activation of RAF. Selective inhibitors of subsets of RAF dimers may allow effective ERK inhibition of large subset of tumors without inhibiting signaling in normal cells.']",
        "Doc_id":"AACR_2014-3706",
        "Doc_title":" Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity",
        "_version_":1606188989855825920},
      {
        "Meeting_name":" Investigating the dependence of canine bladder transitional cell carcinoma on activated mutant BRAF.",
        "Background":"['Transitional cell carcinoma (TCC) accounts for approximately 2% of diagnosed malignancies in canines. The majority of canine TCCs are invasive, intermediate to high grade tumors sharing similarities with human muscle invasive TCCs in risk factors, histology, sites of metastasis, and therapeutic response to single agents. Whole exome sequencing of canine TCC tumors was performed to identify somatic mutations in known cancer driver and repressor genes that could potentially contribute to canine TCC pathogenesis. A valine to glutamic acid mutation in BRAF homologous to the activating V600E mutation identified in human melanoma, colorectal and thyroid cancers was identified in 70% of sequenced tumors. Sensitivity to the BRAFV600E inhibitor Vemurafenib was tested in three BRAF mutant canine TCC cell lines (Bliley, Tyler1 and Tyler2) and two BRAF wild type canine TCC cell lines (Angus1 and Kinsey). All five canine TCC cell lines exhibited IC50s greater than 10M, with BRAF mutant cell lines being slightly more sensitive. These sensitivity ranges are similar to those of some mutant human colorectal cancer cell lines, indicating that additional mechanisms may contribute to Vemurafenib resistance. Western blot analysis was performed to measure relative abundance of pERK, a downstream target of BRAF, in canine TCCs in response to serum starvation. All TCC cell lines showed sustained pERK expression in the absence of serum, indicating constitutive activation of the MAPK pathway. The five canine TCC lines were treated with 15M Vemurafenib for 6 and 24 hours and their lysates were analyzed for pERK protein expression. pERK abundance was decreased in only the BRAF mutant cell lines after 6 hours of treatment. However, this decrease was less pronounced after 24 hours, suggesting that resistance mechanisms are bypassing BRAF to activate ERK. Sequence analysis of an additional panel of formalin-fixed paraffin embedded canine TCCs also revealed a mutation in RanBP2 in 31% of samples. Strikingly, the RanBP2 mutation appeared to be mutually exclusive to BRAF V to E mutant tumors with only two of the analyzed samples carrying both mutations. Significant tumor heterogeneity was implicated due to low level mutant amplification in these samples. It has been reported that loss of RanBP2 is synthetic lethal in BRAF V600E mutant colorectal cancer. Since RanBP2 forms complexes with CRM1 at the nuclear pore complex for nuclear export and at the kinetochore during mitosis, canine TCC cell lines were treated with KPT-185, a CRM1 inhibitor. BRAF mutant TCC cell lines had IC50 values ranging from 45nM to 65nM and were approximately ten-fold more sensitive than wild type cell lines. Overall, this data indicates that the pathogenesis of canine TCC likely depends on driving factors in addition to constitutive BRAF signaling, but Vemurafenib resistant BRAF mutant tumors can be targeted through inhibition of the nucleopore complex.']",
        "Doc_id":"AACR_2017-324",
        "Doc_title":" Investigating the dependence of canine bladder transitional cell carcinoma on activated mutant BRAF.",
        "_version_":1606188999126286336},
      {
        "Meeting_name":" Multiplexed ICE COLD-PCR coupled to NGS and ddPCR enables enhanced detection of low-level DNA mutations in tissues and liquid biopsies",
        "Background":"['Introduction', \" The use of liquid biopsies, where limited or no tumor tissue is available, is increasingly important for molecular demographics, diagnostics and pharmacodynamic monitoring of patients during therapy.The ICE COLD-PCR (ICP) technique preferentially amplifies sequence alterations in samples having either vast excesses of wild-type sequence or when sample DNA quantity is sub-optimal. ICP delivers unbiased, high-level enrichment of gene regions enabling determination of point mutations and insertions/deletions using Sanger sequencing, Next Generation Sequencing (NGS) or droplet digital PCR (ddPCR).This is especially important when sample DNA, e.g. from circulating free DNA, exosomes and circulating tumor cells (CTCs), is insufficient for multiplexed analysis.A critical limitation of mutational analysis of such samples is the need for increasing amounts of DNA for detecting very low-level mutations. A range of 100 to330 ng of substrate DNA is usually needed for reliable detection of alterations present at 0.01% in the sample DNA; this is not feasible with the limited quantities of blood/plasma/serum from clinical trials. ICP's ability to enrich alterations can provide a 100-fold increase in Sanger, NGS and ddPCR sensitivity.Materials and Methods\", ' To increase throughput, address the limiting amounts of DNA present in these samples and provide enriched amplification from many different gene regions in a single DNA sample, a multiplex ICP approach has been developed (MX-ICP). This MX-ICP method provides enrichment of any alteration present in all targeted genes from a single sample of DNA. When MX-ICP products are analyzed by Sanger, NGS or ddPCR, lower quantities of sample DNA can be used for detection of mutations at 0.01%.We compared detection of low-level of mutations in limiting amounts of DNA, with or without the use of MX-ICP prior to NGS and ddPCR, using digitally verified chromosomal DNA mixtures from Horizon Diagnostics. The alterations analyzed were from (1) CTC and NSCLC patients plasma, (2) longitudinal sampling of melanoma patients and (3) CTCs isolated from NSCLC patients. In all cases, use of MX-ICP, prior to analysis using NGS or ddPCR, enabled very sensitive detection with low amounts of input DNA.Conclusion', ' MX-ICP is a key component of procedures for sensitive detection and monitoring of genetic alterations in multiple targets using a single DNA sample. Coupling MX-ICP with platforms such as NGS and ddPCR enables the use of these powerful technologies for high sensitivity detection and monitoring of liquid biopsies from cancer patients. The combination of MX-ICP with NGS and ddPCR platforms means that they can be used efficiently for detection of alterations at0.01% in samples with <100 ng DNA. This enables monitoring and detection of alterations in the low volumes of liquid biopsies obtained from patients and clinical trials.']",
        "Doc_id":"AACR_2015-5438",
        "Doc_title":" Multiplexed ICE COLD-PCR coupled to NGS and ddPCR enables enhanced detection of low-level DNA mutations in tissues and liquid biopsies",
        "_version_":1606189021189373952},
      {
        "Meeting_name":" Single-cell whole-genome sequencing verifies the surrogacy of circulating tumor cells for prostate cancer",
        "Background":"['Background', \" Circulating tumor cells (CTCs) are rare tumor cells shed from a patient's tumors into the circulation. It has been hypothesized that CTCs could be used as a liquid biopsy to obtain repeat molecular characterizations and provide dynamic insight into the biology of an underlying cancer. However, due to the low abundance of CTCs and technical limitations in the single-cell sequencing, it had been very difficult to characterize CTCs on a whole genome scale. The surrogacy of CTCs for conventional tumor tissues has never been demonstrated beyond targeted genomic alterations such as shared ETS fusions in prostate cancer (PC), EGFR mutations in lung cancer and BRAF mutations in melanoma. With recent technical advances in single-cell sequencing and single-CTC isolation technologies, we present the first study using whole genome sequencing (WGS) of isolated serially-collected single CTCs in a PC patient.Method\", ' By combining NanoVelcro CTC Chip with laser microdissection, we developed a robust platform for single-CTC isolation. Subsequent WGS was performed after the multiple displacement amplification of our single-CTC DNA. From a PC patient, we performed WGS on four of his CTCs on two different time point, his primary prostatectomy tissue and liver metastasis along with WBC and normal adjacent tissue from the prostatectomy as controls. Copy number variations, single nucleotide variations (SNVs) and structural variations (SVs), including rearrangements were identified for comparison.Results', ' We successfully performed WGS on isolated single CTCs, achieving 30X depth and >95% coverage. SNV analysis reveals that 33.5% (289/863) of founder somatic mutations (defined as mutations shared between primary and metastatic tumors) can be found in CTCs. Looking into the mutational landscape of CTCs, 48% of the CTC mutations can be traced back to either primary or metastatic tumor. Per SV analysis, we found and validated an intrachromosomal rearrangement in chr3 and an interchromosomal rearrangement between chr13 and chr15. These rearrangements are shared between both tumor tissues and most of the CTCs, but not discovered in WBC and normal adjacent tissue. At the same time, highly heterogeneous short SVs were discovered in PTEN, RB1 and BRCA2 in all tumor samples, suggesting a continuous evolution of SVs in these important tumor suppressor genes.Conclusion', ' Based on our capability to obtain high-quality WGS from single-CTCs, we validate the genomic surrogacy of CTCs by the detection of shared SNVs and rearrangements between CTCs and tumor tissues. The heterogeneous mutational landscapes of SNVs and SVs are also discovered in single-CTCs, indicating the value of our single-CTC WGS approach. We envision our single-CTC WGS approach will be utilized for studying tumor heterogeneity and the biological evolution of cancer during disease progression, even during anticancer therapy.']",
        "Doc_id":"AACR_2014-938",
        "Doc_title":" Single-cell whole-genome sequencing verifies the surrogacy of circulating tumor cells for prostate cancer",
        "_version_":1606189022474928128},
      {
        "Meeting_name":" miR-6883 and family miRNAs induce G1-arrest in colon cancer cells by targeting CDK4/6.",
        "Background":"['Dysregulation of the CDK4/6-Rb pathway is a hallmark of various tumor types. Cancer cells subvert different cell cycle checkpoints to continue unchecked growth and proliferation. Some common mechanisms of overcoming cell cycle checkpoints involve loss of tumor-suppressor proteins such as p16 INK4A or Retinoblastoma (Rb). Alternately, cancer cells can also increase expression of oncogenes like cyclin D1, other CDKs by gene amplification or gene translocation. Thus, targeting different oncogenes in the cell cycle pathway, particularly CDKs has been considered an important therapeutic strategy. Events of overexpression of cell cycle oncogenes and suppression of tumor suppressors are mutually exclusive and tumor-type specific. In colorectal cancer (CRC), it has been shown that there is overexpression of CDK4/6 . We conducted TCGA analysis of 50 matched tumor and normal CRC tumors, and validated that CDK4 and CDK6 are significantly overexpressed in patient tumor samples by RNA-seq (p= 1.55 e-09 and p= 4.439 e-05). Thus, ongoing clinical trials for CRC patients with advanced disease are currently evaluating the efficacy of CDK4/6 inhibitors as single agents and in combination with chemotherapy (J Clin Oncol 33, 2015 ,suppl 3; abstr 626; Zhang 2016). We evaluated the efficacy of miRNAs targeting CDK4/6 as novel therapeutics in CRC. We performed in silico analysis using TargetScan to identify miRNAs that can target the 3UTR regions of CDK4/6. We have identified a novel family of miRNAs (based on seed sequence similarity) that can potently target CDK4/6 mRNA and thereby reduce both the RNA and protein levels of CDK4/6 in cancer cells. Of the four miRNAs in the family, we chose to characterize miR-6883-5p and miR-149* in a panel of CRC, melanoma and pancreatic cancer cell lines. Our preliminary TCGA analysis in 11 matched T/N samples shows miR-149* expression is significantly lost (p= 0.0049) in CRC samples and this further positively correlates with the stage of the tumor. Ongoing in vitro studies using miRNA mimics in CRC cell lines indicate that both miR-6883-5p and miR-149* have anti-proliferative effects as assayed by CellTiterGlo (CTG) and MTT. Further, both miRNAs induce G1-arrest as a consequence of downregulation of CDK4 and CDK6 in all cell lines and we also observe induction of apoptosis in a subset of CRC cell lines. Knockdown of CDK4 and CDK6 mimics the phenotypes observed with restoring expression of both miR-6883 and miR-149* in CRC cell lines. Combination of miR-6883 with FDA-approved drugs Irinotecan and 5-FU showed strong synergy and led to apoptosis as assayed by CTG and PARP cleavage. Our ongoing work is further looking into the mechanisms of synergy and identifying additional target genes in CRC cell lines. Thus, our novel miRNA based strategy to target CDK4 has potential to translate as both a single agent/combinatorial therapy and to identify biomarkers of response, which is critical for understanding the clinical results seen with CDK inhibitors.']",
        "Doc_id":"AACR_2017-2337",
        "Doc_title":" miR-6883 and family miRNAs induce G1-arrest in colon cancer cells by targeting CDK4/6.",
        "_version_":1606189007878750208}]
  }}
